WorldWideScience

Sample records for cannabis dependence symptoms

  1. Cannabis dependence in the San Francisco Family Study: age of onset of use, DSM-IV symptoms, withdrawal, and heritability

    OpenAIRE

    Cindy L. Ehlers; Gizer, Ian R; Vieten, Cassandra; David A. Gilder; Stouffer, Gina M.; Lau, Philip; Wilhelmsen, Kirk C

    2009-01-01

    Cannabis is the most widely used illicit drug in the United States, yet the role of genetics in individual symptoms associated with cannabis use disorders has not been evaluated. The purpose of the present set of analyses was to describe the symptomatology and estimate the heritability of DSM-IV criteria/symptoms of cannabis dependence in a large sample of families. Participants were 2524 adults, participating in the University of California San Francisco (UCSF) Family Study of alcoholism. Se...

  2. Prospective Assessment of Cannabis Withdrawal in Adolescents with Cannabis Dependence: A Pilot Study

    Science.gov (United States)

    Milin, Robert; Manion, Ian; Dare, Glenda; Walker, Selena

    2008-01-01

    A study to identify and assess the withdrawal symptoms in adolescents afflicted with cannabis dependence is conducted. Results conclude that withdrawal symptoms of cannabis were present in adolescents seeking treatment for this substance abuse.

  3. Baclofen in the management of cannabis dependence syndrome

    OpenAIRE

    Imbert, Bruce; Labrune, Nathalie; Lancon, Christophe; Simon, Nicolas

    2014-01-01

    Cannabis is the most commonly used illicit drug in the world. However, only few studies have shown the efficacy of pharmacologic agents in targeting cannabis withdrawal symptoms or reducing the reinforcing effects of cannabis. Baclofen has been shown to reduce cannabis withdrawal symptoms and the subjective effects of cannabis. We think that the clinical utility of baclofen for cannabis dependence is a reasonable approach. A case report using baclofen is presented and provides preliminary sup...

  4. Cannabis Withdrawal is Common among Treatment-Seeking Adolescents with Cannabis Dependence and Major Depression, and is Associated with Rapid Relapse to Dependence

    OpenAIRE

    Cornelius, Jack R; Chung, Tammy; Martin, Christopher; Wood, D. Scott; Clark, Duncan B

    2008-01-01

    Recently, reports have suggested that cannabis withdrawal occurs commonly in adults with cannabis dependence, though it is unclear whether this extends to those with comorbid depression or to comorbid adolescents. We hypothesized that cannabis withdrawal would be common among our sample of comorbid adolescents and young adults, and that the presence of cannabis withdrawal symptoms would be associated with a self-reported past history of rapid reinstatement of cannabis dependence symptoms (rap...

  5. Negative consequences associated with dependence in daily cannabis users

    Directory of Open Access Journals (Sweden)

    Earleywine Mitch

    2007-01-01

    Full Text Available Abstract Background Cannabis is the most widely consumed illicit substance in America, with increasing rates of use. Some theorists tend to link frequency of use with cannabis dependence. Nevertheless, fewer than half of daily cannabis users meet DSM-IV-TR criteria for cannabis dependence. This study seeks to determine whether the negative aspects associated with cannabis use can be explained by a proxy measure of dependence instead of by frequency of use. Results Over 2500 adult daily cannabis users completed an Internet survey consisting of measures of cannabis and other drug use, in addition to measures of commonly reported negative problems resulting from cannabis use. We compared those who met a proxy measure of DSM-IV-TR criteria for cannabis dependence (N = 1111 to those who did not meet the criteria (N = 1770. Cannabis dependent subjects consumed greater amounts of cannabis, alcohol, and a variety of other drugs. They also had lower levels of motivation, happiness, and satisfaction with life, with higher levels of depression and respiratory symptoms. Conclusion Although all of our subjects reported daily use, only those meeting proxy criteria for cannabis dependence reported significant associated problems. Our data suggest that dependence need not arise from daily use, but consuming larger amounts of cannabis and other drugs undoubtedly increases problems.

  6. Decreased respiratory symptoms in cannabis users who vaporize

    OpenAIRE

    Barnwell Sara; Earleywine Mitch

    2007-01-01

    Abstract Cannabis smoking can create respiratory problems. Vaporizers heat cannabis to release active cannabinoids, but remain cool enough to avoid the smoke and toxins associated with combustion. Vaporized cannabis should create fewer respiratory symptoms than smoked cannabis. We examined self-reported respiratory symptoms in participants who ranged in cigarette and cannabis use. Data from a large Internet sample revealed that the use of a vaporizer predicted fewer respiratory symptoms even ...

  7. Decreased respiratory symptoms in cannabis users who vaporize

    Directory of Open Access Journals (Sweden)

    Barnwell Sara

    2007-04-01

    Full Text Available Abstract Cannabis smoking can create respiratory problems. Vaporizers heat cannabis to release active cannabinoids, but remain cool enough to avoid the smoke and toxins associated with combustion. Vaporized cannabis should create fewer respiratory symptoms than smoked cannabis. We examined self-reported respiratory symptoms in participants who ranged in cigarette and cannabis use. Data from a large Internet sample revealed that the use of a vaporizer predicted fewer respiratory symptoms even when age, sex, cigarette smoking, and amount of cannabis used were taken into account. Age, sex, cigarettes, and amount of cannabis also had significant effects. The number of cigarettes smoked and amount of cannabis used interacted to create worse respiratory problems. A significant interaction revealed that the impact of a vaporizer was larger as the amount of cannabis used increased. These data suggest that the safety of cannabis can increase with the use of a vaporizer. Regular users of joints, blunts, pipes, and water pipes might decrease respiratory symptoms by switching to a vaporizer

  8. Sintomas depressivos e uso de Cannabis em adolescentes Síntomas depresivos en adolescentes usuarios de Cannabis Depressive symptoms in young Cannabis users

    Directory of Open Access Journals (Sweden)

    Tânia Moraes Ramos Andrade

    2008-09-01

    Full Text Available A depressão é um dos transtornos psiquiátricos mais comuns na adolescência. Os quadros depressivos costumam apresentar elevadas taxas de comorbidades psiquiátricas, sendo freqüente o abuso de substâncias psicoativas. O artigo investiga a associação dos sintomas depressivos e o uso da cannabis. MÉTODO: Revisão sistemática, análise dos artigos indexados no Medline, PsycInfo, ProQuest, Web of Science e Lilacs, entre 2000 e 2005, descritores: depressive symptoms, depressive, adolescence, teenager e cannabis. RESULTADOS: Revisados 36 artigos completos, resultando no estudo de 9 artigos, que tratam de sintomas depressivos ou depressão e o uso ou dependência de cannabis em adolescentes. Os estudos confirmam a associação entre sintomas depressivos e o uso de cannabis na adolescência, sendo esta associação mais freqüente no uso precoce e regular de cannabis. CONCLUSÃO: Os sintomas depressivos/depressão estão relacionados ao uso/abuso e dependência de cannabis na adolescência. A investigação clínica e os programas de prevenção devem abordar estes transtornos na adolescência.Este artículo busca investigar la asociación de los síntomas depresivos y el uso de cannabis en la adolescencia. MÉTODO: Ha sido realizado, a través de revisión sistemática, el análisis de los artículos indexados localizados en los sistemas Medline, PsycInfo, ProQuest, Web of Science y Lilacs, entre 2000 y 2005, utilizando los descriptores: depressive symptoms, depressive, adolescence, teenager y cannabis. RESULTADOS: La mayoría de los estudios confirma existir una asociación entre síntomas depresivos y el uso de cannabis en la adolescencia, cabe destacar que esta asociación es más frecuente en el uso precoz y regular de cañabais. CONCLUSIÓN: Los síntomas depresivos/Depresión están relacionados al uso/abuso y dependencia de cañabais en la adolescencia, siendo entonces importante que estas variables puedan ser investigadas en la práctica clínica como también en programas de prevención que aborden de forma simultánea estos síntomas/trastornos en este período de la vida.The association between depressive symptoms and cannabis use is investigated. Due to the fact that depression has been a common psyquiatric disorder in adolescence, depressive cases usually present high rates of psychiatric comorbidities and the abuse of psychoactive substances is frequent. Systematic review, studies at PsycInfo, ProQuest, Web of Science and Lilacs databases analyzed between 2000 and 2005 are discussed. Results show that nine out of the thirty-six studies discuss depression and cannabis use or addiction in adolescents. Whereas the association between depressive symptoms and the use of cannabis during adolescence is confirmed, it is more frequent in an early and continuous cannabis use. Research shows that depressive symptoms are related to cannabis use, abuse and dependence during adolescence. Abovementioned variables must be investigated in clinical practice and in prevention programs that simultaneously focus on these disorders.

  9. Sintomas depressivos e uso de Cannabis em adolescentes / Depressive symptoms in young Cannabis users / Síntomas depresivos en adolescentes usuarios de Cannabis

    Scientific Electronic Library Online (English)

    Tânia Moraes Ramos, Andrade; Irani Iracema de Lima, Argimon.

    2008-09-01

    Full Text Available A depressão é um dos transtornos psiquiátricos mais comuns na adolescência. Os quadros depressivos costumam apresentar elevadas taxas de comorbidades psiquiátricas, sendo freqüente o abuso de substâncias psicoativas. O artigo investiga a associação dos sintomas depressivos e o uso da cannabis. MÉTOD [...] O: Revisão sistemática, análise dos artigos indexados no Medline, PsycInfo, ProQuest, Web of Science e Lilacs, entre 2000 e 2005, descritores: depressive symptoms, depressive, adolescence, teenager e cannabis. RESULTADOS: Revisados 36 artigos completos, resultando no estudo de 9 artigos, que tratam de sintomas depressivos ou depressão e o uso ou dependência de cannabis em adolescentes. Os estudos confirmam a associação entre sintomas depressivos e o uso de cannabis na adolescência, sendo esta associação mais freqüente no uso precoce e regular de cannabis. CONCLUSÃO: Os sintomas depressivos/depressão estão relacionados ao uso/abuso e dependência de cannabis na adolescência. A investigação clínica e os programas de prevenção devem abordar estes transtornos na adolescência. Abstract in spanish Este artículo busca investigar la asociación de los síntomas depresivos y el uso de cannabis en la adolescencia. MÉTODO: Ha sido realizado, a través de revisión sistemática, el análisis de los artículos indexados localizados en los sistemas Medline, PsycInfo, ProQuest, Web of Science y Lilacs, entre [...] 2000 y 2005, utilizando los descriptores: depressive symptoms, depressive, adolescence, teenager y cannabis. RESULTADOS: La mayoría de los estudios confirma existir una asociación entre síntomas depresivos y el uso de cannabis en la adolescencia, cabe destacar que esta asociación es más frecuente en el uso precoz y regular de cañabais. CONCLUSIÓN: Los síntomas depresivos/Depresión están relacionados al uso/abuso y dependencia de cañabais en la adolescencia, siendo entonces importante que estas variables puedan ser investigadas en la práctica clínica como también en programas de prevención que aborden de forma simultánea estos síntomas/trastornos en este período de la vida. Abstract in english The association between depressive symptoms and cannabis use is investigated. Due to the fact that depression has been a common psyquiatric disorder in adolescence, depressive cases usually present high rates of psychiatric comorbidities and the abuse of psychoactive substances is frequent. Systemat [...] ic review, studies at PsycInfo, ProQuest, Web of Science and Lilacs databases analyzed between 2000 and 2005 are discussed. Results show that nine out of the thirty-six studies discuss depression and cannabis use or addiction in adolescents. Whereas the association between depressive symptoms and the use of cannabis during adolescence is confirmed, it is more frequent in an early and continuous cannabis use. Research shows that depressive symptoms are related to cannabis use, abuse and dependence during adolescence. Abovementioned variables must be investigated in clinical practice and in prevention programs that simultaneously focus on these disorders.

  10. State of the Art Treatments for Cannabis Dependence

    OpenAIRE

    Danovitch, Itai; Gorelick, David A.

    2012-01-01

    This article reviews established and emerging treatment options for cannabis dependence. Cannabis dependence poses some distinct challenges for treatment providers. The evolving sociocultural context of cannabis use for medical purposes, policy liberalization, and societal normalization has contributed to decreased perceived risk and increased acceptability of use. Simultaneously, the comparatively lower “severity” of cannabis-associated consequences makes it more difficult for some users to ...

  11. Negative consequences associated with dependence in daily cannabis users

    OpenAIRE

    Earleywine Mitch; Looby Alison

    2007-01-01

    Abstract Background Cannabis is the most widely consumed illicit substance in America, with increasing rates of use. Some theorists tend to link frequency of use with cannabis dependence. Nevertheless, fewer than half of daily cannabis users meet DSM-IV-TR criteria for cannabis dependence. This study seeks to determine whether the negative aspects associated with cannabis use can be explained by a proxy measure of dependence instead of by frequency of use. Results Over 2500 adult daily cannab...

  12. MDMA, cannabis, and cocaine produce acute dissociative symptoms.

    Science.gov (United States)

    van Heugten-Van der Kloet, Dalena; Giesbrecht, Timo; van Wel, Janelle; Bosker, Wendy M; Kuypers, Kim P C; Theunissen, Eef L; Spronk, Desirée B; Jan Verkes, Robbert; Merckelbach, Harald; Ramaekers, Johannes G

    2015-08-30

    Some drugs of abuse may produce dissociative symptoms, but this aspect has been understudied. We explored the dissociative potential of three recreational drugs (3,4-methylenedioxymethamphetamine (MDMA), cannabis, and cocaine) during intoxication and compared their effects to literature reports of dissociative states in various samples. Two placebo-controlled studies were conducted. In Study 1 (N=16), participants received single doses of 25, 50, and 100 mg of MDMA, and placebo. In Study 2 (N=21), cannabis (THC 300 µg/kg), cocaine (HCl 300 mg), and placebo were administered. Dissociative symptoms as measured with the Clinician-Administered Dissociative States Scale (CADSS) significantly increased under the influence of MDMA and cannabis. To a lesser extent, this was also true for cocaine. Dissociative symptoms following MDMA and cannabis largely exceeded those observed in schizophrenia patients, were comparable with those observed in Special Forces soldiers undergoing survival training, but were lower compared with ketamine-induced dissociation. Cocaine produced dissociative symptoms that were comparable with those observed in schizophrenia patients, but markedly less than those in Special Forces soldiers and ketamine users. Thus, MDMA and cannabis can produce dissociative symptoms that resemble dissociative pathology. The study of drug induced dissociation is important, because it may shed light on the mechanisms involved in dissociative psychopathology. PMID:26003508

  13. Are the symptoms of cannabis use disorder best accounted for by dimensional, categorical, or factor mixture models? A comparison of male and female young adults

    OpenAIRE

    Gillespie, Nathan A; Michael C. Neale; Legrand, Lisa N.; Iacono, William G.; McGue, Matt

    2011-01-01

    Despite the consensus that criteria for cannabis abuse and dependence and symptoms of withdrawal are best explained by a single latent liability, it remains unknown whether alternate models provide a better explanation of these criteria. A series of latent factor, latent class and hybrid factor mixture models were fitted to data from 872 recent cannabis users from the Minnesota Twin Family Study who completed DSM-III-R and DSM-IV diagnostic criteria for cannabis abuse, dependence and symptoms...

  14. IBD patients find symptom relief in the Cannabis field

    OpenAIRE

    Schicho, Rudolf; Storr, Martin

    2013-01-01

    Cannabis (or marijuana) has been used in traditional medicine to treat intestinal inflammation and is used as a self-medication by patients with inflammatory bowel disease (IBD). A survey by Ravikoff Allegretti et al. 1 at a specialized IBD clinic shows that, in the US, marijuana is used by a significant number of patients with IBD to alleviate their symptoms.

  15. Cross-sectional and prospective relation of cannabis potency, dosing and smoking behaviour with cannabis dependence: an ecological study

    OpenAIRE

    Pol, P., van de; Liebregts, N.; Brunt, T.; Amsterdam, J. van; Graaf, R de; Korf, D.J.; Brink, W. van den; van Laar, M

    2014-01-01

    Background and Aims Increased delta-9-tetrahydrocannabinol (THC) concentrations in cannabis may lead to higher THC exposure, cannabis dependence and treatment need, but users may also adapt the actual intake of THC through reduced inhalation of THC containing smoke (titration). We investigated whether consumers of stronger cannabis use less cannabis per joint or inhale less smoke than those using less potent cannabis and whether these factors predict cannabis dependence severity. Method...

  16. Dependent cannabis users at a music festival - prevalence and correlates

    DEFF Research Database (Denmark)

    Hesse, Morten; Tutenges, Sébastien

    2011-01-01

    Aim: In western countries, the most prevalent type of illicit substance-use dependence is cannabis dependence. This study aimed at estimating the prevalence of cannabis dependence among music festival visitors. Methods: Based on a survey of 380 music festival guests, we estimated the prevalence of cannabis dependence, as defined by a score of 3 or more on the Severity of Dependence Scale (SDS), as well as characteristics of cannabis dependent visitors. Results: 143 (38%) reported having used cannabis within the past year (past year cannabis users), and of these respondents, 21 (15%) screened positive for cannabis dependence. Compared to other cannabis users, the dependent respondents were more likely to be daily smokers, and they scored higher on self-reported sensation seeking. Compared with past-year non-users, both dependent users and non-dependent users were more likely to be men, weekly heavy drinkers, daily smokers and to score high on sensation seeking. Conclusions: Out of the past-year cannabis users recruited at a music festival, one in seven of those respondents showed indication of cannabis dependence. This suggests a need for both available treatment options and primary prevention of dependence.

  17. Cannabis Use and Dependence among French Schizophrenic Inpatients

    Science.gov (United States)

    Lejoyeux, Michel; Basquin, Anne; Koch, Marie; Embouazza, Houcine; Chalvin, Florence; Ilongo, Michaelle

    2014-01-01

    Background: To assess the prevalence of cannabis use and dependence in a population of schizophrenic inpatients and to compare schizophrenics with and without cannabis consumption. Methods: One hundred one schizophrenic patients were examined during their first week of hospitalization. They answered the PANNS scale of schizophrenia, the CAGE and the Fagerström questionnaire, and the DSM-IV-TR criteria for cannabis, alcohol, opiates, and nicotine use dependence were checked. We also assessed socio-demographic characteristics, the motive of cannabis consumption, and the number of cannabis joints and alcoholic drinks taken. Results: The prevalence of cannabis consumption was 33.6% among schizophrenic inpatients. Schizophrenics consuming cannabis were younger than non-schizophrenics (33.3 vs. 44.7?years p?cannabis consumers were dependent on cannabis. They were more often dependent on opiates (17 vs. 0%) and alcohol (32 vs. 7.4%, p?=?0.001) and presented compulsive buying more often (48 vs. 27%, p?=?0.04). Logistic regression revealed that factors associated to cannabis consumption among schizophrenics were cannabis dependence, male gender, pathological gambling, opiate dependence, number of joints smoked each day, and compulsive buying. Conclusion: 33.6% of the schizophrenic patients hospitalized in psychiatry consume cannabis and most of them are dependent on cannabis and alcohol. Hospitalization in psychiatry may provide an opportunity to systematically identify a dependence disorder and to offer appropriate information and treatment. PMID:25076916

  18. Time-course of the DSM-5 cannabis withdrawal symptoms in poly-substance abusers

    DEFF Research Database (Denmark)

    Hesse, Morten; Thylstrup, Birgitte

    2013-01-01

    Background Evidence is accumulating that a cannabis withdrawal syndrome is common, of clinical significance, and has a clear time course. Up till now, very limited data exist on the cannabis withdrawal symptoms in patients with co-morbid substance use disorders, other than cannabis use and tobacco use. Methods Symptoms of withdrawal were assessed through patient self-reports during detoxification in Danish residential rehabilitation centers. Patients (n = 90) completed booklets three times during their first month at the treatment centre. Self-reported withdrawal symptoms was rated using the DSM-5 Withdrawal Symptom Check List with withdrawal symptoms from all classes of substances, with no indication that the described symptoms should be attributed to withdrawal. Self-reported time since last use of cannabis was used as a predictor of cannabis withdrawal severity. Results With the exception of loss of appetite, time since last use of cannabis was associated with all types of withdrawal symptoms listed in the DSM-5. Only four of 19 symptoms intended to measure withdrawal from other substances were related to time since last use of cannabis, including vivid, unpleasant dreams. Conclusions The findings yield strong support to the notion of a cannabis withdrawal syndrome, and gives further evidence for the inclusion of the criterion of vivid, unpleasant dreams. Further, the findings speak against the significance of demand characteristics in determining the course of the symptoms of cannabis withdrawal.

  19. Cannabis use and dependence among French schizophrenic inpatients

    OpenAIRE

    MichelLejoyeux

    2014-01-01

    Background: To assess the prevalence of cannabis use and dependence in a population of schizophrenic inpatients and to compare schizophrenics with and without cannabis consumption. Methods: One hundred one schizophrenic patients were examined during their first week of hospitalization. They answered the PANNS scale of schizophrenia, the CAGE and the Fagerström questionnaire, and the DSM-IV-TR criteria for cannabis, alcohol, opiates, and nicotine use dependence were checked. We also assesse...

  20. Time-course of the DSM-5 cannabis withdrawal symptoms in poly-substance abusers

    DEFF Research Database (Denmark)

    Hesse, Morten; Thylstrup, Birgitte

    2013-01-01

    Background Evidence is accumulating that a cannabis withdrawal syndrome is common, of clinical significance, and has a clear time course. Up till now, very limited data exist on the cannabis withdrawal symptoms in patients with co-morbid substance use disorders, other than cannabis use and tobacco use. Methods Symptoms of withdrawal were assessed through patient self-reports during detoxification in Danish residential rehabilitation centers. Patients (n = 90) completed booklets three times durin...

  1. The Dutch Cannabis Dependence (CanDep) study on the course of frequent cannabis use and dependence: objectives, methods and sample characteristics

    OpenAIRE

    van der Pol, Peggy; Liebregts, Nienke; de Graaf, Ron; Korf, Dirk J; van den Brink, Wim; Van Laar, Margriet

    2011-01-01

    This paper presents an overview of the prospective cohort design of the Dutch Cannabis Dependence (CanDep) study, which investigates (i) the three-year natural course of frequent cannabis use (? three days per week in the past 12 months) and cannabis dependence; and (ii) the factors involved in the transition from frequent non-dependent cannabis use to cannabis dependence, and remission from dependence. Besides its scientific relevance, this knowledge may contribute to improve selective and i...

  2. Are the symptoms of cannabis use disorder best accounted for by dimensional, categorical, or factor mixture models? A comparison of male and female young adults.

    Science.gov (United States)

    Gillespie, Nathan A; Neale, Michael C; Legrand, Lisa N; Iacono, William G; McGue, Matt

    2012-03-01

    Despite the consensus that criteria for cannabis abuse and dependence and symptoms of withdrawal are best explained by a single latent liability, it remains unknown whether alternative models provide a better explanation of these criteria. A series of latent factor, latent class, and hybrid factor mixture models were fitted to data from 872 recent cannabis users from the Minnesota Twin Family Study who completed Diagnostic and Statistical Manual of Mental Disorders (3rd ed., revised, and 4th ed.) diagnostic criteria for cannabis abuse, dependence, and symptoms of withdrawal. Despite theoretical appeal, results did not support latent class or factor mixture modeling. Instead, symptoms of abuse, dependence, and withdrawal were better summarized by a single latent factor Cannabis Use Disorder (CUD) for male and female young adults. An almost 2-fold sex difference in item endorsement was best explained by a single mean difference on the CUD factor, indicating that young men have a greater latent liability toward expressing CUD. PMID:22082343

  3. Cannabis use and childhood trauma interact additively to increase the risk of psychotic symptoms in adolescence.

    LENUS (Irish Health Repository)

    Harley, M

    2010-10-01

    Adolescent cannabis use has been shown in many studies to increase the risk of later psychosis. Childhood trauma is associated with both substance misuse and risk for psychosis. In this study our aim was to investigate whether there is a significant interaction between cannabis use and childhood trauma in increasing the risk for experiencing psychotic symptoms during adolescence.

  4. Polysubstance Use in Cannabis Users Referred for Treatment: Drug Use Profiles, Psychiatric Comorbidity and Cannabis-Related Beliefs

    OpenAIRE

    Connor, Jason P; Gullo, Matthew J.; Chan, Gary; Young, Ross McD.; Hall, Wayne D.; Feeney, Gerald F. X.

    2013-01-01

    Background: Population-based surveys demonstrate cannabis users are more likely to use both illicit and licit substances, compared with non-cannabis users. Few studies have examined the substance use profiles of cannabis users referred for treatment. Co-existing mental health symptoms and underlying cannabis-related beliefs associated with these profiles remains unexplored. Methods: Comprehensive drug use and dependence severity (Severity of Dependence Scale-Cannabis) data were collected o...

  5. Polysubstance use in cannabis users referred for treatment: Drug use profiles, psychiatric comorbidity and cannabis-related beliefs

    OpenAIRE

    JasonPaulConnor; RossMcDonaldYoung; GeraldF.X.Feeney

    2013-01-01

    Background: Population-based surveys demonstrate cannabis users are more likely to use both illicit and licit substances, compared with non-cannabis users. Few studies have examined the substance use profiles of cannabis users referred for treatment. Coexisting mental health symptoms and underlying cannabis-related beliefs associated with these profiles remains unexplored. Methods: Comprehensive drug use and dependence severity (Severity of Dependence Scale- Cannabis [SDS-C]) data were col...

  6. The role of study and work in cannabis use and dependence trajectories among young adult frequent cannabis users

    Directory of Open Access Journals (Sweden)

    NienkeLiebregts

    2013-08-01

    Full Text Available Life course theory considers events in study and work as potential turning points in deviance, including illicit drug use. This qualitative study explores the role of occupational life in cannabis use and dependence in young adults. Two and three years after the initial structured interview, 47 at baseline frequent cannabis users were interviewed in-depth about the dynamics underlying changes in their cannabis use and dependence. Overall, cannabis use and dependence declined, including interviewees who quit using cannabis completely, in particular with students, both during their study and after they got employed. Life course theory appeared to be a useful framework to explore how and why occupational life is related to cannabis use and dependence over time. Our study showed that life events in this realm are rather common in young adults and can have a strong impact on cannabis use. While sometimes changes in use are temporary, turning points can evolve from changes in educational and employment situations; an effect that seems to be related to the consequences of these changes in terms of amount of leisure time and agency (i.e. feelings of being in control.

  7. Actions of delta-9-tetrahydrocannabinol in cannabis: Relation to use, abuse, dependence

    OpenAIRE

    Cooper, Ziva D; Haney, Margaret

    2009-01-01

    Cannabis use disorders have been recently identified as a relevant clinical issue: a subset of cannabis smokers seeks treatment for their cannabis use, yet few succeed in maintaining long-term abstinence. The rewarding and positive reinforcing effects of the primary psychoactive component of smoked cannabis, delta-9-tetrahydrocannabinol (THC) are mediated by the cannabinoid CB1 receptor. The CB1 receptor has also been shown to mediate cannabinoid dependence and expression of withdrawal upon c...

  8. Maintenance Check-ups Following Treatment for Cannabis Dependence.

    Science.gov (United States)

    Walker, Denise D; Stephens, Robert S; Towe, Sheri; Banes, Kelsey; Roffman, Roger

    2015-09-01

    Substance use disorders, including cannabis use disorders and associated negative consequences, are best considered chronic and in need of continuing care. In contrast, most treatment efficacy studies evaluate a fixed number of intervention sessions at a single point in time. The present study evaluated the efficacy of posttreatment maintenance check-ups (MCUs) in maintaining and improving outcomes following nine sessions of motivational enhancement treatment/cognitive behavioral treatment (MET/CBT). Adults dependent on cannabis (n=74) were randomly assigned to the MCU or a no check-up (NCU) condition and followed up at 3- and 9-months. MCU sessions occurred 1 and 4months following the completion of the base treatment. Additional MET/CBT sessions were available to participants throughout the follow-up period. The MCUs specifically encouraged treatment re-entry for those showing ongoing signs of disorder. Participants in the MCU condition reported significantly greater abstinent rates at both follow-ups and were using on fewer days at the 3-month but not the 9-month follow-up. Contrary to hypotheses, MCU participants did not attend more additional treatment and differences in rates of cannabis use emerged prior to the first MCU session. Future research with longer follow-up periods and longer monitoring of outcomes is needed to fully evaluate the utility of MCUs or other forms of continuing care. PMID:25922136

  9. Adverse effects of cannabis.

    Science.gov (United States)

    2011-01-01

    Cannabis, Cannabis sativa L., is used to produce a resin that contains high levels of cannabinoids, particularly delta9-tetrahydrocannabinol (THC), which are psychoactive substances. Although cannabis use is illegal in France and in many other countries, it is widely used for its relaxing or euphoric effects, especially by adolescents and young adults. What are the adverse effects of cannabis on health? During consumption? And in the long term? Does cannabis predispose users to the development of psychotic disorders? To answer these questions, we reviewed the available evidence using the standard Prescrire methodology. The long-term adverse effects of cannabis are difficult to evaluate. Since and associated substances, with or without the user's knowledge. Tobacco and alcohol consumption, and particular lifestyles and behaviours are often associated with cannabis use. Some traits predispose individuals to the use of psychoactive substances in general. The effects of cannabis are dosedependent.The most frequently report-ed adverse effects are mental slowness, impaired reaction times, and sometimes accentuation of anxiety. Serious psychological disorders have been reported with high levels of intoxication. The relationship between poor school performance and early, regular, and frequent cannabis use seems to be a vicious circle, in which each sustains the other. Many studies have focused on the long-term effects of cannabis on memory, but their results have been inconclusive. There do not * About fifteen longitudinal cohort studies that examined the influence of cannabis on depressive thoughts or suicidal ideation have yielded conflicting results and are inconclusive. Several longitudinal cohort studies have shown a statistical association between psychotic illness and self-reported cannabis use. However, the results are difficult to interpret due to methodological problems, particularly the unknown reliability of self-reported data. It has not been possible to establish a causal relationship in either direction, because of these methodological limitations. In Australia, the marked increase in cannabis use has not been accompanied by an increased incidence of schizophrenia. On the basis of the available data, we cannot reach firm conclusions on whether or not cannabis use causes psychosis. It seems prudent to inform apparently vulnerable individuals that cannabis may cause acute psychotic decompensation, especially at high doses. Users can feel dependent on cannabis, but this dependence is usually psychological. Withdrawal symptoms tend to occur within 48 hours following cessation of regular cannabis use, and include increased irritability, anxiety, nervousness, restlessness, sleep difficulties and aggression. Symptoms subside within 2 to 12 weeks. Driving under the influence of cannabis doubles the risk of causing a fatal road accident. Alcohol consumption plays an even greater role. A few studies and a number of isolated reports suggest that cannabis has a role in the occurrence of cardiovascular adverse effects, especially in patients with coronary heart disease. Numerous case-control studies have investigated the role of cannabis in the incidence of some types of cancer. Its role has not been ruled out, but it is not possible to determine whether the risk is distinct from that of the tobacco with which it is often smoked. Studies that have examined the influence of cannabis use on the clinical course of hepatitis C are inconclusive. Alcohol remains the main toxic agent that hepatitis C patients should avoid. In practice, the adverse effects of low-level, recreational cannabis use are generally minor, although they can apparently be serious in vulnerable individuals. The adverse effects of cannabis appear overall to be less serious than those of alcohol, in terms of neuropsychological and somatic effects, accidents and violence. PMID:21462790

  10. Poorer frontolimbic white matter integrity is associated with chronic cannabis use, FAAH genotype, and increased depressive and apathy symptoms in adolescents and young adults

    Directory of Open Access Journals (Sweden)

    Skyler G. Shollenbarger

    2015-01-01

    Conclusions: Consistent with prior findings, cannabis use was associated with reduced frontolimbic WM integrity. WM integrity was also moderated by FAAH genotype, in that cannabis-using FAAH C/C carriers and A carrying controls had reduced WM integrity compared to control C/C carriers. Observed frontolimbic white matter abnormalities were linked with increased depressive and apathy symptoms in the cannabis users.

  11. Comorbid psychiatric disorders and stages of change in cannabis-dependent, treatment-seeking patients

    Scientific Electronic Library Online (English)

    Hercilio P., Oliveira; Andre, Malbergier.

    2014-05-13

    Full Text Available Objectives: To determine whether and to what extent cannabis dependence is associated with comorbid psychiatric disorders and specific stages of change in treatment-seeking patients. Methods: We evaluated 80 cannabis-dependent, treatment-seeking patients residing in an urban area. Data on cannabi [...] s dependence, psychiatric disorders, and motivation were obtained using the Schedules for Clinical Assessment in Neuropsychiatry and the University of Rhode Island Change Assessment (URICA). Results: A diagnosis of schizophrenia was found to correlate with lower motivation scores (p = 0.038), which could have a negative effect on adherence to treatment. Conclusion: The high prevalence of concurrent psychiatric disorders in cannabis-dependent patients should serve as a stimulus for early screening and treatment of such disorders. Health care professionals should be aware of the magnitude of this association to increase the level of motivation in cannabis-dependent patients with severe concurrent psychiatric disorders.

  12. Cannabis e humor / Cannabis and mood

    Scientific Electronic Library Online (English)

    Rafael Faria, Sanches; João Mazzoncini de Azevedo, Marques.

    2010-06-01

    Full Text Available OBJETIVO: Avaliar as relações entre o uso agudo e crônico de cannabis e alterações do humor. MÉTODO: Os artigos foram selecionados por meio de busca eletrônica no indexador PubMed. Capítulos de livros e as listas de referências dos artigos selecionados também foram revisados. RESULTADOS: Observam-se [...] elevados índices de comorbidade entre abuso/dependência de cannabis e transtornos afetivos em estudos transversais e em amostras clínicas. Estudos longitudinais indicam que, em longo prazo, o uso mais intenso de cannabis está relacionado com um risco maior de desenvolvimento de doença bipolar e, talvez, depressão maior em indivíduos inicialmente sem quadros afetivos; porém, os mesmos não encontraram maior risco de uso de cannabis entre aqueles com mania ou depressão sem esta comorbidade. Outra importante observação é que o uso de substâncias psicoativas em bipolares pode estar associado a uma série de características negativas, como dificuldade na recuperação dos sintomas afetivos, maior número de internações, piora na adesão ao tratamento, risco aumentado de suicídio, agressividade e a uma pobre resposta ao lítio. Tratamentos psicossociais e farmacológicos são indicados para o manejo da comorbidade entre cannabis e transtornos afetivos. CONCLUSÃO: As relações entre o uso de cannabis e alterações do humor são observadas tanto epidemiologicamente quanto nos contextos clínicos. Abstract in english OBJECTIVE: Evaluate the relationship between acute and chronic use of cannabis and mood changes. METHOD: Articles were selected by electronic search in PubMed. Chapters in books and reference lists of selected articles were also reviewed. As the research did not involve humans, there was no evaluati [...] on by a Research Ethics Committee. RESULTS: High rates of comorbidity between use/abuse/dependence of cannabis and affective disorders in longitudinal studies and in clinical samples were observed. Longitudinal studies indicate that, in long-term, the higher use of cannabis is associated with an increased risk of developing bipolar disorder, and probably, major depression in subjects initially without affective disorder, but was not found increased risk of cannabis use among those initially only with mania or depression. Another important observation is that substance abuse in bipolar patients may be associated with a number of negative characteristics, such as difficulty in recovering the affective symptoms, more hospitalizations, poor compliance with treatment, increased risk of suicide, aggression and a poor response to lithium. Psychosocial and pharmacological treatments are indicated for the management of comorbidity between cannabis and affective disorders. CONCLUSION: The relationship between cannabis use and mood changes are observed both in the epidemiological research and in the clinical settings.

  13. Cannabis e humor Cannabis and mood

    Directory of Open Access Journals (Sweden)

    Rafael Faria Sanches

    2010-06-01

    Full Text Available OBJETIVO: Avaliar as relações entre o uso agudo e crônico de cannabis e alterações do humor. MÉTODO: Os artigos foram selecionados por meio de busca eletrônica no indexador PubMed. Capítulos de livros e as listas de referências dos artigos selecionados também foram revisados. RESULTADOS: Observam-se elevados índices de comorbidade entre abuso/dependência de cannabis e transtornos afetivos em estudos transversais e em amostras clínicas. Estudos longitudinais indicam que, em longo prazo, o uso mais intenso de cannabis está relacionado com um risco maior de desenvolvimento de doença bipolar e, talvez, depressão maior em indivíduos inicialmente sem quadros afetivos; porém, os mesmos não encontraram maior risco de uso de cannabis entre aqueles com mania ou depressão sem esta comorbidade. Outra importante observação é que o uso de substâncias psicoativas em bipolares pode estar associado a uma série de características negativas, como dificuldade na recuperação dos sintomas afetivos, maior número de internações, piora na adesão ao tratamento, risco aumentado de suicídio, agressividade e a uma pobre resposta ao lítio. Tratamentos psicossociais e farmacológicos são indicados para o manejo da comorbidade entre cannabis e transtornos afetivos. CONCLUSÃO: As relações entre o uso de cannabis e alterações do humor são observadas tanto epidemiologicamente quanto nos contextos clínicos.OBJECTIVE: Evaluate the relationship between acute and chronic use of cannabis and mood changes. METHOD: Articles were selected by electronic search in PubMed. Chapters in books and reference lists of selected articles were also reviewed. As the research did not involve humans, there was no evaluation by a Research Ethics Committee. RESULTS: High rates of comorbidity between use/abuse/dependence of cannabis and affective disorders in longitudinal studies and in clinical samples were observed. Longitudinal studies indicate that, in long-term, the higher use of cannabis is associated with an increased risk of developing bipolar disorder, and probably, major depression in subjects initially without affective disorder, but was not found increased risk of cannabis use among those initially only with mania or depression. Another important observation is that substance abuse in bipolar patients may be associated with a number of negative characteristics, such as difficulty in recovering the affective symptoms, more hospitalizations, poor compliance with treatment, increased risk of suicide, aggression and a poor response to lithium. Psychosocial and pharmacological treatments are indicated for the management of comorbidity between cannabis and affective disorders. CONCLUSION: The relationship between cannabis use and mood changes are observed both in the epidemiological research and in the clinical settings.

  14. Mitigation of post-traumatic stress symptoms by Cannabis resin: a review of the clinical and neurobiological evidence.

    Science.gov (United States)

    Passie, Torsten; Emrich, Hinderk M; Karst, Matthias; Brandt, Simon D; Halpern, John H

    2012-01-01

    It is known from clinical studies that some patients attempt to cope with the symptoms of post-traumatic stress disorder (PTSD) by using recreational drugs. This review presents a case report of a 19-year-old male patient with a spectrum of severe PTSD symptoms, such as intense flashbacks, panic attacks, and self-mutilation, who discovered that some of his major symptoms were dramatically reduced by smoking cannabis resin. The major part of this review is concerned with the clinical and preclinical neurobiological evidence in order to offer a potential explanation of these effects on symptom reduction in PTSD. This review shows that recent studies provided supporting evidence that PTSD patients may be able to cope with their symptoms by using cannabis products. Cannabis may dampen the strength or emotional impact of traumatic memories through synergistic mechanisms that might make it easier for people with PTSD to rest or sleep and to feel less anxious and less involved with flashback memories. The presence of endocannabinoid signalling systems within stress-sensitive nuclei of the hypothalamus, as well as upstream limbic structures (amygdala), point to the significance of this system for the regulation of neuroendocrine and behavioural responses to stress. Evidence is increasingly accumulating that cannabinoids might play a role in fear extinction and antidepressive effects. It is concluded that further studies are warranted in order to evaluate the therapeutic potential of cannabinoids in PTSD. PMID:22736575

  15. Pericyazine in the treatment of cannabis dependence in general practice: a naturalistic pilot trial

    Directory of Open Access Journals (Sweden)

    Morley KC

    2012-05-01

    Full Text Available Kirsten C Morley,1 Paul S Haber,1,2 Madeleine L Morgan,3 Fares Samara3,41Discipline of Addiction Medicine, Sydney Medical School, University of Sydney, NSW, Australia; 2Drug Health Services, Royal Prince Alfred Hospital, Camperdown, NSW, Australia; 3Drug and Alcohol Services, North Coast Area Health Service, Kempsey and Port Macquarie, NSW, Australia; 4Durri Aboriginal Medical Service, Kempsey, NSW, AustraliaAbstract: Cannabis is one of the most widely used illicit drugs worldwide. However, while the rates of cannabis dependence and treatment increase, there remains no medications approved for this use. Due to its sedative effects and low abuse liability, the typical antipsychotic pericyazine has been utilized in some parts of Australia for the treatment of cannabis dependence. We aimed to provide documentation of preliminary outcomes and acceptability of pericyazine treatment in a small sample. A naturalistic case series study was conducted in which 21 patients were enrolled for a 4-week course of pericyazine (up to 8 × 2.5 mg tablets daily and weekly medical review. Levels of cannabis use were reported and side effects with electrocardiography and blood tests were monitored. Measures of dependence severity, depression, anxiety, and insomnia were taken at baseline and follow-up utilizing validated psychometric tools. Significant reductions in cannabis use, depression, anxiety, and insomnia severity occurred across time. Pericyazine appeared to be well tolerated and easily administered in the community clinics. The results provide some preliminary evidence that low-dose short-term pericyazine may be an acceptable mode of treatment in this population. Given the open-label nature of the design, we cannot conclude that pharmacotherapy was uniquely responsible for the treatment effect. Nonetheless, low-dose pericyazine may be a potentially effective approach to the treatment of cannabis dependence, and further evaluation via a randomized placebo-controlled trial is warranted.Keywords: cannabis, antipsychotic, pharmacotherapy, addiction, pericyazine

  16. A multi-center, randomized controlled trial of a group psychological intervention for psychosis with comorbid cannabis dependence over the early course of illness.

    LENUS (Irish Health Repository)

    Madigan, Kevin

    2013-01-01

    Patients who experience the onset of psychotic illness with a comorbid diagnosis of cannabis dependence experience poor clinical outcomes. Few studies have identified interventions that reduce cannabis use and improve clinical outcome in this population.

  17. Clinical Trial of Abstinence-Based Vouchers and Cognitive-Behavioral Therapy for Cannabis Dependence

    Science.gov (United States)

    Budney, Alan J.; Moore, Brent A.; Rocha, Heath L.; Higgins, Stephen T.

    2006-01-01

    Ninety cannabis-dependent adults seeking treatment were randomly assigned to receive cognitive-behavioral therapy, abstinence-based voucher incentives, or their combination. Treatment duration was 14 weeks, and outcomes were assessed for 12 months post treatment. Findings suggest that (a) abstinence-based vouchers were effective for engendering…

  18. Change in cannabis use, clinical symptoms and social functioning among patients with first-episode psychosis

    DEFF Research Database (Denmark)

    Clausen, L; Hjorthøj, C R; Thorup, Anne A.E.; Jeppesen, P; Petersen, Lone Bente; Bertelsen, Mette; Nordentoft, M

    2014-01-01

    BACKGROUND: Several studies indicate that cannabis use among patients with psychotic disorders is associated with worse outcome, but only a few studies have controlled for baseline condition and medication. METHOD: At 5-year follow-up, interviews were carried out with 314 first-episode psychosis patients included in the OPUS trial. The patients included were in the age range of 18 to 45 years old and 59% were male. Cannabis use was extracted from the Schedule for Clinical Assessment in Neuropsyc...

  19. Specificity of Social Anxiety Disorder as a Risk Factor for Alcohol and Cannabis Dependence

    OpenAIRE

    Buckner, Julia D.; Schmidt, Norman B.; Lang, Alan R.; Small, Jason W.; Schlauch, Robert C.; Lewinsohn, Peter M.

    2007-01-01

    Social anxiety disorder (SAD) is highly comorbid with alcohol use disorders (AUDs) and cannabis dependence. However, the temporal sequencing of these disorders has not been extensively studied to determine whether SAD serves as a specific risk factor for problematic substance use. The present study examined these relationships after controlling for theoretically-relevant variables (e.g., gender, other Axis I pathology) in a longitudinal cohort over approximately 14 years. The sample was drawn...

  20. Psychosis and cannabis

    Directory of Open Access Journals (Sweden)

    Heinz Häfner

    2005-01-01

    Full Text Available Alcohol and cannabis misuse is currently the most frequent co-morbidity disorder of schizophrenia. The following four issues will be dealt with: 1 the neurobiological basis of the psychosis-inducing, pathogenic effects of THC, the agent contained in cannabis products. 2 Can cannabis use - and for comparison alcohol abuse - prematurely trigger or even cause schizophrenia? 3 Are persons genetically liable to schizophrenia, psychosis-prone individuals or young persons before completion of brain development at an increased risk? 4 What consequences does cannabis use have on the symptomatology and further course of schizophrenia? Results from recent literature and the ABC Schizophrenia Study show that the risk for cannabis use in schizophrenia is about twice the size in healthy controls. In most cases cannabis use starts before first admission, in a third of cases before schizophrenia onset. There is an increased affinity to misuse already at the prodromal stage. Cannabis can prematurely trigger schizophrenia onset - on average eight years earlier than in non-use - and cause the illness partly in interaction with predisposing factors. Cannabis use in the course of schizophrenia increases positive symptoms and reduces affective flattening, thus leading to dysfunctional coping in some cases.

  1. Psychosis and cannabis

    Scientific Electronic Library Online (English)

    Heinz, Häfner.

    Full Text Available Alcohol and cannabis misuse is currently the most frequent co-morbidity disorder of schizophrenia. The following four issues will be dealt with: 1) the neurobiological basis of the psychosis-inducing, pathogenic effects of THC, the agent contained in cannabis products. 2) Can cannabis use - and for [...] comparison alcohol abuse - prematurely trigger or even cause schizophrenia? 3) Are persons genetically liable to schizophrenia, psychosis-prone individuals or young persons before completion of brain development at an increased risk? 4) What consequences does cannabis use have on the symptomatology and further course of schizophrenia? Results from recent literature and the ABC Schizophrenia Study show that the risk for cannabis use in schizophrenia is about twice the size in healthy controls. In most cases cannabis use starts before first admission, in a third of cases before schizophrenia onset. There is an increased affinity to misuse already at the prodromal stage. Cannabis can prematurely trigger schizophrenia onset - on average eight years earlier than in non-use - and cause the illness partly in interaction with predisposing factors. Cannabis use in the course of schizophrenia increases positive symptoms and reduces affective flattening, thus leading to dysfunctional coping in some cases.

  2. Do patients think cannabis causes schizophrenia? - A qualitative study on the causal beliefs of cannabis using patients with schizophrenia

    Directory of Open Access Journals (Sweden)

    Schaub Michael

    2010-09-01

    Full Text Available Abstract Background There has been a considerable amount of debate among the research community whether cannabis use may cause schizophrenia and whether cannabis use of patients with schizophrenia is associated with earlier and more frequent relapses. Considering that studies exploring patients' view on controversial topics have contributed to our understanding of important clinical issues, it is surprising how little these views have been explored to add to our understanding of the link between cannabis and psychosis. The present study was designed to elucidate whether patients with schizophrenia who use cannabis believe that its use has caused their schizophrenia and to explore these patients other beliefs and perceptions about the effects of the drug. Methods We recruited ten consecutive patients fulfilling criteria for paranoid schizophrenia and for a harmful use of/dependence from cannabis (ICD-10 F20.0 + F12.1 or F12.2 from the in- and outpatient clinic of the Psychiatric University Hospital Zurich. They were interviewed using qualitative methodology. Furthermore, information on amount, frequency, and effects of use was obtained. A grounded theory approach to data analysis was taken to evaluate findings. Results None of the patients described a causal link between the use of cannabis and their schizophrenia. Disease models included upbringing under difficult circumstances (5 or use of substances other than cannabis (e. g. hallucinogens, 3. Two patients gave other reasons. Four patients considered cannabis a therapeutic aid and reported that positive effects (reduction of anxiety and tension prevailed over its possible disadvantages (exacerbation of positive symptoms. Conclusions Patients with schizophrenia did not establish a causal link between schizophrenia and the use of cannabis. We suggest that clinicians consider our findings in their work with patients suffering from these co-occurring disorders. Withholding treatment or excluding patients from certain treatment settings like day-care facilities or in patient care because of their use of cannabis, may cause additional harm to this already heavily burdened patient group.

  3. The Brisbane Longitudinal Twin Study Pathways to Cannabis Use, Abuse and Dependence Project: Current status, preliminary results and future directions

    OpenAIRE

    Gillespie, NA; Henders, AK; Davenport, TA; Hermens, DF; Wright, MJ; Martin, NG (Nick); Hickie, IB

    2012-01-01

    We describe the data being collected from the Brisbane Longitudinal Twin Study (BLTS) in Australia as part of the US National Institute on Drug Abuse (NIDA) funded project Pathways to Cannabis Use, Abuse and Dependence. The history, recruitment, assessment and retention of twin families in this project are described in detail along with preliminary findings and plans for future research. The goal of this NIDA project is to make a significant contribution to the discovery of quantitative trait...

  4. Cannabis withdrawal in adolescent treatment seekers

    OpenAIRE

    Vandrey, Ryan; Budney, Alan J.; Kamon, Jody L.; STANGER, CATHERINE

    2004-01-01

    A valid cannabis withdrawal syndrome has been demonstrated in controlled studies with adult marijuana abusers, yet few published reports have examined cannabis withdrawal among adolescents. Adolescents presenting for outpatient substance abuse treatment, whose primary substance of abuse was cannabis, completed a questionnaire reporting the presence and severity of withdrawal symptoms during past periods of cannabis abstinence. Nearly two-thirds of the sample indicated that they had experience...

  5. Change in cannabis use, clinical symptoms and social functioning among patients with first-episode psychosis : a 5-year follow-up study of patients in the OPUS trial

    DEFF Research Database (Denmark)

    Clausen, L; HjorthØj, C R

    2014-01-01

    BACKGROUND: Several studies indicate that cannabis use among patients with psychotic disorders is associated with worse outcome, but only a few studies have controlled for baseline condition and medication. METHOD: At 5-year follow-up, interviews were carried out with 314 first-episode psychosis patients included in the OPUS trial. The patients included were in the age range of 18 to 45 years old and 59% were male. Cannabis use was extracted from the Schedule for Clinical Assessment in Neuropsychiatry. At follow-up, the patients were divided into different groups according to the variable cannabis use: abstainers, stoppers, starters and continuers. Psychotic, negative and disorganized dimensions (ranging from zero to five) were calculated for each of the four groups based on the Schedule for the Assessment of Positive and Negative Symptoms in Schizophrenia. RESULTS: Cannabis users were younger (24.6 years v. 27.4 years, p < 0.001) and had a lower level of education. At the 5-year follow-up, users of cannabis had higher scores on the psychotic dimension [difference 0.97, 95% confidence interval (CI) 0.41-1.53, p = 0.001] and lower levels of the Global Assessment of Functioning (difference 8.26, 95% CI 2.13-14.39, p = 0.01). Those who stopped using cannabis between entry and 5-year follow-up had a significantly lower level of psychotic symptoms at 5-year follow-up even after controlling for baseline level of psychotic symptoms and for insufficient antipsychotic medication (adjusted difference in psychotic dimension -1.04, 95% CI -1.77 to -0.31, p = 0.006). CONCLUSIONS: Continuous cannabis use was associated with higher levels of psychotic symptoms after 5 years, and this association was only partly explained by insufficient antipsychotic medication.

  6. Concordance of Direct and Indirect Measures of Medication Adherence in A Treatment Trial for Cannabis Dependence.

    Science.gov (United States)

    McRae-Clark, Aimee L; Baker, Nathaniel L; Sonne, Susan C; DeVane, C Lindsay; Wagner, Amanda; Norton, Jessica

    2015-10-01

    The current study compared adherence rates as measured by two indirect measurement methods (pill count and daily medication diary) to two direct measurement methods (urine riboflavin and serum 6-OH-buspirone level measurement) among participants (n = 109) in a medication treatment trial for cannabis dependence. Pill count and diary data showed high levels of percent agreement and strong kappa coefficients throughout the study. Riboflavin levels indicated lower level of percent in adherence during the study as compared to both pill count and self-report. In the subset of participants with 6-OH-buspirone levels (n = 58), the kappa coefficient also showed low to moderate agreement between the pill count and medication diaries with 6-OH-buspirone levels. In contrast to pill count and medication diaries, adherence as measured by riboflavin and 6-OH-buspirone significantly decreased over time. The findings from this study support previous work demonstrating that pill count and patient self-report of medication taking likely overestimate rates of medication adherence, and may become less reliable as the duration of a clinical trial increases. PMID:26028133

  7. Mismatch negativity in tobacco-naïve cannabis users and its alteration with acute nicotine administration.

    Science.gov (United States)

    Impey, Danielle; El-Marj, Nicole; Parks, Andrea; Choueiry, Joelle; Fisher, Derek; Knott, Verner J

    2015-09-01

    Chronic cannabis use may interact with factors, such as age of onset of cannabis use, family history, and genetic factors, to elicit schizophrenia (SZ)-like symptoms, including sensory and cognitive deficits. However, evidence of a relationship between cannabis use and cognitive impairment is confounded by concomitant use of tobacco. The objective of this study was to compare tobacco-naïve cannabis users with individuals without a history of tobacco/cannabis use on the auditory mismatch negativity (MMN) event-related potential (ERP), a neural measure of auditory deviance detection which is diminished in SZ. An exploratory arm of the study, conducted within a randomized, double-blind, placebo controlled design, examined the acute effects of nicotine gum (6mg) on MMN in cannabis users. MMN was recorded in response to 5 deviant stimuli within an optimal MMN paradigm in 44 healthy, non-tobacco smoking volunteers aged 18-26. Cannabis users (n=21) started smoking cannabis prior to age 17, at least 1 joint per month. To examine the effects of chronicity, users were grouped into relatively heavy long-term (HLT; n=11) users and light short-term (LST; n=10) users. Impaired deviance detection was shown in cannabis users vs. nonusers as reflected by a smaller MMN to duration deviants. Chronicity of use was also associated with MMN alterations, as HLTs displayed a reduced duration and gap MMN vs. LSTs. Compared with placebo, nicotine treatment enhanced select MMN deviants in cannabis user subgroups. As deficits associated with early and persistent cannabis use are similar to those seen in SZ, these dose-dependant disturbances in early sensory processing with cannabis use may be one cognitive pathway which mediates an increased risk for SZ in vulnerable youth, and be influenced by concurrent cigarette smoking behavior. PMID:26188167

  8. Burnout among High-School Students and Cannabis Use, Consumption Frequencies, Abuse and Dependence

    Science.gov (United States)

    Walburg, Vera; Moncla, Dany; Mialhes, Aurélie

    2015-01-01

    Background: Cannabis is a substance frequently consumed by adolescents, which is a risk factor for many psychopathological disorders. At the same time, adolescents in high-schools are likely to be exposed to significant stress from school that can sometimes lead to a burnout syndrome. Objective: The purpose of this study is to explore the impact…

  9. Personality Characteristics of Adolescents with Hallucinogen, Methamphetamine, and Cannabis Dependence: A Comparative Study

    Science.gov (United States)

    Palmer, Glen A.; Daiss, Doyle D.

    2005-01-01

    A comparison of personality factors on scales of the Minnesota Multiphasic Personality Inventory-Adolescent (MMPI-A) was conducted with a sample of adolescents referred to a residential substance abuse treatment program. A total of sixty adolescents identified with hallucinogen (n = 20), cannabis (n = 20), or methamphetamine (n = 20) as their drug…

  10. Psychotropic and Nonpsychotropic Cannabis Derivatives Inhibit Human 5-HT3A receptors through a Receptor Desensitization-Dependent Mechanism

    OpenAIRE

    Xiong, Wei; Koo, Bon-Nyeo; Morton, Russell; Zhang, Li

    2011-01-01

    ?9 tetrahydrocannabinol (THC) and cannabidiol (CBD) are the principal psychoactive and non-psychoactive components of cannabis. While most THC-induced behavioral effects are thought to depend on endogenous cannabinoid 1 (CB1) receptors, the molecular targets for CBD remain unclear. Here, we report that CBD and THC inhibited the function of human 5-HT3A receptors (h5-HT3ARs) expressed in HEK 293 cells. The magnitude of THC and CBD inhibition was maximal 5 min after a continuous incubation with...

  11. Pericyazine in the treatment of cannabis dependence in general practice: a naturalistic pilot trial

    OpenAIRE

    Morley KC; Haber PS; Morgan ML; Samara F

    2012-01-01

    Kirsten C Morley,1 Paul S Haber,1,2 Madeleine L Morgan,3 Fares Samara3,41Discipline of Addiction Medicine, Sydney Medical School, University of Sydney, NSW, Australia; 2Drug Health Services, Royal Prince Alfred Hospital, Camperdown, NSW, Australia; 3Drug and Alcohol Services, North Coast Area Health Service, Kempsey and Port Macquarie, NSW, Australia; 4Durri Aboriginal Medical Service, Kempsey, NSW, AustraliaAbstract: Cannabis is one of the most widely used illicit drugs worldwide. However, w...

  12. Quality of Web-Based Information on Cannabis Addiction

    Science.gov (United States)

    Khazaal, Yasser; Chatton, Anne; Cochand, Sophie; Zullino, Daniele

    2008-01-01

    This study evaluated the quality of Web-based information on cannabis use and addiction and investigated particular content quality indicators. Three keywords ("cannabis addiction," "cannabis dependence," and "cannabis abuse") were entered into two popular World Wide Web search engines. Websites were assessed with a standardized proforma designed…

  13. Strain dependence of adolescent Cannabis influence on heroin reward and mesolimbic dopamine transmission in adult Lewis and Fischer 344 rats.

    Science.gov (United States)

    Cadoni, Cristina; Simola, Nicola; Espa, Elena; Fenu, Sandro; Di Chiara, Gaetano

    2015-01-01

    Adolescent Cannabis exposure has been hypothesized to act as a gateway to opiate abuse. In order to investigate the role of genetic background in cannabinoid-opiate interactions, we studied the effect of ?(9) -tetrahydrocannabinol (THC) exposure of adolescent Lewis and Fischer 344 rats on the responsiveness of accumbens shell and core dopamine (DA), as monitored by microdialysis, to THC and heroin at adulthood. Heroin reward and reinstatement by heroin priming were studied by conditioned place preference (CPP) and cognitive and emotional functions by object recognition, Y maze and elevated plus maze paradigms. THC stimulated shell DA in Lewis but not in Fischer 344 rats. Adolescent THC exposure potentiated DA stimulant effects of heroin in the shell and core of Lewis and only in the core of Fischer 344 rats. Control Lewis rats developed stronger CPP to heroin and resistance to extinction compared with Fischer 344 strain. In Lewis rats, THC exposure did not affect heroin CPP but potentiated the effect of heroin priming. In Fischer 344 rats, THC exposure increased heroin CPP and made it resistant to extinction. Lewis rats showed seeking reactions during extinction and hedonic reactions in response to heroin priming. Moreover, adolescent THC exposure affected emotional function only in Lewis rats. These observations suggest that long-term effects of Cannabis exposure on heroin addictive liability and emotionality are dependent on individual genetic background. PMID:23957273

  14. In vivo measurement of neuronal dopamine transporter in tobacco and cannabis dependents subjects with positron tomography and [11C]P E 2 I

    International Nuclear Information System (INIS)

    Modifications of dopamine neurotransmission are classically involved in addictive behaviors and drug reinforcement. However, to date no data are available concerning the effects of cannabis addiction on dopaminergic neurotransmission in Human. The neuronal dopamine transporter (D.A.T.) is essential for the maintenance of normal dopamine homeostasis in the brain by ensuring the re-uptake of extracellular dopamine. Therefore, observation of D.A.T. availability abnormalities in cannabis-dependents subjects could provide further evidence for the implication of dopaminergic dysfunction in this addiction. Thus, as the cannabis dependent subjects are also most of time tobacco-dependents, this work aims studying the D.A.T. availability in age-paired control, tobacco-dependent and cannabis-dependent male subjects using Positron Emission Tomography (PET). Subjects are scanned on High Resolution Research Tomograph (H.R.R.T.) for one hour after injection of a selective D.A.T. radioligand ([11C]P.E. 2 I.) [1]. The binding potential (B.P.) is calculated in order to obtained the specific binding of [11C]P.E. 2 I. to the D.A.T. using the simplified reference tissue model of Lammertsma (S.R.T.M.) [2] and B.P. maps were generated according to Gunn model [3]. Comparison of mean B.P. obtained in Region Of Interest and voxel to voxel comparison of B.P. maps using S.P.M.5 were performed with M.A.N.C.O.V.A. controlled for age between control, tobacco-dependent and cannabis-dependent groups. Preliminary results are concordant between both approaches and shown significant decreases of the D.A.T. availability in the both groups of addicted subjects in comparison to controls at the level of dorsal and ventral striatum and the dorsal midbrain including substantia nigra and ventral tegmental area. However, no difference in D.A.T. binding between tobacco and cannabis dependents subjects was observed. These widespread modifications of D.A.T. availability in the dependents subjects might reflect a modification of dopamine neurotransmission in cannabis and/or tobacco addictions. (authors)

  15. In vivo measurement of neuronal dopamine transporter in tobacco and cannabis dependents subjects with positron tomography and [{sup 11}C]P E 2 I

    Energy Technology Data Exchange (ETDEWEB)

    Leroy, C.; Ribeiro, M.J.; Trichard, C.; Martinot, J.L. [Institut National de la Sante et de la Recherche Medicale (INSERM), U797, Research Unit, Neuroimaging and Psychiatry, IFR49, 91 - Orsay (France); CEA, Neuroimaging and Psychiatry, Unit, Hospital Dept. Frederic Joliot, I2BM, 91 - Orsay (France); Ribeiro, M.J.; Comtat, C.; Dolle, F. [Hospital Dept. Frederic Joliot, Research Medical Dept., I2BM, 91 - Orsay (France); Karila, L.; Lukasiewicz, M.; Reynaud, M. [Paul Brousse Hospital, APHP, Psychiatry and Addictology Dept., 94 - Villejuif (France)

    2008-02-15

    Modifications of dopamine neurotransmission are classically involved in addictive behaviors and drug reinforcement. However, to date no data are available concerning the effects of cannabis addiction on dopaminergic neurotransmission in Human. The neuronal dopamine transporter (D.A.T.) is essential for the maintenance of normal dopamine homeostasis in the brain by ensuring the re-uptake of extracellular dopamine. Therefore, observation of D.A.T. availability abnormalities in cannabis-dependents subjects could provide further evidence for the implication of dopaminergic dysfunction in this addiction. Thus, as the cannabis dependent subjects are also most of time tobacco-dependents, this work aims studying the D.A.T. availability in age-paired control, tobacco-dependent and cannabis-dependent male subjects using Positron Emission Tomography (PET). Subjects are scanned on High Resolution Research Tomograph (H.R.R.T.) for one hour after injection of a selective D.A.T. radioligand ([{sup 11}C]P.E. 2 I.) [1]. The binding potential (B.P.) is calculated in order to obtained the specific binding of [{sup 11}C]P.E. 2 I. to the D.A.T. using the simplified reference tissue model of Lammertsma (S.R.T.M.) [2] and B.P. maps were generated according to Gunn model [3]. Comparison of mean B.P. obtained in Region Of Interest and voxel to voxel comparison of B.P. maps using S.P.M.5 were performed with M.A.N.C.O.V.A. controlled for age between control, tobacco-dependent and cannabis-dependent groups. Preliminary results are concordant between both approaches and shown significant decreases of the D.A.T. availability in the both groups of addicted subjects in comparison to controls at the level of dorsal and ventral striatum and the dorsal midbrain including substantia nigra and ventral tegmental area. However, no difference in D.A.T. binding between tobacco and cannabis dependents subjects was observed. These widespread modifications of D.A.T. availability in the dependents subjects might reflect a modification of dopamine neurotransmission in cannabis and/or tobacco addictions. (authors)

  16. QUELS FUTURS TRAITEMENTS POUR LA DEPENDANCE AU TABAC ET AU CANNABIS?

    OpenAIRE

    Le Foll, Bernard; JUSTINOVA, Zuzana; TANDA, Gianlugi; GOLDBERG, Steven R.

    2008-01-01

    Plus de trois millions de morts sont attribués au tabagisme dans le monde par an, et l’usage de tabac est en progression dans les pays en voie de développement. L’usage de tabac est donc une des rares causes de mortalité qui augmente, avec une prévision de plus de 10 millions de morts par an dans 30–40 ans. Le cannabis ou marijuana est la drogue illicite la plus consommée dans le monde et il n’y a actuellement pas de traitement disponible. Bien que les systèmes dopaminergiques jouent un rôle ...

  17. Two Sides of the Same Coin: Cannabis Dependence and Mental Health Problems in Help-Seeking Adolescent and Young Adult Outpatients

    Science.gov (United States)

    Norberg, Melissa M.; Battisti, Robert A.; Copeland, Jan; Hermens, Daniel F.; Hickie, Ian B.

    2012-01-01

    The aim of the current study was to delineate the psychiatric profile of cannabis dependent young people (14-29 years old) with mental health problems (N = 36) seeking treatment via a research study. To do so, the Structured Clinical Interview for DSM-IV-TR Axis I Disorders and the Structured Clinical Interview for DSM-IV Childhood Diagnoses were…

  18. QUELS FUTURS TRAITEMENTS POUR LA DEPENDANCE AU TABAC ET AU CANNABIS?

    Science.gov (United States)

    LE FOLL, Bernard; JUSTINOVA, Zuzana; TANDA, Gianlugi; GOLDBERG, Steven R.

    2009-01-01

    RESUME Plus de trois millions de morts sont attribués au tabagisme dans le monde par an, et l’usage de tabac est en progression dans les pays en voie de développement. L’usage de tabac est donc une des rares causes de mortalité qui augmente, avec une prévision de plus de 10 millions de morts par an dans 30–40 ans. Le cannabis ou marijuana est la drogue illicite la plus consommée dans le monde et il n’y a actuellement pas de traitement disponible. Bien que les systèmes dopaminergiques jouent un rôle central dans les effets renforçants des drogues, d’autres systèmes sont impliqués. Nous présentons ici des résultats récents obtenus avec des antagonistes des récepteurs cannabinoides CB1, des récepteurs D3 de la dopamine et des récepteurs opioïdes. Ces antagonistes qui modulent de façon directe ou indirecte la transmission dopaminergique cérébrale représentent des approches prometteuses pour le traitement du tabagisme ou de la dépendance au cannabis. Ces approches sont à valider dans des essais cliniques. PMID:18663981

  19. Infant with Altered Consciousness after Cannabis Passive Inhalation

    Science.gov (United States)

    Zarfin, Yehoshua; Yefet, Enav; Abozaid, Said; Nasser, Wael; Mor, Tamer; Finkelstein, Yoram

    2012-01-01

    We report on an infant who was admitted to hospital with severe neurological symptoms following passive inhalation of cannabis. To date, cannabis abuse has been described almost entirely in adolescents and adults. In early childhood, however, cannabis effects were almost exclusively discussed in the context of maternal prenatal exposure, and the…

  20. Abuso de cannabis em pacientes com transtornos psiquiátricos: atualização para uma antiga evidência Cannabis abuse in patients with psychiatric disorders: an update to old evidence

    Directory of Open Access Journals (Sweden)

    Alessandra Diehl

    2010-05-01

    Full Text Available OBJETIVO: Realizar uma atualização sobre o abuso de cannabis em pacientes com transtornos psiquiátricos. MÉTODO: Busca de artigos nas bases de dados eletrônicas Medline, The Cochrane Library Database, Lilacs, PubMed e SciELO, utilizando os descritores "marijuana abuse", "cannabis abuse", "psychiatric disorders" AND "mental disorders"; incluindo artigos que avaliaram ambas as exposições para abuso e dependência de cannabis e qualquer outro transtorno psiquiátrico. Foi considerado o período até dezembro de 2009. RESULTADOS: Observou-se que o abuso frequente de cannabis pode aumentar o risco para o desenvolvimento de esquizofrenia e de sintomas psicóticos crônicos, embora estes achados ainda careçam de comprovação. A cannabis parece ser uma das drogas de escolha de portadores de transtorno afetivo bipolar, sendo que é descrito que estados maníacos podem ser induzidos pelo seu consumo. O abuso de maconha também frequentemente co-ocorre em indivíduos com transtornos ansiosos, sendo que a relação de cronicidade destas condições e o consumo de maconha ainda é incerta. Para depressão ainda não existem evidências claras que apontem que o consumo de cannabis ocorre como forma de automedicação. Em indivíduos com transtornos psiquiátricos, há relatos de que o uso da cannabis pode exacerbar sintomas positivos, somar efeitos negativos no curso do transtorno, contribuir para pior adesão ao tratamento e levar a maior número de hospitalizações. CONCLUSÃO: O abuso de cannabis em pacientes com transtornos psiquiátricos como esquizofrenia, transtornos do humor e ansiosos tem impacto negativo tanto na fase aguda quanto em fases mais avançadas destas condições, embora futuros estudos avaliando estas associações ainda sejam necessários.OBJECTIVE: To perform an update on cannabis abuse by patients with psychiatric disorders. METHOD: A search was performed in the electronic databases Medline, The Cochrane Library Database, Lilacs, PubMed, and SciELO, using the keywords 'marijuana abuse', 'cannabis abuse', 'psychiatric disorders', and 'mental disorders'. Articles published until December 2009, dealing with cannabis abuse and dependence in association with other psychiatric disorders were included. RESULTS: Cannabis abuse was found to be associated with increased risk for the onset of schizophrenia and chronic psychotic symptoms, although these findings require confirmation from additional research. Cannabis seems to be one of the drugs of choice of individuals with bipolar disorder, despite evidence that manic states can be induced by its use. Cannabis abuse also occurs frequently in individuals with anxiety disorders, but the relationship between the chronic nature of these conditions and the use of marijuana remains uncertain. In respect to depression, there is no clear evidence to date that depressive patients use cannabis as a form of self-medication. In individuals with psychiatric disorders, the use of cannabis has been associated with increased positive symptoms, additional negative symptoms in the course of illness, impaired treatment compliance, and more hospitalizations. CONCLUSION: The abuse of cannabis by patients with psychiatric disorders such as schizophrenia and mood and anxious disorders has a negative impact both in the acute and advanced stages of these conditions, although further investigation on this association is still necessary.

  1. Abuso de cannabis em pacientes com transtornos psiquiátricos: atualização para uma antiga evidência / Cannabis abuse in patients with psychiatric disorders: an update to old evidence

    Scientific Electronic Library Online (English)

    Alessandra, Diehl; Daniel Cruz, Cordeiro; Ronaldo, Laranjeira.

    2010-05-01

    Full Text Available OBJETIVO: Realizar uma atualização sobre o abuso de cannabis em pacientes com transtornos psiquiátricos. MÉTODO: Busca de artigos nas bases de dados eletrônicas Medline, The Cochrane Library Database, Lilacs, PubMed e SciELO, utilizando os descritores "marijuana abuse", "cannabis abuse", "psychiatri [...] c disorders" AND "mental disorders"; incluindo artigos que avaliaram ambas as exposições para abuso e dependência de cannabis e qualquer outro transtorno psiquiátrico. Foi considerado o período até dezembro de 2009. RESULTADOS: Observou-se que o abuso frequente de cannabis pode aumentar o risco para o desenvolvimento de esquizofrenia e de sintomas psicóticos crônicos, embora estes achados ainda careçam de comprovação. A cannabis parece ser uma das drogas de escolha de portadores de transtorno afetivo bipolar, sendo que é descrito que estados maníacos podem ser induzidos pelo seu consumo. O abuso de maconha também frequentemente co-ocorre em indivíduos com transtornos ansiosos, sendo que a relação de cronicidade destas condições e o consumo de maconha ainda é incerta. Para depressão ainda não existem evidências claras que apontem que o consumo de cannabis ocorre como forma de automedicação. Em indivíduos com transtornos psiquiátricos, há relatos de que o uso da cannabis pode exacerbar sintomas positivos, somar efeitos negativos no curso do transtorno, contribuir para pior adesão ao tratamento e levar a maior número de hospitalizações. CONCLUSÃO: O abuso de cannabis em pacientes com transtornos psiquiátricos como esquizofrenia, transtornos do humor e ansiosos tem impacto negativo tanto na fase aguda quanto em fases mais avançadas destas condições, embora futuros estudos avaliando estas associações ainda sejam necessários. Abstract in english OBJECTIVE: To perform an update on cannabis abuse by patients with psychiatric disorders. METHOD: A search was performed in the electronic databases Medline, The Cochrane Library Database, Lilacs, PubMed, and SciELO, using the keywords 'marijuana abuse', 'cannabis abuse', 'psychiatric disorders', an [...] d 'mental disorders'. Articles published until December 2009, dealing with cannabis abuse and dependence in association with other psychiatric disorders were included. RESULTS: Cannabis abuse was found to be associated with increased risk for the onset of schizophrenia and chronic psychotic symptoms, although these findings require confirmation from additional research. Cannabis seems to be one of the drugs of choice of individuals with bipolar disorder, despite evidence that manic states can be induced by its use. Cannabis abuse also occurs frequently in individuals with anxiety disorders, but the relationship between the chronic nature of these conditions and the use of marijuana remains uncertain. In respect to depression, there is no clear evidence to date that depressive patients use cannabis as a form of self-medication. In individuals with psychiatric disorders, the use of cannabis has been associated with increased positive symptoms, additional negative symptoms in the course of illness, impaired treatment compliance, and more hospitalizations. CONCLUSION: The abuse of cannabis by patients with psychiatric disorders such as schizophrenia and mood and anxious disorders has a negative impact both in the acute and advanced stages of these conditions, although further investigation on this association is still necessary.

  2. A randomized controlled trial of a brief motivational enhancement for non-treatment-seeking adolescent cannabis users.

    Science.gov (United States)

    de Gee, Elisabeth A; Verdurmen, Jacqueline E E; Bransen, Els; de Jonge, Jannet M; Schippers, Gerard M

    2014-09-01

    Evidence for negative effects of early-onset cannabis use has led to a need for effective interventions targeting adolescent cannabis users. A randomized controlled trial of an Australian two-session intervention based on motivational interviewing (the ACCU, or Weed-Check in Dutch) was replicated in a larger Dutch sample of 119 non-treatment-seeking adolescent cannabis users. Outcome measures at the 3-month follow-up were quantity and frequency of cannabis use, symptoms of dependence, stage of change, and psychosocial functioning. Changes in all measures were in the expected direction, yet not significant. In moderation analyses, heavier cannabis users at baseline receiving the Weed-Check had greater reductions in cannabis use than those in the control condition. These results suggest that the Weed-Check might be beneficial for heavier cannabis-using adolescents. Further research is needed to confirm these results in a sample of adolescent heavy cannabis users and to examine the relationship between MI skills of prevention workers and outcome. PMID:24969735

  3. Cannabis cue-induced brain activation correlates with drug craving in limbic and visual salience regions: Preliminary results

    OpenAIRE

    Charboneau, Evonne J.; Dietrich, Mary S.; Park, Sohee; Cao, Aize; Watkins, Tristan J; Blackford, Jennifer U.; Benningfield, Margaret M; Peter R. Martin; BUCHOWSKI, MACIEJ S.; Cowan, Ronald L.

    2013-01-01

    Craving is a major motivator underlying drug use and relapse but the neural correlates of cannabis craving are not well understood. This study sought to determine whether visual cannabis cues increase cannabis craving and whether cue-induced craving is associated with regional brain activation in cannabis-dependent individuals. Cannabis craving was assessed in 16 cannabis-dependent adult volunteers while they viewed cannabis cues during a functional MRI (fMRI) scan. The Marijuana Craving Ques...

  4. Self-medication of achalasia with cannabis, complicated by a cannabis use disorder.

    Science.gov (United States)

    Luquiens, Amandine; Lourenco, Nelson; Benyamina, Amine; Aubin, Henri-Jean

    2015-05-28

    Achalasia is a rare esophagus motility disorder. Medical, endoscopic and surgical treatments are available, but all endorse high relapse rates. No data has been published to date reporting a therapeutic effect of cannabis use neither in achalasia nor on its influence on manometric measurements. We report the case of a patient diagnosed with achalasia. He could benefit from a large panel of therapeutic interventions, but none of them was effective over the time. He first used cannabis at age 20 and identified benefits regarding achalasia symptoms. He maintained regular moderate cannabis use for 9 years, with minimal digestive inconvenience. A manometry performed without cannabis premedication was realized at age 26 and still found a cardiospasm. Cannabis use could explain the gap between functional symptoms assessment and manometry measurement. Further investigations are warranted to explore a therapeutic effect of cannabis in achalasia and possible influence on outcome measurements. PMID:26034374

  5. Cannabis abuse in patients with schizophrenia pattern and effects on symptomatology

    International Nuclear Information System (INIS)

    To determine the relationship between cannabis abuse and its impact on the short-term outcome and severity of illness. ICD-10 criteria were used for diagnosis of schizophrenia. Severity and type of schizophrenic symptoms were assessed with the help of PANSS. Cases were identified as having problem with cannabis use with the help of section 12 of Schedule for Clinical Assessment in Neuropsychiatry (SCAN) W.H.O. 1994. Amount, duration and frequency of cannabis use was also noted. Patients with cannabis use were younger had shorter duration of illness and earlier age at onset of illness. They exhibited more positive symptoms. A total of 20% cases met ICD-10 criteria of harmful use of cannabinoid, 76% met ICD-10 criteria of cannabinoid dependence syndrome. Schizophrenic patients with comorbid cannabis abuse exhibited more positive symptoms and violent behavior, and may be more likely to lead to dependence in persons with schizophrenia. This has implication for service development to meet the perceived needs of this group. (author)

  6. Does liberalizing cannabis laws increase cannabis use?

    OpenAIRE

    WILLIAMS, JENNY; Bretteville-Jensen, Anne Line

    2014-01-01

    A key question in the ongoing policy debate over cannabis' legal status is whether liberalizing cannabis laws leads to an increase in cannabis use. This paper provides new evidence on the impact of a specific type of liberalization, decriminalization, on initiation into cannabis use. Our identification strategy exploits variation in the timing of cannabis policy reforms and our estimation framework marries a difference-in-difference approach with a discrete time duration model. Our results re...

  7. How high: Quantity as a predictor of cannabis-related problems

    Directory of Open Access Journals (Sweden)

    Earleywine Mitch

    2008-05-01

    Full Text Available Abstract Background Research on cannabis use has emphasized frequency as a predictor of problems. Studies of other drugs reveal that frequency relates to psychological and physiological outcomes, but quantity also plays an important role. In the study of cannabis, quantity has been difficult to assess due to the wide range of products and means of consumption. Methods The present study introduces three new measures of quantity, and examines their contribution to cannabis-related problems. Over 5,900 adults using cannabis once or more per month completed an internet survey that inquired about use, dependence, social problems and respiratory health. In addition to detailing their frequency of cannabis use, participants also reported three measures of quantity: number of quarter ounces consumed per month, usual intensity of intoxication, and maximum intensity of intoxication. Results Frequency of use, monthly consumption, and levels of intoxication predicted respiratory symptoms, social problems and dependence. What is more, each measure of quantity accounted for significant variance in outcomes after controlling for the effects of frequency. Conclusion These findings indicate that quantity is an important predictor of cannabis-related outcomes, and that the three quantity measures convey useful information about use.

  8. What predicts incident use of cannabis and progression to abuse and dependence? A 4-year prospective examination of risk factors in a community sample of adolescents and young adults

    OpenAIRE

    Sydow , Kirsten von; Lieb, Roselind; Pfister, Hildegard; Höfler, Michael; Wittchen, Hans-Ulrich

    2013-01-01

    Objectives: To determine risk factors of incident onset of use, abuse and dependence of cannabis in a community sample of adolescents and young adults. Methods: Risk factors were examined in a prospective longitudinal design across 4 years in a representative sample (N=2446) aged 14-24 at the outset of the study (EDSP). Patterns of DSM-IV defined cannabis use, abuse and dependence were assessed with the Composite International Diagnostic Interview (M-CIDI). Potential risk factors were ass...

  9. [Cannabis use and impairment of respiratory function].

    Science.gov (United States)

    Underner, M; Urban, T; Perriot, J; Peiffer, G; Meurice, J-C

    2013-04-01

    Cannabis is the most commonly smoked illicit substance in many countries including France. It can be smoked alone in plant form (marijuana) but in our country it is mainly smoked in the form of cannabis resin mixed with tobacco. The technique of inhaling cannabis differs from that of tobacco, increasing the time that the smoke spends in contact with the bronchial mucosal and its impact on respiratory function. One cigarette composed of cannabis and tobacco is much more harmful than a cigarette containing only tobacco. In cannabis smokers there is an increased incidence of respiratory symptoms and episodes of acute bronchitis. Cannabis produces a rapid bronchodilator effect; chronic use provokes a reduction in specific conductance and increase in airways resistance. Studies on the decline of Forced Expiratory Volume are discordant. Cannabis smoke and tetrahydrocannabinol irritate the bronchial tree. They bring about histological signs of airways inflammation and alter the fungicidal and antibacterial activity of alveolar macrophages. Inhalation of cannabis smoke is a risk factor for lung cancer. Stopping smoking cannabis will bring about important benefits for lung function. This should encourage clinicians to offer patients support in quitting smoking. PMID:23664286

  10. Epilepsy and Cannabis Treatment

    Science.gov (United States)

    ... news/2_Epilepsy_Cannabis_091015.html Epilepsy and Cannabis Treatment HealthDay News Video - September 11, 2015 To ... page, please enable JavaScript. Play video: Epilepsy and Cannabis Treatment For closed captioning, click the CC button ...

  11. Epilepsy and Cannabis Treatment

    Medline Plus

    Full Text Available ... Videos & Tools You Are Here: Home ? Latest Health News ? Epilepsy and Cannabis Treatment URL of this page: https://www.nlm.nih.gov/medlineplus/videos/news/2_Epilepsy_Cannabis_091015.html Epilepsy and Cannabis ...

  12. Epilepsy and Cannabis Treatment

    Medline Plus

    Full Text Available ... the New England Journal of Medicine reviews available research on cannabis-based treatments to control epilepsy, which ... status of cannabis-derived drugs could accelerate scientific research and help determine whether cannabis-based treatments should ...

  13. Paradoxical Decrease in Striatal Activation on an fMRI Reward Task Following Treatment in Youth with Co-morbid Cannabis Dependence/Major Depression

    OpenAIRE

    Cornelius, Jack R; Aizenstein, Howard J; Chung, Tammy A.; DOUAIHY, Antoine; Hayes, Jeanine; DALEY, DENNIS; Salloum, Ihsan M.

    2012-01-01

    Reward behavior, including reward behavior involving drugs, has been shown to be mediated by the ventral striatum and related structures of the reward system. The aim of this study was to assess reward-related activity as shown by fMRI before and after treatment among youth with comorbid cannabis dependence and major depression. We hypothesized that the reward task (Delgado et al., 2003) would elicit activation in the reward system, and that the level of activation in response to reward would...

  14. Clinical service desires of medical cannabis patients

    OpenAIRE

    Janichek Jennifer L; Reiman Amanda

    2012-01-01

    Abstract Background Medical cannabis dispensaries following the social or hybrid model offer supplementary holistic services in addition to dispensing medical cannabis. Historically, alternative physical health services have been the norm for these dispensaries, including services such as yoga, acupuncture, or chiropractor visits. A clinical service dearth remains for medical cannabis patients seeking substance use, misuse, dependence, and mental health services. This study examined patient d...

  15. Successful and unsuccessful cannabis quitters: Comparing group characteristics and quitting strategies

    Directory of Open Access Journals (Sweden)

    Rooke Sally E

    2011-11-01

    Full Text Available Abstract Background In order to improve treatments for cannabis use disorder, a better understanding of factors associated with successful quitting is required. Method This study examined differences between successful (n = 87 and unsuccessful (n = 78 cannabis quitters. Participants completed a questionnaire addressing demographic, mental health, and cannabis-related variables, as well as quitting strategies during their most recent quit attempt. Results Eighteen strategies derived from cognitive behavioral therapy were entered into a principal components analysis. The analysis yielded four components, representing (1 Stimulus Removal, (2 Motivation Enhancement, (3 (lack of Distraction, and (4 (lack of Coping. Between groups comparisons showed that unsuccessful quitters scored significantly higher on Motivation Enhancement and (lack of Coping. This may indicate that unsuccessful quitters focus on the desire to quit, but do not sufficiently plan strategies for coping. Unsuccessful quitters also had significantly more symptoms of depression and stress; less education; lower exposure to formal treatment; higher day-to-day exposure to other cannabis users; and higher cannabis dependence scores. Conclusions The findings suggest that coping, environmental modification, and co-morbid mental health problems may be important factors to emphasize in treatments for cannabis use disorder.

  16. Pathways to psychosis in cannabis abuse.

    Science.gov (United States)

    Shrivastava, Amresh; Johnston, Megan; Terpstra, Kristen; Bureau, Yves

    2015-04-01

    Cannabis has been implicated as a risk factor for the development of schizophrenia, but the exact biological mechanisms remain unclear. In this review, we attempt to understand the neurobiological pathways that link cannabis use to schizophrenia. This has been an area of great debate; despite similarities between cannabis users and schizophrenia patients, the evidence is not sufficient to establish cause-and-effect. There have been advances in the understanding of the mechanisms of cannabis dependence as well as the role of the cannabinoid system in the development of psychosis and schizophrenia. The neurobiological mechanisms associated with the development of psychosis and effects from cannabis use may be similar but remain elusive. In order to better understand these associations, this paper will show common neurobiological and neuroanatomical changes as well as common cognitive dysfunction in cannabis users and patients of schizophrenia. We conclude that epidemiologic evidence highlights potential causal links; however, neurobiological evidence for causality remains weak. PMID:23491968

  17. Applying a Social Determinants of Health Perspective to Early Adolescent Cannabis Use--An Overview

    Science.gov (United States)

    Hyshka, Elaine

    2013-01-01

    Cannabis is the most widely used illicit drug in the world. Although the risk of problematic cannabis use is relatively low, the lifetime prevalence of dependence is greater than for all other illicit drugs. As such, the population burden of problematic cannabis use warrants attention. Many health and psychosocial risks associated with cannabis

  18. [Cannabis - therapy for the future?].

    Science.gov (United States)

    Hajer, Jan

    2015-01-01

    Despite all the progress achieved in the treatment of chronic gastrointestinal diseases, in some patients the treatment does not reach long-term optimum effectiveness. Therefore a number of patients have turned to complementary and alternative medicine (CAM). Of the different types of CAM patients with GIT diseases tend to prefer in particular homeopathy, acupuncture and not least phytotherapy, where therapeutic use of cannabis may also be included. The pathophysiological basis of therapeutic effect of curative cannabis has not been fully clarified so far. Many scientists in many fields of medicine and pharmacology have been engaged in the study of effects of cannabinoids on the body since the beginning of the 20th century with the interest significantly increasing in the 1980s. The discovery of CB receptors (1988) and endogenous molecules which activate these receptors (1992) led to the discovery of the endocannabinoid system. Pharmacological modulation of the endogenous cannabinoid system offers new therapeutic possibilities of treatment of many illnesses and symptoms including the GIT disorders, including of nausea, vomiting, cachexia, IBS, Crohns disease and some other disorders. Cannabinoids are attractive due to their therapeutic potential - they affect a lot of symptoms with minimum side effects. Experience of patients with GIT disorders show that the use of cannabis is effective and helps in cases where the standard therapy fails.Key words: cannabis - endocannabinoid system - phytotherapy - complementary alternative medicine (CAM). PMID:26375695

  19. Cocaine withdrawal symptoms identify "Type B" cocaine-dependent patients.

    Science.gov (United States)

    Ahmadi, Jamshid; Kampman, Kyle; Dackis, Charles; Sparkman, Thorne; Pettinati, Helen

    2008-01-01

    Recent studies of substance dependence typologies briefly show that multivariate systems originally developed for identifying subtypes of alcoholics, such as Babor's Type A and B system, may also be valid in abusers of other substances, such as cocaine. Type B patients are characterized by an earlier onset of addiction and more severe symptoms of their addiction, psychopathology, and impulsivity. The Type B classification has also been associated with deficits in serotonergic function. We have found that patients who exhibit more severe cocaine withdrawal symptoms, as measured by scores on the Cocaine Selective Severity Assessment (CSSA), have poor treatment outcome and share many characteristics with "Type B" patients. In this paper, we review baseline characteristics of cocaine-dependent patients from several recently completed outpatient cocaine dependence treatment trials to assess the association of cocaine withdrawal symptom severity and the Type B profile. Identifying subtypes of cocaine-dependent patients may improve our ability to treat cocaine dependence by targeting treatments for specific subtypes of patients. We examined the ability of the CSSA scores to capture Type B characteristics in cocaine dependence by analyzing a series of cocaine medication trials that included 255 cocaine-dependent subjects. High CSSA scores at baseline were associated with a history of violent behavior, a family history of substance abuse, antisocial personality disorder, higher addiction severity, and co-morbid psychiatric diseases. Patients with high CSSA scores are also more likely to meet criteria for Type B (Type II) cocaine dependence. Identifying Type B cocaine-dependent patients may help to develop targeted psychosocial or pharmacological treatments for these difficult-to-treat patients. PMID:18214724

  20. Screening of cannabis-related problems among youth: the CPQ-A-S and CAST questionnaires

    Directory of Open Access Journals (Sweden)

    Fernandez-Artamendi Sergio

    2012-04-01

    Full Text Available Abstract Background Cannabis use among young people is a significant problem, making particularly necessary validated screening instruments that permit secondary prevention. The purpose of this study was to analyze and compare the psychometric properties of the CAST and CPQ-A-S questionnaires, two screening instruments specifically addressing the youth population. Methods Information was obtained on sociodemographics, frequency of substance use, psychopathological symptoms and cannabis-use problems, and the CPQ-A-S and CAST were applied, as well as an infrequency scale for discarding responses made randomly. The sample was made up of 144 young people aged 16 to 20 that had used cannabis in the last month, of which 71.5% were boys. Mean age of the sample was 17.38 years (SD = 1.16. Results The results show that from the psychometric point of view both the CAST and the CPQ-A-S are good screening instruments. Conclusions The CAST is shorter and presents slightly better internal consistency than the CPQ-A-S. Both instruments show high sensitivity and specificity in the detection of young people dependent on cannabis according to the DSM IV-TR criteria. The CPQ-A-S appears to show greater capacity for detecting psychopathological distress associated with use. Both questionnaires yield significant odds ratios as predictors of frequent cannabis use and of the DSM IV-TR abuse and dependence criteria. In general, the CPQ-A-S emerges as a better predictor than the CAST.

  1. Impact of Cannabis Use on the Development of Psychotic Disorders

    OpenAIRE

    Wilkinson, Samuel T.; Radhakrishnan, Rajiv; D’Souza, Deepak Cyril

    2014-01-01

    The link between cannabis use and psychosis comprises three distinct relationships: acute psychosis associated with cannabis intoxication, acute psychosis that lasts beyond the period of acute intoxication, and persistent psychosis not time-locked to exposure. Experimental studies reveal that cannabis, tetrahydrocannabinol (THC) and synthetic cannabinoids reliably produce transient positive, negative, and cognitive symptoms in healthy volunteers. Case-studies indicate that cannabinoids can in...

  2. Neurobiologia da Cannabis: do sistema endocanabinoide aos transtornos por uso de Cannabis / Neurobiology of Cannabis: from the endocannabinoid system to cannabis-related disorders

    Scientific Electronic Library Online (English)

    José Luis G. Pinho, Costa; Lucas O., Maia; P., Orlandi-Mattos; João C., Villares; Manuel A. Fernandez, Esteves.

    Full Text Available OBJETIVOS: Diante das lacunas na efetividade das terapêuticas para transtornos por uso de Cannabis, a droga ilícita mais consumida no mundo, este trabalho propõe-se a rever os conhecimentos sobre o substrato neuroanatômico, biomolecular e celular do sistema endocanabinoide, descrever os mecanismos d [...] e neuroplasticidade dependente dos canabinoides e relacioná-los com a neurobiologia dos transtornos por uso de Cannabis (abuso e dependência). MÉTODOS: Recorreu-se às bases de dados Medline, Scopus e ISI Web of Knowledge; as palavras-chave pesquisadas foram "Cannabis", "neurobiology", "endocannabinoid system", "endocannabinoids", "receptors, cannabinoid", "neuronal plasticity", "long-term synaptic depression", "long-term potentiation", "marijuana abuse" e "tetrahydrocannabinol". Foram incluídos 80 trabalhos nesta revisão. DISCUSSÃO: A distribuição neuroanatômica, celular e biomolecular do sistema endocanabinoide adequa-se perfeitamente às suas funções de neuromodulação (via neuroplasticidade e metaplasticidade), nomeadamente em vias relacionadas aos transtornos por uso de substâncias. Os canabinoides exógenos perturbam essas funções. CONCLUSÃO: O sistema endocanabinoide contribui para a definição de setpoints em diversas vias neuronais, incluindo vias cruciais na instalação de transtornos por uso de substâncias; com o uso de Cannabis, esses setpoints tornar-se-ão mais permissivos, facilitando os transtornos por uso de Cannabis. Os avanços no entendimento da neurobiologia da Cannabis abrem uma janela de oportunidades para novas estratégias terapêuticas nos transtornos por uso de Cannabis. Abstract in english OBJECTIVES: Given the challenges arising from the poor effectiveness of therapies for Cannabis-related disorders, the most commonly used illicit drug in the world, this paper aims to review the present knowledge about the neuroanatomic, biomolecular and cellular substrate of the endocannabinoid syst [...] em, describing the mechanisms of cannabinoid-dependent neuronal plasticity and relating them with the neurobiology of Cannabis-related disorders (abuse and dependence). METHODS: Medline, Scopus and ISI Web of Knowledge were searched for the keywords "Cannabis", "neurobiology", "endocannabinoid system", "endocannabinoids", "receptors, cannabinoid", "neuronal plasticity", "long-term synaptic depression", "long-term potentiation", "marijuana abuse" and "tetrahydrocannabinol". Eighty studies were included in this review. DISCUSSION: The neuroanatomical, cellular and biomolecular characterization of the endocannabinoid system serves perfectly its neuromodulatory neuroplastic and metaplastic functions, particularly in pathways related to substance-related disorders. Exogenous cannabinoids disrupt these functions. CONCLUSION: The endocannabinoid system contributes to the definition of setpoints in several neuronal pathways, including pathways critical for the development of substance-related disorders; with Cannabis use these setpoints become more permissive, facilitating Cannabis-related disorders. The advances in understanding the neurobiology of Cannabis open a window of opportunities for new therapeutic strategies in Cannabis-related disorders.

  3. Cannabis in cancer care.

    Science.gov (United States)

    Abrams, D I; Guzman, M

    2015-06-01

    Cannabis has been used in medicine for thousands of years prior to achieving its current illicit substance status. Cannabinoids, the active components of Cannabis sativa, mimic the effects of the endogenous cannabinoids (endocannabinoids), activating specific cannabinoid receptors, particularly CB1 found predominantly in the central nervous system and CB2 found predominantly in cells involved with immune function. Delta-9-tetrahydrocannabinol, the main bioactive cannabinoid in the plant, has been available as a prescription medication approved for treatment of cancer chemotherapy-induced nausea and vomiting and anorexia associated with the AIDS wasting syndrome. Cannabinoids may be of benefit in the treatment of cancer-related pain, possibly synergistic with opioid analgesics. Cannabinoids have been shown to be of benefit in the treatment of HIV-related peripheral neuropathy, suggesting that they may be worthy of study in patients with other neuropathic symptoms. Cannabinoids have a favorable drug safety profile, but their medical use is predominantly limited by their psychoactive effects and their limited bioavailability. PMID:25777363

  4. Epilepsy and Cannabis Treatment

    Medline Plus

    Full Text Available ... from randomized, controlled trials to draw any reliable conclusions regarding effectiveness of the drug in the treatment ... status of cannabis-derived drugs could accelerate scientific research and help determine whether cannabis-based treatments should ...

  5. Cannabis and Breastfeeding

    OpenAIRE

    Raphaël Serreau; Sylvie Aubry; Valérie Fauroux; Ammar Amirouche; Virginie Rigourd; Aurélia Garry

    2009-01-01

    Cannabis is a drug derived from hemp plant, Cannabis sativa, used both as a recreational drug or as medicine. It is a widespread illegal substance, generally smoked for its hallucinogenic properties. Little is known about the adverse effects of postnatal cannabis exposure throw breastfeeding because of a lack of studies in lactating women. The active substance of cannabis is the delta 9 TetraHydroCannabinol (THC). Some studies conclude that it could decrease motor development of the child at ...

  6. Epilepsy and Cannabis Treatment

    Medline Plus

    Full Text Available ... news/2_Epilepsy_Cannabis_091015.html Epilepsy and Cannabis Treatment HealthDay News Video - September 11, 2015 To ... page, please enable JavaScript. Play video: Epilepsy and Cannabis Treatment For closed captioning, click the CC button ...

  7. Cannabis and Breast feeding

    International Nuclear Information System (INIS)

    Cannabis is a drug derived from hemp plant, Cannabis sativa, used both as a recreational drug or as medicine. It is a widespread illegal substance, generally smoked for its hallucinogenic properties. Little is known about the adverse effects of postnatal cannabis exposure throw breast feeding because of a lack of studies in lactating women. The active substance of cannabis is the delta 9 Tetrahydrocannabinol (THC). Some studies conclude that it could decrease motor development of the child at one year of age. Therefore, cannabis use and abuse of other drugs like alcohol, tobacco, or cocaine must be contraindicated during breast feeding. Mothers who use cannabis must stop breast feeding, or ask for medical assistance to stop cannabis use in order to provide her baby with all the benefits of human milk.

  8. Assessing Topographical Orientation Skills in Cannabis Users

    Science.gov (United States)

    Palermo, Liana; Bianchini, Filippo; Iaria, Giuseppe; Tanzilli, Antonio; Guariglia, Cecilia

    2012-01-01

    The long-term effects of cannabis on human cognition are still unclear, but, considering that cannabis is a widely used substance and, overall, its potential use in therapeutic interventions, it is important to evaluate them. We hypothesize that the discrepancies among studies could be attributed to the specific cognitive function investigated and that skills subserved by the hippocampus, such as the spatial orientation abilities and, specifically, the ability to form and use cognitive maps, should be more compromised than others. Indeed it has been showed that cannabis users have a reduced hippocampus and that the hippocampus is the brain region in which cannabis has the greatest effect since it contains the highest concentration of cannabinoid receptors. To test this hypothesis we asked 15 heavy cannabis users and 19 nonusers to perform a virtual navigational test, the CMT, that assesses the ability to form and use cognitive maps. We found that using cannabis has no effect on these hippocampus-dependent orientation skills. We discuss the implications of our findings and how they relate to evidence reported in the literature that the intervention of functional reorganization mechanisms in cannabis user allows them to cope with the cognitive demands of navigational tasks. PMID:22272167

  9. Two cases of "cannabis acute psychosis" following the administration of oral cannabis

    Directory of Open Access Journals (Sweden)

    Pin Marie

    2005-04-01

    Full Text Available Abstract Background Cannabis is the most commonly used illegal drug and its therapeutic aspects have a growing interest. Short-term psychotic reactions have been described but not clearly with synthetic oral THC, especially in occasional users. Case presentations We report two cases of healthy subjects who were occasional but regular cannabis users without psychiatric history who developed transient psychotic symptoms (depersonalization, paranoid feelings and derealisation following oral administration of cannabis. In contrast to most other case reports where circumstances and blood concentrations are unknown, the two cases reported here happened under experimental conditions with all subjects negative for cannabis, opiates, amphetamines, cocaine, benzodiazepines and alcohol, and therefore the ingested dose, the time-events of effects on behavior and performance as well as the cannabinoid blood levels were documented. Conclusion While the oral route of administration achieves only limited blood concentrations, significant psychotic reactions may occur.

  10. Can Cannabis be Considered a Substitute Medication for Alcohol?

    OpenAIRE

    Subbaraman, Meenakshi Sabina

    2014-01-01

    Aims: Substituting cannabis for alcohol may reduce drinking and related problems among alcohol-dependent individuals. Some even recommend prescribing medical cannabis to individuals attempting to reduce drinking. The primary aim of this review is to assess whether cannabis satisfies the seven previously published criteria for substitute medications for alcohol [e.g. ‘reduces alcohol-related harms’; ‘is safer in overdose than alcohol’; ‘should offer significant health economic benefits’; see C...

  11. Chemistry, Metabolism, and Toxicology of Cannabis: Clinical Implications

    OpenAIRE

    M.M. Srinivas Bharath; Pratima Murthy; Priyamvada Sharma

    2012-01-01

    Cannabis is one of the most widely abused substances throughout the world. The primary psychoactive constituent of cannabis, delta 9-tetrahydrocannabinol (?9_THC), produces a myriad of pharmacological effects in animals and humans. Although it is used as a recreational drug, it can potentially lead to dependence and behavioral disturbances and its heavy use may increase the risk for psychotic disorders.Many studies that endeavor to understand the mechanism of action of cannabis concentrate on...

  12. New insights into cannabis consumption; abuses and possible therapeutic effects

    Directory of Open Access Journals (Sweden)

    Daniela Luiza Baconi

    2014-10-01

    Full Text Available Cannabis is one of the oldest psychotropic drugs known to humanity. The paper assesses the current knowledge on the cannabis, including the mechanisms of action and the therapeutic potential of cannabinoids. Three varieties of Cannabis plant are recognised: Cannabis sativa, Cannabis indica, and Cannabis ruderalis. The variety indica is used predominantly to obtain the drugs. Cannabis herb is usually named marijuana, while the cannabis oleoresin secreted by the glandular hairs found mainly on the flowering or fruiting tops of the plant is known as hashish. More than 400 known chemicals are present in cannabis, at least 70 of which are called cannabinoids. The major psychoactive constituent in cannabis is delta-9-tetrahydrocannabinol (?9-THC. It is now recognized that there are three types of cannabinoids: natural (phytocannabinoids, endogenous cannabinoids, and synthetic cannabioids. Cannabinoids exert their actions by binding to specific membrane protein, the cannabinoid receptor. To date, two subtypes of cannabinoid receptors, named cannabinoid-1 (CB1, most abundantly expressed in the central nervous system and cannabinoid-2 (CB2 receptors, found predominantly in peripheral tissues with immune functions have been cloned. Therefore, the concept of endogenous cannabinoid system (endocannabinoid system, SEC has been developed. Based on the current scientific evidence, there are several effects of cannabinoids with potential therapeutic use: antiemetic, analgesic in cancerous pains, and chronic neuropathic pain, in multiple sclerosis or spinal cord injuries. Cannabis consume can result in a state of drug dependency and cannabis withdrawal has been included in DSM-V. Cannabis plant remains controversial in the twenty-first century and the potential therapeutic of specific cannabinoid compounds and medical marijuana remains under active medical research.

  13. Cannabis e humor Cannabis and mood

    OpenAIRE

    Rafael Faria Sanches; João Mazzoncini de Azevedo Marques

    2010-01-01

    OBJETIVO: Avaliar as relações entre o uso agudo e crônico de cannabis e alterações do humor. MÉTODO: Os artigos foram selecionados por meio de busca eletrônica no indexador PubMed. Capítulos de livros e as listas de referências dos artigos selecionados também foram revisados. RESULTADOS: Observam-se elevados índices de comorbidade entre abuso/dependência de cannabis e transtornos afetivos em estudos transversais e em amostras clínicas. Estudos longitudinais indicam que, em longo prazo, o uso ...

  14. Stimulants and Cannabis Use Among a Marginalized Population in British Columbia, Canada: Role of Trauma and Incarceration.

    Science.gov (United States)

    Saddichha, Sahoo; Werker, Gregory R; Schuetz, Christian; Krausz, Michael R

    2015-12-01

    High rates of substance use, especially cannabis and stimulant use, have been associated with homelessness, exposure to trauma, and involvement with the criminal justice system. This study explored differences in substance use (cannabis vs. stimulants) and associations with trauma and incarceration among a homeless population. Data were derived from the BC Health of the Homeless Study (BCHOHS), carried out in three cities in British Columbia, Canada. Measures included sociodemographic information, the Maudsley Addiction Profile (MAP), the Childhood Trauma Questionnaire (CTQ), and the Mini International Neuropsychiatric Interview (MINI) Plus. Stimulant users were more likely to be female (43%), using multiple substances (3.2), and engaging in survival sex (14%). Cannabis users had higher rates of lifetime psychotic disorders (32%). Among the incarcerated, cannabis users had been subjected to greater emotional neglect (p abuse and Caucasian ethnicity were also associated with greater crack cocaine use. One explanation for the results is that a history of childhood abuse may lead to a developmental cascade of depressive symptoms and other psychopathology, increasing the chances of cannabis dependence and the development of psychosis. PMID:25028364

  15. Cannabis and schizophrenia: impact on onset, course, psychopathology and outcomes.

    Science.gov (United States)

    Bersani, G; Orlandi, V; Kotzalidis, G D; Pancheri, P

    2002-04-01

    Cannabis consuming schizophrenic patients are younger at onset, are likely to have started abuse before onset of schizophrenia and show more prominent positive symptoms than nonabusers. It has been suggested that cannabis is a risk-factor for schizophrenia. Our aim was to assess prevalence and pattern of cannabis use in 125 chronic male schizophrenic subjects and its impact on socioepidemiological and clinical variables as well as which disorder precedes the other in onset. Assessment of consumption was made with a semi-structured clinical interview. Clinical status was assessed by means of the SANS, SAPS, PANSS and BPRS scales. Cannabis consumption was found in 54 subjects (43%), 66.7% of whom started it at least three years before onset of schizophrenia. Consumers were younger and with lower negative symptoms, specially abusers and polysubstance abusers. Family history positive for psychosis was more frequent in consumers, especially when consumption started before onset of schizophrenia. Subjects whose onset of schizophrenia preceded the beginning of cannabis abuse had more positive symptoms than those who started abuse before the onset of schizophrenia. On these grounds, our sample could be subdivided into two main groups, one that uses substances to counter distressing symptoms of schizophrenia and another in which cannabis might be one of the factors predisposing to the disease; the former had less negative symptoms than nonabusers. Our data support both heterogeneity of schizophrenia and genetic susceptibility to environmental agents. PMID:12111342

  16. Cannabis and psychosis/schizophrenia: human studies

    OpenAIRE

    D’Souza, Deepak Cyril; Sewell, Richard Andrew; Ranganathan, Mohini

    2009-01-01

    The association between cannabis use and psychosis has long been recognized. Recent advances in knowledge about cannabinoid receptor function have renewed interest in this association. Converging lines of evidence suggest that cannabinoids can produce a full range of transient schizophrenia-like positive, negative, and cognitive symptoms in some healthy individuals. Also clear is that in individuals with an established psychotic disorder, cannabinoids can exacerbate symptoms, trigger relapse,...

  17. Cannabis use and schizotypy: the role of social anxiety and other negative affective states.

    Science.gov (United States)

    Najolia, Gina M; Buckner, Julia D; Cohen, Alex S

    2012-12-30

    Emerging research suggests that cannabis use might be related to psychosis onset in people vulnerable to developing schizophrenia-spectrum disorders. Furthermore, individuals with high-positive and disorganized schizotypy traits report more cannabis use and cannabis-related problems than controls. Social anxiety, a frequently co-occurring schizotypal feature, is related to increased cannabis-related problems in the general population. Building on this research, we explored the impact of social anxiety, measured by the Social Interaction Anxiety Scale (SIAS), and depression and trait anxiety reported on the Brief Symptom Inventory (BSI), on the relationship of schizotypy, measured by the Schizotypy Personality Questionnaire-Brief Revised (SPQ-BR), to cannabis use (n=220 schizotypy, 436 controls) and frequent use and cannabis-related problems among users (n=88 schizotypy, 83 controls) in college undergraduates. Among cannabis users, social anxiety moderated the relationships of schizotypy to frequent cannabis use and more cannabis-related problems in the total schizotypy group, and across high-positive, negative, and disorganized schizotypy subgroups. Depression and trait anxiety also moderated the relationship of schizotypy to frequent cannabis use and more cannabis-related problems, but results varied across high-positive, negative, and disorganized schizotypy subgroups. Results suggest therapeutically targeting negative affective states may be useful in psychosocial intervention for cannabis-related problems in schizotypy. PMID:22920791

  18. Survey of Australians using cannabis for medical purposes

    Directory of Open Access Journals (Sweden)

    Dillon Paul

    2005-10-01

    Full Text Available Abstract Background The New South Wales State Government recently proposed a trial of the medical use of cannabis. Australians who currently use cannabis medicinally do so illegally and without assurances of quality control. Given the dearth of local information on this issue, this study explored the experiences of medical cannabis users. Methods Australian adults who had used cannabis for medical purposes were recruited using media stories. A total of 147 respondents were screened by phone and anonymous questionnaires were mailed, to be returned by postage paid envelope. Results Data were available for 128 participants. Long term and regular medical cannabis use was frequently reported for multiple medical conditions including chronic pain (57%, depression (56%, arthritis (35%, persistent nausea (27% and weight loss (26%. Cannabis was perceived to provide "great relief" overall (86%, and substantial relief of specific symptoms such as pain, nausea and insomnia. It was also typically perceived as superior to other medications in terms of undesirable effects, and the extent of relief provided. However, nearly one half (41% experienced conditions or symptoms that were not helped by its use. The most prevalent concerns related to its illegality. Participants reported strong support for their use from clinicians and family. There was almost universal interest (89% in participating in a clinical trial of medical cannabis, and strong support (79% for investigating alternative delivery methods. Conclusion Australian medical cannabis users are risking legal ramifications, but consistent with users elsewhere, claim moderate to substantial benefits from its use in the management of their medical condition. In addition to strong public support, medical cannabis users show strong interest in clinical cannabis research, including the investigation of alternative delivery methods.

  19. Cannabidiol attenuates the appetitive effects of ?9-tetrahydrocannabinol in humans smoking their chosen cannabis.

    OpenAIRE

    Morgan, Celia Janet Ann; Freeman, Tom P; Schafer, Gráinne L; Curran, Helen Valerie

    2010-01-01

    Worldwide cannabis dependence is increasing, as is the concentration of ?9-tetrahydrocannabinol (THC) in street cannabis. At the same time, the concentration of the second most abundant cannabinoid in street cannabis, cannabidiol (CBD), is decreasing. These two cannabinoids have opposing effects both pharmacologically and behaviorally when administered in the laboratory. No research has yet examined how the ratio of these constituents impacts on the appetitive/reinforcing effects of cannabis ...

  20. Cannabis and Cannabinoids (PDQ)

    Science.gov (United States)

    ... nor nabilone is approved by the FDA for pain management. Whole Cannabis plant extract medicine: A study of a whole-plant extract of Cannabis that contained specific amounts of cannabinoids, which was ... cancer whose pain was not relieved by strong opioids alone. Patients ...

  1. Cannabis Allergy: What do We Know Anno 2015.

    Science.gov (United States)

    Decuyper, Ine; Ryckebosch, Hanne; Van Gasse, Athina L; Sabato, Vito; Faber, Margaretha; Bridts, Chris H; Ebo, Didier G

    2015-10-01

    For about a decade, IgE-mediated cannabis (marihuana) allergy seems to be on the rise. Both active and passive exposure to cannabis allergens may lead to a cannabis sensitization and/or allergy. The clinical manifestations of a cannabis allergy can vary from mild to life-threatening reactions, often depending on the route of exposure. In addition, sensitization to cannabis allergens can trigger various secondary cross-allergies, mostly for plant-derived food. This clinical entity, which we have designated as the "cannabis-fruit/vegetable syndrome" might also imply cross-reactivity with tobacco, latex and plant-food derived alcoholic beverages. These secondary cross-allergies are mainly described in Europe and appear to result from cross-reactivity between non-specific lipid transfer proteins or thaumatin-like proteins present in Cannabis sativa and their homologues that are ubiquitously distributed throughout plant kingdom. At present, diagnosis of cannabis-related allergies rests upon a thorough history completed with skin testing using native extracts from buds and leaves. However, quantification of specific IgE antibodies and basophil activation tests can also be helpful to establish correct diagnosis. In the absence of a cure, treatment comprises absolute avoidance measures including a stop of any further cannabis (ab)use. PMID:26178655

  2. A Comparison of Independent Depression and Substance-Induced Depression in Cannabis, Cocaine, and Opioid Dependent Treatment Seekers

    OpenAIRE

    Dakwar, Elias; Nunes, Edward V.; Bisaga, Adam; Carpenter, Kenneth C.; Mariani, John P.; Sullivan, Maria A.; Raby, Wilfrid N.; Levin, Frances R

    2011-01-01

    Depressive symptoms often co-exist with substance use disorders (SUDs). The DSM-IV has identified two distinct categories for depression coexisting with SUDs – independent depression and substance-induced depression. While this distinction has important therapeutic and prognostic implications, it remains difficult to make in clinical practice; the differentiation is often guided by chronological and symptom severity criteria that patients may be unable to precisely provide. Furthermore, it is...

  3. Evaluation of herbal cannabis characteristics by medical users: a randomized trial

    OpenAIRE

    Ducruet Thierry; Ware Mark A; Robinson Ann R

    2006-01-01

    Abstract Background Cannabis, in herbal form, is widely used as self-medication by patients with diseases such as HIV/AIDS and multiple sclerosis suffering from symptoms including pain, muscle spasticity, stress and insomnia. Valid clinical studies of herbal cannabis require a product which is acceptable to patients in order to maximize adherence to study protocols. Methods We conducted a randomized controlled crossover trial of 4 different herbal cannabis preparations among 8 experienced and...

  4. CANNABIS RELATED PSYCHIATRIC SYNDROMES: A SELECTIVE REVIEW

    OpenAIRE

    Basu, Debasish; Malhotra, Anil; Varma, Vijoy K.

    1994-01-01

    Association between cannabis use and various psychiatric syndromes does exist, but their nature remains elusive. Cannabis intoxication, ‘cannabis psychosis’ and certain other conditions related with cannabis use like flashbacks and prolonged depersonalization are discussed in this paper. The controversial nature of the cannabis - schizophrenia link is noted, and various methodological issues in clinical cannabis research are highlighted.

  5. Permitted Medical Cannabis Dispensaries

    Data.gov (United States)

    U.S. Department of Health & Human Services — As of December 31st, 2014, there were 28 Permitted Medical Cannabis Dispensaries (MCD) operating in the City and County of San Francisco. SFDPH issues a permit to...

  6. Epilepsy and Cannabis Treatment

    Medline Plus

    Full Text Available ... in children and adults with epilepsy? A new study in the New England Journal of Medicine reviews ... safety and side effects of cannabis come from studies looking at recreational use. They warn of possible ...

  7. Cannabis y canabinoides (PDQ®)

    Science.gov (United States)

    Resumen de información revisada por expertos sobre el uso del Cannabis y canabinoides para el tratamiento de los efectos secundarios relacionados con el tratamiento del cáncer como la náusea y el vómito.

  8. Epilepsy and Cannabis Treatment

    Medline Plus

    Full Text Available ... including memory loss, impaired motor function and irreversible effects on brain development. The study concludes that relaxation of the regulatory status of cannabis-derived drugs could accelerate scientific research and help determine whether ...

  9. Epilepsy and Cannabis Treatment

    Medline Plus

    Full Text Available ... seizures, the authors say there is not enough data from randomized, controlled trials to draw any reliable ... point out that a lot of the current data on safety and side effects of cannabis come ...

  10. Epilepsy and Cannabis Treatment

    Medline Plus

    Full Text Available ... keyboard shortcuts Transcript Does medical marijuana improve seizure control in children and adults with epilepsy? A new ... reviews available research on cannabis-based treatments to control epilepsy, which affects an estimated 1.3 to ...

  11. Cannabis Use When it's Legal

    OpenAIRE

    Ours, J.C.

    2005-01-01

    This paper uses information about prime age individuals living in Amsterdam, to study whether the use of alcohol, or tobacco stimulates the use cannabis, i.e. whether alcohol or cannabis are stepping stones for cannabis.The special element of the study is that it concerns the use in an environment where not only alcohol and tobacco but also cannabis is a legal drug.It turns out that alcohol and cannabis are intertemporal substitutes while tobacco and cannabis are intertemporal complements.Onl...

  12. Cannabis masks diabetic ketoacidosis

    OpenAIRE

    Hennessy, Annemarie

    2011-01-01

    This is the first series to identify that diabetic ketosis presenting in cannabis users has a different and conflicting acid base profile compared to non-cannabis users and can confuse the need for intensive or critical care in these at-risk patients. This association of drugtaking history and clinical presentation has implications for how the authors treat the drug using sector of the population with diabetes.

  13. The medicalization of cannabis

    OpenAIRE

    2010-01-01

    Cannabis has been considered as both an illicit drug and a medicine throughout its history. Introduced to the UK as a medicine in the nineteenth century, its medical utility was limited and it was not until tetrahydrocannabinol (THC), one of the principal active components in cannabis, was isolated in 1964 by Raphael Mechoulam and his team in Israel that scientific research on the drug expanded. Further major developments came in the 1980s, when the cannabinoid receptors in the brain were dis...

  14. Nicotine Dependence, PTSD Symptoms, and Depression Proneness Among Male and Female Smokers

    OpenAIRE

    Thorndike, Frances P.; Wernicke, Rachel; Pearlman, Michelle Y.; David A. F. Haaga

    2006-01-01

    Several studies have linked posttraumatic stress disorder with heavy smoking. It is not known to what extent this association is specific, as opposed to being a function of a joint association of PTSD and heavy smoking with a third variable such as depression proneness. In a cross-sectional study of 157 current regular smokers, severity of nicotine dependence (but not cigarettes smoked per day) was positively correlated with total PTSD symptoms, hyperarousal symptoms, and avoidance symptoms. ...

  15. Adolescent Nicotine Dependence Symptom Profiles and Risk for Future Daily Smoking

    OpenAIRE

    Rose, Jennifer S; Lee, Chien-Ti; Dierker, Lisa C.; Selya, Arielle S.; Mermelstein, Robin J

    2012-01-01

    Recent research on adolescent smokers suggests that there are important differences in the types of nicotine dependence (ND) symptoms that emerge and different patterns of ND symptoms. The purpose of this study was to use data from the longitudinal Social and Emotional Contexts of Adolescent Smoking Patterns Study to identify latent subgroups of adolescent experimental and nondaily smokers varying in number and types of endorsed ND symptoms. Profiles were identified using baseline level of sm...

  16. Abuso e dependência de maconha: comparação entre sexos e preparação para mudanças comportamentais entre usuários que iniciam a busca por tratamento Cannabis abuse and dependency: differences between men and women and readiness to behavior change among users seeking treatment

    Directory of Open Access Journals (Sweden)

    Simone Fernandes

    2010-01-01

    Full Text Available OBJETIVOS: Descrever o perfil sociodemográfico de usuários de maconha que iniciam tratamento e comparar os sexos dos indivíduos em relação aos estágios de prontidão para mudança e uso associado de outras drogas. MÉTODO: Estudo transversal descritivo, com amostra não probabilística de indivíduos que ligaram para um teleatendimento especializado em dependência química. RESULTADOS: A amostra se constituiu de 72% de indivíduos do sexo masculino na faixa etária de 12 a 25 anos. Um percentual de 85,5% fazia uso associado de outras drogas. O estágio motivacional predominante foi de ação (56%, sem diferenças entre sexos (p = 0,4. Os homens mais frequentemente procuraram auxílio para o tratamento do uso de maconha. CONCLUSÕES: Com base nesses dados, foi possível delinear o perfil dos usuários de maconha para auxiliar no direcionamento de informações e atendimento adequado.OBJECTIVES: To describe the social and demographic profile of cannabis users seeking treatment and to compare differences between sex in relation to readiness to behavior change and in relation to associated use of marijuana and other drugs. METHOD: A cross-sectional, descriptive study including a nonprobability sample of individuals who called a chemical dependency hotline. RESULTS: The sample comprised 72% male individuals aged between 12 and 25 years. The sample was composed by 85.5% used other drugs in association with cannabis. The action stage was the most frequent stage of readiness to behavior change observed, in 56% of the callers, with no differences between sex (p = 0.4. Men more frequently sought treatment for the use of cannabis. CONCLUSIONS: Our findings allowed delineating a profile of cannabis users, so as to better guide the provision of adequate information and treatment services.

  17. Abuso e dependência de maconha: comparação entre sexos e preparação para mudanças comportamentais entre usuários que iniciam a busca por tratamento / Cannabis abuse and dependency: differences between men and women and readiness to behavior change among users seeking treatment

    Scientific Electronic Library Online (English)

    Simone, Fernandes; Maristela, Ferigolo; Mariana Canellas, Benchaya; Pollianna Sangalli, Pierozan; Taís de Campos, Moreira; Vagner dos, Santos; Cláudia Galvão, Mazoni; Helena Maria Tannhauser, Barros.

    Full Text Available OBJETIVOS: Descrever o perfil sociodemográfico de usuários de maconha que iniciam tratamento e comparar os sexos dos indivíduos em relação aos estágios de prontidão para mudança e uso associado de outras drogas. MÉTODO: Estudo transversal descritivo, com amostra não probabilística de indivíduos que [...] ligaram para um teleatendimento especializado em dependência química. RESULTADOS: A amostra se constituiu de 72% de indivíduos do sexo masculino na faixa etária de 12 a 25 anos. Um percentual de 85,5% fazia uso associado de outras drogas. O estágio motivacional predominante foi de ação (56%), sem diferenças entre sexos (p = 0,4). Os homens mais frequentemente procuraram auxílio para o tratamento do uso de maconha. CONCLUSÕES: Com base nesses dados, foi possível delinear o perfil dos usuários de maconha para auxiliar no direcionamento de informações e atendimento adequado. Abstract in english OBJECTIVES: To describe the social and demographic profile of cannabis users seeking treatment and to compare differences between sex in relation to readiness to behavior change and in relation to associated use of marijuana and other drugs. METHOD: A cross-sectional, descriptive study including a n [...] onprobability sample of individuals who called a chemical dependency hotline. RESULTS: The sample comprised 72% male individuals aged between 12 and 25 years. The sample was composed by 85.5% used other drugs in association with cannabis. The action stage was the most frequent stage of readiness to behavior change observed, in 56% of the callers, with no differences between sex (p = 0.4). Men more frequently sought treatment for the use of cannabis. CONCLUSIONS: Our findings allowed delineating a profile of cannabis users, so as to better guide the provision of adequate information and treatment services.

  18. Culture and Environment as Predictors of Alcohol Abuse/Dependence Symptoms In American Indian Youths

    OpenAIRE

    Yu, ManSoo; Stiffman, Arlene Rubin

    2007-01-01

    This study utilizes Bronfenbrenner's ecological model (1979) to examine multiple and interactive environmental (familial, social, and cultural) predictors of adolescent alcohol abuse/dependence symptoms. A stratified random sample of 401 American Indian youths was interviewed in 2001. The findings showed that family members' substance problems, peer misbehaviors, and participation in generic cultural activities positively predicted adolescent alcohol symptoms. Conversely, cultural pride/spiri...

  19. Alcohol Abuse and Dependence Symptoms: A Multidimensional Model of Common and Specific Etiology

    OpenAIRE

    Simons, Jeffrey S.; Carey, Kate B; Wills, Thomas A.

    2009-01-01

    This study tested a theoretical model hypothesizing differential pathways from five predictors to alcohol abuse and dependence symptoms. The participants were college students (N= 2,270) surveyed on two occasions in a 6-month prospective design. Social norms, perceived utility of alcohol use, and family history of alcohol problems were indirectly associated with Time 2 (T2) abuse and dependence symptoms through influencing level of alcohol consumption. Poor behavioral control had a direct eff...

  20. Alcohol Abuse/Dependence Symptoms Among Hospital Employees Exposed to a SARS Outbreak

    OpenAIRE

    Wu, Ping; Xinhua LIU; Fang, Yunyun; Fan, Bin; Fuller, Cordelia J.; Guan , ZhiQiang; Yao, Zhongling; Kong, Junhui; Lu, Jin; Litvak, Iva J.

    2008-01-01

    Aims: The aim of this study was to examine alcohol abuse/dependence symptoms among hospital employees exposed to a severe acute respiratory syndrome (SARS) outbreak, and the relationship between types of exposure to the SARS outbreak and subsequent alcohol abuse/dependence symptoms. Methods: A survey was conducted among 549 randomly selected hospital employees in Beijing, China, concerning the psychological impact of the 2003 SARS outbreak. Subjects were assessed on sociodemographic factors a...

  1. Co-occurring Psychiatric Symptoms are Associated with Increased Psychological, Social and Medical Impairment in Opioid Dependent Pregnant Women

    OpenAIRE

    Benningfield, Margaret M; Arria, Amelia M; Kaltenbach, Karol; HEIL, SARAH H.; Stine, Susan M.; Coyle, Mara G.; FISCHER, GABRIELE; Jones, Hendrée E; Peter R. Martin

    2010-01-01

    The interaction of psychiatric symptoms with drug dependence during pregnancy is not well understood. This study examines the relationship of psychiatric symptoms to severity of drug use and drug related problems among participants in a clinical trial of pharmacologic treatment of opioid dependence during pregnancy (N=174). 64.6% reported additional psychiatric symptoms (48.6% mood symptoms, 40.0% anxiety symptoms, and 12.6% suicidal thinking). Women who endorsed co-occurring psychiatric symp...

  2. Cannabinoid replacement therapy (CRT): Nabiximols (Sativex) as a novel treatment for cannabis withdrawal.

    Science.gov (United States)

    Allsop, D J; Lintzeris, N; Copeland, J; Dunlop, A; McGregor, I S

    2015-06-01

    Cannabis is a common recreational drug that is generally considered to have low addictive potential. However, an increasing number of cannabis users are seeking treatment for dependence on the drug. There is interest in using agonist (substitution) pharmacotherapies to treat cannabis dependence and here we outline a novel approach involving a buccal spray (nabiximols) that contains tetrahydrocannabinol (THC) and cannabidiol (CBD). We review recent research with nabiximols and highlight findings relevant to clinical practice. PMID:25777582

  3. The Medical Necessity for Medicinal Cannabis: Prospective, Observational Study Evaluating the Treatment in Cancer Patients on Supportive or Palliative Care

    OpenAIRE

    Ella Muller; Anat Omer; Saher Drawsheh; Gil Bar-Sela; Marina Vorobeichik; Victoria Goldberg

    2013-01-01

    Background. Cancer patients using cannabis report better influence from the plant extract than from synthetic products. However, almost all the research conducted to date has been performed with synthetic products. We followed patients with a medicinal cannabis license to evaluate the advantages and side effects of using cannabis by cancer patients. Methods. The study included two interviews based on questionnaires regarding symptoms and side effects, the first held on the day the license was...

  4. Epilepsy and Cannabis Treatment

    Medline Plus

    Full Text Available ... About MedlinePlus Site Map FAQs Contact Us Health Topics Drugs & Supplements Videos & Tools You Are Here: Home ? Latest Health News ? Epilepsy and Cannabis Treatment URL of this page: https://www.nlm.nih.gov/medlineplus/videos/news/ ...

  5. Epilepsy and Cannabis Treatment

    Medline Plus

    Full Text Available ... Transcript Does medical marijuana improve seizure control in children and adults with epilepsy? A new study in the New England Journal of Medicine reviews available research on cannabis-based treatments to control ... National Library of Medicine 8600 Rockville Pike, Bethesda, MD 20894 ...

  6. Epilepsy and Cannabis Treatment

    Medline Plus

    Full Text Available ... the player. Video player keyboard shortcuts Transcript Does medical marijuana improve seizure control in children and adults with epilepsy? A new study in the New England Journal of Medicine reviews available research on cannabis-based treatments to control epilepsy, which ...

  7. Correlates to the variable effects of cannabis in young adults: a preliminary study

    Directory of Open Access Journals (Sweden)

    Camera Ariella A

    2012-03-01

    Full Text Available Abstract Background Cannabis use can frequently have adverse affects in those that use it and these can be amplified by various characteristics of an individual, from demographic and environmental variations to familial predisposition for mental illnesses. Methods The current study of 100 individuals, who were cannabis users during their adolescence and may still be users, was a survey of the self perceived effects of cannabis and their correlates. A reliable family member was also interviewed for determination of family history of various major mental illnesses and substance use. Results As many as 40% of cannabis users had paranoid feelings (suspiciousness when using cannabis, although the most frequent effect was feeling relaxed (46%. Having a familial background for mental illnesses such as depression or schizophrenia did not determine the effects of cannabis nor its pattern of use, although the number of subjects with such a history was small. An age at which an individual began using cannabis did have an effect on how heavily it was used and the heavier the cannabis use, the more likely the individual was also to have had psychotic symptoms after use. There were no sex differences in effects of cannabis. These results are tempered by the reliance on self-report for many of the variables ascertained. Conclusion Cannabis can frequently have negative effects in its users, which can be amplified by certain demographic and/or psychosocial factors. Thus, users with a specific profile may be at a higher risk of unpleasant effects from cannabis use and caution should be noted when cannabis is administered to young people for medicinal purposes.

  8. Clinical service desires of medical cannabis patients

    Directory of Open Access Journals (Sweden)

    Janichek Jennifer L

    2012-03-01

    Full Text Available Abstract Background Medical cannabis dispensaries following the social or hybrid model offer supplementary holistic services in addition to dispensing medical cannabis. Historically, alternative physical health services have been the norm for these dispensaries, including services such as yoga, acupuncture, or chiropractor visits. A clinical service dearth remains for medical cannabis patients seeking substance use, misuse, dependence, and mental health services. This study examined patient desires for various clinical services and level of willingness to participate in specific clinical services. Methods Anonymous survey data (N = 303 were collected at Harborside Health Center (HHC, a medical cannabis dispensary in Oakland, CA. The sample was 70% male, 48% Caucasian and 21% African American. The mean male age was 38 years old and female mean age was 30. Sixty two percent of the male participants and 44% of the female participants are single. Sixteen percent of the population reported having a domestic partner. Forty six percent of the participants are employed full time, 41% have completed at least some college, and 49% make less than $40,000 a year. Results A significant portion of the sample, 62%, indicated a desire to participate in free clinical services at HHC, 34% would like more information about substances and use, and 41% want to learn more about reducing harms from substance use. About one quarter of the participants marked "would" or "likely would" participate in individual services such as consultation. Approximately 20% indicated "would" or "likely would" participate in psycho-educational forums, harm reduction information sharing sessions, online support groups, and coping, life, and social skills group. There was little interest in traditional NA/AA 12-step groups or adapted 12-step groups. Conclusions Desired clinical services can be qualified as a combination of harm reduction, educational, skills-based, peer support and therapeutic individual and group services. Results suggest that medical cannabis patients seek more information about various substances, including cannabis. Dispensaries can help to decrease gaps in substance education and clinical services and fulfill unmet clinical desires. More research is necessary in additional medical cannabis dispensaries in different geographic settings with different service delivery models.

  9. Chemistry, Metabolism, and Toxicology of Cannabis: Clinical Implications

    Directory of Open Access Journals (Sweden)

    M.M. Srinivas Bharath

    2012-12-01

    Full Text Available Cannabis is one of the most widely abused substances throughout the world. The primary psychoactive constituent of cannabis, delta 9-tetrahydrocannabinol (?9_THC, produces a myriad of pharmacological effects in animals and humans. Although it is used as a recreational drug, it can potentially lead to dependence and behavioral disturbances and its heavy use may increase the risk for psychotic disorders.Many studies that endeavor to understand the mechanism of action of cannabis concentrate on pharmacokinetics and pharmacodynamics of cannabinoids in humans. However, there is limited research on the chronic adverse effects and retention of cannabinoids in human subjects.Cannabis can be detected in body fluids following exposure through active/passive inhalation and exposure through breastfeeding. Cannabis detection is directly dependent on accurate analytical procedures for detection of metabolites and verification of recent use.In this review, an attempt has been made to summarize the properties of cannabis and its derivatives, and to discuss the implications of its use with emphasis on bioavailability, limit of detection, carry over period and passive inhalation, important factors for detection and diagnosis.

  10. Psychiatric treatment following participation in the CapOpus randomized trial for patients with comorbid cannabis use disorder and psychosis

    DEFF Research Database (Denmark)

    HjorthØj, Carsten Rygaard; Orlovska, Sonja

    2013-01-01

    Randomized trials targeting cannabis use disorders in patients with psychosis have generally been unsuccessful. One of the largest such trials was the CapOpus trial, which had an impact on the number of monthly joints used, but not on the number of days with cannabis use or positive or negative symptoms.

  11. Cannabis use and mood disorders: patterns of clinical presentations among adolescents in a developing country.

    Science.gov (United States)

    Konings, M; Maharajh, Hari D

    2006-01-01

    Notwithstanding the increase use of cannabis among adolescents in both developing and developed countries, few studies have looked at cannabis use and mood disorders. In a series of case studies, this research project seeks to investigate patterns of clinical presentations seen among cannabis users in psychiatric outpatients in Trinidad. Five clinical patterns of presentations are identified among cannabis users and abusers based on variables of dosing, age of initial use, duration of use, tolerance and reverse tolerance and poly-drug abuse. All patients in these case studies were standardized for method of use and potency of cannabis used. Patients were screened by urine tests to determine co-morbid use of other substances. Other variables such as environmental factors and genetic vulnerability were reviewed as far as possible from historical accounts of family members. The five patterns described are low, controlled use with mild euphoria and heightened awareness, moderate use with mixed depressive symptoms and suicidal behaviour, heavy, short term use with manic symptoms, long term incremental use with psychotic symptoms due to the trumping of depressive symptoms and cannabis mixed with other substances resulting in florid psychosis. Mood disorders appear to be a common finding among adolescents using cannabis. Sensitization to symptomatic presentation and early detection of cannabis use in young adolescents are necessary. Further research is needed on the effect of cannabinoids on emotions, behaviour and thinking and its relationship to mental disorders. This study is useful as a guideline for the implementation of public health strategies and legislation concerning the use of cannabis in youths. PMID:16894861

  12. Cannabis abuse and risk for psychosis in a prodromal sample

    OpenAIRE

    Kristensen,Karin; Cadenhead, Kristin S

    2007-01-01

    The goal of the present study was to examine the rate of cannabis use among participants in the Cognitive Assessment and Risk Evaluation (CARE) Program, a longitudinal program for individuals who are “at risk” for developing a psychotic disorder. Cannabis abuse was assessed in 48 individuals identified as “at risk” for schizophrenia based on subsyndromal psychotic symptoms and/or family history. At 1 year follow-up, 6 of the 48 (12.5%) at risk subjects had made the transition to psychosis. Of...

  13. An Australian Twin Study of Cannabis and Other Illicit Drug Use and Misuse, and Other Psychopathology

    OpenAIRE

    Lynskey, Michael T.; Agrawal, Arpana; Henders, Anjali; Nelson, Elliot C.; MADDEN, PAMELA A.F.; Martin, Nicholas G.

    2012-01-01

    Cannabis is the most widely used illicit drug throughout the developed world and there is consistent evidence of heritable influences on multiple stages of cannabis involvement including initiation of use and abuse/dependence. In this paper, we describe the methodology and preliminary results of a large-scale interview study of 3,824 young adult twins (born 1972–1979) and their siblings. Cannabis use was common with 75.2% of males and 64.7% of females reporting some lifetime use of cannabis w...

  14. Cannabis as a substitute for alcohol and other drugs

    Directory of Open Access Journals (Sweden)

    Reiman Amanda

    2009-12-01

    Full Text Available Abstract Background Substitution can be operationalized as the conscious choice to use one drug (legal or illicit instead of, or in conjunction with, another due to issues such as: perceived safety; level of addiction potential; effectiveness in relieving symptoms; access and level of acceptance. This practice of substitution has been observed among individuals using cannabis for medical purposes. This study examined drug and alcohol use, and the occurrence of substitution among medical cannabis patients. Methods Anonymous survey data were collected at the Berkeley Patient's Group (BPG, a medical cannabis dispensary in Berkeley, CA. (N = 350 The sample was 68% male, 54% single, 66% White, mean age was 39; 74% have health insurance (including MediCal, 41% work full time, 81% have completed at least some college, 55% make less than $40,000 a year. Seventy one percent report having a chronic medical condition, 52% use cannabis for a pain related condition, 75% use cannabis for a mental health issue. Results Fifty three percent of the sample currently drinks alcohol, 2.6 was the average number of drinking days per week, 2.9 was the average number of drinks on a drinking occasion. One quarter currently uses tobacco, 9.5 is the average number of cigarettes smoked daily. Eleven percent have used a non-prescribed, non OTC drug in the past 30 days with cocaine, MDMA and Vicodin reported most frequently. Twenty five percent reported growing up in an abusive or addictive household. Sixteen percent reported previous alcohol and/or drug treatment, and 2% are currently in a 12-step or other recovery program. Forty percent have used cannabis as a substitute for alcohol, 26% as a substitute for illicit drugs and 66% as a substitute for prescription drugs. The most common reasons given for substituting were: less adverse side effects (65%, better symptom management (57%, and less withdrawal potential (34% with cannabis. Conclusion The substitution of one psychoactive substance for another with the goal of reducing negative outcomes can be included within the framework of harm reduction. Medical cannabis patients have been engaging in substitution by using cannabis as an alternative to alcohol, prescription and illicit drugs.

  15. Association between Depressive Symptoms and Negative Dependent Life Events from Late Childhood to Adolescence

    Science.gov (United States)

    Johnson, Daniel P.; Whisman, Mark A.; Corley, Robin P.; Hewitt, John K.; Rhee, Soo Hyun

    2012-01-01

    The association between stressful life events and depression has been consistently supported in the literature; however, studies of the developmental trajectories of these constructs and the nature of their association over time are limited. We examined trajectories of depressive symptoms and negative dependent life events and the associations…

  16. When Cannabis Is Available and Visible at School--A Multilevel Analysis of Students' Cannabis Use

    Science.gov (United States)

    Kuntsche, Emmanuel

    2010-01-01

    Aims: To investigate the links between the visibility of cannabis use in school (measured by teachers' reports of students being under the influence of cannabis on school premises), the proportion of cannabis users in the class, perceived availability of cannabis, as well as adolescent cannabis use. Methods: A multilevel regression model was…

  17. Cannabis in the Treatment of Dystonia, Dyskinesias, and Tics.

    Science.gov (United States)

    Koppel, Barbara S

    2015-10-01

    Cannabis has been used for many medicinal purposes, including management of spasms, dystonia, and dyskinesias, with variable success. Its use for tetanus was described in the second century BCE, but the literature continues to include more case reports and surveys of its beneficial effects in managing symptoms of hyperkinetic movement disorders than randomized controlled trials, making evidence-based recommendations difficult. This paper reviews clinical research using various formulations of cannabis (botanical products, oral preparations containing ?(9)-tetrahydrocannabinol and/or cannabidiol) and currently available preparations in the USA (nabilone and dronabinol). This has been expanded from a recent systematic review of cannabis use in several neurologic conditions to include case reports and case series and results of anonymous surveys of patients using cannabis outside of medical settings, with the original evidence classifications marked for those papers that followed research protocols. Despite overlap in some patients, dyskinesias will be treated separately from dystonia and chorea; benefit was not established beyond individual patients for these conditions. Tics, usually due to Tourettes, did respond to cannabis preparations. Side effects reported in the trials will be reviewed but those due to recreational use, including the dystonia that can be secondary to synthetic marijuana preparations, are outside the scope of this paper. PMID:26271953

  18. Further Evidence That Cannabis Moderates Familial Correlation of Psychosis-Related Experiences

    Science.gov (United States)

    van Winkel, Ruud

    2015-01-01

    Background Familial correlations underlie heritability estimates of psychosis. If gene-environment interactions are important, familial correlation will vary as a function of environmental exposure. Methods Associations between sibling and parental schizotypy (n = 669 pairs, n = 1222 observations), and between sibling schizotypy and patient CAPE psychosis (n = 978 pairs, n = 1723 observations) were examined as a function of sibling cannabis use. This design is based on the prediction that in unaffected siblings who are not exposed, vulnerability for psychosis will remain latent, whereas in case of exposure, latent psychosis vulnerability may become expressed, at the level of schizotypal symptoms, causing the phenotypic correlation between relatives to become “visible” under the influence of cannabis. Results Siblings exposed to recent cannabis use resembled their patient-relative more closely in terms of positive schizotypy (urinalysis(+):B = 0.30, Pcannabis (urinalysis(+):B = 0.78, Pcannabis frequency of use as exposure instead of recent use. Parental schizotypy did not predict cannabis use in the healthy sibling, nor in the patient. Similarly, parental cannabis use was not associated with level of schizotypy in the sibling, nor with psychotic symptoms in the patient, making gene-environment correlation unlikely. Conclusion Familial correlation of psychosis-related experiences varies considerably as a function of exposure to cannabis, confirming the importance of gene-cannabis interaction in shifts of expression of psychosis-related experiences. PMID:26384217

  19. [Cannabis smoking and lung cancer].

    Science.gov (United States)

    Underner, M; Urban, T; Perriot, J; de Chazeron, I; Meurice, J-C

    2014-06-01

    Cannabis is the most commonly smoked illicit substance in the world. It can be smoked alone in plant form (marijuana) but it is mainly smoked mixed with tobacco. The combined smoking of cannabis and tobacco is a common-place phenomenon in our society. However, its use is responsible for severe pulmonary consequences. The specific impact of smoking cannabis is difficult to assess precisely and to distinguish from the effect of tobacco. Marijuana smoke contains polycyclic aromatic hydrocarbons and carcinogens at higher concentration than tobacco smoke. Cellular, tissue, animal and human studies, and also epidemiological studies, show that marijuana smoke is a risk factor for lung cancer. Cannabis exposure doubles the risk of developing lung cancer. This should encourage clinicians to identify cannabis use and to offer patients support in quitting. PMID:25012035

  20. Cannabis Use and Mental Health Problems

    OpenAIRE

    Ours, J.C.; WILLIAMS, J

    2009-01-01

    This paper investigates whether cannabis use leads to worse mental health. To do so, we account for common unobserved factors affecting mental health and cannabis consumption by modeling mental health jointly with the dynamics of cannabis use. Our main finding is that using cannabis increases the likelihood of mental health problems, with current use having a larger effect than past use. The estimates suggest a dose response relationship between the frequency of recent cannabis use and the pr...

  1. Cannabis use and cognition in schizophrenia

    OpenAIRE

    KennethHugdahl

    2009-01-01

    People with schizophrenia frequently report cannabis use, and cannabis may be a risk factor for schizophrenia, mediated through effects on brain function and biochemistry. Thus, it is conceivable that cannabis may also influence cognitive functioning in this patients group. We report data from our own laboratory on the use of cannabis by schizophrenia patients, and review the existing literature on the effects of cannabis on cognition in schizophrenia and related psychosis. Of the 23 studies ...

  2. Cannabis Use and Cognition in Schizophrenia

    OpenAIRE

    Løberg, Else-Marie; HUGDAHL, KENNETH

    2009-01-01

    People with schizophrenia frequently report cannabis use, and cannabis may be a risk factor for schizophrenia, mediated through effects on brain function and biochemistry. Thus, it is conceivable that cannabis may also influence cognitive functioning in this patient group. We report data from our own laboratory on the use of cannabis by schizophrenia patients, and review the existing literature on the effects of cannabis on cognition in schizophrenia and related psychosis. Of the 23 studies t...

  3. Statistics on cannabis users skew perceptions of cannabis use

    Directory of Open Access Journals (Sweden)

    RachelMelissaBurns

    2013-11-01

    Full Text Available Collecting information about the prevalence of cannabis use is necessary but not sufficient for understanding the size, dynamics, and outcomes associated with cannabis markets. This paper uses two data sets describing cannabis consumption in the United States and Europe to highlight 1 differences in inferences about sub-populations based on the measure used to quantify cannabis-related activity; 2 how different measures of cannabis-related activity can be used to more accurately describe trends in cannabis usage over time; and 3 the correlation between frequency of use in the past month and average grams consumed per day. Key findings: Focusing on days of use instead of prevalence shows substantially greater increases in U.S. cannabis use in recent years; however, the recent increase is mostly among adults, not youth. Relatively more rapid growth in use days also occurred among the college-educated and Hispanic. Further, data from a survey conducted in several European countries show a strong positive correlation between frequency of use and quantity consumed per day of use, suggesting consumption is even more skewed toward the minority of heavy users than is suggested by days-of-use calculations.

  4. Screening of cannabis-related problems among youth: the CPQ-A-S and CAST questionnaires

    OpenAIRE

    Fernandez-Artamendi Sergio; Fernández-Hermida José; Muñiz-Fernández José; Secades-Villa Roberto; García-Fernández Gloria

    2012-01-01

    Abstract Background Cannabis use among young people is a significant problem, making particularly necessary validated screening instruments that permit secondary prevention. The purpose of this study was to analyze and compare the psychometric properties of the CAST and CPQ-A-S questionnaires, two screening instruments specifically addressing the youth population. Methods Information was obtained on sociodemographics, frequency of substance use, psychopathological symptoms and cannabis-use pr...

  5. Cannabis Withdrawal Among Detained Adolescents: Exploring the Impact of Nicotine and Race

    OpenAIRE

    Soenksen, Shayna; Stein, L. A. R.; Brown, Joanna D.; Stengel, JoAnn R.; Rossi, Joseph S; Lebeau, Rebecca

    2015-01-01

    Rates of marijuana use among detained youths are exceptionally high. Research suggests a cannabis withdrawal syndrome is valid and clinically significant; however, these studies have mostly been conducted in highly controlled laboratory settings with treatment-seeking, White adults. The present study analyzed archival data to explore the magnitude of cannabis withdrawal symptoms within a diverse sample of detained adolescents while controlling for tobacco use and investigating the impact of r...

  6. Functional capacity and dependency in transfer and dressing are associated with depressive symptoms in older people

    OpenAIRE

    Boström G; Conradsson M; Rosendahl E; Nordström P; Gustafson Y; Littbr; H.

    2014-01-01

    Gustaf Boström,1 Mia Conradsson,1 Erik Rosendahl,1,2 Peter Nordström,1 Yngve Gustafson,1 Håkan Littbrand1,21Department of Community Medicine and Rehabilitation, Geriatric Medicine, Umeå University, Umeå, Sweden; 2Department of Community Medicine and Rehabilitation, Physiotherapy, Umeå University, Umeå, SwedenBackground: This study examined associations between depressive symptoms and functional capacity, overall dependency in personal activities of dail...

  7. Functional capacity and dependency in transfer and dressing are associated with depressive symptoms in older people

    Directory of Open Access Journals (Sweden)

    Boström G

    2014-02-01

    Full Text Available Gustaf Boström,1 Mia Conradsson,1 Erik Rosendahl,1,2 Peter Nordström,1 Yngve Gustafson,1 Håkan Littbrand1,21Department of Community Medicine and Rehabilitation, Geriatric Medicine, Umeå University, Umeå, Sweden; 2Department of Community Medicine and Rehabilitation, Physiotherapy, Umeå University, Umeå, SwedenBackground: This study examined associations between depressive symptoms and functional capacity, overall dependency in personal activities of daily living (ADLs, and dependency in individual ADL tasks, respectively, in people with a high mean age, large range of functional capacity, and wide spectrum of dependency in ADLs.Methods: Cross-sectional data from three studies were used. A total of 392 individuals living in community and residential care facilities were included. Mean age was 86.2 years, 72% were women, 75% were dependent in ADLs, 42% had depression, and 39% had dementia. Depressive symptoms were assessed with the 15-item Geriatric Depression Scale (GDS-15, functional capacity with the Berg Balance Scale (BBS, and ADLs with the Barthel ADL Index. Multiple linear regression analyses with comprehensive adjustments were performed between GDS-15 and BBS, GDS-15 and Barthel ADL Index, and GDS-15 and each individual ADL task, separately.Results: GDS-15 score was associated with BBS score (unstandardized b =-0.03, P=0.008, but not with Barthel ADL Index score (unstandardized b =-0.07, P=0.068. No significant interaction effects of sex, dementia, or living conditions were found in these associations. Among individual ADL tasks, dependency in transfer (unstandardized b =-1.03, P=0.007 and dressing (unstandardized b =-0.70, P=0.035 were associated with depressive symptoms.Conclusion: Functional capacity seems to be independently associated with depressive symptoms in older people living in community and residential care facilities, whereas overall ADL performance may not be associated. Dependency in the individual ADL tasks of transfer and dressing appear to be independently associated with depressive symptoms and may be an important focus of future interdisciplinary multifactorial intervention studies.Keywords: aged 80 and over, residential facilities, independent living, depression, activities of daily living

  8. CANNABIS, UNA OPCIÓN TERAPÉUTICA / CANNABIS, A THERAPEUTIC OPTION

    Scientific Electronic Library Online (English)

    José Henry, Osorio; Hugo Fernando, Tangarife.

    2009-12-01

    Full Text Available Las preparaciones de Cannabis sativa L. tales como marihuana, hashish y dagga, han sido usadas en medicina por varios siglos. Ahora se sabe que el ?9tetrahidrocannabinol (?9-THC) y sus compuestos relacionados, ejercen una amplia gama de efectos sobre los sistemas inmune, digestivo, reproductivo, ocu [...] lar, cardiovascular, y nervioso central. La presente revisión analiza la literatura disponible relacionada con los efectos terapéuticos de la Cannabis. Abstract in english Cannabis sativa L. preparations, such as marijuana, hashish and dagga, have been used in medicine for many centuries. It is now known that ?9tetrahydrocannabinol (?9-THC) and its related compounds, exert a wide array of effects on the immune, digestive, reproductive, ocular, cardiovascular, and cent [...] ral nervous systems. The present review analyses the literature related to the therapeutic effects of Cannabis.

  9. Long term stability of cannabis resin and cannabis extracts

    DEFF Research Database (Denmark)

    Lindholst, Christian

    2010-01-01

      The aim of the present study was to investigate the stability of cannabinoids in cannabis resin slabs and cannabis extracts upon long-term storage. The levels of tetrahydrocannabinol (THC), cannabinol (CBN), cannabidiol (CBD) and cannabigerol (CBG) on both neutral and acidic form were measured at room temperature, 4 °C and - 20 °C for up to 4 years. Acidic THC degrades exponentially via decarboxylation with concentration halve-lives of approximately 330 and 462 days in daylight and darkness, r...

  10. Implicit associations and explicit expectancies towards cannabis in heavy cannabis users and controls

    Directory of Open Access Journals (Sweden)

    JannaCousijn

    2013-06-01

    Full Text Available Cognitive biases, including implicit memory associations are thought to play an important role in the development of addictive behaviors. The aim of the present study was to investigate implicit affective memory associations in heavy cannabis users. Implicit positive-arousal, sedation, and negative associations towards cannabis were measured with three Single Category Implicit Association Tests (SC-IAT’s and compared between 59 heavy cannabis users and 89 controls. Moreover, we investigated the relationship between these implicit affective associations and explicit expectancies, subjective craving, cannabis use, and cannabis related problems. Results show that heavy cannabis users had stronger implicit positive-arousal associations but weaker implicit negative associations towards cannabis compared to controls. Moreover, heavy cannabis users had stronger sedation but weaker negative explicit expectancies towards cannabis compared to controls. Within heavy cannabis users, more cannabis use was associated with stronger implicit negative associations whereas more cannabis use related problems was associated with stronger explicit negative expectancies, decreasing the overall difference on negative associations between cannabis users and controls. No other associations were observed between implicit associations, explicit expectancies, measures of cannabis use, cannabis use related problems, or subjective craving. These findings indicate that, in contrast to other substances of abuse like alcohol and tobacco, the relationship between implicit associations and cannabis use appears to be weak in heavy cannabis users.

  11. Age at Initiation of Cannabis Use Predicts Age at Onset of Psychosis: The 7- to 8-Year Trend

    OpenAIRE

    Stefanis, Nikos C.; Dragovic, Milan; Power, Brian D.; Jablensky, Assen; Castle, David; Morgan, Vera Anne

    2013-01-01

    We investigated the existence of a temporal association between age at initiation of cannabis use and age at onset of psychotic illness in 997 participants from the 2010 Survey of High Impact Psychosis (SHIP) in Australia. We tested for group differences in age at onset of psychotic illness and in the duration of premorbid exposure to cannabis (DPEC). Analyses were repeated in subgroups of participants with a schizophrenia-spectrum disorder (SSD), a diagnosis of lifetime cannabis dependence (...

  12. Evaluation of herbal cannabis characteristics by medical users: a randomized trial

    Directory of Open Access Journals (Sweden)

    Ducruet Thierry

    2006-11-01

    Full Text Available Abstract Background Cannabis, in herbal form, is widely used as self-medication by patients with diseases such as HIV/AIDS and multiple sclerosis suffering from symptoms including pain, muscle spasticity, stress and insomnia. Valid clinical studies of herbal cannabis require a product which is acceptable to patients in order to maximize adherence to study protocols. Methods We conducted a randomized controlled crossover trial of 4 different herbal cannabis preparations among 8 experienced and authorized cannabis users with chronic pain. Preparations were varied with respect to grind size, THC content and humidity. Subjects received each preparation on a separate day and prepared the drug in their usual way in a dedicated and licensed clinical facility. They were asked to evaluate the products based on appearance (smell, colour, humidity, grind size, ease of preparation and overall appearance and smoking characteristics (burn rate, hotness, harshness and taste. Five-point Likert scores were assigned to each characteristic. Scores were compared between preparations using ANOVA. Results Seven subjects completed the study, and the product with highest THC content (12%, highest humidity (14% and largest grind size (10 mm was rated highest overall. Significant differences were noted between preparations on overall appearance and colour (p = 0.003. Discussion While the small size of the study precludes broad conclusions, the study shows that medical cannabis users can appreciate differences in herbal product. A more acceptable cannabis product may increase recruitment and retention in clinical studies of medical cannabis.

  13. What to make of cannabis and cognition in MS: In search of clarity amidst the haze.

    Science.gov (United States)

    Feinstein, Anthony; Banwell, Emma; Pavisian, Bennis

    2015-12-01

    Given data showing that cannabis (herbal drug from the Cannabis sativa plant) can impair cognition in healthy subjects, the possibility that it may also do so in people with multiple sclerosis (MS) should be cause for concern. Approximately 20% of people with MS inhale or ingest cannabis for a variety of symptoms, or as a lifestyle choice. In addition, pharmaceutically manufactured cannabis (in capsules or spray) is prescribed most often for pain and spasticity; however, there is a dearth of literature on the cognitive effects of cannabis. Furthermore, methodological limitations introduce a cautionary note when interpreting the data. The evidence, which must therefore be considered preliminary, suggests that smoked cannabis may further compromise information processing speed and memory, with magnetic resonance imaging (fMRI) demonstrating more inefficient patterns of cerebral activation during task performance. The findings related to pharmaceutically manufactured cannabis are equivocal. There is a pressing need for further research to inform clinical opinion, which at present reflects a combination of uncertainty and dogma. PMID:26453678

  14. Cannabis use in the community.

    OpenAIRE

    Robertson, J R; Miller, P.; Anderson, R.

    1996-01-01

    BACKGROUND: The illegal use of cannabis has been increasing in many Western countries for the past two decades. Recently, some interest has been shown in modifying legislation and control. The need for general practitioners to be aware of the short- and long-term consequences of cannabis use is increasing, and more information is required about its effects on behaviour, psychological states and the respiratory and cardiovascular systems. The use of general practice populations to study the pr...

  15. Prescribing cannabis for harm reduction

    OpenAIRE

    Collen Mark

    2012-01-01

    Abstract Neuropathic pain affects between 5% and 10% of the US population and can be refractory to treatment. Opioids may be recommended as a second-line pharmacotherapy but have risks including overdose and death. Cannabis has been shown to be effective for treating nerve pain without the risk of fatal poisoning. The author suggests that physicians who treat neuropathic pain with opioids should evaluate their patients for a trial of cannabis and prescribe it when appropriate prior to using o...

  16. Oral cytology in cannabis smokers.

    Science.gov (United States)

    Darling, Mark R; Learmonth, Genevieve M; Arendorf, Trevor M

    2002-04-01

    The effects of cannabis/methaqualone/tobacco smoking on the epithelial cells of the tongue, buccal mucosa and floor of the mouth were examined. Oral mucosal smears for detection of cellular changes were taken from 4 sites in 16 patients. The tongue blade scraping technique was used. The sites sampled included the buccal mucosa (left and right sides), the posterior dorsum of the tongue and the anterior floor of the mouth. Tobacco smoking and non-smoking controls were also examined. The only significant difference between cannabis users and controls was the greater prevalence of bacterial cells in the smears taken from cannabis users. However, there were also greater numbers of degenerate and atypical squamous cells in cannabis smokers than in cigarette-smoking and non-smoking controls. Epithelial cells in smears taken from cannabis users and tobacco-smoking controls also showed koilocytic changes, which were not seen in smears taken from non-smoking controls. Koilocytosis is indicative of human papilloma virus infection, although no apparent lesions were seen in the patients from whom smears had been taken. It would appear that there is a greater tendency towards damaged and immature surface epithelial cells in cannabis smokers. PMID:12078330

  17. Cannabis as a substitute for alcohol and other drugs

    OpenAIRE

    Reiman Amanda

    2009-01-01

    Abstract Background Substitution can be operationalized as the conscious choice to use one drug (legal or illicit) instead of, or in conjunction with, another due to issues such as: perceived safety; level of addiction potential; effectiveness in relieving symptoms; access and level of acceptance. This practice of substitution has been observed among individuals using cannabis for medical purposes. This study examined drug and alcohol use, and the occurrence of substitution among medical cann...

  18. Cannabis Responsive Head Injury Induced Mutiple Disabilities: A Case Report

    OpenAIRE

    Manju Sharma

    2012-01-01

    In recent years cannabinoids and their derivatives have drawn renewed attention because of their diverse pharmacologic activities. We report here one such case, where all types of medical & psychiatric treatment failed to improve the symptoms; however cannabis use was able to bring back this patient to normal productive & meaningful life. The patient was a 47 year old left handed Caucasian had minor subdural hematoma at the posterior vertex and a minor focal subarachnoid haemorrhage f...

  19. Intervention Efficacy in Trials Targeting Cannabis Use Disorders in Patients with Comorbid Psychosis

    DEFF Research Database (Denmark)

    Hjorthoj, Carsten Rygaard; Baker, Amanda

    2014-01-01

    Introduction: Cannabis use disorders are highly prevalent in patients with schizophrenia and other psychoses, and are probably associated with a range of poor outcomes. Several trials have been conducted on this population, the results of which have been summarized in several systematic reviews but never in meta-analyses specifically regarding cannabis use. Methods: PubMed, PsycINFO, EMBASE, and The Cochrane Central Register of Controlled Trials were searched using predefined search terms. We included randomized trials of all types of interventions targeting cannabis use disorders in patients with schizophrenia spectrum disorders. We extracted information on intervention types, efficacy, trial characteristics, and risk of bias. Results: There was no evidence of an effect on frequency of cannabis use, but intervention effects of motivational intervention with or without cognitive behavior therapy were observed on quantity of use and on positive symptoms of schizophrenia. Psychosocial intervention did not have an appreciable effect on negative symptoms. Longer interventions appear to be more efficacious, and efficacy may be better in trials with comparatively few women. Larger trials may be better at establishing effects on positive symptoms. Conclusion: Psychosocial interventions appear moderately efficacious in reducing quantity of cannabis-use and positive symptoms.

  20. Distance to Cannabis Shops and Age of Onset of Cannabis Use.

    Science.gov (United States)

    Palali, Ali; van Ours, Jan C

    2015-11-01

    In the Netherlands, cannabis use is quasi-legalized. Small quantities of cannabis can be bought in cannabis shops. We investigate how the distance to the nearest cannabis shop affects the age of onset of cannabis use. We use a mixed proportional hazard rate framework to take account of observable as well as unobservable characteristics that influence the uptake of cannabis. We find that distance matters. Individuals who grow up within 20km of a cannabis shop have a lower age of onset. Copyright © 2014 John Wiley & Sons, Ltd. PMID:25294622

  1. Distance to Cannabis-Shops and Age of Onset of Cannabis Use

    OpenAIRE

    Palali, A.; Ours, J.C.

    2013-01-01

    Abstract: In the Netherlands cannabis use is quasi-legalized. Small quantities of cannabis can be bought in cannabis-shops. We investigate how the distance to the nearest cannabis- shop affects the age of onset of cannabis use. We use a Mixed Proportional Hazard rate framework to take account of observable as well as unobservable characteristics that in uence the uptake of cannabis. We find that distance matters. Individuals who grow up within 20 kilometers of a cannabis-shop have a lower age...

  2. Cannabis, motivation, and life satisfaction in an internet sample

    Directory of Open Access Journals (Sweden)

    Wilcox Rand

    2006-01-01

    Full Text Available Abstract Although little evidence supports cannabis-induced amotivational syndrome, sources continue to assert that the drug saps motivation 1, which may guide current prohibitions. Few studies report low motivation in chronic users; another reveals that they have higher subjective wellbeing. To assess differences in motivation and subjective wellbeing, we used a large sample (N = 487 and strict definitions of cannabis use (7 days/week and abstinence (never. Standard statistical techniques showed no differences. Robust statistical methods controlling for heteroscedasticity, non-normality and extreme values found no differences in motivation but a small difference in subjective wellbeing. Medical users of cannabis reporting health problems tended to account for a significant portion of subjective wellbeing differences, suggesting that illness decreased wellbeing. All p-values were above p = .05. Thus, daily use of cannabis does not impair motivation. Its impact on subjective wellbeing is small and may actually reflect lower wellbeing due to medical symptoms rather than actual consumption of the plant.

  3. Effects of environmental enrichment during induction of methamphetamine dependence on the behavioral withdrawal symptoms in rats.

    Science.gov (United States)

    Hajheidari, Samira; Miladi-Gorji, Hossein; Bigdeli, Imanollah

    2015-09-25

    This study was designed to examine the effect of environmental enrichment during METH administration on the behavioral withdrawal symptoms after drug abstinence in rats. Rats reared in standard (SE) or enriched environment (EE) during induction of METH dependence with bi-daily injections of METH (2mg/kg, at 12-h. intervals) for 14 days. Then, rats were evaluated for behavioral withdrawal symptoms, and also for anxiety (elevated plus maze-EPM) and depression (Forced swim test-FST) over a ten day period of abstinence. The results showed that stereotypic behaviors score and the number of rearing were significantly lower in METH/EE rats compared to the SE group during 1-4 days. Also, The METH/EE group exhibited more weight gain during 6-10 days of abstinence. The METH/EE rats exhibited lower levels of immobility after METH abstinence than control group in the FST. EE had no effect on anxiety-like behavior. This study showed that exposure to EE diminished the severity of withdrawal symptoms and depressive-like behavior during spontaneous withdrawal from METH. PMID:26275348

  4. Therapeutic Benefits of Cannabis: A Patient Survey

    OpenAIRE

    Webb, Charles W; Webb, Sandra M

    2014-01-01

    Clinical research regarding the therapeutic benefits of cannabis (“marijuana”) has been almost non-existent in the United States since cannabis was given Schedule I status in the Controlled Substances Act of 1970. In order to discover the benefits and adverse effects perceived by medical cannabis patients, especially with regards to chronic pain, we hand-delivered surveys to one hundred consecutive patients who were returning for yearly re-certification for medical cannabis use in Hawai‘i.

  5. Cannabis Use and Performance in Adolescents

    Science.gov (United States)

    Malhotra, Anil; Biswas, Parthasarathy

    2006-01-01

    Cannabis is a widely used illicit drug among adolescents, many of whom perceive little risk from cannabis. Cannabis use is associated with poor academic performance and increased school drop-outs. It is also associated with high-risk behaviors in adolescents like crime, violence, unprotected sexual encounters, and car accidents. Many of these…

  6. Cognitive control moderates the association between emotional instability and alcohol dependence symptoms.

    Science.gov (United States)

    Stevenson, Brittany L; Dvorak, Robert D; Kuvaas, Nicholas J; Williams, Thomas J; Spaeth, Destini T

    2015-06-01

    Previous research has linked emotional instability with problematic alcohol use. This may be a function of increased "hot" information processing (which is relatively automatic in nature and highly influenced by emotional states) for individuals with more emotional instability. According to dual-process models, cognitive control may attenuate the impact of emotional instability by preventing an overreliance on hot information processing. It was hypothesized that emotional instability would be positively associated with alcohol-related consequences, but that cognitive control would moderate this association. Participants were undergraduate students (n = 80) who endorsed drinking at moderate levels. Participants completed laboratory assessments of emotional instability, alcohol use and its consequences, and cognitive control. An observed variable path model examined the association between emotional instability and alcohol problems. Consistent with hypotheses, emotional instability was positively associated with alcohol consequences, and this relationship was moderated by cognitive control, at least for dependence symptoms. At low levels of cognitive control, there was a positive association between emotional instability and dependence symptoms (? = 0.514, p information processing. Consistent with dual-process theory, this relationship is diminished among individuals with more cognitive control. Interventions focusing on increasing cognitive control may be effective in reducing alcohol pathology associated with emotional instability. (PsycINFO Database Record PMID:25621417

  7. Cannabinoid Hyperemesis Syndrome: A Paradoxical Cannabis Effect

    Science.gov (United States)

    Figueroa-Rivera, Ivonne Marie; Estremera-Marcial, Rodolfo; Sierra-Mercado, Marielly; Gutiérrez-Núñez, José; Toro, Doris H.

    2015-01-01

    Despite well-established antiemetic properties of marijuana, there has been increasing evidence of a paradoxical effect in the gastrointestinal tract and central nervous system, given rise to a new and underrecognized clinical entity called the Cannabinoid Hyperemesis Syndrome. Reported cases in the medical literature have established a series of patients exhibiting a classical triad of symptoms: cyclic vomiting, chronic marijuana use, and compulsive bathing. We present a case of a 29-year-old man whose clinical presentation strongly correlates with cannabinoid hyperemesis syndrome. Despite a diagnosis of exclusion, this syndrome should be considered plausible in the setting of a patient with recurrent intractable vomiting and a strong history of cannabis use as presented in this case. PMID:26266060

  8. Passive inhalation of cannabis smoke

    Energy Technology Data Exchange (ETDEWEB)

    Law, B.; Mason, P.A.; Moffat, A.C.; King, L.J.; Marks, V.

    1984-09-01

    Six volunteers each smoked simultaneously, in a small unventilated room (volume 27 950 liter), a cannabis cigarette containing 17.1 mg delta 9-tetrahydrocannabinol (THC). A further four subjects - passive inhalers - remained in the room during smoking and afterwards for a total of 3 h. Blood and urine samples were taken from all ten subjects and analyzed by radioimmunoassay for THC metabolites. The blood samples from the passive subjects taken up to 3 h after the start of exposure to cannabis smoke showed a complete absence of cannabinoids. In contrast, their urine samples taken up to 6 h after exposure showed significant concentrations of cannabinoid metabolites (less than or equal to 6.8 ng ml-1). These data, taken with the results of other workers, show passive inhalation of cannabis smoke to be possible. These results have important implications for forensic toxicologists who are frequently called upon to interpret cannabinoid levels in body fluids.

  9. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug

    Directory of Open Access Journals (Sweden)

    Zuardi A.W.

    2006-01-01

    Full Text Available A high dose of delta9-tetrahydrocannabinol, the main Cannabis sativa (cannabis component, induces anxiety and psychotic-like symptoms in healthy volunteers. These effects of delta9-tetrahydrocannabinol are significantly reduced by cannabidiol (CBD, a cannabis constituent which is devoid of the typical effects of the plant. This observation led us to suspect that CBD could have anxiolytic and/or antipsychotic actions. Studies in animal models and in healthy volunteers clearly suggest an anxiolytic-like effect of CBD. The antipsychotic-like properties of CBD have been investigated in animal models using behavioral and neurochemical techniques which suggested that CBD has a pharmacological profile similar to that of atypical antipsychotic drugs. The results of two studies on healthy volunteers using perception of binocular depth inversion and ketamine-induced psychotic symptoms supported the proposal of the antipsychotic-like properties of CBD. In addition, open case reports of schizophrenic patients treated with CBD and a preliminary report of a controlled clinical trial comparing CBD with an atypical antipsychotic drug have confirmed that this cannabinoid can be a safe and well-tolerated alternative treatment for schizophrenia. Future studies of CBD in other psychotic conditions such as bipolar disorder and comparative studies of its antipsychotic effects with those produced by clozapine in schizophrenic patients are clearly indicated.

  10. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug

    Scientific Electronic Library Online (English)

    A.W., Zuardi; J.A.S., Crippa; J.E.C., Hallak; F.A., Moreira; F.S., Guimarães.

    2006-04-01

    Full Text Available A high dose of delta9-tetrahydrocannabinol, the main Cannabis sativa (cannabis) component, induces anxiety and psychotic-like symptoms in healthy volunteers. These effects of delta9-tetrahydrocannabinol are significantly reduced by cannabidiol (CBD), a cannabis constituent which is devoid of the typ [...] ical effects of the plant. This observation led us to suspect that CBD could have anxiolytic and/or antipsychotic actions. Studies in animal models and in healthy volunteers clearly suggest an anxiolytic-like effect of CBD. The antipsychotic-like properties of CBD have been investigated in animal models using behavioral and neurochemical techniques which suggested that CBD has a pharmacological profile similar to that of atypical antipsychotic drugs. The results of two studies on healthy volunteers using perception of binocular depth inversion and ketamine-induced psychotic symptoms supported the proposal of the antipsychotic-like properties of CBD. In addition, open case reports of schizophrenic patients treated with CBD and a preliminary report of a controlled clinical trial comparing CBD with an atypical antipsychotic drug have confirmed that this cannabinoid can be a safe and well-tolerated alternative treatment for schizophrenia. Future studies of CBD in other psychotic conditions such as bipolar disorder and comparative studies of its antipsychotic effects with those produced by clozapine in schizophrenic patients are clearly indicated.

  11. What does a mouse tell us about neuregulin 1 – cannabis interactions?

    Directory of Open Access Journals (Sweden)

    Tim Karl

    2013-02-01

    Full Text Available The link between cannabis and psychosis has been debated although there is substantial epidemiological evidence showing that cannabis increases the risk of psychosis. It has been hypothesized that schizophrenia patients carrying particular risk genes might be more sensitive to the psychosis-inducing effects of cannabis than other patients and healthy test subjects. Here we review the effects of cannabinoids on a mutant mouse model for the schizophrenia candidate gene neuregulin 1 (Nrg1. The studies suggest a complex interaction between cannabis and Nrg1: the neuro-behavioural effects of cannabinoids were different in Nrg1 mutant and control mice and depended on exposure time, sex and age of test animals. This research provides the first evidence of complex cannabis-Nrg1 interactions suggesting Nrg1 as a prime target for future clinical investigations. Furthermore, it highlights that animal model research can broaden our understanding of the complex multi-factorial aetiology of schizophrenia. Finally, the findings are important to preventive psychiatry: if the genes that confer genetic vulnerability to cannabis-induced psychosis were identified patients at-high risk could be forewarned of the potential dangers of cannabis abuse.

  12. The Importance of Family Relations for Cannabis Users: The Case of Serbian Adolescents

    Directory of Open Access Journals (Sweden)

    Zorica Terzic Supic

    2013-03-01

    Full Text Available Background: Adolescence is transitional stage of physical and mental human development occuring between childhood and adult life. Social interactions and environmental factors together are important predictors of adolescent cannabis use. This study aimed to examine the relationship between the social determinants and adolescents behavior with cannabis consumption.Methods: A cross sectional study as part of the European School Survey Project on Alcohol and other Drugs was conducted among 6.150 adolescents aged 16 years in three regions of Serbia, and three types of schools (gymnasium, vocational – professional, and vocational – handicraft during May – June 2008. A multivariate logistic regression analysis was carried out to obtain adjusted odds ratios with 95% con?dence intervals in which the dependent variable was cannabis consumption non-user and user.Results: Among 6.7% of adolescents who had tried cannabis at least one in their lives, boys were more involved in cannabis use than girls, especially boys from gymnasium school. Well off family, lower education of mother, worse relations with parents were significantly associated with cannabis use (P < 0.05. Behaviors like skipping from schools, frequent evening outs, and playing on slot machines were also related to cannabis use (P < 0.05.Conclusions: The study confirmed the importance of family relationship development. Drug use preventive programmes should include building interpersonal trust in a family lifecycle and school culture.

  13. Induction of sister-chromatid exchanges in heroin-cannabis, heroin and cannabis addicts

    OpenAIRE

    Vassiliades, N.; ??????????, ?.; Mourelatos, D; Dozi-Vassiliades, J.; Epivatianos, P.; Hatzitheodoridou, P.; ??????????, ?.; ???????????, ?.; ???????????????, ?.

    2009-01-01

    The aim of this study was to determine the frequency of sister-chromatid exchanges (SCEs) in heroin-cannabis, heroin and cannabis addicts. The group of 84 subjects consisted of 42 controls, 16 heroin-cannabis addicts, 12 heroin addicts and 14 cannabis addicts. The mean number of SCEs/cell was 12.95 in heroin-cannabis addicts, 12.05 in heroin addicts and 11.99 in cannabis addicts. These values are significantly (P less than 0.002) higher than the mean values found in controls. This increase in...

  14. Studies on cannabis, 3

    International Nuclear Information System (INIS)

    The seedlings from Cannabis sativa L. seeds irradiated with different doses of ?-rays were examined, in order to determine the dose sufficient to kill the young plants naturally, before their hallucinnogenic component increases. The seeds of ''Minamioshihara No. 1'', which were harvested in 1972 in Tochigi Prefecture, were irradiated with eight different doses of 60Co ?-rays in January 17, 1973, and the seedlings were examined several times during the subsequent 9 months, from March to November 1973, and their morphological and histological effects were examined, and the results are summarized as follows: Samples irradiated with 1500 and 1000 krads developed radicles about 3 mm in length. Samples irradiated with 500, 200, and 50 krads grew into young plants with the first set of leaves, without lateral roots. Samples irradiated with 30 krads grew to about 10 cm high with a few lateral roots, and the epicotyls about 1 cm in length. These young plants from the irradiated seeds stayed in the same condition and then died. Samples irradiated with 15 and 5 krads grew in the same way as the controls until the stage of flowering. Samples irradiated with 500, 200, 50, and 30 krads showerd the cell membranes of endodermis and pericycle to be partially lignified and suberized. The degree of change was related to the dose of ?-rays. Samples irradiated with 30 krads showed withered cells near the end of the lateral nerves on the first and second set of leaves. The economical dose of 60Co ?-rays for inhibiting young plants from developing into adult ones was a minimum of 30 krads which made the young plants die. Irradiation with 50 krads of ?-rays will be required to kill the young plants completely before they develop the hallucinogenic component. (auth.)

  15. Presentations to the Emergency Department Following Cannabis use-a Multi-Centre Case Series from Ten European Countries.

    Science.gov (United States)

    Dines, Alison M; Wood, David M; Galicia, Miguel; Yates, Christopher M; Heyerdahl, Fridtjof; Hovda, Knut Erik; Giraudon, Isabelle; Sedefov, Roumen; Dargan, Paul I

    2015-12-01

    Cannabis is the most commonly used illicit drug in Europe, and is generally regarded as having low acute toxicity. We present the findings of the first 6 months of data collection from the Euro-DEN project on presentations related to cannabis use to further understand the acute toxicity related to the use of cannabis. Data was extracted on clinical features, treatment and outcome from the Euro-DEN minimum dataset for all cases of acute recreational drug toxicity reported 1st October 2013 to 31st March 2014 for all cannabis-related presentations. Of 2198 presentations reported by 14 of the 16 Euro-DEN centres, 356 (16.2 %) involved cannabis either alone or together with other drugs/alcohol. There were 36 that involved lone use of cannabis (1.6 % of all presentations). Of the 35 non-fatal lone cannabis presentations, the most commonly reported features were neuro-behavioural (agitation/aggression 8 (22.9 %), psychosis 7 (20.0 %), anxiety 7 (20.0 %)) and vomiting 6 (17.1 %). Most patients (25, 71.4 %) received no treatment and 30 (85.7 %) were discharged/self-discharged from the ED. There was one fatality amongst these lone-cannabis cases: an 18-year-old male collapsed with an asystolic cardiac arrest whilst smoking cannabis and suffered hypoxic brain injury related to prolonged cardiac arrest. THC was detected in a urine sample taken at ED arrival; no other drugs were detected. Lone acute cannabis toxicity was typically associated with neuro-behavioural symptoms and vomiting. Although uncommon, severe toxicity including cardiovascular toxicity and death may be under-recognised, and it is important that Emergency Physicians are aware of this. PMID:25652342

  16. An fMRI-Based Neural Signature of Decisions to Smoke Cannabis.

    Science.gov (United States)

    Bedi, Gillinder; Lindquist, Martin A; Haney, Margaret

    2015-11-01

    Drug dependence may be at its core a pathology of choice, defined by continued decisions to use drugs irrespective of negative consequences. Despite evidence of dysregulated decision making in addiction, little is known about the neural processes underlying the most clinically relevant decisions drug users make: decisions to use drugs. Here, we combined functional magnetic resonance imaging (fMRI), machine learning, and human laboratory drug administration to investigate neural activation underlying decisions to smoke cannabis. Nontreatment-seeking daily cannabis smokers completed an fMRI choice task, making repeated decisions to purchase or decline 1-12 placebo or active cannabis 'puffs' ($0.25-$5/puff). One randomly selected decision was implemented. If the selected choice had been bought, the cost was deducted from study earnings and the purchased cannabis smoked in the laboratory; alternatively, the participant remained in the laboratory without cannabis. Machine learning with leave-one-subject-out cross-validation identified distributed neural activation patterns discriminating decisions to buy cannabis from declined offers. A total of 21 participants were included in behavioral analyses; 17 purchased cannabis and were thus included in fMRI analyses. Purchasing varied lawfully with dose and cost. The classifier discriminated with 100% accuracy between fMRI activation patterns for purchased vs declined cannabis at the level of the individual. Dorsal striatum, insula, posterior parietal regions, anterior and posterior cingulate, and dorsolateral prefrontal cortex all contributed reliably to this neural signature of decisions to smoke cannabis. These findings provide the basis for a brain-based characterization of drug-related decision making in drug abuse, including effects of psychological and pharmacological interventions on these processes. PMID:25962875

  17. [Spanish adaptation and validation of The Adolescent-Cannabis Problems Questionnaire (CPQ-A)].

    Science.gov (United States)

    Fernández-Artamendi, Sergio; Fernández-Hermida, José Ramón; García-Cueto, Eduardo; Secades-Villa, Roberto; García-Fernández, Gloria; Barrial-Barbén, Silvia

    2012-01-01

    Cannabis is a widely used substance among adolescents and young adults, but demand for help and treatment from this age group continues to be low. It is therefore essential to develop instruments especially designed for the early detection of problems associated with cannabis use in this population. The purpose of this work is to adapt and validate the CPQ-A (Adolescent Cannabis Problems Questionnaire) for its use as a screening instrument in Spanish population. The sample was made up of 144 young people (71.5% male) aged 16 to 20 (M = 17.12; SD = 1.17) who had used cannabis in the last month and were on some kind of study or training course at various educational institutions in Asturias (a region in northern Spain). Factor analysis of the CPQ-A in this sample provides evidence of a unidimensional structure, with a Cronbach's Alpha of 0.86 for the questionnaire. The evidence also shows that the instrument's convergent validity is good. The CPQ-A score permits discrimination between moderate and excessive cannabis users over the last month, is positively related to score on the CAST (Cannabis Abuse Screening Test), and presents adequate sensitivity and specificity for identifying cases of cannabis abuse and dependence according to the DSM IV-TR criteria. It is also sensitive to young people's degree of concern about cannabis use and the psychopathological effects associated with it. In accordance with the results obtained, the CPQ-A can be considered a useful screening tool for young cannabis users with problems. PMID:22508016

  18. Pharmacokinetic and pharmacodynamic profile of supratherapeutic oral doses of ?9-THC in cannabis users

    OpenAIRE

    Lile, Joshua A.; Kelly, Thomas H.; Charnigo, Richard J.; Stinchcomb, Audra L; Hays, Lon R.

    2013-01-01

    Oral ?9-tetrahydrocannabinol (?9-THC) has been evaluated as a medication for cannabis dependence, but repeated administration of acute oral doses up to 40 mg has not been effective at reducing drug-taking behavior. Larger doses might be necessary to affect cannabis use. The purpose of the present study was therefore to determine the physiological and behavioral effects of oral ?9-THC at acute doses higher than those tested previously. The pharmacokinetic and pharmacodynamic profile of oral ?9...

  19. Study Parses Comorbidity of Cannabis Use and Social Anxiety

    Science.gov (United States)

    ... Parses Comorbidity of Cannabis Use and Social Anxiety Study Parses Comorbidity of Cannabis Use and Social Anxiety ... October 25, 2013 A recent large-scale epidemiological study sheds light on the relationship between cannabis use ...

  20. Simultaneous cannabis and tobacco use and cannabis-related outcomes in young women

    OpenAIRE

    Agrawal, Arpana; Lynskey, Michael T.; MADDEN, PAMELA A.F.; Pergadia, Michele L.; Bucholz, Kathleen K.; Heath, Andrew C.

    2008-01-01

    Compared to those who reported a lifetime co-occurrence of cannabis and tobacco use, individuals who report simultaneous use of cannabis and tobacco are more likely to also report higher rates of substance-related problems and psychopathology. In a sample of young women, we examine (a) co-occurring use, or whether regular cigarette smoking is associated with increased cannabis involvement and (b) simultaneous use, a special form of co-occurring use where cannabis and cigarettes are typically ...

  1. Prevalence of eating disorder attitudes among men and women with exercise dependence symptoms: a non-athlete population study

    Directory of Open Access Journals (Sweden)

    Elaine Fernanda da Silva

    2013-09-01

    Full Text Available The present study sought to describe the prevalence of Secondary Exercise Dependence (ScED, i.e. eating disorders attitudes along with exercise dependence symptoms may differ between men and women in a broader exercising population. In this study, 174 regularly exerciser, aged 18-62 years old, who were invited to respond the Exercise Dependence Scale (EDS and the Eating Attitudes Test (EAT-26. There were more women than men with ScED. However, only men in the sample presented exercise dependence symptoms without eating disorders attitudes. Eating disorders may or may not exist in those who are exercise dependent in the broad exercising population, although there is a higher prevalence of ScED in women than men.

  2. Dutch coffee shops and trends in cannabis use.

    Science.gov (United States)

    Korf, Dirk J

    2002-01-01

    Conflicting predictions have been made to the influence of decriminalization on cannabis use. Prohibitionists forecast that decriminalization will lead to an increase in consumption of cannabis, while their opponents hypothesise that cannabis use will decline after decriminalization. Most probably cannabis use in the Netherlands so far evolved in two waves, with a first peak around 1970, a low during the late 1970s and early 1980s, and a second peak in the mid-1990s. It is striking that this trend in cannabis use among youth in the Netherlands rather parallels four identified stages in the availability of cannabis. The number of cannabis users peaked when the cannabis was distributed through an underground market (late 1960s and early 1970s). Then the number decreased as house dealers were superseeding the underground market (1970s), and went up again after coffee shops took over the sale of cannabis (1980s), and stabilised or slightly decreased by the end of the 1990s when the number of coffee shops was reduced. Although changes in cannabis policy went along with changes in availability of cannabis and prevalence of cannabis use, it is questionable whether changes in cannabis policy were causally related to trends in cannabis use. Cannabis use also developed in waves in other European countries that did not decriminalize cannabis, as well as in the US. Consequently, trends in cannabis use seem to develop rather independently of cannabis policy. PMID:12369472

  3. Gone to Pot - A Review of the Association between Cannabis and Psychosis.

    Science.gov (United States)

    Radhakrishnan, Rajiv; Wilkinson, Samuel T; D'Souza, Deepak Cyril

    2014-01-01

    Cannabis is the most commonly used illicit drug worldwide, with ~5 million daily users worldwide. Emerging evidence supports a number of associations between cannabis and psychosis/psychotic disorders, including schizophrenia. These associations-based on case-studies, surveys, epidemiological studies, and experimental studies indicate that cannabinoids can produce acute, transient effects; acute, persistent effects; and delayed, persistent effects that recapitulate the psychopathology and psychophysiology seen in schizophrenia. Acute exposure to both cannabis and synthetic cannabinoids (Spice/K2) can produce a full range of transient psychotomimetic symptoms, cognitive deficits, and psychophysiological abnormalities that bear a striking resemblance to symptoms of schizophrenia. In individuals with an established psychotic disorder, cannabinoids can exacerbate symptoms, trigger relapse, and have negative consequences on the course of the illness. Several factors appear to moderate these associations, including family history, genetic factors, history of childhood abuse, and the age at onset of cannabis use. Exposure to cannabinoids in adolescence confers a higher risk for psychosis outcomes in later life and the risk is dose-related. Individuals with polymorphisms of COMT and AKT1 genes may be at increased risk for psychotic disorders in association with cannabinoids, as are individuals with a family history of psychotic disorders or a history of childhood trauma. The relationship between cannabis and schizophrenia fulfills many but not all of the standard criteria for causality, including temporality, biological gradient, biological plausibility, experimental evidence, consistency, and coherence. At the present time, the evidence indicates that cannabis may be a component cause in the emergence of psychosis, and this warrants serious consideration from the point of view of public health policy. PMID:24904437

  4. Gone to Pot - A Review of the Association between Cannabis and Psychosis

    Directory of Open Access Journals (Sweden)

    DeepakCD'Souza

    2014-05-01

    Full Text Available Cannabis is the most commonly used illicit drug worldwide, with approximately 5 million daily users worldwide. Emerging evidence supports a number of associations between cannabis and psychosis/psychotic disorders, including schizophrenia. These associations based on case-studies, surveys, epidemiological studies, and experimental studies indicate that cannabinoids can produce acute, transient effects; acute, persistent effects as well as delayed, persistent effects that recapitulate the psychopathology and psychophysiology seen in psychotic illness such as schizophrenia. Acute exposure to both cannabis and synthetic cannabinoids (Spice/ K2 can produce a full range of transient psychotomimetic symptoms, cognitive deficits, and psychophysiological abnormalities that bear a striking resemblance to symptoms of schizophrenia. In individuals with an established psychotic disorder, cannabinoids can exacerbate symptoms, trigger relapse, and have negative consequences on the course of the illness. Several factors appear to moderate these associations, including family history, genetic factors, history of childhood abuse, and the age at onset of cannabis use. Exposure to cannabinoids in adolescence confers a higher risk for psychosis outcomes in later life and the risk is dose-related. Individuals with polymorphisms of COMT and AKT1 genes may be at increased risk for psychotic disorders in association with cannabinoids, as are individuals with a family history of psychotic disorders or a history of childhood trauma. The relationship between cannabis and schizophrenia fulfills many but not all of the standard criteria for causality, including temporality, biological gradient, biological plausibility, experimental evidence, consistency, and coherence. At the present time, the evidence indicates that cannabis may be a “component cause” in the emergence of psychosis, and warrants serious consideration from the point of view of public health policy.

  5. Determination of Pesticide Residues in Cannabis Smoke

    OpenAIRE

    Nicholas Sullivan; Sytze Elzinga; Raber, Jeffrey C.

    2013-01-01

    The present study was conducted in order to quantify to what extent cannabis consumers may be exposed to pesticide and other chemical residues through inhaled mainstream cannabis smoke. Three different smoking devices were evaluated in order to provide a generalized data set representative of pesticide exposures possible for medical cannabis users. Three different pesticides, bifenthrin, diazinon, and permethrin, along with the plant growth regulator paclobutrazol, which are readily available...

  6. Intervention efficacy in trials targeting cannabis use disorders in patients with comorbid psychosis systematic review and meta-analysis

    DEFF Research Database (Denmark)

    Hjorthoj, Carsten Rygaard; Baker, Amanda

    2014-01-01

    INTRODUCTION: Cannabis use disorders are highly prevalent in patients with schizophrenia and other psychoses, and are probably associated with a range of poor outcomes. Several trials have been conducted on this population, the results of which have been summarized in several systematic reviews but never in meta-analyses specifically regarding cannabis use. METHODS: PubMed, PsycINFO, EMBASE, and The Cochrane Central Register of Controlled Trials were searched using predefined search terms. We included randomized trials of all types of interventions targeting cannabis use disorders in patients with schizophrenia spectrum disorders. We extracted information on intervention types, efficacy, trial characteristics, and risk of bias. RESULTS: There was no evidence of an effect on frequency of cannabis use, but intervention effects of motivational intervention with or without cognitive behavior therapy were observed on quantity of use and on positive symptoms of schizophrenia. Psychosocial intervention did not have an appreciable effect on negative symptoms. Longer interventions appear to be more efficacious, and efficacy may be better in trials with comparatively few women. Larger trials may be better at establishing effects on positive symptoms. CONCLUSION: Psychosocial interventions appear moderately efficacious in reducing quantity of cannabis-use and positive symptoms.

  7. Cannabis use and cognition in schizophrenia

    Directory of Open Access Journals (Sweden)

    Kenneth Hugdahl

    2009-11-01

    Full Text Available People with schizophrenia frequently report cannabis use, and cannabis may be a risk factor for schizophrenia, mediated through effects on brain function and biochemistry. Thus, it is conceivable that cannabis may also influence cognitive functioning in this patients group. We report data from our own laboratory on the use of cannabis by schizophrenia patients, and review the existing literature on the effects of cannabis on cognition in schizophrenia and related psychosis. Of the 23 studies that were found, 14 reported that the cannabis users had better cognitive performance than the schizophrenia non-users. Eight studies reported no or minimal differences in cognitive performance in the two groups, but only one study reported better cognitive performance in the schizophrenia non-user group. Our own results confirm the overall impression from the literature review of better cognitive performance in the cannabis user group. These paradoxical findings may have several explanations, which are discussed. We suggest that cannabis causes a transient cognitive breakdown enabling the development of psychosis, imitating the typical cognitive vulnerability seen in schizophrenia. This is further supported by an earlier age of onset and fewer neurological soft signs in the cannabis-related schizophrenia group, suggesting an alternative pathway to psychosis.

  8. Quantification of Cannabinoid Content in Cannabis

    Science.gov (United States)

    Tian, Y.; Zhang, F.; Jia, K.; Wen, M.; Yuan, Ch.

    2015-09-01

    Cannabis is an economically important plant that is used in many fields, in addition to being the most commonly consumed illicit drug worldwide. Monitoring the spatial distribution of cannabis cultivation and judging whether it is drug- or fiber-type cannabis is critical for governments and international communities to understand the scale of the illegal drug trade. The aim of this study was to investigate whether the cannabinoids content in cannabis could be spectrally quantified using a spectrometer and to identify the optimal wavebands for quantifying the cannabinoid content. Spectral reflectance data of dried cannabis leaf samples and the cannabis canopy were measured in the laboratory and in the field, respectively. Correlation analysis and the stepwise multivariate regression method were used to select the optimal wavebands for cannabinoid content quantification based on the laboratory-measured spectral data. The results indicated that the delta-9-tetrahydrocannabinol (THC) content in cannabis leaves could be quantified using laboratory-measured spectral reflectance data and that the 695 nm band is the optimal band for THC content quantification. This study provides prerequisite information for designing spectral equipment to enable immediate quantification of THC content in cannabis and to discriminate drug- from fiber-type cannabis based on THC content quantification in the field.

  9. Therapeutic potential of cannabis-related drugs.

    Science.gov (United States)

    Alexander, Stephen P H

    2016-01-01

    In this review, I will consider the dual nature of Cannabis and cannabinoids. The duality arises from the potential and actuality of cannabinoids in the laboratory and clinic and the 'abuse' of Cannabis outside the clinic. The therapeutic areas currently best associated with exploitation of Cannabis-related medicines include pain, epilepsy, feeding disorders, multiple sclerosis and glaucoma. As with every other medicinal drug of course, the 'trick' will be to maximise the benefit and minimise the cost. After millennia of proximity and exploitation of the Cannabis plant, we are still playing catch up with an understanding of its potential influence for medicinal benefit. PMID:26216862

  10. Is cannabis a stepping stone for cocaine?

    OpenAIRE

    Ours, J.C.

    2003-01-01

    This paper uses a unique dataset collected among inhabitants of Amsterdam, to study the dynamics in the consumption of cannabis and cocaine.If people start using these drugs they are most likely to do so at age 18-20 for cannabis and age 20-25 for cocaine.An analysis of the starting rates shows some evidence of cannabis being a "stepping stone" for cocaine.However, the fact that some individuals use both cannabis and cocaine has to do mostly with (unobserved) personal characteristics and not ...

  11. Therapeutic benefits of cannabis: a patient survey.

    Science.gov (United States)

    Webb, Charles W; Webb, Sandra M

    2014-04-01

    Clinical research regarding the therapeutic benefits of cannabis ("marijuana") has been almost non-existent in the United States since cannabis was given Schedule I status in the Controlled Substances Act of 1970. In order to discover the benefits and adverse effects perceived by medical cannabis patients, especially with regards to chronic pain, we hand-delivered surveys to one hundred consecutive patients who were returning for yearly re-certification for medical cannabis use in Hawai'i. The response rate was 94%. Mean and median ages were 49.3 and 51 years respectively. Ninety-seven per cent of respondents used cannabis primarily for chronic pain. Average pain improvement on a 0-10 pain scale was 5.0 (from 7.8 to 2.8), which translates to a 64% relative decrease in average pain. Half of all respondents also noted relief from stress/anxiety, and nearly half (45%) reported relief from insomnia. Most patients (71%) reported no adverse effects, while 6% reported a cough or throat irritation and 5% feared arrest even though medical cannabis is legal in Hawai'i. No serious adverse effects were reported. These results suggest that Cannabis is an extremely safe and effective medication for many chronic pain patients. Cannabis appears to alleviate pain, insomnia, and may be helpful in relieving anxiety. Cannabis has shown extreme promise in the treatment of numerous medical problems and deserves to be released from the current Schedule I federal prohibition against research and prescription. PMID:24765558

  12. [Therapeutic use of cannabis derivatives].

    Science.gov (United States)

    Benyamina, Amine; Reynaud, Michel

    2014-02-01

    The therapeutic use of cannabis has generated a lot of interest in the past years, leading to a better understanding of its mechanisms of action. Countries like the United States and Canada have modified their laws in order to make cannabinoid use legal in the medical context. It's also the case in France now, where a recent decree was issued, authorizing the prescription of medication containing "therapeutic cannabis" (decree no. 2013-473, June 5, 2013). Cannabinoids such as dronabinol, Sativex and nabilone have been tested for the treatment of acute and chronic pain. These agents are most promising to relieve chronic pain associated with cancer, with human immunodeficiency virus infection and with multiple sclerosis. However, longer-term studies are required to determine potential long-term adverse effects and risks of misuse and addiction. PMID:24701869

  13. Escitalopram is Associated with Reductions in Pain Severity and Pain Interference in Opioid Dependent Patients with Depressive Symptoms

    OpenAIRE

    Tsui, Judith I.; Herman, Debra S.; Kettavong, Malyna; Anderson, Bradley J; STEIN, Michael D.

    2011-01-01

    Pain is common among opioid dependent patients, yet pharmacologic strategies are limited. The aim of this study was to explore whether escitalopram, a selective serotonin reuptake inhibitor, was associated with reductions in pain. The study used longitudinal data from a randomized, controlled trial that evaluated the effects of escitalopram on treatment retention in patients with depressive symptoms who were initiating buprenorphine/naloxone for treatment of opioid dependence. Participants we...

  14. Regulating compassion: an overview of Canada's federal medical cannabis policy and practice

    Directory of Open Access Journals (Sweden)

    Lucas Philippe G

    2008-01-01

    Full Text Available Abstract Background In response to a number of court challenges brought forth by Canadian patients who demonstrated that they benefited from the use of medicinal cannabis but remained vulnerable to arrest and persecution as a result of its status as a controlled substance, in 1999 Canada became the second nation in the world to initiate a centralized medicinal cannabis program. Over its six years of existence, this controversial program has been found unconstitutional by a number of courts, and has faced criticism from the medical establishment, law enforcement, as well as the patient/participants themselves. Methods This critical policy analysis is an evidence-based review of court decisions, government records, relevant studies and Access to Information Act data related to the three main facets of Health Canada's medicinal cannabis policy – the Marihuana Medical Access Division (MMAD; the Canadians Institute of Health Research Medical Marijuana Research Program; and the federal cannabis production and distribution program. This analysis also examines Canada's network of unregulated community-based dispensaries. Results There is a growing body of evidence that Health Canada's program is not meeting the needs of the nation's medical cannabis patient community and that the policies of the Marihuana Medical Access Division may be significantly limiting the potential individual and public health benefits achievable though the therapeutic use of cannabis. Canada's community-based dispensaries supply medical cannabis to a far greater number of patients than the MMAD, but their work is currently unregulated by any level of government, leaving these organizations and their clients vulnerable to arrest and prosecution. Conclusion Any future success will depend on the government's ability to better assess and address the needs and legitimate concerns of end-users of this program, to promote and fund an expanded clinical research agenda, and to work in cooperation with community-based medical cannabis dispensaries in order to address the ongoing issue of safe and timely access to this herbal medicine.

  15. The HUNT study: participation is associated with survival and depends on socioeconomic status, diseases and symptoms

    Directory of Open Access Journals (Sweden)

    Langhammer Arnulf

    2012-09-01

    Full Text Available Abstract Background Population based studies are important for prevalence, incidence and association studies, but their external validity might be threatened by decreasing participation rates. The 50 807 participants in the third survey of the HUNT Study (HUNT3, 2006-08, represented 54% of the invited, necessitating a nonparticipation study. Methods Questionnaire data from HUNT3 were compared with data collected from several sources: a short questionnaire to nonparticipants, anonymous data on specific diagnoses and prescribed medication extracted from randomly selected general practices, registry data from Statistics Norway on socioeconomic factors and mortality, and from the Norwegian Prescription Database on drug consumption. Results Participation rates for HUNT3 depended on age, sex and type of symptoms and diseases, but only small changes were found in the overall prevalence estimates when including data from 6922 nonparticipants. Among nonparticipants, the prevalences of cardiovascular diseases, diabetes mellitus and psychiatric disorders were higher both in nonparticipant data and data extracted from general practice, compared to that reported by participants, whilst the opposite pattern was found, at least among persons younger than 80 years, for urine incontinence, musculoskeletal pain and headache. Registry data showed that the nonparticipants had lower socioeconomic status and a higher mortality than participants. Conclusion Nonparticipants had lower socioeconomic status, higher mortality and showed higher prevalences of several chronic diseases, whilst opposite patterns were found for common problems like musculoskeletal pain, urine incontinence and headache. The impact on associations should be analyzed for each diagnosis, and data making such analyses possible are provided in the present paper.

  16. Do gender differences in the role of dysfunctional attitudes in depressive symptoms depend on depression history?

    OpenAIRE

    You, Sungeun; Merritt, Rebecca Davis; Conner, Kenneth R.

    2009-01-01

    Gender differences in the moderating role of dysfunctional attitudes in the relationship between life stress and depressive symptoms were examined with and without controlling for the presence of lifetime history of depression. When lifetime history of depression was controlled, dysfunctional attitudes played a moderating role in the relationship between life stress and depressive symptoms for both men and women. However, when lifetime history of depression was not controlled, dysfunctional a...

  17. Cannabis og cannabinoidreceptorer misbrug og psykose

    DEFF Research Database (Denmark)

    Hjorthoj, C.; Nordentoft, M.

    2008-01-01

    Abuse of alcohol and drugs often co-occur with psychotic disorders. In this article, we introduce to the reader a number of receptors and neurotransmitter-systems involved in cannabis-abuse. Subsequently, we introduce the connection between abuse - particularly cannabis-abuse - and psychotic disorders Udgivelsesdato: 2008/11/10

  18. Cannabis og cannabinoidreceptorer--misbrug og psykose

    DEFF Research Database (Denmark)

    HjorthØj, Carsten; Nordentoft, Merete

    2008-01-01

    Abuse of alcohol and drugs often co-occur with psychotic disorders. In this article, we introduce to the reader a number of receptors and neurotransmitter-systems involved in cannabis-abuse. Subsequently, we introduce the connection between abuse - particularly cannabis-abuse - and psychotic disorders.

  19. Recreational cannabis use: Pleasures and pitfalls.

    Science.gov (United States)

    Rella, Joseph G

    2015-11-01

    Cannabis is widely used for a variety of reasons, and its changing legal status may foster more new users. Although the acute clinical effects of cannabis are generally benign, clinicians should be aware of health complications and testing limitations. PMID:26540327

  20. Naltrexone Maintenance Decreases Cannabis Self-Administration and Subjective Effects in Daily Cannabis Smokers.

    Science.gov (United States)

    Haney, Margaret; Ramesh, Divya; Glass, Andrew; Pavlicova, Martina; Bedi, Gillinder; Cooper, Ziva D

    2015-10-01

    Given that cannabis use is increasing in the United States, pharmacological treatment options to treat cannabis use disorder are needed. Opioid antagonists modulate cannabinoid effects and may offer a potential approach to reducing cannabis use. In this double-blind, placebo-controlled human laboratory study, we assessed the effects of naltrexone maintenance on the reinforcing, subjective, psychomotor, and cardiovascular effects of active and inactive cannabis. Nontreatment-seeking, daily cannabis smokers were randomized to receive naltrexone (50?mg: n=18 M and 5 F) or placebo (0?mg; n=26 M and 2 F) capsules for 16 days. Before, during, and after medication maintenance, participants completed 10 laboratory sessions over 4-6 weeks, assessing cannabis' behavioral and cardiovascular effects. Medication compliance was verified by observed capsule administration, plasma naltrexone, and urinary riboflavin. Relative to placebo, maintenance on naltrexone significantly reduced both active cannabis self-administration and its positive subjective effects ('good effect'). Participants in the placebo group had 7.6 times (95% CI: 1.1-51.8) the odds of self-administering active cannabis compared with the naltrexone group. This attenuation of reinforcing and positive subjective effects also influenced cannabis use in the natural ecology. Naltrexone had intrinsic effects: decreasing ratings of friendliness, food intake, and systolic blood pressure, and increasing spontaneous reports of stomach upset and headache, yet dropout rates were comparable between groups. In summary, we show for the first time that maintenance on naltrexone decreased cannabis self-administration and ratings of 'good effect' in nontreatment-seeking daily cannabis smokers. Clinical studies in patients motivated to reduce their cannabis use are warranted to evaluate naltrexone's efficacy as a treatment for cannabis use disorder. PMID:25881117

  1. Cannabis, Cocaine and the Wages of Prime Age Males

    OpenAIRE

    Ours, J.C.

    2005-01-01

    This paper uses a dataset collected among inhabitants of Amsterdam, to study whether wages of prime age male workers are affected by the use of cannabis and cocaine.The analysis shows that cocaine use and infrequent cannabis use do not affect wages.Frequent cannabis use has a negative wage effect.The age of onset is also important.The earlier current cannabis users have started to use cannabis the larger the negative impact on their wage.

  2. Societal images of Cannabis use : comparing three countries

    OpenAIRE

    Cunningham John A; Blomqvist Jan; Koski-Jännes Anja; Raitasalo Kirsimarja

    2012-01-01

    Abstract Background Differences in beliefs about Cannabis were compared between Canada, Sweden and Finland using nationally representative population surveys containing similar items. Findings Compared to Finnish and Swedish respondents, Canadians were both more likely to have tried Cannabis and to view Cannabis as a less serious problem for society. Conclusions These findings emphasize the extent to which views about Cannabis can vary. It is possible that views about Cannabis are, at least i...

  3. Age-dependent expression of attention-deficit/hyperactivity disorder symptoms.

    Science.gov (United States)

    Mick, Eric; Faraone, Stephen V; Biederman, Joseph

    2004-06-01

    The authors' research indicates that most adults with ADHD continue to struggle with substantial number of ADHD symptoms and high levels of dysfunction despite a sizable syndromatic remission. Furthermore, in-attention was more persistent than hyperactivity or impulsivity as children progress throughout adolescence and into early adulthood. These results stress the critical importance of carefully choosing the appropriate definition of remission in longitudinal studies of youth with ADHD and that symptom clusters and Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition-defined ADHD subtypes (ie, combined, inattentive., or hyperactive/'impulsive) should be considered separately. PMID:15063994

  4. Do PTSD Symptoms and Course Predict Continued Substance Use for Homeless Individuals in Contingency Management for Cocaine Dependence?

    OpenAIRE

    Burns, Michelle Nicole; Lehman, Kenneth A.; Milby, Jesse B.; Wallace, Dennis; Schumacher, Joseph E.

    2010-01-01

    Homeless individuals (n = 187) entering contingency management (CM) for cocaine dependence were assessed for PTSD diagnosis, and a subset of 102 participants reporting traumatic exposure also periodically completed a self-report measure of PTSD symptoms. Patients with PTSD in full remission at 6 months (end of active treatment) and 12 months (end of aftercare) used substances much less frequently during aftercare than those with no PTSD diagnosis. Those whose PTSD diagnosis improved to full r...

  5. Analysis of Cannabis Seizures in NSW, Australia: Cannabis Potency and Cannabinoid Profile

    OpenAIRE

    Swift, Wendy; Wong, Alex; Li, Kong M.; Arnold, Jonathon C.; McGregor, Iain S.

    2013-01-01

    Recent analysis of the cannabinoid content of cannabis plants suggests a shift towards use of high potency plant material with high levels of ?9-tetrahydrocannabinol (THC) and low levels of other phytocannabinoids, particularly cannabidiol (CBD). Use of this type of cannabis is thought by some to predispose to greater adverse outcomes on mental health and fewer therapeutic benefits. Australia has one of the highest per capita rates of cannabis use in the world yet there has been no previous s...

  6. Implicit Associations and Explicit Expectancies toward Cannabis in Heavy Cannabis Users and Controls

    OpenAIRE

    Beraha, Esther M.; Cousijn, Janna; Hermanides, Elisa; Goudriaan, Anna E; Wiers, Reinout W

    2013-01-01

    Cognitive biases, including implicit memory associations are thought to play an important role in the development of addictive behaviors. The aim of the present study was to investigate implicit affective memory associations in heavy cannabis users. Implicit positive-arousal, sedation, and negative associations toward cannabis were measured with three Single Category Implicit Association Tests (SC-IAT’s) and compared between 59 heavy cannabis users and 89 controls. Moreover, we investigated t...

  7. Implicit associations and explicit expectancies towards cannabis in heavy cannabis users and controls

    OpenAIRE

    JannaCousijn; AnnaEGoudriaan

    2013-01-01

    Cognitive biases, including implicit memory associations are thought to play an important role in the development of addictive behaviors. The aim of the present study was to investigate implicit affective memory associations in heavy cannabis users. Implicit positive-arousal, sedation, and negative associations towards cannabis were measured with three Single Category Implicit Association Tests (SC-IAT’s) and compared between 59 heavy cannabis users and 89 controls. Moreover, we investigated ...

  8. History of cannabis as a medicine: a review História da cannabis como medicamento: uma revisão

    OpenAIRE

    Antonio Waldo Zuardi

    2006-01-01

    Cannabis as a medicine was used before the Christian era in Asia, mainly in India. The introduction of cannabis in the Western medicine occurred in the midst of the 19th century, reaching the climax in the last decade of that century, with the availability and usage of cannabis extracts or tinctures. In the first decades of the 20th century, the Western medical use of cannabis significantly decreased largely due to difficulties to obtain consistent results from batches of plant material of di...

  9. Reprint of "Treatment of cannabis use disorders in people with schizophrenia spectrum disorders--a systematic review"

    DEFF Research Database (Denmark)

    HjorthØj, Carsten; Fohlmann, Allan

    2009-01-01

    Cannabis use disorders (CUD) are prevalent among people with schizophrenia spectrum disorders (SSD), with a range of detrimental effects, e.g. reduced compliance to medication and psychosocial interventions, and increased level of psychotic-dimension symptoms. The aim of this study was to review literature on treatments of CUD in SSD-patients.

  10. Short scales to assess cannabis-related problems: a review of psychometric properties

    Directory of Open Access Journals (Sweden)

    Klempova Danica

    2008-12-01

    Full Text Available Abstract Aims The purpose of this paper is to summarize the psychometric properties of four short screening scales to assess problematic forms of cannabis use: Severity of Dependence Scale (SDS, Cannabis Use Disorders Identification Test (CUDIT, Cannabis Abuse Screening Test (CAST and Problematic Use of Marijuana (PUM. Methods A systematic computer-based literature search was conducted within the databases of PubMed, PsychINFO and Addiction Abstracts. A total of 12 publications reporting measures of reliability or validity were identified: 8 concerning SDS, 2 concerning CUDIT and one concerning CAST and PUM. Studies spanned adult and adolescent samples from general and specific user populations in a number of countries worldwide. Results All screening scales tended to have moderate to high internal consistency (Cronbach's ? ranging from .72 to .92. Test-retest reliability and item total correlation have been reported for SDS with acceptable results. Results of validation studies varied depending on study population and standards used for validity assessment, but generally sensitivity, specificity and predictive power are satisfactory. Standard diagnostic cut-off points that can be generalized to different populations do not exist for any scale. Conclusion Short screening scales to assess dependence and other problems related to the use of cannabis seem to be a time and cost saving opportunity to estimate overall prevalences of cannabis-related negative consequences and to identify at-risk persons prior to using more extensive diagnostic instruments. Nevertheless, further research is needed to assess the performance of the tests in different populations and in comparison to broader criteria of cannabis-related problems other than dependence.

  11. A Case of Cannabis-Induced Pancreatitis

    Directory of Open Access Journals (Sweden)

    Grant P

    2004-01-01

    Full Text Available CONTEXT: There are no previous reports of acute pancreatitis associated with cannabis use in the general population. Drugs of all types are related to the aetiology of pancreatitis in approximately 1.4-2.0% of cases. CASE REPORT: We report the case of a 29 year old man who presented with acute pancreatitis after a period of heavy cannabis smoking. Other causes of the disease were ruled out. The pancreatitis resolved itself after the cannabis was stopped and this was confirmed by urinary cannabinoid metabolite monitoring in the community. CONCLUSION: To our knowledge this is the first description of a case of cannabis induced pancreatitis. However, the link is difficult to establish and further evidence is required to prove the association.

  12. Electrophysiological evidence of early attentional bias to drug-related pictures in chronic cannabis users.

    Science.gov (United States)

    Asmaro, Deyar; Carolan, Patrick L; Liotti, Mario

    2014-01-01

    Behavioral and electrophysiological correlates of attentional bias to cannabis-related cues were investigated in a marijuana dependent group and a non-user group employing a drug Stroop task in which cannabis-related, negative and neutral images were presented. Behaviorally, cannabis users were less accurate during drug-containing blocks than non-users. Electrophysiologically, in chronic marijuana-users, an early positive ERP enhancement over left frontal scalp (EAP, 200-350ms) was present in response to drug-containing blocks relative to negative blocks. This effect was absent in the non-user group. Furthermore, drug-containing blocks gave rise to enhanced voltage of a posterior P300 (300-400ms), and a posterior sustained slow wave (LPP, 400-700ms) relative to negative blocks. However, such effects were similar between cannabis users and non-users. Brain source imaging in cannabis users revealed a generator for the EAP effect to drug stimuli in left ventromedial prefrontal cortex/medial orbitofrontal cortex, a region active in fMRI studies of drug cue-reactivity and a target of the core dopaminergic mesolimbic pathway involved in the processing of substances of abuse. This study identifies the timing and brain localization of an ERP correlate of early attentional capture to drug-related pictures in chronic marijuana users. The EAP to drug cues may identify a new electrophysiological marker with clinical implications for predicting abstinence versus relapse or to evaluate treatment interventions. PMID:24126204

  13. Biological aspects of cannabis consumption in schizophrenia

    Directory of Open Access Journals (Sweden)

    Serban Ionela Lacramioara

    2015-01-01

    Full Text Available Schizophrenia and psychotic disorders are major health issues with particular implications for both the individual and the medical system. Epidemiological data show a more frequent consumption of drugs in schizophrenic patients when compared to the general population. Studies have shown that the abuse of substances is the most common comorbidity associated with schizophrenia. Among illicit substances, cannabis is the most commonly encountered among patients with schizophrenia. Similar clinical features of schizophrenia and cannabis consumption could be explained by some common neurobiological implications. N-methyl-D-aspartate (NMDA receptor stimulation is associated with psychotic-type phenomena and schizophrenia and NMDA receptors are involved in the clinical effects of cannabis consumption. Thus, the CB1 receptors that are spread mainly at the level of the NMDA secretory neurons are activated by tetrahydrocannabinol, the psychoactive component of cannabis. Moreover, cannabis abuse in association with other factors may contribute in triggering schizophrenia. Therefore, patients diagnosed with schizophrenia that abuse substances such as cannabis could represent a special category of patients that require a complex therapeutic approach, especially considering the multiple problems implicated, such as reduced compliance with treatment, unfavorable evolution and prognosis with multiple relapses and frequent hospitalizations.

  14. Escitalopram is associated with reductions in pain severity and pain interference in opioid dependent patients with depressive symptoms.

    Science.gov (United States)

    Tsui, Judith I; Herman, Debra S; Kettavong, Malyna; Anderson, Bradley J; Stein, Michael D

    2011-11-01

    Pain is common among opioid-dependent patients, yet pharmacologic strategies are limited. The aim of this study was to explore whether escitalopram, a selective serotonin reuptake inhibitor, was associated with reductions in pain. The study used longitudinal data from a randomized, controlled trial that evaluated the effects of escitalopram on treatment retention in patients with depressive symptoms who were initiating buprenorphine/naloxone for treatment of opioid dependence. Participants were randomized to receive escitalopram 10 mg or placebo daily. Changes in pain severity, pain interference, and depression were assessed at 1-, 2-, and 3-month visits with the visual analog scale, Brief Pain Inventory, and the Beck Depression Inventory II, respectively. Fixed-effects estimators for panel regression models were used to assess the effects of intervention on changes in outcomes over time. Additional models were estimated to explore whether the intervention effect was mediated by within-person changes in depression. In this sample of 147 adults, we found that participants randomized to escitalopram had significantly larger reductions on both pain severity (b=-14.34, t=-2.66, Pdepression, the estimated effects of escitalopram on pain severity and pain interference were virtually identical to the unadjusted effects. This study of opioid-dependent patients with depressive symptoms found that treatment with escitalopram was associated with clinically meaningful reductions in pain severity and pain interference during the first 3 months of therapy. PMID:21924552

  15. Impaired error awareness and anterior cingulate cortex hypoactivity in chronic cannabis users

    OpenAIRE

    Hester, Robert; Nestor, Liam; Garavan, Hugh

    2009-01-01

    Drug abuse and other psychiatric conditions (e.g., schizophrenia) have been associated with a diminished neural response to errors, particularly in the anterior cingulate cortex (ACC) thought critical to error processing. A diminished capacity for detecting errors has been linked to clinical symptoms including the loss of insight, delusions and perseverative behaviour. Sixteen active chronic cannabis users and 16 control participants were administered a Go/No-go response inhibition task durin...

  16. Unilateral Angle-Closure Glaucoma with Ciliochoroidal Effusion after the Consumption of Cannabis: A Case Report

    OpenAIRE

    Hanna, Rana; Tiosano, Beatrice; Dbayat, Noora; Gaton, Dan

    2014-01-01

    A 35-year-old male patient, diagnosed with acute angle-closure glaucoma, did not improve despite intensive treatment with antiglaucoma medications. Ultrasound biomicroscopy revealed a ciliochoroidal effusion. Due to his past history of drug abuse, a urine test was analyzed and found to be positive for cannabis. After topical cycloplegia and oral steroid therapy, his symptoms improved substantially. The present case highlights the role of ultrasound biomicroscopy in evaluating patients with ac...

  17. Cannabis Reclassification: What Is the Message to the Next Generation of Cannabis Users?

    Science.gov (United States)

    McCrystal, Patrick; Winning, Kerry

    2009-01-01

    At the beginning of 2004 the UK government downgraded the legal status of cannabis from a Class B to a Class C drug. Following a review of this decision two years later, cannabis remained a Class C substance--which for some contrasted with the potential harmful social and health effects associated with its use, particularly for young people. These…

  18. Plasma Cannabinoid Pharmacokinetics After Controlled Smoking and Ad libitum Cannabis Smoking in Chronic Frequent Users.

    Science.gov (United States)

    Lee, Dayong; Bergamaschi, Mateus M; Milman, Garry; Barnes, Allan J; Queiroz, Regina H C; Vandrey, Ryan; Huestis, Marilyn A

    2015-10-01

    More Americans are dependent on cannabis than any other illicit drug. The main analytes for cannabis testing include the primary psychoactive constituent, ?(9)-tetrahydrocannabinol (THC), equipotent 11-hydroxy-THC (11-OH-THC) and inactive 11-nor-9-carboxy-THC (THCCOOH). Eleven adult chronic frequent cannabis smokers resided on a closed research unit with unlimited access to 5.9% THC cannabis cigarettes from 12:00 to 23:00 during two ad libitum smoking phases, followed by a 5-day abstinence period in seven participants. A single cigarette was smoked under controlled topography on the last day of the smoking and abstinence phases. Plasma cannabinoids were quantified by two-dimensional gas chromatography-mass spectrometry. Median plasma maximum concentrations (Cmax) were 28.3 (THC), 3.9 (11-OH-THC) and 47.0 ?g/L (THCCOOH) 0.5 h after controlled single cannabis smoking. Median Cmax 0.2-0.5 h after ad libitum smoking was higher for all analytes: 83.5 (THC), 14.2 (11-OH-THC) and 155 ?g/L (THCCOOH). All 11 participants' plasma samples were THC and THCCOOH-positive, 58.3% had THC ?5 ?g/L and 79.2% were 11-OH-THC-positive 8.1-14 h after last cannabis smoking. Cannabinoid detection rates in seven participants 106-112 h (4-5 days) after last smoking were 92.9 (THC), 35.7 (11-OH-THC) and 100% (THCCOOH), with limits of quantification of 0.5 ?g/L for THC and THCCOOH, and 1.0 ?g/L for 11-OH-THC. These data greatly expand prior research findings on cannabinoid excretion profiles in chronic frequent cannabis smokers during ad libitum smoking. Smoking multiple cannabis cigarettes led to higher Cmax and AUC compared with smoking a single cigarette. The chronic frequent cannabis smokers exhibited extended detection windows for plasma cannabinoids, reflecting a large cannabinoid body burden. PMID:26378131

  19. Cannabinoids for the Treatment of Schizophrenia? A Balanced Neurochemical Framework for Both Adverse and Therapeutic Effects of Cannabis Use

    OpenAIRE

    Malhi, Gin S.; Henderson, Antony F.; Michael Perdices; Coulston, Carissa M.

    2010-01-01

    Recent studies have found that cannabinoids may improve neuropsychological performance, ameliorate negative symptoms, and have antipsychotic properties for a subgroup of the schizophrenia population. These findings are in contrast to the longstanding history of adverse consequences of cannabis use, predominantly on the positive symptoms, and a balanced neurochemical basis for these opposing views is lacking. This paper details a review of the neurobiological substrates of schizophrenia and th...

  20. Impulsivity and symptoms of nicotine dependence in a young adult population

    OpenAIRE

    Chase, Henry W.; Hogarth, Lee

    2011-01-01

    Introduction: Impulsivity is widely regarded as a risk factor for drug dependence. However, its relationship with the symptomatology of nicotine dependence is poorly understood. Methods: To examine the nature of these relationships, we recruited 404 daily and occasional smokers from a predominantly student population and assessed the association between impulsivity, as measured by the Barratt Impulsiveness Scale (BIS-11) and several self-reported measures of smoking rate and nicot...

  1. Application of medical cannabis in patients with the neurodegeneration disorders

    OpenAIRE

    Lidia Kotu?a; Paulina Sobstyl; Jan Sobstyl; Paulina Chwil; Karol Terlecki; Jolanta Karwat; Paulina Gil-Kulik; Alicja Niedojad?o; Janusz Kocki

    2014-01-01

    Medical cannabis is the dried flowers of the female Cannabis sativa L. plant. Cannabis contains a number of active elements, including dronabinol (THC) and cannabidiol (CBD). Dronabinol is usually the main ingredient. The body’s own cannabinoid system has been identified. The discovery of this system, which comprises endocannabinoids and receptors, confirmed that cannabis has a positive effect on certain illnesses and conditions. Two types of cannabinoid receptors have been identified: CB1 an...

  2. Survey of Australians using cannabis for medical purposes

    OpenAIRE

    Dillon Paul; Gates Peter; Swift Wendy

    2005-01-01

    Abstract Background The New South Wales State Government recently proposed a trial of the medical use of cannabis. Australians who currently use cannabis medicinally do so illegally and without assurances of quality control. Given the dearth of local information on this issue, this study explored the experiences of medical cannabis users. Methods Australian adults who had used cannabis for medical purposes were recruited using media stories. A total of 147 respondents were screened by phone a...

  3. The Effects of Cannabis Use on Physical and Mental Health

    OpenAIRE

    Ours, J.C.; WILLIAMS, J

    2011-01-01

    This paper investigates whether cannabis use aects physical and mental health. To do so, information on prime aged individuals living in Amsterdam in 1994 is used. Dutch data offer a clear advantage in estimating the health impacts of cannabis use because the legal status of cannabis in the Netherlands ensures that estimates are free from confounding with the physical and psychological effects of engaging in a criminal activity. Accounting for selection into cannabis use and shared frailties ...

  4. THE EFFECT OF CANNABIS COMPARED WITH ALCOHOL ON DRIVING

    OpenAIRE

    Sewell, R. Andrew; Poling, James; Sofuoglu, Mehmet

    2009-01-01

    The prevalence of both alcohol and cannabis use and the high morbidity associated with motor vehicle crashes has lead to a plethora of research on the link between the two. Drunk drivers are involved in 25% of motor vehicle fatalities, and many accidents involve drivers who test positive for cannabis. Cannabis and alcohol acutely impair several driving-related skills in a dose-related fashion, but the effects of cannabis vary more between individuals than they do with alcohol because of toler...

  5. Neuronal substrates and functional consequences of prenatal cannabis exposure

    OpenAIRE

    Calvigioni, Daniela; Hurd, Yasmin L; Harkany, Tibor; Keimpema, Erik

    2014-01-01

    Cannabis remains one of the world’s most widely used substance of abuse amongst pregnant women. Trends of the last 50 years show an increase in popularity in child-bearing women together with a constant increase in cannabis potency. In addition, potent herbal “legal” highs containing synthetic cannabinoids that mimic the effects of cannabis with unknown pharmacological and toxicological effects have gained rapid popularity amongst young adults. Despite the surge in cannabis use during pregnan...

  6. Anormalidades cognitivas no uso da cannabis Cognitive abnormalities and cannabis use

    Directory of Open Access Journals (Sweden)

    Nadia Solowij

    2010-05-01

    Full Text Available OBJETIVO: Evidências de que o uso de cannabis prejudica funções cognitivas em humanos têm-se acumulado nas décadas recentes. O propósito desta revisão é o de atualizar o conhecimento nesta área com novos achados a partir da literatura mais recente. MÉTODO: As buscas na literatura foram realizadas utilizando-se o banco de dados Web of Science até fevereiro de 2010. Foram buscados os termos "cannabi*" ou "marijuana" e "cogniti*" ou "memory" ou "attention" ou "executive function", e os estudos em humanos foram revisados preferencialmente em relação aos estudos em animais. DISCUSSÃO: O uso de cannabis prejudica a memória, a atenção, o controle inibitório, as funções executivas e a tomada de decisões, tanto durante como após o período de intoxicação aguda, persistindo por horas, dias, semanas ou mais após o último uso. Os estudos de desafio farmacológico em humanos estão elucidando a natureza e os substratos neurais das alterações cognitivas associadas a vários canabinoides. O uso pesado ou de longo prazo de cannabis parece resultar em anormalidades cognitivas mais duradouras e possivelmente em alterações cerebrais estruturais. Efeitos cognitivos adversos maiores estão associados ao uso de cannabis quando este começa no início da adolescência. CONCLUSÃO: O sistema canabinoide endógeno está envolvido nos mecanismos de regulação neural que modulam os processos subjacentes a uma gama de funções cognitivas que estão prejudicadas pela cannabis. Os déficits em usuários humanos muito provavelmente refletem, portanto, neuroadaptações e o funcionamento alterado do sistema canabinoide endógeno.OBJECTIVE: Evidence that cannabis use impairs cognitive function in humans has been accumulating in recent decades. The purpose of this overview is to update knowledge in this area with new findings from the most recent literature. METHOD: Literature searches were conducted using the Web of Science database up to February 2010. The terms searched were: "cannabi*" or "marijuana", and "cogniti*" or "memory" or "attention" or "executive function", and human studies were reviewed preferentially over the animal literature. DISCUSSION: Cannabis use impairs memory, attention, inhibitory control, executive functions and decision making, both during the period of acute intoxication and beyond, persisting for hours, days, weeks or more after the last use of cannabis. Pharmacological challenge studies in humans are elucidating the nature and neural substrates of cognitive changes associated with various cannabinoids. Long-term or heavy cannabis use appears to result in longer-lasting cognitive abnormalities and possibly structural brain alterations. Greater adverse cognitive effects are associated with cannabis use commencing in early adolescence. CONCLUSION: The endogenous cannabinoid system is involved in regulatory neural mechanisms that modulate processes underlying a range of cognitive functions that are impaired by cannabis. Deficits in human users most likely therefore reflect neuroadaptations and altered functioning of the endogenous cannabinoid system.

  7. Anormalidades cognitivas no uso da cannabis / Cognitive abnormalities and cannabis use

    Scientific Electronic Library Online (English)

    Nadia, Solowij; Nicole, Pesa.

    2010-05-01

    Full Text Available OBJETIVO: Evidências de que o uso de cannabis prejudica funções cognitivas em humanos têm-se acumulado nas décadas recentes. O propósito desta revisão é o de atualizar o conhecimento nesta área com novos achados a partir da literatura mais recente. MÉTODO: As buscas na literatura foram realizadas ut [...] ilizando-se o banco de dados Web of Science até fevereiro de 2010. Foram buscados os termos "cannabi*" ou "marijuana" e "cogniti*" ou "memory" ou "attention" ou "executive function", e os estudos em humanos foram revisados preferencialmente em relação aos estudos em animais. DISCUSSÃO: O uso de cannabis prejudica a memória, a atenção, o controle inibitório, as funções executivas e a tomada de decisões, tanto durante como após o período de intoxicação aguda, persistindo por horas, dias, semanas ou mais após o último uso. Os estudos de desafio farmacológico em humanos estão elucidando a natureza e os substratos neurais das alterações cognitivas associadas a vários canabinoides. O uso pesado ou de longo prazo de cannabis parece resultar em anormalidades cognitivas mais duradouras e possivelmente em alterações cerebrais estruturais. Efeitos cognitivos adversos maiores estão associados ao uso de cannabis quando este começa no início da adolescência. CONCLUSÃO: O sistema canabinoide endógeno está envolvido nos mecanismos de regulação neural que modulam os processos subjacentes a uma gama de funções cognitivas que estão prejudicadas pela cannabis. Os déficits em usuários humanos muito provavelmente refletem, portanto, neuroadaptações e o funcionamento alterado do sistema canabinoide endógeno. Abstract in english OBJECTIVE: Evidence that cannabis use impairs cognitive function in humans has been accumulating in recent decades. The purpose of this overview is to update knowledge in this area with new findings from the most recent literature. METHOD: Literature searches were conducted using the Web of Science [...] database up to February 2010. The terms searched were: "cannabi*" or "marijuana", and "cogniti*" or "memory" or "attention" or "executive function", and human studies were reviewed preferentially over the animal literature. DISCUSSION: Cannabis use impairs memory, attention, inhibitory control, executive functions and decision making, both during the period of acute intoxication and beyond, persisting for hours, days, weeks or more after the last use of cannabis. Pharmacological challenge studies in humans are elucidating the nature and neural substrates of cognitive changes associated with various cannabinoids. Long-term or heavy cannabis use appears to result in longer-lasting cognitive abnormalities and possibly structural brain alterations. Greater adverse cognitive effects are associated with cannabis use commencing in early adolescence. CONCLUSION: The endogenous cannabinoid system is involved in regulatory neural mechanisms that modulate processes underlying a range of cognitive functions that are impaired by cannabis. Deficits in human users most likely therefore reflect neuroadaptations and altered functioning of the endogenous cannabinoid system.

  8. Neurobiologia da Cannabis: do sistema endocanabinoide aos transtornos por uso de Cannabis

    Directory of Open Access Journals (Sweden)

    José Luis G. Pinho Costa

    2011-01-01

    Full Text Available OBJETIVOS: Diante das lacunas na efetividade das terapêuticas para transtornos por uso de Cannabis, a droga ilícita mais consumida no mundo, este trabalho propõe-se a rever os conhecimentos sobre o substrato neuroanatômico, biomolecular e celular do sistema endocanabinoide, descrever os mecanismos de neuroplasticidade dependente dos canabinoides e relacioná-los com a neurobiologia dos transtornos por uso de Cannabis (abuso e dependência. MÉTODOS: Recorreu-se às bases de dados Medline, Scopus e ISI Web of Knowledge; as palavras-chave pesquisadas foram "Cannabis", "neurobiology", "endocannabinoid system", "endocannabinoids", "receptors, cannabinoid", "neuronal plasticity", "long-term synaptic depression", "long-term potentiation", "marijuana abuse" e "tetrahydrocannabinol". Foram incluídos 80 trabalhos nesta revisão. DISCUSSÃO: A distribuição neuroanatômica, celular e biomolecular do sistema endocanabinoide adequa-se perfeitamente às suas funções de neuromodulação (via neuroplasticidade e metaplasticidade, nomeadamente em vias relacionadas aos transtornos por uso de substâncias. Os canabinoides exógenos perturbam essas funções. CONCLUSÃO: O sistema endocanabinoide contribui para a definição de setpoints em diversas vias neuronais, incluindo vias cruciais na instalação de transtornos por uso de substâncias; com o uso de Cannabis, esses setpoints tornar-se-ão mais permissivos, facilitando os transtornos por uso de Cannabis. Os avanços no entendimento da neurobiologia da Cannabis abrem uma janela de oportunidades para novas estratégias terapêuticas nos transtornos por uso de Cannabis.

  9. Physician Introduction to Opioids for Pain Among Patients with Opioid Dependence and Depressive Symptoms

    OpenAIRE

    Tsui, Judith I.; Herman, Debra S.; Kettavong, Malyna; Alford, Daniel; Anderson, Bradley J; STEIN, Michael D.

    2010-01-01

    This study determined the frequency of reporting being introduced to opioids by a physician among opioid dependent patients. Cross-sectional analyses were performed using baseline data from a cohort of opioid addicts seeking treatment with buprenorphine. The primary outcome was response to the question: “Who introduced you to opiates?” Covariates included sociodemographics, depression, pain, current and prior substance use. Of 140 participants, 29% reported that they had been introduced to op...

  10. History of cannabis as a medicine: a review / História da cannabis como medicamento: uma revisão

    Scientific Electronic Library Online (English)

    Antonio Waldo, Zuardi.

    2006-06-01

    Full Text Available Antes da Era Cristã, a cannabis foi utilizada na Ásia como medicamento, com grande importância na Índia. A introdução da cannabis na Medicina Ocidental ocorreu em meados do século XIX, atingindo o clímax na última década deste século, com a disponibilidade e o uso de extratos e tinturas da cannabis. [...] Nas primeiras décadas do século XX, o uso médico da cannabis no Ocidente diminuiu significativamente, em grande parte pela dificuldade na obtenção de resultados consistentes de amostras da planta com diferentes potências. A identificação da estrutura química de componentes da cannabis e a possibilidade de se obter seus constituintes puros foram relacionadas a um aumento significativo no interesse científico pela planta, desde 1965. Este interesse foi renovado nos anos 90, com a descrição dos receptores de canabinóides e a identificação de um sistema canabinóide endógeno no cérebro. Usos terapêuticos. Um novo e mais consistente ciclo de uso dos derivados de cannabis como medicamento começa, já que a sua eficácia e segurança no tratamento começam a estar cientificamente provados. Abstract in english Cannabis as a medicine was used before the Christian era in Asia, mainly in India. The introduction of cannabis in the Western medicine occurred in the midst of the 19th century, reaching the climax in the last decade of that century, with the availability and usage of cannabis extracts or tinctures [...] . In the first decades of the 20th century, the Western medical use of cannabis significantly decreased largely due to difficulties to obtain consistent results from batches of plant material of different potencies. The identification of the chemical structure of cannabis components and the possibility of obtaining its pure constituents were related to a significant increase in scientific interest in such plant, since 1965. This interest was renewed in the 1990's with the description of cannabinoid receptors and the identification of an endogenous cannabinoid system in the brain. A new and more consistent cycle of the use of cannabis derivatives as medication begins, since treatment effectiveness and safety started to be scientifically proven.

  11. History of cannabis as a medicine: a review História da cannabis como medicamento: uma revisão

    Directory of Open Access Journals (Sweden)

    Antonio Waldo Zuardi

    2006-06-01

    Full Text Available Cannabis as a medicine was used before the Christian era in Asia, mainly in India. The introduction of cannabis in the Western medicine occurred in the midst of the 19th century, reaching the climax in the last decade of that century, with the availability and usage of cannabis extracts or tinctures. In the first decades of the 20th century, the Western medical use of cannabis significantly decreased largely due to difficulties to obtain consistent results from batches of plant material of different potencies. The identification of the chemical structure of cannabis components and the possibility of obtaining its pure constituents were related to a significant increase in scientific interest in such plant, since 1965. This interest was renewed in the 1990's with the description of cannabinoid receptors and the identification of an endogenous cannabinoid system in the brain. A new and more consistent cycle of the use of cannabis derivatives as medication begins, since treatment effectiveness and safety started to be scientifically proven.Antes da Era Cristã, a cannabis foi utilizada na Ásia como medicamento, com grande importância na Índia. A introdução da cannabis na Medicina Ocidental ocorreu em meados do século XIX, atingindo o clímax na última década deste século, com a disponibilidade e o uso de extratos e tinturas da cannabis. Nas primeiras décadas do século XX, o uso médico da cannabis no Ocidente diminuiu significativamente, em grande parte pela dificuldade na obtenção de resultados consistentes de amostras da planta com diferentes potências. A identificação da estrutura química de componentes da cannabis e a possibilidade de se obter seus constituintes puros foram relacionadas a um aumento significativo no interesse científico pela planta, desde 1965. Este interesse foi renovado nos anos 90, com a descrição dos receptores de canabinóides e a identificação de um sistema canabinóide endógeno no cérebro. Usos terapêuticos. Um novo e mais consistente ciclo de uso dos derivados de cannabis como medicamento começa, já que a sua eficácia e segurança no tratamento começam a estar cientificamente provados.

  12. Physician introduction to opioids for pain among patients with opioid dependence and depressive symptoms.

    Science.gov (United States)

    Tsui, Judith I; Herman, Debra S; Kettavong, Malyna; Alford, Daniel; Anderson, Bradley J; Stein, Michael D

    2010-12-01

    This study determined the frequency of reporting being introduced to opioids by a physician among opioid-dependent patients. Cross-sectional analyses were performed using baseline data from a cohort of opioid addicts seeking treatment with buprenorphine. The primary outcome was a response to the question: "Who introduced you to opiates?" Covariates included sociodemographics, depression, pain, and current and prior substance use. Of 140 participants, 29% reported that they had been introduced to opioids by a physician. Of those who were introduced to opioids by a physician, all indicated that they had initially used opioids for pain, versus only 11% of those who did not report being introduced to opioids by a physician (p < .01). There was no difference in current pain (78% vs. 85%, p = .29); however, participants who were introduced to opioids by a physician were more likely to have chronic pain (63% vs. 43%, p = .04). A substantial proportion of individuals with opioid dependence seeking treatment may have been introduced to opioids by a physician. PMID:20727704

  13. Exercise dependencesymptoms and mechanisms [Uzale?nienie od ?wicze? fizycznych – objawy i mechanizmy

    Directory of Open Access Journals (Sweden)

    Guszkowska, Monika

    2012-10-01

    Full Text Available The aim of this article is to synthesise the knowledge about the phenomenon of exercise dependence (ED, which is now characterised by an obsessive preoccupation with exercise, negative in nature. ED could be operationalized as a multidimensional maladaptive pattern of exercise, leading to clinically impairment or distress. Its criteria are: tolerance, withdrawal effects, lack of control, reductions in other activities, impaired psychological, social or physical functioning. For primary ED, the physical activity is an end in itself; for secondary ED, motivation is extrinsic – to control or alter body mass and shape. Estimates of the prevalence of ED range from 2–3% to 20–30%. Hypotheses of ED development concentrate on ß-endorphin, sympathetic arousal, affect regulation or some psychological explanations (e.g. exercise as distractor.

  14. Increased Blood Pressure Following Abrupt Cessation of Daily Cannabis Use

    Science.gov (United States)

    Vandrey, Ryan; Umbricht, Annie; Strain, Eric C.

    2010-01-01

    Objective Cannabis is the most widely used illicit drug. Acute cannabis administration increases blood pressure and heart rate and tolerance develops to these effects with heavy use. A valid and reliable withdrawal syndrome occurs in most daily users, but few studies have assessed the cardiovascular effects of withdrawal. The objective of this report is to describe unexpected changes in cardiovascular function during brief periods of supervised cannabis use and abstinence in daily cannabis users. Methods A within-subjects ABAC crossover study in which inpatient volunteers smoked cannabis ad-libitum (A), and abstained from cannabis (B/C). Vital signs were obtained three times daily during eleven inpatient days for thirteen daily cannabis users (11 Male, 8 African American). Results Blood pressure increased significantly during periods of cannabis abstinence compared with periods of cannabis use. The magnitude of increase was substantial in a subset (N=6) of participants, with mean increases of up to 22.8mmHg systolic and 12.3mmHg diastolic blood pressure observed. Heart rate also increased during abstinence when measures collected during periods of acute intoxication were excluded, but the magnitude of effect was not clinically significant. Conclusions Abrupt cessation of heavy cannabis use may cause clinically significant increases in blood pressure in a subset of users. Blood pressure should be monitored among those attempting to reduce or quit frequent cannabis use, particularly those with preexisting hypertension. The time course of this effect is currently unknown and requires further study. PMID:21359104

  15. Pathways from cannabis to psychosis: a review of the evidence

    Directory of Open Access Journals (Sweden)

    JonathanKBurns

    2013-10-01

    Full Text Available The nature of the relationship between cannabis use and psychosis is complex and remains unclear. Researchers and clinicians remain divided regarding key issues such as whether or not cannabis is an independent cause of psychosis and schizophrenia. This paper reviews the field in detail, examining questions of causality, the neurobiological basis for such causality and for differential inter-individual risk, the clinical and cognitive features of psychosis in cannabis users, and patterns of course and outcome of psychosis in the context of cannabis use. The author proposes two major pathways from cannabis to psychosis based on a differentiation between early-initiated lifelong cannabis use and a scenario where vulnerable individuals without a lifelong pattern of use consume cannabis over a relatively brief period of time just prior to psychosis onset. Additional key factors determining the clinical and neurobiological manifestation of psychosis as well as course and outcome in cannabis users include: underlying genetic and developmental vulnerability to schizophrenia-spectrum disorders; and whether or not cannabis use ceases or continues after the onset of psychosis. Finally, methodological guidelines are presented for future research aimed at both elucidating the pathways that lead from cannabis to psychosis and clarifying the long-term outcome of the disorder in those who have a history of using cannabis.

  16. The cannabis and the endocannabinoid system. Psychotropic and metabolic effects

    Directory of Open Access Journals (Sweden)

    Romana Vulturar

    2011-11-01

    Full Text Available Evidence has been provided that a sustained use (smoking of cannabis (indian hemp, marijuana leads to impaired psychomotor performance, interacting and interfering with the organism’s endocannabinoid system. The effects are dependent on the used dose and the duration of such a habit and about one in ten consumers may develop dependence. More accentuated adverse effects were recorded in subjects with preexistent psychiatric illness and schizofrenics were found to be particularly vulne-rable to cannabis, which triggered relapses and aggravation. The endocannabinoid system includes specific receptors (CB1 and CB2 and the lipidic endocannabinoids anandamide and 2-arachidonoilglycerol (2-AG, acting as activating ligands for the specific receptors. Enzymes ensuring the synthesis, as well as enyzmes involved in the degradation of endocannabinoids were also identified. A hyperactivation of this system leads to an exagerated appetite, hyperphagia, and subsequent obesity as well as to the development of an atherogenic dyslipidemia. The synthetic compound rimonabant, a blocker of the CB1 receptor reduced the exagerated appetite and the body weight, also normalising the plasma lipoprotein pattern. Unfortunately, adverse effects of such a therapy were reported emphasizing an increased incidence of depressive and/or anxious moods. Such observations were suggesting that the endo-cannabinoid system may also be involved in establishing a stable statisfied mood and connexions between this system and serotoninergic mediation were actually documented.

  17. The Differential Role of Symptoms of Anxiety and Social Withdrawal in Chinese Children's Dependency on Their Teachers during the Transition to Nursery Care

    Science.gov (United States)

    Zhang, Xiao

    2015-01-01

    Research Findings: Based on a short-term longitudinal sample of Chinese children, the present study examined the role of symptoms of anxiety and social withdrawal in dependency on teachers during the transition to nursery care. Children's dependency on their teachers was assessed first at 3 months after nursery entry (Time 1) and then at the end…

  18. Counselling young cannabis users by text message

    DEFF Research Database (Denmark)

    Laursen, Ditte

    2010-01-01

    This article presents the results of a study of two SMS services aimed at providing young people with information on cannabis and helping them to reduce their consumption of the drug. The attitude of the 12 participants in the study towards the SMS services is generally positive, but they prefer factual information to advice and counselling. The messages prompt reflection and awareness among the recipients, and their repetitive, serial nature plays a significant part in the process of change. This is especially true of the young people whose use of cannabis is recreational. For them, the SMS services offer a less demanding, potentially less confrontational alternative to traditional forms of counselling and treatment.

  19. Ammonia release from heated "street" cannabis leaf and its potential toxic effects on cannabis users.

    Czech Academy of Sciences Publication Activity Database

    Bloor, R.; Wang, T. S.; Špan?l, Patrik; Smith, D.

    2008-01-01

    Ro?. 103, ?. 10 (2008), s. 1671-1677. ISSN 0965-2140 Institutional research plan: CEZ:AV0Z40400503 Keywords : ammonia * cannabis * respiratory Subject RIV: CF - Physical ; Theoretical Chemistry Impact factor: 4.244, year: 2008

  20. Factores asociados al inicio del consumo de cannabis: una revisión sistemática de estudios de cohortes Factors associated with the onset of cannabis use: a systematic review of cohort studies

    Directory of Open Access Journals (Sweden)

    Mònica Guxens

    2007-06-01

    Full Text Available Objetivo: Determinar los factores asociados al inicio del consumo de cannabis a partir de una revisión sistemática de estudios de cohortes. Métodos: Se realizó una búsqueda bibliográfica informatizada utilizando diversas palabras clave y sus combinaciones. Entre los estudios identificados se seleccionaron los estudios originales de diseño longitudinal que utilizaran como variable dependiente el inicio de consumo de cannabis, así como los estudios de revisión, publicados entre enero de 1980 y mayo de 2004. Se evaluó la calidad metodológica de los estudios mediante 2 revisores, de manera independiente y a partir de unos criterios prestablecidos, clasificando los artículos en 3 categorías: alta, intermedia o baja calidad. Se midió el nivel de concordancia de los revisores a partir del coeficiente kappa. Resultados: Se identificaron 32 estudios que cumplían los criterios de selección, de los cuales 13 fueron determinados de alta calidad. Las causas de exclusión fueron el sesgo de selección, por la inclusión de consumidores al inicio de la cohorte estudiada, y la falta de ajuste por los potenciales confusores. Los factores que se relacionaron con una mayor evidencia con el inicio del consumo de cannabis fueron el sexo masculino, el consumo de tabaco y alcohol, tener una relación problemática con los padres y el consumo de cannabis por parte de los amigos. Conclusiones: Los resultados señalan la importancia de diversos factores individuales, familiares y del entorno en el inicio del consumo de cannabis, que deberían considerarse de forma conjunta en el abordaje preventivo entre los adolescentes.Objective: To determine the factors associated with the onset of cannabis use through a systematic review of cohort studies. Methods: An internet-based search was performed using several keywords and their combinations. Original studies with longitudinal design and the onset of cannabis use as dependent variable, as well as review studies were included, published between January 1980 and May 2004. Methodology quality of the studies was assessed independently by two reviewers, according to pre-established criteria, in order to classify studies in high, mid or low quality. Agreement between reviewers was assessed through kappa coefficient. Results: A total of 32 relevant studies were identified, of which 13 were of higher quality. Selection bias for the inclusion of consumers at the baseline measurement and lack or insufficient adjustment for confounders were the causes of exclusion. The factors of great evidence related to the onset of cannabis use were masculine sex, consumption of tobacco or alcohol, having a problematic relationship with parents, and cannabis consumption by friends. Conclusion: Results highlight the importance of different individual, family and environmental factors on the onset of cannabis use. These must be considered to properly arrange intervention programs focusing on primary prevention among teenagers.

  1. Self-medication of achalasia with cannabis, complicated by a cannabis use disorder

    OpenAIRE

    Luquiens, Amandine; Lourenco, Nelson; Benyamina, Amine; Aubin, Henri-Jean

    2015-01-01

    Achalasia is a rare esophagus motility disorder. Medical, endoscopic and surgical treatments are available, but all endorse high relapse rates. No data has been published to date reporting a therapeutic effect of cannabis use neither in achalasia nor on its influence on manometric measurements. We report the case of a patient diagnosed with achalasia. He could benefit from a large panel of therapeutic interventions, but none of them was effective over the time. He first used cannabis at age 2...

  2. The effect of cannabis use on memory function: an update

    Directory of Open Access Journals (Sweden)

    Schoeler T

    2013-01-01

    Full Text Available Tabea Schoeler, Sagnik BhattacharyyaDepartment of Psychosis Studies, King's College London, Institute of Psychiatry, London, UKAbstract: Investigating the effects of cannabis use on memory function appears challenging. While early observational investigations aimed to elucidate the longer-term effects of cannabis use on memory function in humans, findings remained equivocal and pointed to a pattern of interacting factors impacting on the relationship between cannabis use and memory function, rather than a simple direct effect of cannabis. Only recently, a clearer picture of the chronic and acute effects of cannabis use on memory function has emerged once studies have controlled for potential confounding factors and started to investigate the acute effects of delta-9-tetrahydrocannabinol (?9-THC and cannabidiol (CBD, the main ingredients in the extract of the cannabis plant in pharmacological challenge experiments. Relatively consistent findings have been reported regarding the acute impairments induced by a single dose of ?9-THC on verbal and working memory. It is unclear whether they may persist beyond the intoxication state. In the long-term, these impairments seem particularly likely to manifest and may also persist following abstinence if regular and heavy use of cannabis strains high in ?9-THC is started at an early age. Although still at an early stage, studies that employed advanced neuroimaging techniques have started to model the neural underpinnings of the effects of cannabis use and implicate a network of functional and morphological alterations that may moderate the effects of cannabis on memory function. Future experimental and epidemiological studies that take into consideration individual differences, particularly previous cannabis history and demographic characteristics, but also the precise mixture of the ingredients of the consumed cannabis are necessary to clarify the magnitude and the mechanisms by which cannabis-induced memory impairments occur and to elucidate underlying neurobiological mechanisms.Keywords: cannabis, THC, CBD, memory, neuroimaging, fMRI

  3. Adolescent cannabis exposure interacts with mutant DISC1 to produce impaired adult emotional memory.

    Science.gov (United States)

    Ballinger, Michael D; Saito, Atsushi; Abazyan, Bagrat; Taniguchi, Yu; Huang, Ching-Hsun; Ito, Koki; Zhu, Xiaolei; Segal, Hadar; Jaaro-Peled, Hanna; Sawa, Akira; Mackie, Ken; Pletnikov, Mikhail V; Kamiya, Atsushi

    2015-10-01

    Cannabis is an increasingly popular and controversial drug used worldwide. Cannabis use often begins during adolescence, a highly susceptible period for environmental stimuli to alter functional and structural organization of the developing brain. Given that adolescence is a critical time for the emergence of mental illnesses before full-onset in early adulthood, it is particularly important to investigate how genetic insults and adolescent cannabis exposure interact to affect brain development and function. Here we show for the first time that a perturbation in disrupted in schizophrenia 1 (DISC1) exacerbates the response to adolescent exposure to delta-9-tetrahydrocannabinol (?(9)-THC), a major psychoactive ingredient of cannabis, consistent with the concept that gene-environment interaction may contribute to the pathophysiology of psychiatric conditions. We found that chronic adolescent treatment with ?(9)-THC exacerbates deficits in fear-associated memory in adult mice that express a putative dominant-negative mutant of DISC1 (DN-DISC1). Synaptic expression of cannabinoid receptor 1 (CB1R) is down-regulated in the prefrontal cortex, hippocampus, and amygdala, critical brain regions for fear-associated memory, by either expression of DN-DISC1 or adolescent ?(9)-THC treatment. Notably, elevation of c-Fos expression evoked by context-dependent fear memory retrieval is impaired in these brain regions in DN-DISC1 mice. We also found a synergistic reduction of c-Fos expression induced by cue-dependent fear memory retrieval in DN-DISC1 with adolescent ?(9)-THC exposure. These results suggest that alteration of CB1R-mediated signaling in DN-DISC1 mice may underlie susceptibility to detrimental effects of adolescent cannabis exposure on adult behaviors. PMID:26093170

  4. Hemp (Cannabis sativa L.) as an Environmentally Friendly Energyplant

    Science.gov (United States)

    Poisa, Liena; Adamovics, Aleksandrs

    2010-01-01

    Hemp is suitable as a renewable energy resource. The aim of this study was to clarify local hemp's (Cannabis sativa L.) possibilities for energy use. Arsenic (As), cadmium (Cd), lead (Pb) and titanium (Ti) presence in hemp was determined using an inductively coupled plasma optical emission spectrometer Optima 2100 DV. If there were increased N fertilizer rates, there were increased hemp `P?ri?i' seeds and shive yield increases, but the oil content was reduced. Arsenic content was higher in the shives than in the stems with fibre. The ash content depends on non-organic substances which the plants absorb during the vegetation season. The lignin content depends on several factors: plant parts, and the N fertilizer rate. The unexplored factors have a great effect on the ash and lignin content. Hemp is suitable for cultivation and for bio-energy production in the agro-climatic conditions in Latvia.

  5. Poor School Satisfaction and Number of Cannabis Using Peers within School Classes as Individual Risk Factors for Cannabis Use among Adolescents

    Science.gov (United States)

    Hoff, Dominic A.; Andersen, Anette; Holstein, Bjorn E.

    2010-01-01

    There is little information available on the topic of poor school satisfaction as a risk factor for cannabis use among adolescents. We examined if there was an association between poor school satisfaction, school class cannabis use and individual cannabis use. Further, we investigated if many cannabis users within the school class statistically…

  6. Social Anxiety and Cannabis Use: An Analysis from Ecological Momentary Assessment

    OpenAIRE

    Buckner, Julia D.; Crosby, Ross D.; Wonderlich, Stephen A.; Schmidt, Norman B.

    2011-01-01

    Individuals with elevated social anxiety appear especially vulnerable to cannabis-related problems, yet little is known about the antecedents of cannabis-related behaviors among this high-risk population. The present study used ecological momentary assessment (EMA) to examine the relations among social anxiety, cannabis craving, state anxiety, situational variables, and cannabis use in the natural environment during ad-lib cannabis use episodes. Participants were 49 current cannabis users. Du...

  7. Symptoms of Depression Depend on Rigid Parenting Attitudes, Gender, and Race in an At-Risk Sample of Early Adolescents

    Science.gov (United States)

    Weed, Keri; Morales, Dawn A.; Harjes, Rachel

    2013-01-01

    Trajectories of depressive symptoms were compared between European American and African American boys and girls from ages 8 to 14 in a longitudinal sample of 130 children born to adolescent mothers. Mixed-effects regression modeling was used to analyze individual and group differences in level of depressive symptoms and their changes over time.…

  8. Cannabis and Schizophrenia Spectrum Disorders: A Review of Clinical Studies

    OpenAIRE

    Rodrigo Chaturaka; Rajapakse Senaka

    2009-01-01

    Cannabis is the most widely used illegitimate substance in the world, and the number of users has increased by 10% over the last decade worldwide. Therefore, it is important to review the evidence on psychoactive properties of cannabis and its possible association with schizophrenia spectrum disorders (SSD). We searched MEDLINE with the key words cannabis and schizophrenia. The search was limited to articles published in English over the last 10 years (1999-2009). Bibliographies of cit...

  9. Cannabis, schizophrenia and other psychoses : longitudinal studies on Swedish conscripts

    OpenAIRE

    Manrique-Garcia, Edison

    2014-01-01

    AIM The overall aim of this thesis was to investigate the association between cannabis use and psychiatric disorders with emphasis on schizophrenia, other psychoses, depression and long term effects on mortality. Specific objectives were to: 1) investigate the long-term risk of schizophrenia, and other psychoses including brief psychoses among users and non-users of cannabis, (2) assess the risk of depression among users and non-users of cannabis, (3) determinate whet...

  10. The effect of cannabis use on memory function: an update

    OpenAIRE

    Schoeler T; Bhattacharyya S.

    2013-01-01

    Tabea Schoeler, Sagnik BhattacharyyaDepartment of Psychosis Studies, King's College London, Institute of Psychiatry, London, UKAbstract: Investigating the effects of cannabis use on memory function appears challenging. While early observational investigations aimed to elucidate the longer-term effects of cannabis use on memory function in humans, findings remained equivocal and pointed to a pattern of interacting factors impacting on the relationship between cannabis use and memory fu...

  11. Cannabis use correlates with schizotypy in healthy people.

    OpenAIRE

    Williams, JH; Wellman, NA; Rawlins, JN

    1996-01-01

    Cannabis use or high scores on self-report schizotypy questionnaires predict an increased risk of developing clinical psychosis. We tested whether cannabis use correlated with schizotypal and other personality traits in 211 healthy adults. Subjects who had used cannabis showed higher scores on schizotypy, borderline and psychoticism scales than never-users. Multivariate analysis, covarying lie scale scores, age and educational level indicated that high schizotypal traits best discriminated su...

  12. Cannabis and tobacco smoke are not equally carcinogenic

    OpenAIRE

    Melamede Robert

    2005-01-01

    Abstract More people are using the cannabis plant as modern basic and clinical science reaffirms and extends its medicinal uses. Concomitantly, concern and opposition to smoked medicine has occurred, in part due to the known carcinogenic consequences of smoking tobacco. Are these reactions justified? While chemically very similar, there are fundamental differences in the pharmacological properties between cannabis and tobacco smoke. Cannabis smoke contains cannabinoids whereas tobacco smoke c...

  13. Eysenck Personality Dimensions in a Sample of Cannabis Users

    OpenAIRE

    Arash Vahdat; Hamed Azimi; Azizeh A. Ebrahimi; Mehrdad Eftekhar; Hamid Reza Ahmadkhaniha

    2007-01-01

        Objective: The objective of this study is to examine Eysenck personality dimensions in cannabis users  Method:100 regular cannabis users were selected and completed Eysenck Personality Questionnaire (EPQ) which easures Neuroticism (N),Extraversion-Introversion (E-I) and Psychoticism (P) dimensions of Eysenck personality structures  Results:The scores of 51% of cannabis users were higher than mean in all dimensions of EPQ. Also the mean score of N and P were higher than...

  14. Gender Differences in the Correlates of Adolescents' Cannabis Use

    OpenAIRE

    Tu, Andrew W.; Pamela A Ratner; Joy L. Johnson

    2008-01-01

    Adolescents' gender-specific cannabis use rates and their correlates were examined. Data were obtained via a cross-sectional survey conducted in 2004 in British Columbia, Canada, funded by the Canadian Institutes of Health Research. School districts were invited to participate, and schools within consenting districts were recruited. In total, 8,225 students (50% male)from Grades 7 to 12 participated. About 73% were “White” and 47% had used cannabis in their lifetime. Cannabis users were group...

  15. The Development of Self-Criticism and Dependency in Early Adolescence and Their Role in the Development of Depressive and Anxiety Symptoms.

    Science.gov (United States)

    Kopala-Sibley, Daniel C; Zuroff, David C; Hankin, Benjamin L; Abela, John R Z

    2015-08-01

    According to Blatt and others (e.g., A. T. Beck), self-definition, or one's sense of self, and one's sense of relatedness to others represent core lifespan developmental tasks. This study examined the role of events pertaining to self-definition or relatedness in the development of personality traits from each domain (self-criticism and dependency), and their relationship to the development of depressive and anxiety symptoms. Two hundred seventy-six early adolescents completed a measure of self-criticism and dependency at baseline and again 24 months later, along with measures of depressive and anxiety symptoms. Every 3 months, participants completed a measure of life events, which were coded as self-definitional or relatedness oriented (80% rater agreement, kappa = .70). Structural equation models showed that self-definitional events predicted increases in self-criticism, which in turn predicted increases in depressive symptoms, whereas relatedness events predicted increases in dependency, although dependency was unrelated to change in symptoms. PMID:26091911

  16. Depressive Symptoms, Substance Use and HIV-Related High Risk Behaviors among Opioid-Dependent Individuals: Results from the Clinical Trials Network

    OpenAIRE

    PILOWSKY, DANIEL; WU, LI-TZY; Burchett, Bruce; Blazer, Dan G.; Ling, Walter

    2011-01-01

    The sample included 343 opioid-dependent adults enrolled in two national multisite studies of the National Drug Abuse Treatment Clinical Trials Network (CTN001-002). Opioid-dependent individuals were recruited from 12 sites across the United States from January 2001 to July 2002. We examined associations between depressive symptoms, co-occurring substance use (i.e. the use of substances other than opioids), and HIV-related sexual and injection risk behaviors. Data were collected using the Add...

  17. Cannabis and schizophrenia spectrum disorders: A review of clinical studies

    Directory of Open Access Journals (Sweden)

    Rodrigo Chaturaka

    2009-01-01

    Full Text Available Cannabis is the most widely used illegitimate substance in the world, and the number of users has increased by 10% over the last decade worldwide. Therefore, it is important to review the evidence on psychoactive properties of cannabis and its possible association with schizophrenia spectrum disorders (SSD. We searched MEDLINE with the key words cannabis and schizophrenia. The search was limited to articles published in English over the last 10 years (1999-2009. Bibliographies of cited literature were also searched. Data sources included reviews published in core clinical journals, cohort studies, interventional studies, case-control studies, cross-sectional analyses and epidemiological data. Results are discussed under 2 topics. Firstly, evidence related to biochemical functioning of cannabinoids and their relationship to endocannabinoid system is discussed briefly. Secondly, the evidence from clinical studies on cannabis, psychosis proneness and SSD are discussed in detail. The discussion is structured to fit in the evidence from results section to 3 plausible hypotheses on cannabis use and SSD. The evidence for and against each hypothesis is discussed. Despite new evidence, the exact relationship between cannabis and SSD is unclear. There is no firm evidence that cannabis causes SSD. The evidence for the argument that schizophrenic patients are attracted to cannabis is also not strong. The most plausible explanation is that cannabis use and psychosis proneness may have synergistic effects in a vulnerable minority.

  18. Cannabis use during adolescent development: susceptibility to psychiatric illness

    Directory of Open Access Journals (Sweden)

    MichaelLawrenceMiller

    2013-10-01

    Full Text Available Cannabis use is increasingly pervasive among adolescents today, even more common than cigarette smoking. The evolving policy surrounding the legalization of cannabis reaffirms the need to understand the relationship between cannabis exposure early in life and psychiatric illnesses. Cannabis contains psychoactive components, notably ?9-tetrahydrocannbinol (THC, that interfere with the brain’s endogenous endocannabinoid system, which is critically involved in both pre- and post-natal neurodevelopment. Consequently, THC and related compounds could potentially usurp normal adolescent neurodevelopment, shifting the brain’s developmental trajectory towards a disease-vulnerable state, predisposing early cannabis-users to motivational, affective and psychotic disorders. Numerous human studies, including prospective longitudinal studies, demonstrate that early cannabis use is associated with major depressive disorder and drug addiction. A strong association between schizophrenia and cannabis use is also apparent, especially when considering genetic factors that interact with this environmental exposure. These human studies set a foundation for carefully controlled animal studies which demonstrate similar patterns following early cannabinoid exposure. Given the vulnerable nature of adolescent neurodevelopment and the persistent changes that follow early cannabis exposure, the experimental findings outlined should be carefully considered by policymakers. In order to fully address the growing issues of psychiatric illnesses and to ensure a healthy future, measures should be taken to reduce cannabis use among teens.

  19. Cannabis and tobacco smoke are not equally carcinogenic

    Directory of Open Access Journals (Sweden)

    Melamede Robert

    2005-10-01

    Full Text Available Abstract More people are using the cannabis plant as modern basic and clinical science reaffirms and extends its medicinal uses. Concomitantly, concern and opposition to smoked medicine has occurred, in part due to the known carcinogenic consequences of smoking tobacco. Are these reactions justified? While chemically very similar, there are fundamental differences in the pharmacological properties between cannabis and tobacco smoke. Cannabis smoke contains cannabinoids whereas tobacco smoke contains nicotine. Available scientific data, that examines the carcinogenic properties of inhaling smoke and its biological consequences, suggests reasons why tobacco smoke, but not cannabis smoke, may result in lung cancer.

  20. Self-reported efficacy of cannabis and other complementary medicine modalities by Parkinson's disease patients in colorado.

    Science.gov (United States)

    Finseth, Taylor Andrew; Hedeman, Jessica Louise; Brown, Robert Preston; Johnson, Kristina I; Binder, Matthew Sean; Kluger, Benzi M

    2015-01-01

    Introduction. Complementary and alternative medicine (CAM) is frequently used by Parkinson's disease (PD) patients. We sought to provide information on CAM use and efficacy in PD patients in the Denver metro area with particular attention to cannabis use given its recent change in legal status. Methods. Self-administered surveys on CAM use and efficacy were completed by PD patients identified in clinics and support groups across the Denver metro area between 2012 and 2013. Results. 207 patients (age 69 ± 11; 60% male) completed the survey. Responses to individual CAM therapy items showed that 85% of respondents used at least one form of CAM. The most frequently reported CAMs were vitamins (66%), prayer (59%), massage (45%), and relaxation (32%). Self-reported improvement related to the use of CAM was highest for massage, art therapy, music therapy, and cannabis. While only 4.3% of our survey responders reported use of cannabis, it ranked among the most effective CAM therapies. Conclusions. Overall, our cross-sectional study was notable for a high rate of CAM utilization amongst PD patients and high rates of self-reported efficacy across most CAM modalities. Cannabis was rarely used in our population but users reported high efficacy, mainly for nonmotor symptoms. PMID:25821504

  1. Legalising medical use of cannabis in South Africa: Is the empirical evidence sufficient to support policy shifts in this direction?

    Scientific Electronic Library Online (English)

    C D H, Parry; B J, Myers.

    2014-06-01

    Full Text Available Inkatha Freedom Party MP Mario Oriani-Ambrosini's impassioned plea to legalise the medical use of cannabis must be understood in the context of his own condition as well as legislative changes in at least ten countries. This article argues that any decisions to shift policy must be based on a consid [...] eration of the evidence on the risks and benefits associated with the medical use of cannabis for the individual and broader society. It concludes that there are important gaps in the evidence base, particularly in human trials supporting the efficacy of cannabis use for treating and preventing medical conditions and alleviating negative symptoms associated with these conditions. South African researchers should be enabled actively to support development of the necessary evidence base by conducting preclinical and clinical research in this area. Human trials to establish the efficacy of the use of cannabis/cannabinoids in addressing AIDS wasting syndrome and other negative sequelae of HIV and AIDS are especially needed.

  2. Exposure to Terrorism and Israeli Youths’ Cigarette, Alcohol, and Cannabis Use

    Science.gov (United States)

    Schiff, Miriam; Zweig, Hillah Haim; Benbenishty, Rami; Hasin, Deborah S.

    2007-01-01

    Objectives. We investigated the consequences of exposure to acts of terrorism among Israeli adolescents. We examined whether exposure to terrorism predicted adolescents’ use of cigarettes, alcohol (including binge drinking), and cannabis after we controlled for posttraumatic stress and depressive symptoms and background variables. Methods. Anonymous self-administered questionnaires were given to a random sample of 960 10th and 11th grade students (51.6% boys, 48.4% girls) in a large city in northern Israel. Results. Close physical exposure to acts of terrorism predicted higher levels of alcohol consumption (including binge drinking among drinkers) and cannabis use. These relationships remained even after we controlled for posttraumatic stress and depressive symptoms. Conclusions. In addition to posttraumatic stress symptoms, negative consequences of terrorism exposure among adolescents included substance abuse. The similarity between our findings among Israeli adolescents and previous findings among US adults suggests cross-cultural generalizability. Given the risks for later problems from early-onset substance abuse, the consequences of terrorism exposure among adolescents merit greater research and clinical attention. PMID:17761574

  3. Trait mindfulness, reasons for living and general symptom severity as predictors of suicide probability in males with substance abuse or dependence.

    Directory of Open Access Journals (Sweden)

    Parvaneh Mohammadkhani

    2015-03-01

    Full Text Available The aim of this study was to evaluate suicide probability in Iranian males with substance abuse or dependence disorder and to investigate the predictors of suicide probability based on trait mindfulness, reasons for living and severity of general psychiatric symptoms.Participants were 324 individuals with substance abuse or dependence in an outpatient setting and prison. Reasons for living questionnaire, Mindfulness Attention Awareness Scale and Suicide probability Scale were used as instruments. Sample was selected based on convenience sampling method. Data were analyzed using SPSS and AMOS.The life-time prevalence of suicide attempt in the outpatient setting was35% and it was 42% in the prison setting. Suicide probability in the prison setting was significantly higher than in the outpatient setting (p<0.001. The severity of general symptom strongly correlated with suicide probability. Trait mindfulness, not reasons for living beliefs, had a mediating effect in the relationship between the severity of general symptoms and suicide probability. Fear of social disapproval, survival and coping beliefs and child-related concerns significantly predicted suicide probability (p<0.001.It could be suggested that trait mindfulness was more effective in preventing suicide probability than beliefs about reasons for living in individuals with substance abuse or dependence disorders. The severity of general symptom should be regarded as an important risk factor of suicide probability.

  4. Cannabis use by children and young people

    OpenAIRE

    McArdle, P.A.

    2006-01-01

    A popular internet site1 describes cannabis as “a leafy plant, the leaves and flowering tops (buds) of which may be either smoked or eaten. It also comes in a more concentrated resinous form called hashish, and as a sticky black liquid called hash oil”. It is said that users often report a pleasant “subjective enhancement of visual and auditory perception, sometimes with synaesthesia (sounds take on visual colourful qualities)” and the sense that time passes more quickly than real time, a “fa...

  5. Etat limite, adolescence, cannabis et cocaïne

    Scientific Electronic Library Online (English)

    Didier, Lauru.

    2014-08-01

    Full Text Available Borderline, teenagers, cannabis and cocaine. Teenagers are fond of psychoactive products. Somme of them, according to their personality, go to the limits of their psychic structure. In the practical field, we can often observe the revealing of borderline states, very different from the usual problem [...] atic teenagers. Psychoactive substances, used for the first time as anxiolytics, become quickly a cause of anxiety, therefore revealing the subjects in borderline states.

  6. Counselling young cannabis users by text message

    DEFF Research Database (Denmark)

    Laursen, Ditte

    2010-01-01

    This article presents the results of a study of two SMS services aimed at providing young people with information on cannabis and helping them to reduce their consumption of the drug. The attitude of the 12 participants in the study towards the SMS services is generally positive, but they prefer factual information to advice and counselling. The messages prompt reflection and awareness among the recipients, and their repetitive, serial nature plays a significant part in the process of change. Th...

  7. Harm reduction-the cannabis paradox

    OpenAIRE

    Melamede Robert

    2005-01-01

    Abstract This article examines harm reduction from a novel perspective. Its central thesis is that harm reduction is not only a social concept, but also a biological one. More specifically, evolution does not make moral distinctions in the selection process, but utilizes a cannabis-based approach to harm reduction in order to promote survival of the fittest. Evidence will be provided from peer-reviewed scientific literature that supports the hypothesis that humans, and all animals, make and u...

  8. The pharmacologic and clinical effects of medical cannabis.

    Science.gov (United States)

    Borgelt, Laura M; Franson, Kari L; Nussbaum, Abraham M; Wang, George S

    2013-02-01

    Cannabis, or marijuana, has been used for medicinal purposes for many years. Several types of cannabinoid medicines are available in the United States and Canada. Dronabinol (schedule III), nabilone (schedule II), and nabiximols (not U.S. Food and Drug Administration approved) are cannabis-derived pharmaceuticals. Medical cannabis or medical marijuana, a leafy plant cultivated for the production of its leaves and flowering tops, is a schedule I drug, but patients obtain it through cannabis dispensaries and statewide programs. The effect that cannabinoid compounds have on the cannabinoid receptors (CB(1) and CB(2) ) found in the brain can create varying pharmacologic responses based on formulation and patient characteristics. The cannabinoid ?(9) -tetrahydrocannabinol has been determined to have the primary psychoactive effects; the effects of several other key cannabinoid compounds have yet to be fully elucidated. Dronabinol and nabilone are indicated for the treatment of nausea and vomiting associated with cancer chemotherapy and of anorexia associated with weight loss in patients with acquired immune deficiency syndrome. However, pain and muscle spasms are the most common reasons that medical cannabis is being recommended. Studies of medical cannabis show significant improvement in various types of pain and muscle spasticity. Reported adverse effects are typically not serious, with the most common being dizziness. Safety concerns regarding cannabis include the increased risk of developing schizophrenia with adolescent use, impairments in memory and cognition, accidental pediatric ingestions, and lack of safety packaging for medical cannabis formulations. This article will describe the pharmacology of cannabis, effects of various dosage formulations, therapeutics benefits and risks of cannabis for pain and muscle spasm, and safety concerns of medical cannabis use. PMID:23386598

  9. Affect dysregulation in cannabis abusers: a study in adolescents and young adults.

    Science.gov (United States)

    Dorard, Géraldine; Berthoz, Sylvie; Phan, Olivier; Corcos, Maurice; Bungener, Catherine

    2008-08-01

    Psychiatric comorbidity and impaired emotional functioning have been previously reported in adult substance abusers but have been less well documented in adolescents. Thus, we investigated mental health problems and emotion regulation abilities in adolescents and young adults with cannabis dependence. Moreover, we explored the relationships between consumption modalities and affective style. Therefore, 32 cannabis abusers (CA) and 30 healthy controls completed a battery of self-reports measuring depression (BDI-13), anxiety (STAI-Y), alexithymia (TAS20; BVAQ-B), anhedonia (PAS; SAS), and sensation seeking (SSS). The MINI was administered to evaluate cannabis dependence and axis I DSM-IV comorbid diagnoses. A semi-structured clinical interview was given to determine psychoactive substance use. Statistical analyses revealed that more than half of the CA reported at least one other non-drug or alcohol comorbid diagnosis. The most common were mood and anxiety disorders. CA subjects scored significantly higher on all affective dimensions except alexithymia total scores; however, they had greater scores for the two subscales measuring the difficulties in identifying feelings. Logistic regressions demonstrated that CA subjects were more likely to experience high levels of trait anxiety, physical anhedonia and sensation seeking than the controls. Various correlations were observed between the affective scores and the substance considered. The amount of substance use and, particularly, the prevalence of polydrug use we observed are alarming. This study demonstrates that cannabis dependence in adolescents and young adults is related to a great psychological distress and specific emotional dimensions and puts emphasis on the importance of substance use prevention as early as middle school. PMID:18301941

  10. Cannabis Smoking in 2015: A Concern for Lung Health?

    Science.gov (United States)

    Biehl, Jason R; Burnham, Ellen L

    2015-09-01

    Recent legislative successes allowing expanded access to recreational and medicinal cannabis have been associated with its increased use by the public, despite continued debates regarding its safety within the medical and scientific communities. Despite legislative changes, cannabis is most commonly used by smoking, although alternatives to inhalation have also emerged. Moreover, the composition of commercially available cannabis has dramatically changed in recent years. Therefore, developing sound scientific information regarding its impact on lung health is imperative, particularly because published data conducted prior to widespread legalization are conflicting and inconclusive. In this commentary, we delineate major observations of epidemiologic investigations examining cannabis use and the potential associated development of airways disease and lung cancer to highlight gaps in pulmonary knowledge. Additionally, we review major histopathologic alterations related to smoked cannabis and define specific areas in animal models and human clinical translational investigations that could benefit from additional development. Given that cannabis has an ongoing classification as a schedule I medication, federal funding to support investigations of modern cannabis use in terms of medicinal efficacy and safety profile on lung health have been elusive. It is clear, however, that the effects of inhaled cannabis on lung health remain uncertain and given increasing use patterns, are worthy of further investigation. PMID:25996274

  11. Multiple sclerosis, cannabis, and cognition: A structural MRI study

    Directory of Open Access Journals (Sweden)

    Kristoffer Romero

    2015-01-01

    Interpretation: These results suggest that cannabis use in MS results in more widespread cognitive deficits, which correlate with tissue volume in subcortical, medial temporal, and prefrontal regions. These are the first findings demonstrating an association between cannabis use, cognitive impairment and structural brain changes in MS patients.

  12. Standardized cannabis in multiple sclerosis: a case report

    OpenAIRE

    Hornby, Paul; Sharma, Manju

    2010-01-01

    A 52 year old female suffering from severe progressive multiple sclerosis was administered quantifiable amounts of standardized cannabis and monitored over the period of one year, while providing daily pain charts and records of her condition. An average daily intake of 500 mg of Tetrahydrocannabinol as cannabis was required to achieve a desired quality of life.

  13. Neuronal substrates and functional consequences of prenatal cannabis exposure.

    Science.gov (United States)

    Calvigioni, Daniela; Hurd, Yasmin L; Harkany, Tibor; Keimpema, Erik

    2014-10-01

    Cannabis remains one of the world's most widely used substance of abuse amongst pregnant women. Trends of the last 50 years show an increase in popularity in child-bearing women together with a constant increase in cannabis potency. In addition, potent herbal "legal" highs containing synthetic cannabinoids that mimic the effects of cannabis with unknown pharmacological and toxicological effects have gained rapid popularity amongst young adults. Despite the surge in cannabis use during pregnancy, little is known about the neurobiological and psychological consequences in the exposed offspring. In this review, we emphasize the importance of maternal programming, defined as the intrauterine presentation of maternal stimuli to the foetus, in neurodevelopment. In particular, we focus on cannabis-mediated maternal adverse effects, resulting in direct central nervous system alteration or sensitization to late-onset chronic and neuropsychiatric disorders. We compare clinical and preclinical experimental studies on the effects of foetal cannabis exposure until early adulthood, to stress the importance of animal models that permit the fine control of environmental variables and allow the dissection of cannabis-mediated molecular cascades in the developing central nervous system. In sum, we conclude that preclinical experimental models confirm clinical studies and that cannabis exposure evokes significant molecular modifications to neurodevelopmental programs leading to neurophysiological and behavioural abnormalities. PMID:24793873

  14. Cannabis use and destructive periodontal diseases among adolescents

    DEFF Research Database (Denmark)

    López, Rodrigo; Baelum, Vibeke

    2009-01-01

    AIM: The aim of this experiment was to investigate the association between cannabis use and destructive periodontal disease among adolescents. MATERIAL AND METHODS: Data from a population screening examination carried out among Chilean high school students from the Province of Santiago were used to determine whether there was an association between the use of cannabis and signs of periodontal diseases as defined by (1) the presence of necrotizing ulcerative gingival (NUG) lesions or (2) the presence of clinical attachment loss (CAL) > or =3 mm. The cannabis exposures variables considered were "Ever use of cannabis" (yes/no) and "Regular use of cannabis" (yes/no). The associations were investigated using multiple logistic regression analyses adjusted for age, gender, paternal income, paternal education, frequency of tooth-brushing and time since last dental visit. RESULTS: Multiple logistic regression analyses showed that "Ever use of cannabis" was significantly negatively associated with the presence of NUG lesions (OR=0.47 [0.2;0.9]) among non-smokers only. No significant associations were observed between the presence of CAL > or =3 mm and cannabis use in either of the smoking groups. CONCLUSIONS: There was no evidence to suggest that the use of cannabis is positively associated with periodontal diseases in this adolescent population.

  15. Reduction of stem growth and site dependency of leaf injury in Massachusetts black cherries exhibiting ozone symptoms

    International Nuclear Information System (INIS)

    Ozone symptomatic trees had a reduced stem growth and symptom expression was enhanced on moister and better growing stands. - Leaf ozone symptoms in natural ecosystems are increasingly reported but ozone effects on tree growth and the mediation of site conditions are still little documented. This study tests two hypotheses: (1) leaf injury in black cherry is associated with decline in radial growth, (2) symptoms are more prevalent on mesic sites. On sites supporting black cherry across Massachusetts, tree growth and leaf ozone injury were surveyed in 1996 using a randomized plot network established in the 1960s. Forty-seven percent of 120 trees sampled for ozone symptoms were symptomatic with generally low levels of injury. Over a 31-year period symptomatic trees had 28% lower stem growth rates than asymptomatic trees. Ozone symptom expression was enhanced in well growing stands on moister, cooler and more elevated sites. Ozone appeared to increase environmental stress and had a more pronounced effect on growth in better growing black cherry stands. This complicates management decisions as thinning increases growth and moisture availability

  16. Anorexia nervosa and cannabis abuse: a case report

    Directory of Open Access Journals (Sweden)

    semra karayilan

    2013-01-01

    Full Text Available It is known that there is a high rate of comorbidity of alcohol-substance abuse and eating disorders. The compounds of cannabis, such as tetrahydrocannabinol, activate endogenous cannabinoid receptors (CB1 and CB2 in the brain. Stimulating the CB1 receptor is known to cause increased appetite and an antiemetic effect and because of these effects cannabinoids are used clinically. In this case report, a young girl diagnosed anorexia nervosa and using cannabis will be presented. The patient, a 17 year-old, had complaints of loss weight and had used cannabis for three years. It was found that, although cannabis caused increased appetite, she induced weight loss by self-induction of vomiting and excessive exercise. According to a scan of the literature in Turkey, such a case of using cannabis comorbid with anorexia nervosa has not previously been reported. In this respect, discussion of the case in detail is important.

  17. Four decades of cannabis criminals in Canada: 1970-2010

    Directory of Open Access Journals (Sweden)

    Patricia G. Erickson

    2010-10-01

    Full Text Available

    Canada was one of the first countries in the world to criminalise cannabis in 1923. It was not until the late 1960s and an associated upsurge of youthful cannabis use that the government and various stakeholders seriously interrogated the appropriateness of this punitive prohibition. Nevertheless, despite numerous opportunities for law reform for over four decades, cannabis possession continues to be illegal and as a result, hundreds of thousands of Canadians have received criminal records under these laws. This article reviews federal attempts at cannabis law reform and uses data spanning several decades to examine the characteristics of individuals convicted of cannabis possession and the implications of criminalisation on their lives.

  18. Genetic association between APOE*4 and neuropsychiatric symptoms in patients with probable Alzheimer's disease is dependent on the psychosis phenotype

    Directory of Open Access Journals (Sweden)

    Christie Drew

    2012-12-01

    Full Text Available Abstract Background Neuropsychiatric symptoms such as psychosis are prevalent in patients with probable Alzheimer’s disease (AD and are associated with increased morbidity and mortality. Because these disabling symptoms are generally not well tolerated by caregivers, patients with these symptoms tend to be institutionalized earlier than patients without them. The identification of protective and risk factors for neuropsychiatric symptoms in AD would facilitate the development of more specific treatments for these symptoms and thereby decrease morbidity and mortality in AD. The E4 allele of the apolipoprotein E (APOE gene is a well-documented risk factor for the development of AD. However, genetic association studies of the APOE 4 allele and BPS in AD have produced conflicting findings. Methods This study investigates the association between APOE and neuropsychiatric symptoms in a large sample of clinically well-characterized subjects with probable AD (n=790 who were systematically evaluated using the Consortium to Establish a Registry for Alzheimer’s Disease (CERAD Behavioral Rating Scale for Dementia (BRSD. Results Our study found that hallucinations were significantly more likely to occur in subjects with no APO?4 alleles than in subjects with two ?4 alleles (15% of subjects and 5% of subjects, respectively; p=.0066, whereas there was no association between the occurrence of delusions, aberrant motor behavior, or agitation and the number of ?4 alleles. However, 94% of the subjects with hallucinations also had delusions (D+H. Conclusion These findings suggest that in AD the ?4 allele is differentially associated with D+H but not delusions alone. This is consistent with the hypothesis that distinct psychotic subphenotypes may be associated with the APOE allele.

  19. Moral regulation and the presumption of guilt in Health Canada's medical cannabis policy and practice.

    Science.gov (United States)

    Lucas, Philippe

    2009-07-01

    This paper is a sociological examination of policies and practices in Health Canada's Marihuana Medical Access Division (MMAD) that presume the illicit intentions and inherent "guilt" of medical cannabis users, hampering safe access to a medicine to which many are legally entitled, and raising doubts about this federal programme's overall effectiveness and constitutional legitimacy. Beginning with a brief historical overview of Canada's federal medical cannabis programme, this paper examines the failure of the MMAD to meet the needs of many sick and suffering Canadians through Hunt's [Hunt, A. (1999). Governing morals: A social history of moral regulation. Cambridge, UK: Cambridge University Press] work on moral regulation and Wodak's [Wodak, A. (2007). Ethics and drug policy. Psychiatry, 6(2), 59-62] critique of "deontological" drug policy strategies. I then cite Tupper's [Tupper, K. W. (2007). The globalization of ayahuasca: Harm reduction or benefit maximization? International Journal of Drug Policy, doi:10.1016/j.drugpo.2006.11.001] argument that shifting to a generative metaphor that constructs certain entheogenic substances as potentially useful "tools" rather than regulating them through inherently moralistic prohibitionist policies would better serve public health, and incorporate Young's [Young, I. M. (1990). Justice and the politics of difference. Princeton, New Jersey: Princeton University Press] theories of domination and oppression to examine the rise of community-base medical cannabis dispensaries as "new social movements". First-hand accounts by medical cannabis patients, federally funded studies, and internal Health Canada communication and documents suggest that current federal policies and practices are blocking safe access to this herbal medicine. The community-based dispensary model of medical cannabis access is a patient-centered "new social movement" that mitigates the stigmatization and moral regulation of their member-clients by creating opportunities for engagement, empowerment and joint knowledge creation. In light of ongoing Charter challenges and patient criticism, the survival of this federal programme will depend on the government's ability to shift away from policies based on the oppression and moral regulation, and towards consequentialist policies that balance harm reduction and benefit maximization. The effectiveness of such an approach is exemplified by the success of the community-based dispensary model which is currently producing more peer-reviewed research and supplying medical cannabis to a far greater number of patients than Health Canada's Marihuana Medical Access Division. PMID:19124233

  20. Self-administration of cocaine, cannabis and heroin in the human laboratory: benefits and pitfalls.

    Science.gov (United States)

    Haney, Margaret

    2009-01-01

    The objective of this review is to describe self-administration procedures for modeling addiction to cocaine, cannabis and heroin in the human laboratory, the benefits and pitfalls of the approach, and the methodological issues unique to each drug. In addition, the predictive validity of the model for testing treatment medications will be addressed. The results show that all three drugs of abuse are reliably and robustly self-administered by non-treatment-seeking research volunteers. In terms of pharmacotherapies, cocaine use is extraordinarily difficult to disrupt either in the laboratory or in the clinic. A range of medications has been shown to significantly decrease cocaine's subjective effects and craving without decreasing either cocaine self-administration or cocaine abuse by patients. These negative data combined with recent positive findings with modafinil suggest that self-administration procedures are an important intermediary step between pre-clinical and clinical studies. In terms of cannabis, a recent study suggests that medications that improve sleep and mood during cannabis withdrawal decrease the resumption of marijuana self-administration in abstinent volunteers. Clinical data on patients seeking treatment for their marijuana use are needed to validate these laboratory findings. Finally, in contrast to cannabis or cocaine dependence, there are three efficacious Food and Drug Administration-approved medications to treat opioid dependence, all of which decrease both heroin self-administration and subjective effects in the human laboratory. In summary, self-administration procedures provide meaningful behavioral data in a small number of individuals. These studies contribute to our understanding of the variables maintaining cocaine, marijuana and heroin intake, and are important in guiding the development of more effective drug treatment programs. PMID:18855806

  1. Achieving cannabis cessation -- evaluating N-acetylcysteine treatment (ACCENT): design and implementation of a multi-site, randomized controlled study in the National Institute on Drug Abuse Clinical Trials Network.

    Science.gov (United States)

    McClure, Erin A; Sonne, Susan C; Winhusen, Theresa; Carroll, Kathleen M; Ghitza, Udi E; McRae-Clark, Aimee L; Matthews, Abigail G; Sharma, Gaurav; Van Veldhuisen, Paul; Vandrey, Ryan G; Levin, Frances R; Weiss, Roger D; Lindblad, Robert; Allen, Colleen; Mooney, Larissa J; Haynes, Louise; Brigham, Gregory S; Sparenborg, Steve; Hasson, Albert L; Gray, Kevin M

    2014-11-01

    Despite recent advances in behavioral interventions for cannabis use disorders, effect sizes remain modest, and few individuals achieve long-term abstinence. One strategy to enhance outcomes is the addition of pharmacotherapy to complement behavioral treatment, but to date no efficacious medications targeting cannabis use disorders in adults through large, randomized controlled trials have been identified. The National Institute on Drug Abuse Clinical Trials Network (NIDA CTN) is currently conducting a study to test the efficacy of N-acetylcysteine (NAC) versus placebo (PBO), added to contingency management, for cannabis cessation in adults (ages 18-50). This study was designed to replicate positive findings from a study in cannabis-dependent adolescents that found greater odds of abstinence with NAC compared to PBO. This paper describes the design and implementation of an ongoing 12-week, intent-to-treat, double-blind, randomized, placebo-controlled study with one follow-up visit four weeks post-treatment. Approximately 300 treatment-seeking cannabis-dependent adults will be randomized to NAC or PBO across six study sites in the United States. The primary objective of this 12-week study is to evaluate the efficacy of twice-daily orally-administered NAC (1200 mg) versus matched PBO, added to contingency management, on cannabis abstinence. NAC is among the first medications to demonstrate increased odds of abstinence in a randomized controlled study among cannabis users in any age group. The current study will assess the cannabis cessation efficacy of NAC combined with a behavioral intervention in adults, providing a novel and timely contribution to the evidence base for the treatment of cannabis use disorders. PMID:25179587

  2. Achieving Cannabis Cessation - Evaluating N-acetylcysteine Treatment (ACCENT): Design and implementation of a multi-site, randomized controlled study in the National Institute on Drug Abuse Clinical Trials Network

    Science.gov (United States)

    McClure, Erin A.; Sonne, Susan C.; Winhusen, Theresa; Carroll, Kathleen M.; Ghitza, Udi E.; McRae-Clark, Aimee L.; Matthews, Abigail G.; Sharma, Gaurav; Van Veldhuisen, Paul; Vandrey, Ryan G.; Levin, Frances R.; Weiss, Roger D.; Lindblad, Robert; Allen, Colleen; Mooney, Larissa J.; Haynes, Louise; Brigham, Gregory S.; Sparenborg, Steve; Hasson, Albert L.; Gray, Kevin M.

    2014-01-01

    Despite recent advances in behavioral interventions for cannabis use disorders, effect sizes remain modest, and few individuals achieve long-term abstinence. One strategy to enhance outcomes is the addition of pharmacotherapy to complement behavioral treatment, but to date no efficacious medications targeting cannabis use disorders in adults through large, randomized controlled trials have been identified. The National Institute on Drug Abuse Clinical Trials Network (NIDA CTN) is currently conducting a study to test the efficacy of N-acetylcysteine (NAC) versus placebo (PBO), added to contingency management, for cannabis cessation in adults (ages 18–50). This study was designed to replicate positive findings from a study in cannabis-dependent adolescents that found greater odds of abstinence with NAC compared to PBO. This paper describes the design and implementation of an ongoing 12-week, intent-to-treat, double-blind, randomized, placebo-controlled study with one follow-up visit four weeks post-treatment. Approximately 300 treatment-seeking cannabis-dependent adults will be randomized to NAC or PBO across six study sites in the United States. The primary objective of this 12-week study is to evaluate the efficacy of twice-daily orally-administered NAC (1200 mg) versus matched PBO, added to contingency management, on cannabis abstinence. NAC is among the first medications to demonstrate increased odds of abstinence in a randomized controlled study among cannabis users in any age group. The current study will assess the cannabis cessation efficacy of NAC combined with a behavioral intervention in adults, providing a novel and timely contribution to the evidence base for the treatment of cannabis use disorders. PMID:25179587

  3. Specialized psychosocial treatment plus treatment as usual (TAU) versus TAU for patients with cannabis use disorder and psychosis : the CapOpus randomized trial

    DEFF Research Database (Denmark)

    HjorthØj, C R; Fohlmann, A

    2013-01-01

    BACKGROUND: Cannabis abuse in psychotic patients is associated with rehospitalizations, reduced adherence and increased symptom severity. Previous psychosocial interventions have been ineffective in cannabis use, possibly because of low sample sizes and short interventions. We investigated whether adding CapOpus to treatment as usual (TAU) reduces cannabis use in patients with cannabis use disorder and psychosis. Method A total of 103 patients with psychosis and cannabis use disorder were centrally randomized to 6 months of CapOpus plus TAU (n = 52) or TAU (n = 51). CapOpus consisted mainly of motivational interviewing and cognitive behaviour therapy (CBT). TAU was targeted primarily at the psychotic disorder. The primary outcome was self-reported days with cannabis use in the preceding month. RESULTS: Pre-randomization cannabis use frequency was 14.9 [95% confidence interval (CI) 12.7-17.1] days/month. Post-treatment, the ratio of days/month with cannabis use in CapOpus versus TAU was 0.76 (95% CI 0.38-1.50)(p = 0.42), and 0.80 (95% CI 0.21-3.10) (p = 0.75) at the 4-month follow-up. From 46.4 (95% CI 36.4-56.3) monthly joints pre-randomization, consumption fell to 27.3 (95% CI 12.6-41.9) joints in CapOpus and 48.2 (95% CI 31.8-64.6) in TAU (p = 0.06). Follow-up amounts were 28.4 (95% CI 13.5-43.2) and 41.6 (95% CI 25.2-58.0) joints (p = 0.23). Several subgroup analyses suggested benefits of CapOpus. CONCLUSIONS: CapOpus did not reduce the frequency, but possibly the amount, of cannabis use. This is similar to the findings of previous trials in this population. Implementation of CapOpus-type interventions is thus not warranted at present but subgroup analyses call for further trials.

  4. It can't hurt to ask; a patient-centered quality of service assessment of health canada's medical cannabis policy and program

    Directory of Open Access Journals (Sweden)

    Lucas Philippe

    2012-01-01

    Full Text Available Abstract Background In 2001 Health Canada responded to a series of Ontario court decisions by creating the Marihuana Medical Access Division (MMAD and the Marihuana Medical Access Regulations (MMAR. Although Health Canada has conducted a small number of stakeholder consultations, the federal government has never polled federally authorized cannabis patients. This study is an attempt to learn more about patient needs, challenges and experiences with the MMAD. Methods Launched in the spring of 2007, Quality of Service Assessment of Health Canada's Medical Cannabis Policy and Program pairs a 50 question online survey addressing the personal experiences of patients in the federal cannabis program with 25 semi-guided interviews. Data gathering for this study took place from April 2007 to Jan. 2008, eventually garnering survey responses from 100 federally-authorized users, which at the time represented about 5% of the patients enrolled in Health Canada's program. This paper presents the results of the survey portion of the study. Results 8% of respondents report getting their cannabis from Health Canada, while 66% grow it for themselves. >50% report that they frequent compassion clubs or dispensaries, which remain illegal and unregulated in Canada. 81% of patients would chose certified organic methods of cultivation; >90% state that not all strains are equally effective at relieving symptoms, and 97% would prefer to obtain cannabis from a source where multiple strains are available. Of the 48 patients polled that had tried the Health Canada cannabis supply, >75% rank it as either "1" or "2" on a scale of 1-10 (with "1" being "very poor", and 10 being "excellent". Discussion 72% of respondents report they are either "somewhat" or "totally unsatisfied" with Canada's medical cannabis program. These survey results and relevant court decisions suggest that the MMAR are not meeting the needs of most of the nation's medical cannabis patient community. It is hoped this research will help inform policy changes that will better address the needs of Canada's critically and chronically ill medical cannabis patient population, including the integration of community-based dispensaries into this novel healthcare delivery model.

  5. Psychosocial Factors Related to Cannabis Use Disorders

    OpenAIRE

    BROOK, JUDITH S.; LEE, JUNG YEON; Finch, Stephen J; Koppel, Jonathan; BROOK, DAVID. W.

    2011-01-01

    The objective of this study was to explore the association between psychosocial risk and protective factors and cannabis use disorders (CUDs) in a cohort of African American and Puerto Rican young adults. A representative sample (N=838) from the East Harlem area of New York City was assessed at four points in time (at mean ages 14.1, 19.2, 24.5, and 29.2). The psychosocial measures came from six domains: personality attributes, family, peer, work, neighborhood, and substance use The psychosoc...

  6. Synthetic Cannabis-Induced Mania

    OpenAIRE

    Ustundag, Mehmet Fatih; Ozhan Ibis, Esra; YUCEL, Atakan; Ozcan, Halil

    2015-01-01

    Synthetic cannabinoids (SC), cannabinoid 1 and cannabinoid 2 receptors agonists, are the psychoactive substances. SC was originally produced to treat medical conditions. Compared to other narcotics, SC is easier to obtain, cheap, and highly potent and has a long half-life. In addition, routine analysis does not detect SC, which has led to widespread use. A case is presented that manic episode was developed with the use of SC. Hospitalization and admission to psychiatric units depending on SC ...

  7. Striatal and extra-striatal dopamine transporter in cannabis and tobacco addiction: a high resolution PET study

    International Nuclear Information System (INIS)

    The dopamine (DA) system is known to be involved in the reward and dependence mechanisms of addiction. However, modifications in dopaminergic neurotransmission associated with long-term tobacco and cannabis use have been poorly documented in vivo. In order to assess striatal and extra-striatal dopamine transporter (DAT) availability in tobacco and cannabis addiction, three groups of male age-matched subjects were compared: 11 healthy non-smoker subjects, 14 tobacco-dependent smokers (17.6 ± 5.3 cigarettes/day for 12.1 ± 8.5 years) and 13 cannabis and tobacco smokers (CTS) (4.8 ± 5.3 cannabis joints/day for 8.7 ± 3.9 years). DAT availability was examined in positron emission tomography (HRRT) with a high resolution research tomograph after injection of [11C]PE2I, a selective DAT radioligand. Region of interest and voxel-by-voxel approaches using a simplified reference tissue model were performed for the between-group comparison of DAT availability. Measurements in the dorsal striatum from both analyses were concordant and showed a mean 20% lower DAT availability in drug users compared with controls. Whole-brain analysis also revealed lower DAT availability in the ventral striatum, the midbrain, the middle cingulate and the thalamus (ranging from -15 to -30%). The DAT availability was slightly lower in all regions in CTS than in subjects who smoke tobacco only, but the difference does not reach a significant level. These results support the existence of a decrease in DAT availability associated with tobacco and cannabis addictions involving all dopaminergic brain circuits. These findings are consistent with the idea of a global decrease in cerebral DA activity in dependent subjects. (authors)

  8. Roadside sobriety tests and attitudes toward a regulated cannabis market

    Directory of Open Access Journals (Sweden)

    Earleywine Mitch

    2007-01-01

    Full Text Available Abstract Background Many argue that prohibition creates more troubles than alternative policies, but fewer than half of American voters support a taxed and regulated market for cannabis. Some oppose a regulated market because of concerns about driving after smoking cannabis. Although a roadside sobriety test for impairment exists, few voters know about it. The widespread use of a roadside sobriety test that could detect recent cannabis use might lead some voters who currently oppose a regulated market to support it. In contrast, a question that primes respondents about the potential for driving after cannabis use might lead respondents to be less likely to support a regulated market. Methods Phone interviews with a national sample of 1002 registered voters asked about support for a regulated cannabis market and support for such a market if a reliable roadside sobriety test were widely available. Results In this sample of registered voters, 36% supported a regulated cannabis market. Exploratory chi-square tests revealed significantly higher support among men and Caucasians but no link to age or education. These demographic variables covaried significantly. Logistic regression revealed that gender, ethnicity, and political party were significant when all predictors were included. Support increased significantly with a reliable roadside sobriety test to 44%, but some respondents who had agreed to the regulated market no longer agreed when the sobriety test was mentioned. Logistic regression revealed that ethnicity and political affiliation were again significant predictors of support with a reliable sobriety test, but gender was no longer significant. None of these demographic variables could identify who would change their votes in response to the reliable roadside test. Conclusion Increased awareness and use of roadside sobriety tests that detect recent cannabis use could increase support for a regulated cannabis market. Identifying concerns of voters who are not Caucasian or Democrats could help alter cannabis policy.

  9. Vaping cannabis (marijuana): parallel concerns to e-cigs?

    Science.gov (United States)

    Budney, Alan J; Sargent, James D; Lee, Dustin C

    2015-11-01

    The proliferation of vaporization ('vaping') as a method for administering cannabis raises many of the same public health issues being debated and investigated in relation to e-cigarettes (e-cigs). Good epidemiological data on the prevalence of vaping cannabis are not yet available, but with current trends towards societal approval of medicinal and recreational use of cannabis, the pros and cons of vaping cannabis warrant study. As with e-cigs, vaping cannabis portends putative health benefits by reducing harm from ingesting toxic smoke. Indeed, vaping is perceived and being sold as a safer way to use cannabis, despite the lack of data on the health effects of chronic vaping. Other perceived benefits include better taste, more efficient and intense effects and greater discretion which allows for use in more places. Unfortunately, these aspects of vaping could prompt an increased likelihood of trying cannabis, earlier age of onset, more positive initial experiences, and more frequent use, thereby increasing the probability of problematic use or addiction. Sales and marketing of vaping devices with no regulatory guidelines, especially related to advertising or product development targeting youth, parallels concerns under debate related to e-cigs and youth. Thus, the quandary of whether or not to promote vaping as a safer method of cannabis administration for those wishing to use cannabis, and how to regulate vaping and vaping devices, necessitates substantial investigation and discussion. Addressing these issues in concert with efforts directed towards e-cigs may save time and energy and result in a more comprehensive and effective public health policy on vaping. PMID:26264448

  10. Effects of cannabis smoking on oral soft tissues.

    Science.gov (United States)

    Darling, M R; Arendorf, T M

    1993-04-01

    The oral effects of cigarette smoking have been well documented but the effects of cannabis smoke on the oral environment have been poorly documented. Three-hundred cannabis/tobacco/methaqualone smokers were examined. Two control groups consisting of 152 tobacco- and 189 non-smokers respectively were examined similarly. Health of the oral tissues and oral dryness was recorded. Lesions present included leukoedema, leukoplakia and numerous others. The only significant differences between lesions and conditions noted in cannabis users and controls occurred with respect to leukoedema, dry mouth and traumatic ulcer. PMID:8485974

  11. The Motivational Enhancement Therapy and Cognitive Behavioral Therapy Supplement: 7 Sessions of Cognitive Behavioral Therapy for Adolescent Cannabis Users, Cannabis Youth Treatment (CYT) Series, Volume 2.

    Science.gov (United States)

    Webb, Charles; Scudder, Meleney; Kaminer, Yifrah; Kaden, Ron

    This manual, a supplement to "Motivational Enhancement Therapy and Cognitive Behavioral Therapy for Adolescent Cannabis Users: 5 Sessions, Cannabis Youth Treatment (CYT) Series, Volume 1", presents a seven-session cognitive behavioral treatment (CBT7) approach designed especially for adolescent cannabis users. It addresses the implementation and…

  12. Premenstrual symptoms.

    Science.gov (United States)

    1973-03-24

    Data is reviewed on premenstrual symptoms which have been related to high suicide and accident rates, employment absentee rates, poor academic performance and acute psychiatric problems. A recent study of healthy young women indicated that 39% had troublesome premenstrual symptoms, 54% passed clots in their menses, 70% had cyclical localized acneiform eruptions and only 17% failed to experience menstrual pain. Common menstrual disorders are classified as either dysmenorrhea or the premenstrual syndrome. Symptoms for the latter usually begin 2-12 days prior to menstruation and include nervous tension, irritability, anxiety, depression, bloated breasts and abdomen, swollen fingers and legs, headaches, dizziness, occasional hypersomia, excessive thirst and appetite. Some women may display an increased susceptibility to migraine, vasomotor rhinitis, asthma, urticaria and epilepsy. Symptoms are usually relieved with the onset of menses. While a definitive etiological theory remains to be substantiated, symptomatic relief has been reported with salt and water restriction and simple diuretics used 7 to 10 days premenstrually. Diazapam or chlordiazepoxide treatment is recommended before oral contraceptive therapy. The premenstrual syndrome may persist after menopause, is unaffected by parity, and sufferers score highly on neuroticism tests. Primary or spasmodic dysmenorrhea occurs in young women, tends to decline with age and parity and has no correlation with premenstrual symptoms or neuroticism. Spasmodic or colicky pain begins and is most severe on the first day of menstruation and may continue for 2-3 days. Treatment of dysmenorrhea with psychotropic drugs or narcotics is discouraged due to the risk of dependence and abuse. Temporary relief for disabling pain may be obtained with oral contraceptives containing synthetic estrogen and progestogen but the inherent risks should be acknowledged. Both disorders have been correlated to menstrual irregularity. Amenorrhea in many women may be precipitated by simple psychological events such as leaving home, while severely stressful events produce a higher incidence. Unless a physiological factor such as malnutrition is operating, menses usually recur spontaneously within a few months. Amenorrhea is a constant feature of anorexia nervosa and may precede related attitudes toward eating and body weight. This syndrome is best regarded as a chronic and often severe neurotic disorder requiring combined physiological and psychological treatment, although some evidence exists to indicate an endocrine disorder. Extensive basic research is needed on the complex relationship between the neuroendocrine system and emotion. PMID:4735136

  13. Activation of serotonin 5-HT2C receptor suppresses behavioral sensitization and naloxone-precipitated withdrawal symptoms in morphine-dependent mice.

    Science.gov (United States)

    Zhang, Gongliang; Wu, Xian; Zhang, Yong-Mei; Liu, Huan; Jiang, Qin; Pang, Gang; Tao, Xinrong; Dong, Liuyi; Stackman, Robert W

    2016-02-01

    Opioid abuse and dependence have evolved into an international epidemic as a significant clinical and societal problem with devastating consequences. Repeated exposure to the opioid, for example morphine, can induce profound, long-lasting behavioral sensitization and physical dependence, which are thought to reflect neuroplasticity in neural circuitry. Central serotonin (5-HT) neurotransmission participates in the development of dependence on and the expression of withdrawal from morphine. Serotonin 5-HT2C receptor (5-HT2CR) agonists suppress psychostimulant nicotine or cocaine-induced behavioral sensitization and drug-seeking behavior; however, the impact of 5-HT2CR agonists on behaviors relevant to opioid abuse and dependence has not been reported. In the present study, the effects of 5-HT2CR activation on the behavioral sensitization and naloxone-precipitated withdrawal symptoms were examined in mice underwent repeated exposure to morphine. Male mice received morphine (10 mg/kg, s.c.) to develop behavioral sensitization. Lorcaserin, a 5-HT2CR agonist, prevented the induction and expression, but not the development, of morphine-induced behavioral sensitization. Another cohort of mice received increasing doses of morphine over a 7-day period to induce morphine-dependence. Pretreatment of lorcaserin, or the positive control clonidine (an alpha 2-adrenoceptor agonist), ameliorated the naloxone-precipitated withdrawal symptoms. SB 242084, a selective 5-HT2CR antagonist, prevented the lorcaserin-mediated suppression of behavioral sensitization and withdrawal. Chronic morphine treatment was associated with an increase in the expression of 5-HT2CR protein in the ventral tegmental area, locus coeruleus and nucleus accumbens. These findings suggest that 5-HT2CR can modulate behavioral sensitization and withdrawal in morphine-dependent mice, and the activation of 5-HT2CR may represent a new avenue for the treatment of opioid addiction. PMID:26432939

  14. Cannabis y canabinoides–para profesionales de salud (PDQ®)

    Science.gov (United States)

    Resumen de información revisada por expertos de información sobre el uso del Cannabis y canabinoides para el tratamiento de los efectos secundarios relacionados con el tratamiento del cáncer como la náusea y el vómito.

  15. Cannabis misinterpretation and misadventure in a coroner's court.

    LENUS (Irish Health Repository)

    Tormey, William Patrick

    2012-10-01

    A 37-year-old, one-pack-per-day tobacco smoker collapsed and died at home. At autopsy, he had an occluded left anterior descending coronary artery. ?(9)-Tetrahydrocannabinol-carboxylic acid was found in his urine but no cannabinoids were detected in his blood. Misadventure was the inquest verdict on the basis of the urinary cannabis, with acute myocardial infarction as the primary cause and cannabis as the secondary cause of death. Such a conclusion is a misinterpretation of the evidence when the time duration for cannabis as a trigger for myocardial infarction is at most two hours. The absence of cannabis in the blood likely places the time since inhalation at more than two hours. The role of tobacco smoking as a trigger was ignored. Cotinine, the biochemical marker of tobacco smoke, should be added to the standard toxicological screen in the guidelines on autopsy practice of the Royal College of Pathologists.

  16. Eysenck Personality Dimensions in a Sample of Cannabis Users

    Directory of Open Access Journals (Sweden)

    Arash Vahdat

    2007-06-01

    Full Text Available     Objective: The objective of this study is to examine Eysenck personality dimensions in cannabis users  Method:100 regular cannabis users were selected and completed Eysenck Personality Questionnaire (EPQ which easures Neuroticism (N,Extraversion-Introversion (E-I and Psychoticism (P dimensions of Eysenck personality structures  Results:The scores of 51% of cannabis users were higher than mean in all dimensions of EPQ. Also the mean score of N and P were higher than the score which Eysenck has reported for Iranian population Conclusions:This research reinforces our call for a public health information campaign about a drug which may young people still see as being risk-free.Psychiatric morbidity and cases of psychotic disorder could be prevented by discouraging cannabis use among vulnerable youths.

  17. Menopausal symptoms

    OpenAIRE

    Rymer, Janice; Morris, Edward P.

    2011-01-01

    In the UK, the median age for onset of menopausal symptoms is 45.5 to 47.5 years. Symptoms associated with the menopause include vasomotor symptoms, sleeplessness, mood changes, reduced energy levels, loss of libido, vaginal dryness, and urinary symptoms.Many symptoms, such as hot flushes, are temporary, but those resulting from reduced hormone levels, such as genital atrophy, may be permanent.

  18. The Normalization of Cannabis Use among Young People

    DEFF Research Database (Denmark)

    Järvinen, Margaretha; Demant, Jakob Johan

    2011-01-01

    This paper analyses ‘techniques of neutralisation’ among young people discussing cannabis in focus group interviews. The paper is based on data from focus group interviews with young Danes followed from when they were 14–15 years old in 2004 until they were 18–19 years old in 2008. In this period, the participants’ attitudes towards cannabis undergo a radical change from being negative and sceptical into being predominantly positive and accepting; a change we describe as a ‘normalisation’ of can...

  19. Low Dose Vaporized Cannabis Significantly Improves Neuropathic Pain

    OpenAIRE

    Wilsey, Barth; Marcotte, Thomas D.; Deutsch, Reena; Gouaux, Ben; Sakai, Staci; Donaghe, Haylee

    2012-01-01

    We conducted a double-blind, placebo-controlled, crossover study evaluating the analgesic efficacy of vaporized cannabis in subjects, the majority of whom were experiencing neuropathic pain despite traditional treatment. Thirty-nine patients with central and peripheral neuropathic pain underwent a standardized procedure for inhaling either medium dose (3.53%), low dose (1.29%), or placebo cannabis with the primary outcome being VAS pain intensity. Psychoactive side-effects, and neuropsycholog...

  20. Cannabis, motivation, and life satisfaction in an internet sample

    OpenAIRE

    Wilcox Rand; Earleywine Mitch; Barnwell Sara

    2006-01-01

    Abstract Although little evidence supports cannabis-induced amotivational syndrome, sources continue to assert that the drug saps motivation 1, which may guide current prohibitions. Few studies report low motivation in chronic users; another reveals that they have higher subjective wellbeing. To assess differences in motivation and subjective wellbeing, we used a large sample (N = 487) and strict definitions of cannabis use (7 days/week) and abstinence (never). Standard statistical techniques...

  1. Cannabis use and destructive periodontal diseases among adolescents

    DEFF Research Database (Denmark)

    López, Rodrigo; Baelum, Vibeke

    2009-01-01

    AIM: The aim of this experiment was to investigate the association between cannabis use and destructive periodontal disease among adolescents. MATERIAL AND METHODS: Data from a population screening examination carried out among Chilean high school students from the Province of Santiago were used to determine whether there was an association between the use of cannabis and signs of periodontal diseases as defined by (1) the presence of necrotizing ulcerative gingival (NUG) lesions or (2) the pres...

  2. Application of medical cannabis in patients with the neurodegeneration disorders

    Directory of Open Access Journals (Sweden)

    Lidia Kotu?a

    2014-04-01

    Full Text Available Medical cannabis is the dried flowers of the female Cannabis sativa L. plant. Cannabis contains a number of active elements, including dronabinol (THC and cannabidiol (CBD. Dronabinol is usually the main ingredient. The body’s own cannabinoid system has been identified. The discovery of this system, which comprises endocannabinoids and receptors, confirmed that cannabis has a positive effect on certain illnesses and conditions. Two types of cannabinoid receptors have been identified: CB1 and CB2 receptors. The first type CB1 is mostly found in the central nervous system, modulate pain. It also has an anti-emetic effect, and has influence on the memory and the motor system. The second type of receptors CB2 is peripheral, and it is primarily found in immune system cells and it is responsible for the immunomodulatory effects of cannabinoids. Medical cannabis can help in cases of the neurodegeneration disorders, for example Parkinson’s disease, Huntington’s Disease, Amyotrophic Lateral Sclerosis. Patients generally tolerate medical cannabis well.

  3. Revisão: funcionamento executivo e uso de maconha Review: executive functioning and cannabis use

    Directory of Open Access Journals (Sweden)

    Priscila Previato Almeida

    2008-03-01

    Full Text Available OBJETIVO: A maconha é a droga ilícita mais consumida no mundo, porém ainda existem poucos estudos examinando eventuais prejuízos cognitivos relacionados ao seu uso. As manifestações clínicas associadas a esses déficits incluem síndrome amotivacional, prejuízo na flexibilidade cognitiva, desatenção, dificuldade de raciocínio abstrato e formação de conceitos, aspectos intimamente ligados às funções executivas, as quais potencialmente exercem um papel central na dependência de substâncias. O objetivo do estudo foi fazer uma revisão a respeito das implicações do uso da maconha no funcionamento executivo. MÉTODO: Esta revisão foi conduzida utilizando-se bases de dados eletrônicas (MedLine, Pubmed, SciELO and Lilacs. DISCUSSÃO: Em estudos de efeito agudo, doses maiores de tetrahidrocanabinol encontram-se associadas a maior prejuízo no desempenho de usuários leves em tarefas de controle inibitório e planejamento; porém, este efeito dose-resposta não ocorre em usuários crônicos. Embora haja controvérsias no que se refere a efeitos residuais da maconha, déficits persistentes parecem estar presentes após 28 dias de abstinência, ao menos em um subgrupo de usuários crônicos. CONCLUSÕES: Os estudos encontrados não tiveram como objetivo principal a avaliação das funções executivas. A seleção de testes padronizados, desenhos de estudos mais apropriados e o uso concomitante com técnicas de neuroimagem estrutural e funcional podem auxiliar na melhor compreensão das conseqüências deletérias do uso crônico da maconha no funcionamento executivo.OBJECTIVE: Cannabis is the most used illicit drug worldwide, however only a few studies have examined cognitive deficits related to its use. Clinical manifestations associated with those deficits include amotivational syndrome, impairment in cognitive flexibility, inattention, deficits in abstract reasoning and concept formation, aspects intimately related to the executive functions, which potentially exert a central role in substance dependence. The objective was to make a review about consequences of cannabis use in executive functioning. METHOD: This review was carried out on reports drawn from MedLine, SciELO, and Lilacs. DISCUSSION: In studies investigating acute use effects, higher doses of tetrahydrocannabinol are associated to impairments in performance of nonsevere users in planning and control impulse tasks. However, chronic cannabis users do not show those impairments. Although demonstration of residual effects of cannabis in the executive functioning is controversial, persistent deficits seem to be present at least in a subgroup of chronic users after 28 days of abstinence. CONCLUSIONS: The neuropsychological studies found did not have as a main aim the evaluation of executive functioning. A criterial selection of standardized neuropsychological tests, more appropriate study designs as well as concomitant investigations with structural and functional neuroimaging techniques may improve the understanding of eventual neurotoxicity associated with cannabis use.

  4. Revisão: funcionamento executivo e uso de maconha / Review: executive functioning and cannabis use

    Scientific Electronic Library Online (English)

    Priscila Previato, Almeida; Maria Alice Fontes Pinto, Novaes; Rodrigo Affonseca, Bressan; Acioly Luiz Tavares de, Lacerda.

    2008-03-01

    Full Text Available OBJETIVO: A maconha é a droga ilícita mais consumida no mundo, porém ainda existem poucos estudos examinando eventuais prejuízos cognitivos relacionados ao seu uso. As manifestações clínicas associadas a esses déficits incluem síndrome amotivacional, prejuízo na flexibilidade cognitiva, desatenção, [...] dificuldade de raciocínio abstrato e formação de conceitos, aspectos intimamente ligados às funções executivas, as quais potencialmente exercem um papel central na dependência de substâncias. O objetivo do estudo foi fazer uma revisão a respeito das implicações do uso da maconha no funcionamento executivo. MÉTODO: Esta revisão foi conduzida utilizando-se bases de dados eletrônicas (MedLine, Pubmed, SciELO and Lilacs). DISCUSSÃO: Em estudos de efeito agudo, doses maiores de tetrahidrocanabinol encontram-se associadas a maior prejuízo no desempenho de usuários leves em tarefas de controle inibitório e planejamento; porém, este efeito dose-resposta não ocorre em usuários crônicos. Embora haja controvérsias no que se refere a efeitos residuais da maconha, déficits persistentes parecem estar presentes após 28 dias de abstinência, ao menos em um subgrupo de usuários crônicos. CONCLUSÕES: Os estudos encontrados não tiveram como objetivo principal a avaliação das funções executivas. A seleção de testes padronizados, desenhos de estudos mais apropriados e o uso concomitante com técnicas de neuroimagem estrutural e funcional podem auxiliar na melhor compreensão das conseqüências deletérias do uso crônico da maconha no funcionamento executivo. Abstract in english OBJECTIVE: Cannabis is the most used illicit drug worldwide, however only a few studies have examined cognitive deficits related to its use. Clinical manifestations associated with those deficits include amotivational syndrome, impairment in cognitive flexibility, inattention, deficits in abstract r [...] easoning and concept formation, aspects intimately related to the executive functions, which potentially exert a central role in substance dependence. The objective was to make a review about consequences of cannabis use in executive functioning. METHOD: This review was carried out on reports drawn from MedLine, SciELO, and Lilacs. DISCUSSION: In studies investigating acute use effects, higher doses of tetrahydrocannabinol are associated to impairments in performance of nonsevere users in planning and control impulse tasks. However, chronic cannabis users do not show those impairments. Although demonstration of residual effects of cannabis in the executive functioning is controversial, persistent deficits seem to be present at least in a subgroup of chronic users after 28 days of abstinence. CONCLUSIONS: The neuropsychological studies found did not have as a main aim the evaluation of executive functioning. A criterial selection of standardized neuropsychological tests, more appropriate study designs as well as concomitant investigations with structural and functional neuroimaging techniques may improve the understanding of eventual neurotoxicity associated with cannabis use.

  5. The carbon footprint of indoor Cannabis production

    International Nuclear Information System (INIS)

    The emergent industry of indoor Cannabis production – legal in some jurisdictions and illicit in others – utilizes highly energy intensive processes to control environmental conditions during cultivation. This article estimates the energy consumption for this practice in the United States at 1% of national electricity use, or $6 billion each year. One average kilogram of final product is associated with 4600 kg of carbon dioxide emissions to the atmosphere, or that of 3 million average U.S. cars when aggregated across all national production. The practice of indoor cultivation is driven by criminalization, pursuit of security, pest and disease management, and the desire for greater process control and yields. Energy analysts and policymakers have not previously addressed this use of energy. The unchecked growth of electricity demand in this sector confounds energy forecasts and obscures savings from energy efficiency programs and policies. While criminalization has contributed to the substantial energy intensity, legalization would not change the situation materially without ancillary efforts to manage energy use, provide consumer information via labeling, and other measures. Were product prices to fall as a result of legalization, indoor production using current practices could rapidly become non-viable. - Highlights: ? The emergent industry of indoor Cannabis production utilizes highly energy intensive processes and is highly inefficient. ? In the United States, this represents an annual energy expenditure of $6 billion. ? One kg of final product is associated with emissions of 4600 kg of CO2 emissions to the atmosphere. ? Aggregate U.S. emissions are equivalent those of 3 million cars. ? Energy analysts and policymakers have not previously addressed this use of energy.

  6. El Cannabis en la práctica Clínica

    Scientific Electronic Library Online (English)

    CL, Expósito.

    2003-07-01

    Full Text Available RESUMEN. La marihuana ha sido utilizada por cientos de años, es una de las drogas de abuso más usadas. Tiene una larga historia de usos médicos, tanto el Cannabis, como sus derivados, preparaciones y sus formas sintéticas se emplean para aliviar una gran variedad de síntomas de diversas enfermedades [...] , tales como: alivio de las náuseas y vómitos asociados con las terapias del cáncer y del SIDA; alivio del dolor muscular y espasmos; para reducir la frecuencia de convulsiones en la epilepsia; para reducir la presión intraocular en pacientes con glaucoma; para estimular el apetito en pacientes con cáncer y SIDA. Actualmente están disponibles en el mercado dos productos comerciales sintéticos relacionados con la marihuana, de administración oral, el dronabinol (MARINOL®) y la nabilona (CESAMET®). Se han identificado en el cerebro, receptores para los cannabinoides, el CB1 y el CB2, así como ligandos endógenos: la anandamina, el 2-araquinoilglicerol, la homo-gamma -linolenil etanolamina y la palmitoiletanolamina. Abstract in english ABSTRACT: Marijuana has been widely used for hundreds of years, it is perhaps one of the most popular drug of abuse. It has a long medical history, Cannabis, its preparations, derivates and similar synthetic prepartions are use to relieve symtoms associated with some medical conditions, such as: to [...] relief nauseas and vomiting associate with cancer and AIDS therapies; for the relief of muscle pain and spasms; to help reduce the frequency of epileptic seizures; to lower intra ocular pressure in Glaucoma; to stimulate appetite and produce weight gain in AIDS and cancer patients. There are two commercially available drug products related to marijuana: dronabinol (MARINOL®) and nabilone (CESAMET®). Cannabinoids receptors CB1 and CB2, and some endogenous ligands named anandamide, 2-araquinoilglicerol, homo-gamma -linolenil etanolamine and palmitoiletanolamine, have been identified in brain.

  7. Do patients think cannabis causes schizophrenia? – A qualitative study on the causal beliefs of cannabis using patients with schizophrenia

    OpenAIRE

    Schaub Michael; Schulze Beate; Stohler Rudolf; Buadze Anna; Liebrenz Michael

    2010-01-01

    Abstract Background There has been a considerable amount of debate among the research community whether cannabis use may cause schizophrenia and whether cannabis use of patients with schizophrenia is associated with earlier and more frequent relapses. Considering that studies exploring patients' view on controversial topics have contributed to our understanding of important clinical issues, it is surprising how little these views have been explored to add to our understanding of the link betw...

  8. Cannabis abuse in adolescence and the risk of psychosis: a brief review of the preclinical evidence.

    Science.gov (United States)

    Rubino, T; Parolaro, D

    2014-07-01

    Epidemiological studies suggest that Cannabis use during adolescence confers an increased risk for developing psychotic symptoms later in life. However, despite their interest, the epidemiological data are not conclusive, due to their heterogeneity; thus modeling the adolescent phase in animals is useful for investigating the impact of Cannabis use on deviations of adolescent brain development that might confer a vulnerability to later psychotic disorders. Although scant, preclinical data seem to support the presence of impaired social behaviors, cognitive and sensorimotor gating deficits as well as psychotic-like signs in adult rodents after adolescent cannabinoid exposure, clearly suggesting that this exposure may trigger a complex behavioral phenotype closely resembling a schizophrenia-like disorder. Similar treatments performed at adulthood were not able to produce such phenotype, thus pointing to a vulnerability of the adolescent brain towards cannabinoid exposure. The neurobiological substrate of the adolescent vulnerability is still largely unknown and experimental studies need to elucidate the cellular and molecular mechanism underlying these effects. However, the few data available seem to suggest that heavy adolescent exposure to cannabinoids is able to modify neuronal connectivity in specific brain areas long after the end of the treatment. This is likely due to disruption of maturational events within the endocannabinoid system during adolescence that in turn impact on the correct neuronal refinement peculiar of the adolescent brain, thus leading to altered adult brain functionality and behavior. PMID:23916409

  9. Passive cannabis smoke exposure and oral fluid testing.

    Science.gov (United States)

    Niedbala, Sam; Kardos, Keith; Salamone, Sal; Fritch, Dean; Bronsgeest, Matth; Cone, Edward J

    2004-10-01

    Oral fluid testing for Delta(9)-tetrahydrocannabinol (THC) provides a convenient means of detection of recent cannabis usage. In this study, the risk of positive oral fluid tests from passive cannabis smoke exposure was investigated by housing four cannabis-free volunteers in a small, unventilated, and sealed room with an approximate volume of 36 m(3). Five active cannabis smokers were also present in the room, and each smoked a single cannabis cigarette (1.75% THC). Cannabis smoking occurred over the first 20 min of the study session. All subjects remained in the room for approximately 4 h. Oral fluid specimens were collected with the Intercept DOA Oral Specimen Collection Device. Three urine specimens were collected (0, 20, and 245 min). In addition, three air samples were collected for measurement of THC content. All oral fluid specimens were screened by enzyme immunoassay (EIA) for cannabinoids (cutoff concentration = 3 ng/mL) and tested by gas chromatography-tandem mass spectrometry (GC-MS-MS) for THC (LOQ/LOD = 0.75 ng/mL). All urine specimens were screened by EIA for cannabinoids (cutoff concentration = 50 ng/mL) and tested by GC-MS-MS for THCCOOH (LOQ/LOD = 1 ng/mL). Air samples were measured for THC by GC-MS (LOD = 1 ng/L). A total of eight oral fluid specimens (collected 20 to 50 min following initiation of smoking) from the four passive subjects screened and confirmed positive for THC at concentrations ranging from 3.6 to 26.4 ng/mL. Two additional specimens from one passive subject, collected at 50 and 65 min, screened negative but contained THC in concentrations of 4.2 and 1.1 ng/mL, respectively. All subsequent specimens for passive participants tested negative by EIA and GC-MS-MS for the remainder of the 4-h session. In contrast, oral fluid specimens collected from the five cannabis smokers generally screened and confirmed positive for THC throughout the session at concentrations substantially higher than observed for passive subjects. Urine specimens from active cannabis smokers also screened and confirmed positive at conventional cutoff concentrations. A biphasic pattern of decline for THC was observed in oral fluid specimens collected from cannabis smokers, whereas a linear decline was seen for passive subjects suggesting that initial oral fluid contamination is cleared rapidly and is followed by THC sequestration in the oral mucosa. It is concluded that the risk of positive oral fluid tests from passive cannabis smoke inhalation is limited to a period of approximately 30 min following exposure. PMID:15516313

  10. Correlations and agreement between delta-9-tetrahydrocannabinol (THC) in blood plasma and Timeline Follow-Back (TLFB)-assisted self-reported use of cannabis of patients with cannabis use disorder and psychotic illness attending the CapOpus randomized clinical trial

    DEFF Research Database (Denmark)

    HjorthØj, Carsten Rygaard; Fohlmann, Allan

    2012-01-01

    Aims:? To assess correlations and agreement between Timeline Follow-Back (TLFB)-assisted self-report and blood samples for cannabis use. Design:? Secondary analysis of a randomized trial. Setting:? Copenhagen, Denmark. Participants:? 103 patients from the CapOpus trial with cannabis use disorder and psychosis, providing 239 self-reports of cannabis use and 88 valid blood samples. Measurements:? Delta-9-tetrahydrocannabinol (THC), 11-hydroxy-delta-9-tetrahydrocannabinol (11-OH-THC), and 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid (THC-COOH) detected in plasma using high-performance liquid chromatography with tandem mass spectrometry detection. Self-report of cannabis-use last month by TLFB. Pearson's r, sensitivity and specificity calculated as measures of correlation or agreement. Findings:? Correlations were strong; r = 0.75 for number of days and r = 0.83 for number of standard joints in the preceding month when excluding outliers. Including outliers, coefficients were moderate to strong (r = 0.49and r = 0.51, respectively). There were differences in subgroups, mostly inconsistent depending on inclusion or exclusion of outliers. Sensitivity and specificity for TLFB detecting presence or absence of cannabis use were 95.7 % (95 % confidence interval 88.0 % to 99.1 %) and 72.2 % (46.5 % to 90.3 %), respectively. Using 19 days as cutoff on TLFB, they were 94.3 % (86.0 % to 98.4 %) and 94.4 % (72.2 % to 99.9 %), respectively. Area under the receiver operating characteristic (ROC)-curve was 0.96. Conclusions:? Time Line Follow-Back (TLFB)-assisted self-report of cannabis use correlates highly with plasma-THC in patients with comorbid cannabis use disorder and psychosis. Sensitivity and specificity of TLFB appear to be optimised with 19 days as cutoff-point. As such TLFB may be superior to analysis of blood when going beyond 19 days of recall.

  11. Symptom Management

    Science.gov (United States)

    ... Service Members & Veterans Family & Caregivers Medical Providers Symptom Management A brain injury can affect a person physically ... Diagnosis and Assessment Treatment and Recovery Caregiving Symptom Management Life After TBI Defense and Veterans Brain Injury ...

  12. Neurobiological effects of early life cannabis exposure in relation to the gateway hypothesis

    OpenAIRE

    Ellgren, Maria

    2007-01-01

    The use of Cannabis sativa preparations, such as hashish and marijuana, is wide-spread among young people, including pregnant women. Despite this concern, the consequences of cannabis exposure on the brain during periods of active brain development, such as the prenatal phase and adolescence, is not well known. Several epidemiological studies support the cannabis gateway hypothesis, where early cannabis use is suggested to increase the risk of initiating use of other illicit...

  13. The medicalisation of revolt: a sociological analysis of medical cannabis users.

    Science.gov (United States)

    Pedersen, Willy; Sandberg, Sveinung

    2013-01-01

    In a qualitative study, we investigated the medical motives of 100 Norwegian cannabis users, none of whom had legal access to medical cannabis. Cannabis was used therapeutically for conditions such as multiple sclerosis, attention deficit hyperactivity disorder and rheumatism, as well as for quality of life conditions such as quality of sleep, relaxation and wellbeing. The borders between medical and recreational cannabis use were blurred. This article identifies strategies of medical cannabis users to gain social acceptance. Several respondents downplayed effects such as intoxication and euphoria. Others used the language of medicine and knowledge of current research in psychopharmacology. Cannabis was contrasted with the potential for abuse of prescription medicines. The medical cannabis movement has had little success in Norway. Medical professionals are unable to accept that users may be more knowledgeable than experts and medical users cannot discard the values of traditional cannabis culture. Calls for medical cannabis use are thus perceived as a gambit in attempts to have cannabis legalised. We argue that, despite having had little effect on health authorities, the medical cannabis movement may be having the unintended effect of medicalising cannabis use and using it as a cure for everyday problems. PMID:22827932

  14. Smoke your troubles away: exploring the effects of death cognitions on cannabis craving and consumption.

    Science.gov (United States)

    Nagar, Maayan; Rabinovitz, Sharon

    2015-01-01

    Two studies informed by the terror management health model were conducted to examine the question of how death cognition affects cannabis craving and whether actual cannabis smoking alleviates death cognitions. The first study examined whether priming thoughts of death are associated with subjective cannabis craving among 42 frequent cannabis users randomly assigned to either a mortality salience or control task. When reminded of their death, participants craved cannabis, even though there was no change in their conscious negative mood. The second study examined the effect of cannabis smoking on death cognitions in an exploratory field setting. Fifty frequent cannabis users were randomly assigned to either mortality reminders or control task and completed death-related words accessibility measures before and after smoking cannabis. Results indicate that cannabis served as a buffer and prevented death-related thoughts from entering consciousness, thus acting as a defense mechanism against death anxiety. These findings indicate that death-related concerns may play a hitherto unsuspected role in cannabis craving and consumption. Also discussed are the implications of a terror management perspective in communication of negative health consequences of recreational cannabis smoking and in the use of cannabis for medical purposes among people with terminal illness. PMID:25950588

  15. Feasibility of Momentary Sampling Assessment of Cannabis Use in Adolescents and Young Adults

    Science.gov (United States)

    Black, Shimrit K.; de Moor, Carl; Kendall, Ashley D.; Shrier, Lydia A.

    2014-01-01

    This study examines the feasibility of recruiting and retaining adolescents and young adults with frequent cannabis use for a 2-week momentary sampling study of cannabis use. Participants responded to random signals on a handheld computer with reports of their use. Participants also initiated reports pre- and post-cannabis use. Participants had…

  16. Intrauterine Cannabis Exposure Affects Fetal Growth Trajectories: The Generation R Study

    Science.gov (United States)

    El Marroun, Hanan; Tiemeier, Henning; Steegers, Eric A. P.; Jaddoe, Vincent W. V.; Hofman, Albert; Verhulst, Frank C.; van den Brink, Wim; Huizink, Anja C.

    2009-01-01

    Objective: Cannabis is the most commonly consumed illicit drug among pregnant women. Intrauterine exposure to cannabis may result in risks for the developing fetus. The importance of intrauterine growth on subsequent psychological and behavioral child development has been demonstrated. This study examined the relation between maternal cannabis use…

  17. A Meta-Analysis of Interventions to Reduce Adolescent Cannabis Use

    Science.gov (United States)

    Bender, Kimberly; Tripodi, Stephen J.; Sarteschi, Christy; Vaughn, Michael G.

    2011-01-01

    Objective: This meta-analytic review assesses the effectiveness of substance abuse interventions to reduce adolescent cannabis use. Method: A systematic search identified 15 randomized controlled evaluations of interventions to reduce adolescent cannabis use published between 1960 and 2008. The primary outcome variables, frequency of cannabis use,…

  18. A genome wide association study of alcohol dependence symptom counts in extended pedigrees identifies C15orf53

    OpenAIRE

    Wang, Jen-Chyong; FOROUD, TATIANA; Hinrichs, Anthony L.; Le, Nhung XH; Bertelsen, Sarah; Budde, John P.; Harari, Oscar; Koller, Daniel L; Wetherill, Leah; AGRAWAL, ARPANA; Almasy, Laura; Brooks, Andrew I.; Bucholz, Kathleen; Dick, Danielle; Hesselbrock, Victor

    2012-01-01

    Several studies have identified genes associated with alcohol use disorders, but the variation in each of these genes explains only a small portion of the genetic vulnerability. The goal of the present study was to perform a genome-wide association study (GWAS) in extended families from the Collaborative Study on the Genetics of Alcoholism (COGA) to identify novel genes affecting risk for alcohol dependence. To maximize the power of the extended family design we used a quantitative endophenot...

  19. Associations of unhealthy Behaviors and Depressive Symptoms with School Difficulties and Role of Socioeconomics Factors in Early Adolescence

    OpenAIRE

    Chau, Kénora; Baumann, Michèle

    2013-01-01

    Unhealthy behaviors such as alcohol, tobacco, cannabis and hard drugs uses and depressive symptoms are common in early adolescence and they are well known to affect physical, mental and cognitive functions. These factors can thus favor persistent school difficulties. Socioeconomic factors are known to favor unhealthy behaviors and depressive symptoms as well as school difficulties. This study assessed the associations of unhealthy and depressive symptoms with learning difficulty, low school p...

  20. Cannabis, possible cardiac deaths and the coroner in Ireland.

    LENUS (Irish Health Repository)

    Tormey, W P

    2012-01-10

    BACKGROUND: The elevated risk of triggering a myocardial infarction by smoking cannabis is limited to the first 2 h after smoking. AIM: To examine the possible role of cannabis in cardiac deaths. CASES AND RESULTS: From 3,193 coroners\\' cases over 2 years, there were 13 cases where the clinical information was compatible with a primary cardiac cause of death. An inquest was held in three cases. Myocardial infarction was the primary cause of death in 54%. Other causes were sudden adult death syndrome, sudden death in epilepsy, and poisoning by alcohol and diazepam. Cannabis was mentioned once only on a death certificate, but not as a cause of death. Blood delta9-tetrahydrocannabinol-carboxylic acid was recorded in one case and in no case was plasma tetrahydrocannabinol (THC) measured. CONCLUSIONS: To attribute sudden cardiac death to cannabis, plasma THC should be measured in the toxicology screen in coroners\\' cases where urine cannabinoids are positive. A positive urine cannabinoids immunoassay alone is insufficient evidence in the linkage of acute cardiac death and cannabis.

  1. SYNTHESIS AND CHARACTERIZATION OF CANNABIS INDICA FIBER REINFORCED COMPOSITES

    Directory of Open Access Journals (Sweden)

    Amar Singh Singha

    2011-04-01

    Full Text Available This paper reports on the synthesis of Cannabis indica fiber-reinforced composites using Urea-Resorcinol-Formaldehyde (URF as a novel matrix through compression molding technique. The polycondensation between urea, resorcinol, and formaldehyde in different molar ratios was applied to the synthesis of the URF polymer matrix. A thermosetting matrix based composite, reinforced with lignocellulose from Cannabis indica with different fiber loadings 10, 20, 30, 40, and 50% by weight, was obtained. The mechanical properties of randomly oriented intimately mixed fiber particle reinforced composites were determined. Effects of fiber loadings on mechanical properties such as tensile, compressive, flexural strength, and wear resistance were evaluated. Results showed that mechanical properties of URF resin matrix increased considerably when reinforced with particles of Cannabis indica fiber. Thermal (TGA/DTA/DTG and morphological studies (SEM of the resin, fiber and polymer composite thus synthesized were carried out.

  2. Effect of cannabis use on oral candidal carriage.

    Science.gov (United States)

    Darling, M R; Arendorf, T M; Coldrey, N A

    1990-08-01

    The effects of cigarette smoking on oral candidal carriage and candidosis have been well documented but few similar studies on cannabis smoking have appeared, therefore it was felt that such a study needed to be undertaken. In this investigation, the effect of cannabis smoking combined with methaqualone and tobacco on candidal prevalence, density and candidosis was examined in 55 users. Age and sex matched tobacco-smoking (n = 58) and non-smoking controls (n = 50) were examined similarly. The imprint culture technique was used for harvesting Candida. Results showed an increased prevalence and density of C. albicans in cannabis users while there was no apparent difference in the prevalence of candidiasis. However, two subjects presented with oral multifocal candidiasis. PMID:2231436

  3. Antisocial Behavioral Syndromes in Cocaine and Cannabis Dependence

    OpenAIRE

    Mariani, John J; Horey, Jonathan; Bisaga, Adam; Aharonovich, Efrat; Raby, Wilfrid; Cheng, Wendy Y; Nunes, Edward; Levin, Frances R.

    2008-01-01

    Antisocial personality disorder (ASPD) is highly associated with substance use disorders (SUD). In addition to the full ASPD syndrome, which requires both childhood conduct disorder and the adult features, other antisocial behavioral syndromes, including conduct disorder (CD) alone without the adult syndrome, and the adult antisocial behavioral syndrome without childhood CD (AABS) are also frequently diagnosed in patients with SUD. The aim of this study was to compare the rates of these vario...

  4. Sex-Dependent Vulnerability to Cannabis Abuse in Adolescence

    OpenAIRE

    Rubino, Tiziana; Parolaro, Daniela

    2015-01-01

    The goal of this review is to summarize current evidence for sex differences in the response to cannabinoid compounds, focusing mainly on a specific age of exposure, i.e., adolescence. Preclinical as well as clinical studies are examined. Among the different possible underlying mechanisms, the consistent dimorphism in the endocannabinoid system and delta9-tetrahydrocannabinol metabolism may play a part. All the collected data point to the need of including females in basic research as well as...

  5. Anthrax: Symptoms

    Science.gov (United States)

    ... History of Anthrax Recommendations Anthrax-Related EID Journal Articles Anthrax-Related MMWRs Medscape Commentaries Symptoms Language: English Español (Spanish) Recommend on Facebook Tweet Share Compartir ...

  6. The psychoactive compound of Cannabis sativa, ?(9)-tetrahydrocannabinol (THC) inhibits the human trophoblast cell turnover.

    Science.gov (United States)

    Costa, M A; Fonseca, B M; Marques, F; Teixeira, N A; Correia-da-Silva, G

    2015-08-01

    The noxious effects of cannabis consumption for fertility and pregnancy outcome are recognized for years. Its consumption during gestation is associated with alterations in foetal growth, low birth weight and preterm labor. The main psychoactive molecule of cannabis, ?(9)-tetrahydrocannabinol (THC) impairs the production of reproductive hormones and is also able to cross the placenta barrier. However, its effect on the main placental cells, the trophoblasts, are unknown. Actually, the role of THC in cell survival/death of primary human cytotrophoblasts (CTs) and syncytiotrophoblasts (STs) and in the syncytialization process remains to be explored. Here, we show that THC has a dual effect, enhancing MTT metabolism at low concentrations, whereas higher doses decreased cell viability, on both trophoblast phenotypes, though the effects on STs were more evident. THC also diminished the generation of oxidative and nitrative stress and the oxidized form of glutathione, whereas the reduced form of this tripeptide was increased, suggesting that THC prevents ST cell death due to an antioxidant effect. Moreover, this compound enhanced the mitochondrial function of STs, as observed by the increased MTT metabolism and intracellular ATP levels. These effects were independent of cannabinoid receptors activation. Besides, THC impaired CT differentiation into STs, since it decreased the expression of biochemical and morphological biomarkers of syncytialization, through a cannabinoid receptor-dependent mechanism. Together, these results suggest that THC interferes with trophoblast turnover, preventing trophoblast cell death and differentiation, and contribute to disclose the cellular mechanisms that lead to pregnancy complications in women that consume cannabis-derived drugs during gestation. PMID:26070387

  7. Future time perspective as predictor of cannabis use: Exploring the role of substance perception among French adolescents.

    OpenAIRE

    Apostolidis, Thémis; Fieulaine, Nicolas; Florence, Soulé

    2006-01-01

    This study explored the relation of Future time perspective (FTP) to cannabis use and tested the potential mediating role of cannabis perception, with a sample of 276 French adolescents. FTP was assessed using ZTPI subscale, cannabis perception was evaluated from a list of nine items related to drug-oriented perception (DOP), and participants were asked to report both their cannabis use and the level of use. Results showed that FTP acts as a significant predictor of cannabis use, and is signi...

  8. Long term marijuana users seeking medical cannabis in California (2001–2007): demographics, social characteristics, patterns of cannabis and other drug use of 4117 applicants

    OpenAIRE

    Bou-Matar Ché B; O'Connell Thomas J

    2007-01-01

    Abstract Background Cannabis (marijuana) had been used for medicinal purposes for millennia. Cannabinoid agonists are now attracting growing interest and there is also evidence that botanical cannabis is being used as self-medication for stress and anxiety as well as adjunctive therapy by the seriously ill and by patients with terminal illnesses. California became the first state to authorize medicinal use of cannabis in 1996, and it was recently estimated that between 250,000 and 350,000 Cal...

  9. The Normalization of Cannabis Use among Young People - Symbolic Boundary Work in Focus Groups

    DEFF Research Database (Denmark)

    Järvinen, Margaretha; Demant, Jakob

    2011-01-01

    This paper analyzes "techniques of neutralization" among young people discussing cannabis in focus group interviews. The paper is based on data from focus group interviews with young Danes followed from when they were 14-15 years old in 2004 until they were 18-19 years old in 2008. In this period, the participants' attitudes towards cannabis undergo a radical change from being negative and sceptical into being predominantly positive and accepting - a change we describe as a "normalization" of cannabis use. Four techniques of neutralization are identified in this process: First, the participants redefine the setting of cannabis use, simultaneously creating a new type of togetherness: relaxed social intoxication. Second, the effects of cannabis use are transformed from being "strange" and "unpredictable" to being "controllable" by the individual user. Third, participants change their classification of cannabis in relation to other substances: While 14-15 year olds draw a clear dividing-line between alcohol and illegal drugs (including cannabis), 18-19 year olds put cannabis on the same footing as alcohol but differentiate it from "hard" drugs. Forth, participants dichotomize cannabis use into spontaneous, social use, which they accept, and habitual, individual use which most of them reject. In combination, these four techniques of neutralization turn cannabis into a normal drug - not normal in the sense that everybody uses it but normal in the sense that cannabis use is seen as legitimate by both users and non-users.

  10. Cannabis induces different cognitive changes in schizophrenic patients and in healthy controls.

    Science.gov (United States)

    Jockers-Scherübl, Maria C; Wolf, Theresa; Radzei, Nicole; Schlattmann, Peter; Rentzsch, Johannes; Gómez-Carrillo de Castro, Ana; Kühl, Klaus-Peter

    2007-06-30

    It is known that 60 to 80% of schizophrenic patients show deficits in cognition. There may be an increase in these deficits as a result of additional regular use of cannabis. The aim of the study was to evaluate the effect of chronic cannabis consumption on the cognitive functions of schizophrenic patients and healthy control subjects after a minimum abstinence time of 28 days. The study sample consisted of 39 schizophrenics (19 cannabis-abusers and 20 non-abusers) and 39 healthy controls (18 cannabis-abusers, 21 non-abusers). In a 2x2-factorial design (Diagnostic Groups [healthy controls, schizophrenic patients]xCannabis abuse [without, with]) with diagnostic group and cannabis consumption considered between-subject factors) we tested the hypothesis that dually diagnosed patients (i.e. suffering both from schizophrenia and cannabis abuse) perform worse in neuropsychological tests than schizophrenic patients without cannabis abuse. On the whole, schizophrenic patients performed worse than healthy control subjects. Surprisingly, rather than deteriorating neuropsychological performance, regular cannabis abuse prior to the first psychotic episode improved cognition in some tests. This was even more pronounced when regular consumption started before the age of 17. On the other hand, cannabis use deteriorated test performance in healthy controls, especially in cases when regular consumption started before the age of 17. To sum up, regular cannabis abuse has a different effect on cognitive function in schizophrenic patients and healthy controls. PMID:17482741

  11. Differential impact of heavy cannabis use on sensory gating in schizophrenic patients and otherwise healthy controls.

    Science.gov (United States)

    Rentzsch, Johannes; Penzhorn, Almut; Kernbichler, Kim; Plöckl, Doris; Gómez-Carrillo de Castro, Ana; Gallinat, Jürgen; Jockers-Scherübl, Maria C

    2007-05-01

    Cannabis abuse may precipitate the onset of schizophrenia and a dysfunction of the endocannabinoid system may be involved in the pathology of schizophrenia. Nevertheless, only few studies have addressed the neurobiological consequences of cannabis abuse for the development and course of schizophrenia. We measured the long-term effect of chronic cannabis abuse on the inhibitory function of the brain by the auditory P50 sensory gating in schizophrenic (n=15) and otherwise healthy chronic cannabis abusers (i.e. cannabis controls; n=11) and compared it to that of schizophrenic patients (n=12) and healthy controls (n=18) without cannabis or other drug abuse. All study subjects had to be abstinent from cannabis for at least 28 days. The main finding of our study was a P50 sensory gating deficit in cannabis controls that was correlated with the number of years with daily consumption (r=0.81; p=0.003). In contrast, we found no differences in P50 sensory gating between schizophrenic cannabis-abusers and non-abusers or healthy controls and no correlation with the number of years with daily consumption in those groups. To our knowledge this is the first study comparing the influence of chronic cannabis abuse in schizophrenic and otherwise healthy abusers on the inhibitory function of the brain. Our data provide some evidence that chronic cannabis abuse may affect sensory cortical circuits even after prolonged abstinence and they point to a possible differential effect in schizophrenic and otherwise healthy users. PMID:17368620

  12. The cannabis pathway to non-affective psychosis may reflect less neurobiological vulnerability

    Directory of Open Access Journals (Sweden)

    Else-Marie Løberg

    2014-11-01

    Full Text Available There is a high prevalence of cannabis use reported in non-affective psychosis. Early prospective longitudinal studies conclude that cannabis use is a risk factor for psychosis, and neurochemical studies on cannabis have suggested potential mechanisms for this effect. Recent advances in the field of neuroscience and genetics may have important implications for our understanding of this relationship. Importantly, we need to better understand the vulnerability x cannabis interaction to shed light on the mediators of cannabis as a risk factor for psychosis. Thus, the present study reviews recent literature on several variables relevant for understanding the relationship between cannabis and psychosis, including age of onset, cognition, brain functioning, family history, genetics and neurological soft signs (NSS in non-affective psychosis. Compared with non-using non-affective psychosis, the present review shows that there seem to be fewer stable cognitive deficits in patients with cannabis use and psychosis, in addition to fewer NSS and possibly more normalized brain functioning, indicating less neurobiological vulnerability for psychosis. There are, however, some familiar and genetic vulnerabilities present in the cannabis psychosis group which may influence the cannabis pathway to psychosis by increasing sensitivity to cannabis. Furthermore, an earlier age of onset suggests a different pathway to psychosis in the cannabis-using patients. Two alternative vulnerability models are presented to integrate these seemingly paradoxical findings.

  13. Cannabis in palliative medicine: improving care and reducing opioid-related morbidity.

    Science.gov (United States)

    Carter, Gregory T; Flanagan, Aaron M; Earleywine, Mitchell; Abrams, Donald I; Aggarwal, Sunil K; Grinspoon, Lester

    2011-08-01

    Unlike hospice, long-term drug safety is an important issue in palliative medicine. Opioids may produce significant morbidity. Cannabis is a safer alternative with broad applicability for palliative care. Yet the Drug Enforcement Agency (DEA) classifies cannabis as Schedule I (dangerous, without medical uses). Dronabinol, a Schedule III prescription drug, is 100% tetrahydrocannabinol (THC), the most psychoactive ingredient in cannabis. Cannabis contains 20% THC or less but has other therapeutic cannabinoids, all working together to produce therapeutic effects. As palliative medicine grows, so does the need to reclassify cannabis. This article provides an evidence-based overview and comparison of cannabis and opioids. Using this foundation, an argument is made for reclassifying cannabis in the context of improving palliative care and reducing opioid-related morbidity. PMID:21444324

  14. Cannabis and Exercise Science: A Commentary on Existing Studies and Suggestions for Future Directions.

    Science.gov (United States)

    Gillman, Arielle S; Hutchison, Kent E; Bryan, Angela D

    2015-10-01

    Policies regarding cannabis use are rapidly changing, yet public officials have limited access to scientific information that might inform the creation of these policies. One important area in which to begin investigations is the link between recreational cannabis use and health, specifically exercise. There are common anecdotal reports that cannabis decreases motivation, including motivation to exercise. On the other hand, there are also anecdotal reports that cannabis is used prior to athletic activity. In fact, the World Anti-Doping Agency includes cannabis as a prohibited substance in sport, partly because it is believed that it may enhance sports performance. At the current time, there is limited scientific evidence to support either one of these opposing lay perspectives. Given recent political, cultural, and legal trends, and the growing acceptance of recreational cannabis use, it is important to develop a more nuanced understanding of the relationship between cannabis and exercise, specifically the potential effects of use on exercise performance, motivation, and recovery. PMID:26178329

  15. How Robustly Does Cannabis Use Associate to College Grades? Findings From Two Cohorts.

    Science.gov (United States)

    Martinez, Julia A; Roth, Madeline G; Johnson, Douglas N; Jones, Jane A

    2015-01-01

    Along with recent changes in cannabis legalization and decriminalization, there has been an increasing amount of attention aimed at cannabis use and outcomes in college. Although some amount of cannabis use might be expected under theories of collegiate identity development, public health research indicates that cannabis use ultimately associates with negative vocational outcomes. To examine how cannabis use associates with college grade point average specifically, we surveyed n = 1,080 full-time college students and a replication sample of n = 590. Results showed that even after accounting for other measures of student identity formation and drug use, increased cannabis use was robustly associated with lower grade point average. Future research should examine the mechanisms underlying this association. Nevertheless, while laws and attitudes toward cannabis evolve, initiatives to decrease college use should continue. PMID:26224748

  16. Drinking, cannabis use and driving among Ontario students

    OpenAIRE

    Adlaf, Edward M.; Mann., Robert E.; Paglia, Angela

    2003-01-01

    LITTLE IS KNOWN ABOUT THE RISK OF INJURY among adolescents who drive after the use of alcohol or cannabis or ride in cars driven by drunk drivers. We examined data from self-administered interviews with 1846 students in grades 7 to 13 who participated in the 2001 Ontario Student Drug Use Survey about their experiences related to alcohol, cannabis and driving during the 12 months preceding the survey. In all, 31.9% of the students reported being a passenger in a car driven by a drunk driver; o...

  17. Aspectos terapêuticos de compostos da planta Cannabis sativa

    Directory of Open Access Journals (Sweden)

    Honório Káthia Maria

    2006-01-01

    Full Text Available Several cannabinoid compounds present therapeutic properties, but also have psychotropic effects, limiting their use as medicine. Nowadays, many important discoveries on the compounds extracted from the plant Cannabis sativa (cannabinoids have contributed to understand the therapeutic properties of these compounds. The main discoveries in the last years on the cannabinoid compounds were: the cannabinoid receptors CB1 and CB2, the endogenous cannabinoids and the possible mechanisms of action involved in the interaction between cannabinoid compounds and the biological receptors. So, from the therapeutical aspects presented in this work, we intended to show the evolution of the Cannabis sativa research and the possible medicinal use of cannabinoid compounds.

  18. Cannabis and psychosis: what causes what?

    OpenAIRE

    David J. Castle

    2013-01-01

    Converging lines of evidence suggest that cannabinoids can produce a full range of transient schizophrenia-like positive, negative and cognitive symptoms. Cannabinoids also produce some psychophysiological deficits also known to be present in schizophrenia. It is also clear that, in individuals with an established psychotic disorder, cannabinoids can exacerbate symptoms, trigger relapse, and have negative consequences on the course of the illness. Increasing evidence suggests that early and h...

  19. Prevalence of Psychotic Symptoms and Their Risk Factors in Urban Tanzania

    Directory of Open Access Journals (Sweden)

    Rachel Jenkins

    2010-06-01

    Full Text Available This study aimed to determine the prevalence of psychotic symptoms in urban Tanzania and their relationship with demographic, socio-economic and social factors. A random sample of 899 adults aged 15–59 was surveyed. The main outcome measure was endorsement of one or more psychotic symptoms identified by the Psychosis Screening Questionnaire. 3.9% respondents reported one or more psychotic symptoms in the preceding year. Significantly higher rates of symptoms were found in those who had recently experienced two or more stressful life events, those with CMD and people who had used cannabis in the preceding year.

  20. HIV Symptoms

    Science.gov (United States)

    ... Submit Home > HIV/AIDS > What is HIV/AIDS? HIV/AIDS This information in Spanish ( en español ) HIV symptoms Photo courtesy of AIDS.gov Facing AIDS ... and brain Return to top More information on HIV symptoms Explore other publications and websites Basic Information ...

  1. Prescrire du cannabis fumé pour la douleur chronique non cancéreuse

    Science.gov (United States)

    Kahan, Meldon; Srivastava, Anita; Spithoff, Sheryl; Bromley, Lisa

    2014-01-01

    Résumé Objectif Offrir des conseils préliminaires sur la prescription de cannabis fumé pour la douleur chronique avant la publication de lignes directrices officielles. Qualité des données Nous avons examiné les ouvrages scientifiques sur l’efficacité analgésique du cannabis fumé et les dommages causés par la consommation de cannabis à des fins médicales et récréatives. Nous avons élaboré des recommandations concernant les indications et les contre-indications du cannabis fumé, les précautions à prendre et son dosage et nous avons classé les recommandations en fonction du niveau des données probantes. La plupart des données probantes sont de niveau II (études observationnelles bien effectuées) et de niveau III (opinion d’experts). Message principal Le cannabis fumé pourrait être indiqué chez des patients souffrant de douleurs neuropathiques sévères qui n’ont pas répondu à des essais suffisants de cannabinoïdes pharmaceutiques et d’analgésiques standards (données probantes de niveau II). Le cannabis fumé est contre-indiqué chez les patients de 25 ans ou moins (données probantes de niveau II); ceux qui font actuellement ou ont fait par le passé une psychose ou encore ont de forts antécédents familiaux de psychose (données probantes de niveau II); ceux qui ont ou ont eu un problème de consommation de cannabis (données probantes de niveau III); ceux qui ont un problème actuel de toxicomanie ou d’alcoolisme (données probantes de niveau III); ceux qui ont une maladie cardiovasculaire ou respiratoire (données probantes de niveau III); ou celles qui sont enceintes ou planifient une grossesse (données probantes de niveau II). Il devrait être utilisé avec précaution par les patients qui fument du tabac (données probantes de niveau II), qui sont à risque accru de maladies cardiovasculaires (données probantes de niveau III), qui ont des troubles d’anxiété ou de l’humeur (données probantes de niveau II) ou qui prennent de fortes doses d’opioïdes ou de benzodiazépines (données probantes de niveau III). Il faut conseiller aux utilisateurs de cannabis d’attendre au moins 3 à 4 heures avant de conduire s’ils en ont fumé, au moins 6 heures s’ils en ont consommé par la bouche et au moins 8 heures s’ils ont ressenti un «high» subjectif (données probantes de niveau II). La dose maximale recommandée est de 1 inhalation 4 fois par jour (environ 400 mg par jour) de cannabis séché contenant 9 % de delta-9-tétrahydrocannabinol (données probantes de niveau III)). Les médecins devraient éviter de demander une consultation pour les patients auprès de cliniques «cannabinoïdes» (données probantes de niveau III). Conclusion Les lignes directrices futures devraient se fonder sur une révision systématique des ouvrages scientifiques sur la sécurité et l’efficacité du cannabis fumé. D’autres recherches sont nécessaires sur l’efficacité et la sécurité à long terme du cannabis fumé par rapport à d’autres cannabinoïdes pharmaceutiques, aux opioïdes et à d’autres analgésiques standards.

  2. Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review

    Directory of Open Access Journals (Sweden)

    Rowland Marie

    2009-12-01

    Full Text Available Abstract Background Cannabis therapy has been considered an effective treatment for spasticity, although clinical reports of symptom reduction in multiple sclerosis (MS describe mixed outcomes. Recently introduced therapies of combined ?9-tetrahydrocannabinol (THC and cannabidiol (CBD extracts have potential for symptom relief with the possibility of reducing intoxication and other side effects. Although several past reviews have suggested that cannabinoid therapy provides a therapeutic benefit for symptoms of MS, none have presented a methodical investigation of newer cannabinoid treatments in MS-related spasticity. The purpose of the present review was to systematically evaluate the effectiveness of combined THC and CBD extracts on MS-related spasticity in order to increase understanding of the treatment's potential effectiveness, safety and limitations. Methods We reviewed MEDLINE/PubMed, Ovid, and CENTRAL electronic databases for relevant studies using randomized controlled trials. Studies were included only if a combination of THC and CBD extracts was used, and if pre- and post-treatment assessments of spasticity were reported. Results Six studies were systematically reviewed for treatment dosage and duration, objective and subjective measures of spasticity, and reports of adverse events. Although there was variation in the outcome measures reported in these studies, a trend of reduced spasticity in treated patients was noted. Adverse events were reported in each study, however combined TCH and CBD extracts were generally considered to be well-tolerated. Conclusion We found evidence that combined THC and CBD extracts may provide therapeutic benefit for MS spasticity symptoms. Although some objective measures of spasticity noted improvement trends, there were no changes found to be significant in post-treatment assessments. However, subjective assessment of symptom relief did often show significant improvement post-treatment. Differences in assessment measures, reports of adverse events, and dosage levels are discussed.

  3. Finding cannabinoids in hair does not prove cannabis consumption.

    Science.gov (United States)

    Moosmann, Bjoern; Roth, Nadine; Auwärter, Volker

    2015-01-01

    Hair analysis for cannabinoids is extensively applied in workplace drug testing and in child protection cases, although valid data on incorporation of the main analytical targets, ?9-tetrahydrocannabinol (THC) and 11-nor-9-carboxy-THC (THC-COOH), into human hair is widely missing. Furthermore, ?9-tetrahydrocannabinolic acid A (THCA-A), the biogenetic precursor of THC, is found in the hair of persons who solely handled cannabis material. In the light of the serious consequences of positive test results the mechanisms of drug incorporation into hair urgently need scientific evaluation. Here we show that neither THC nor THCA-A are incorporated into human hair in relevant amounts after systemic uptake. THC-COOH, which is considered an incontestable proof of THC uptake according to the current scientific doctrine, was found in hair, but was also present in older hair segments, which already grew before the oral THC intake and in sebum/sweat samples. Our studies show that all three cannabinoids can be present in hair of non-consuming individuals because of transfer through cannabis consumers, via their hands, their sebum/sweat, or cannabis smoke. This is of concern for e.g. child-custody cases as cannabinoid findings in a child's hair may be caused by close contact to cannabis consumers rather than by inhalation of side-stream smoke. PMID:26443501

  4. Finding cannabinoids in hair does not prove cannabis consumption

    Science.gov (United States)

    Moosmann, Bjoern; Roth, Nadine; Auwärter, Volker

    2015-01-01

    Hair analysis for cannabinoids is extensively applied in workplace drug testing and in child protection cases, although valid data on incorporation of the main analytical targets, ?9-tetrahydrocannabinol (THC) and 11-nor-9-carboxy-THC (THC-COOH), into human hair is widely missing. Furthermore, ?9-tetrahydrocannabinolic acid A (THCA-A), the biogenetic precursor of THC, is found in the hair of persons who solely handled cannabis material. In the light of the serious consequences of positive test results the mechanisms of drug incorporation into hair urgently need scientific evaluation. Here we show that neither THC nor THCA-A are incorporated into human hair in relevant amounts after systemic uptake. THC-COOH, which is considered an incontestable proof of THC uptake according to the current scientific doctrine, was found in hair, but was also present in older hair segments, which already grew before the oral THC intake and in sebum/sweat samples. Our studies show that all three cannabinoids can be present in hair of non-consuming individuals because of transfer through cannabis consumers, via their hands, their sebum/sweat, or cannabis smoke. This is of concern for e.g. child-custody cases as cannabinoid findings in a child’s hair may be caused by close contact to cannabis consumers rather than by inhalation of side-stream smoke. PMID:26443501

  5. Cannabis ruderalis Janisch., 1924 - konop? rumištní.

    Czech Academy of Sciences Publication Activity Database

    Mandák, Bohumil

    Praha : ?SOP, 2006 - (Mlíkovský, J.; Stýblo, P.), s. 67-67 ISBN 80-86770-17-6 Grant ostatní: GA MŽP(CZ) SM/6/37/04 Institutional research plan: CEZ:AV0Z60050516 Keywords : Cannabis ruderalis * distribution * invasibility Subject RIV: EF - Botanics

  6. Complete sequence of a cryptic virus from hemp (Cannabis sativa).

    Czech Academy of Sciences Publication Activity Database

    Ziegler, A.; Matoušek, Jaroslav; Steger, G.; Schubert, J.

    2012-01-01

    Ro?. 157, ?. 2 (2012), s. 383-385. ISSN 0304-8608 R&D Projects: GA ?R GCP501/10/J018 Institutional research plan: CEZ:AV0Z50510513 Keywords : Cannabis sativa * Partitivirus * cryptic virus Subject RIV: EE - Microbiology, Virology Impact factor: 2.030, year: 2012

  7. Hemp (Cannabis sativa L.) seeds after plasma treatment.

    Czech Academy of Sciences Publication Activity Database

    Šerá, Božena; Gajdová, Iveta; Gavril, B.; Hnatiuc, E.; Šerý, M.; Špatenka, P.

    Brasov : Universitatea Transilvania din Brasov, 2012 - (Clotea, L.; Cernat, M.). s. 251-251 ISBN 978-1-4673-1650-7. [International Conference on Optimization of Electrical and Electronic Equipment /13./ OPTIM 2012. 24.05.-26.05.2012, Brasov] Institutional support: RVO:67179843 Keywords : Cannabis sativa L. * plasma treatment Subject RIV: EI - Biotechnology ; Bionics

  8. DETECTION OF ILLEGAL CANNABIS CULTIVATION USING REMOTE SENSING

    Science.gov (United States)

    Detection of illegal Cannabis cultivation by law enforcement agencies currently relies on low flying aircraft manned by trained aerial spotters. This is physically tiring for the aircrew, inefficient for large or complex landscapes, and is often foiled by camouflaged grow sites. A solution for det...

  9. Relationship between cannabis and psychosis: Reasons for use and associated clinical variables.

    Science.gov (United States)

    Mané, Anna; Fernández-Expósito, Miguel; Bergé, Daniel; Gómez-Pérez, Laura; Sabaté, Agnés; Toll, Alba; Diaz, Laura; Diez-Aja, Cristobal; Perez, Victor

    2015-09-30

    The mechanism underneath the relationship between cannabis and psychosis remains controversial, for which several hypotheses have been proposed, including cannabis as self-medication and cannabis as a risk for the development of psychosis. The aim of this work was to study the relationship between cannabis and psychosis in first-episode psychosis cannabis users and non-users, and non-psychotic cannabis users. The age at the first psychotic episode, duration of untreated psychosis, psychopathology and reasons for cannabis use were assessed. First-episode psychosis cannabis users showed an earlier age at psychosis onset than non-user patients. No significant differences in symptomatology were found. The distinguishing reasons to use cannabis for patients with first-episode psychosis with respect to non-psychotic users were to arrange their thoughts and deal with hallucinations and suspiciousness. These findings are in agreement with both hypotheses: self-medication and secondary psychosis hypothesis. However, longitudinal prospective cohort studies assessing reasons for cannabis use are needed to investigate both hypotheses and their complementarity. PMID:26235479

  10. Avoiding emotional bonds: An examination of the dimensions of therapeutic alliance among cannabis users

    Directory of Open Access Journals (Sweden)

    FrancesKay-Lambkin

    2013-07-01

    Full Text Available There is a growing need to provide treatment for cannabis users, yet engaging and maintaining this population in treatment is particularly difficult. Although past research has focused on the importance of therapeutic alliance on drug treatment outcomes, this is the first study to examine the dimensions of therapeutic alliance for cannabis users compared with users of alcohol or other drugs in a naturalistic setting. The acceptability of Internet-delivered interventions for drug and alcohol treatments is also investigated. Participants (N = 77 included clients who were receiving outpatient drug and alcohol treatment at a publicly-funded health service, including a Specialist Cannabis Clinic. The results indicated that one particular domain of alliance, Bond, was consistently lower, from both client and clinician perspectives, for current cannabis users relative to those not currently using cannabis. Client perceptions of Bond decreased as the severity of cannabis use increased (r =-0.373, p=0.02. Cannabis Clinic clients did not report a significantly lower Bond with their clinicians, suggesting that specialised cannabis services may be better placed to provide appropriate treatment for this population than embedding cannabis treatment within traditional drug and alcohol treatment teams. In addition, Internet/computer based treatments may be one potential way to engage, transition or retain cannabis users in treatment. Trial Registration: Australian Clinical Trial Registration Number: ACTRN12611000382976

  11. Cannabis and Tobacco Use: Where Are the Boundaries? A Qualitative Study on Cannabis Consumption Modes among Adolescents

    Science.gov (United States)

    Akre, Christina; Michaud, Pierre-Andre; Berchtold, Andre; Suris, Joan-Carles

    2010-01-01

    The purpose of this article is to identify tobacco and cannabis co-consumptions and consumers' perceptions of each substance. A qualitative research including 22 youths (14 males) aged 15-21 years in seven individual interviews and five focus groups. Discussions were recorded, transcribed verbatim and transferred to Atlas.ti software for narrative…

  12. Psychomotor Performance, Subjective and Physiological Effects and Whole Blood ?9-Tetrahydrocannabinol Concentrations in Heavy, Chronic Cannabis Smokers Following Acute Smoked Cannabis

    OpenAIRE

    Schwope, David M.; Bosker, Wendy M.; Ramaekers, Johannes G.; Gorelick, David A.; Huestis, Marilyn A.

    2012-01-01

    ?9-tetrahydrocannabinol (THC) is the illicit drug most frequently observed in accident and driving under the influence of drugs investigations. Whole blood is often the only available specimen collected during such investigations, yet few studies have examined relationships between cannabis effects and whole blood concentrations following cannabis smoking.

  13. Los productos de Cannabis sativa: situación actual y perspectivas en medicina / Cannabis sativa products: current status and perspectives in medicine

    Scientific Electronic Library Online (English)

    Rodolfo, Rodríguez Carranza.

    2012-06-01

    Full Text Available Los productos psicoactivos de la Cannabis sativa, como marihuana y hachís, se han usado desde hace varios siglos con fines medicinales, religiosos y recreativos. Ahora, la marihuana es la droga ilegal de mayor consumo en el mundo, particularmente por adolescentes y adultos jóvenes. La adolescencia e [...] s una etapa crítica en el desarrollo y maduración del Sistema Nervioso Central. La marihuana está constituida por un gran número y variedad de substancias químicas que pueden interactuar entre sí. Sus efectos agudos se caracterizan por euforia, relajación e intensificación de las experiencias sensoriales ordinarias. Su consumo crónico induce tolerancia, dependencia, síndrome de carencia, déficit cognitivo y aumenta el riesgo de enfermedades psiquiátricas. El descubrimiento de un sistema cannabinoide endógeno renovó el interés médico por la marihuana y los datos de los últimos 20 años indican que el sistema endocannabinoide regula la función de diversos tipos de sinapsis y juega un papel importante en el desarrollo cerebral extrauterino. Recientemente el interés sobre la marihuana se centró en sus propiedades medicinales y existe un buen número de ensayos clínicos controlados que apoyan su uso en ciertas condiciones médicas; sin embargo, su eficacia y seguridad siguen siendo motivo de controversia. En este artículo se analizan los conocimientos farmacológicos sobre la marihuana, se establecen los riesgos de su consumo, la información sobre sus propiedades medicinales y, con base en la evidencia disponible, se opina contra su legalización. Finalmente, aquí se postula que la marihuana en su forma herbaria, por vía enteral, puede ser de gran valor para mitigar el sufrimiento de pacientes con enfermedad terminal. Abstract in english Psychoactive preparations of Cannabis sativa, such as marijuana and hashish, have been used for centuries for medicinal, religious and recreational purposes. Today marijuana is the most widely used illegal drug worldwide, particularly among teenagers and young adults. Adolescence is a critical phase [...] in Central Nervous System development, characterized by neuronal maturation and rearrangement processes. Marijuana is very complex in its chemistry due to the large number of active constituents capable of interacting with each other. With inhaled marihuana, subjects experience euphoria, a feeling of relaxation, and intensification of ordinary sensory experiences. Chronic consumption results in tolerance, dependence, withdrawal syndrome, cognitive deterioration, and increased risk of psychiatric illnesses. The discovery of an endogenous cannabinoid system renewed the medical interest in marijuana and data from the last 20 years have shown that, in the postnatal brain, endocannabinoids regulate the function of many synapses and play an important role in brain development; also, that chronic consumption of marijuana early in life negatively affects Central Nervous System development. Recently, interest on marijuana has centered on its medicinal properties, and a good number of controlled clinical studies support its use in certain medical conditions; however, safety and efficacy of marijuana remains controversial. In this article we analyze the pharmacological knowledge on marijuana, the risks of its consumption, data on its medicinal properties and, based on the available evidence, we conclude that its legalization should be discouraged. Finally, we postulate that marijuana in its herbal form, by the enteral route, could be of a great value in mitigating suffering in patients with terminal illness.

  14. Passive cannabis smoke exposure and oral fluid testing. II. Two studies of extreme cannabis smoke exposure in a motor vehicle.

    Science.gov (United States)

    Niedbala, R Sam; Kardos, Keith W; Fritch, Dean F; Kunsman, Kenneth P; Blum, Kristen A; Newland, Gregory A; Waga, Joe; Kurtz, Lisa; Bronsgeest, Matth; Cone, Edward J

    2005-10-01

    Two studies were conducted to determine if extreme passive exposure to cannabis smoke in a motor vehicle would produce positive results for delta-tetrahydrocannabinol (THC) in oral fluid. Passive exposure to cannabis smoke in an unventilated room has been shown to produce a transient appearance of THC in oral fluid for up to 30 min. However, it is well known that such factors as room size and extent of smoke exposure can affect results. Questions have also been raised concerning the effects of tobacco when mixed with marijuana and THC content. We conducted two passive cannabis studies under severe passive smoke exposure conditions in an unventilated eight-passenger van. Four passive subjects sat alongside four active cannabis smokers who each smoked a single cannabis cigarette containing either 5.4%, 39.5 mg THC (Study 1) or 10.4%, 83.2 mg THC (Study 2). The cigarettes in Study 1 contained tobacco mixed with cannabis; cigarettes in Study 2 contained only cannabis. Oral fluid specimens were collected from passive and active subjects with the Intercept Oral Specimen Collection Device for 1 h after smoking cessation while inside the van (Study 1) and up to 72 h (passive) or 8 h (active) outside the van. Additionally in Study 1, Intercept collectors were exposed to smoke in the van to assess environmental contamination during collection procedures. For Study 2, all oral fluid collections were outside the van following smoking cessation to minimize environmental contamination. Oral samples were analyzed with the Cannabinoids Intercept MICRO-PLATE EIA and quantitatively by gas chromatography-tandem mass spectrometry (GC-MS-MS). THC concentrations were adjusted for dilution (x 3). The screening and confirmation cutoff concentrations for THC in neat oral fluid were 3 ng/mL and 1.5 ng/mL, respectively. The limits of detection (LOD) and quantitation (LOQ) for THC in the GC-MS-MS assay were 0.3 and 0.75 ng/mL, respectively. Urine specimens were collected, screened (EMIT, 50 ng/mL cutoff), and analyzed by GC-MS-MS for THCCOOH (LOD/LOQ = 1.0 ng/mL). Peak oral fluid THC concentrations in passive subjects recorded at the end of cannabis smoke exposure were up to 7.5 ng/mL (Study 1) and 1.2 ng/mL (Study 2). Thereafter, THC concentrations quickly declined to negative levels within 30-45 min in Study 1. It was found that environmentally exposed Collectors contained 3-14 ng/mL in Study 1. When potential contamination during collection was eliminated in Study 2, all passive subjects were negative at screening/confirmation cutoff concentrations throughout the study. Oral fluid specimens from active smokers had peak concentrations of THC approximately 100-fold greater than passive subjects in both studies. Positive oral fluid results were observed for active smokers 0-8 h. Urine analysis confirmed oral fluid results. These studies clarify earlier findings on the effects of passive cannabis smoke on oral fluid results. Oral fluid specimens collected in the presence of cannabis smoke appear to have been contaminated, thereby falsely elevating THC concentrations in oral fluid. The risk of a positive test for THC was virtually eliminated when specimens were collected in the absence of THC smoke. PMID:16419389

  15. Anhedonia and substance dependence: clinical correlates and treatment options

    Directory of Open Access Journals (Sweden)

    GiovanniMartinotti

    2011-03-01

    Full Text Available Anhedonia is a condition in which the capacity of experiencing pleasure is totally or partially lost, and it refers to both a state symptom in various psychiatric disorders and a personality trait. It has a putative neural substrate, consisting in the dopaminergic mesolimbic and mesocortical reward circuit. Anhedonia frequently occurs in mood disorders, as a negative symptom in schizophrenia, and in substance use disorders. In particular, we focus our attention on the relationships occurring between anhedonia and substance use disorders, as highlighted by many studies. Several authors suggested that anhedonia is an important factor involved in relapse as well as in the transition from recreational use to excessive drug intake. In particular, anhedonia has been found to be a frequent feature in alcoholics and addicted patients during acute and chronic withdrawal as well as in cocaine, stimulant and cannabis abusers. Furthermore, in subjects with a substance dependence disorder, there is a significant correlation between anhedonia, craving, intensity of withdrawal symptoms and psychosocial and personality characteristics. Therefore treating anhedonia in detoxified alcohol dependent subjects could be critical in terms of relapse prevention strategies, given its strong relationship with craving. On this purpose many different strategies have been proposed.

  16. U.S. Policy Responses to Calls for the Medical Use of Cannabis.

    Science.gov (United States)

    Hall, Wayne

    2015-09-01

    This paper discusses the evolution of U.S. policy responses to calls to allow patients to use cannabis for medical purposes. It first summarizes the research evidence on the safety and efficacy of cannabinoids for various medical uses. It then outlines the challenges in developing new pharmaceutical cannabinoids that are safe, effective, and acceptable to patients. It briefly describes the strengths and limitations of the different ways in which U.S. states have allowed patients to use cannabis for medical purposes. These include allowing access for research trials only, allowing medical necessity as a defense against prosecution, and allowing commercial medical dispensaries to provide cannabis to approved patients. It argues that liberal definitions of indications for medical cannabis use and the commercialization of medical cannabis supply in California have produced the de facto legalization of recreational cannabis use. PMID:26339208

  17. U.S. Policy Responses to Calls for the Medical Use of Cannabis

    Science.gov (United States)

    Hall, Wayne

    2015-01-01

    This paper discusses the evolution of U.S. policy responses to calls to allow patients to use cannabis for medical purposes. It first summarizes the research evidence on the safety and efficacy of cannabinoids for various medical uses. It then outlines the challenges in developing new pharmaceutical cannabinoids that are safe, effective, and acceptable to patients. It briefly describes the strengths and limitations of the different ways in which U.S. states have allowed patients to use cannabis for medical purposes. These include allowing access for research trials only, allowing medical necessity as a defense against prosecution, and allowing commercial medical dispensaries to provide cannabis to approved patients. It argues that liberal definitions of indications for medical cannabis use and the commercialization of medical cannabis supply in California have produced the de facto legalization of recreational cannabis use. PMID:26339208

  18. Cannabis Exposure in an Omani Child: First case report from Oman

    OpenAIRE

    Al-Shidhani, Thuraya A.; Arora, Vinita

    2011-01-01

    We report a confirmed case of cannabis exposure in an Omani female child with developmental delay. Cannabis exposure in children can lead to many consequences; for example, chronic use can result in developmental delay, abnormal behaviour, and hyperactivity while there is a risk of coma with acute exposure. It is important for clinicians to consider substance abuse as a differential diagnosis for similar presentations in paediatric patients, noting that children are at risk of cannabis exposu...

  19. Telling true from false: cannabis users show increased susceptibility to false memories

    OpenAIRE

    Riba, J; Valle, M; Sampedro, F; Rodríguez-Pujadas, A; Martínez-Horta, S; Kulisevsky, J.; Rodríguez-Fornells, A

    2015-01-01

    Previous studies on the neurocognitive impact of cannabis use have found working and declarative memory deficits that tend to normalize with abstinence. An unexplored aspect of cognitive function in chronic cannabis users is the ability to distinguish between veridical and illusory memories, a crucial aspect of reality monitoring that relies on adequate memory function and cognitive control. Using functional magnetic resonance imaging, we show that abstinent cannabis users have an increased s...

  20. Development of an analytical method for detection and quantification of cannabis and cannabinoid analogues in urine

    OpenAIRE

    Steinshamn, Eirin Berge

    2010-01-01

    Cannabis is a drug mainly consumed for its euphoric effects; users may become happy, careless and relaxed. The direct effects of cannabis in sports are performance decreasing, but cannabis can be used as a doping agent due to its relaxing properties. For these reasons, cannabinoids are prohibited in sports during competition by the World Anti-Doping Agency (WADA). In the context of the fight against doping, urine is screened for the metabolite THC-COOH (11-nor-delta(9)-tetrahydrocannabino...

  1. Extraction of High Quality DNA from Seized Moroccan Cannabis Resin (Hashish)

    OpenAIRE

    El Alaoui, Moulay Abdelaziz; Melloul, Marouane; Alaoui Amine, Sanaâ; Stambouli, Hamid; El Bouri, Aziz; Soulaymani, Abdelmajid; El Fahime, Elmostafa

    2013-01-01

    The extraction and purification of nucleic acids is the first step in most molecular biology analysis techniques. The objective of this work is to obtain highly purified nucleic acids derived from Cannabis sativa resin seizure in order to conduct a DNA typing method for the individualization of cannabis resin samples. To obtain highly purified nucleic acids from cannabis resin (Hashish) free from contaminants that cause inhibition of PCR reaction, we have tested two protocols: the CTAB protoc...

  2. Cannabis Use and Anxiety: Is Stress the Missing Piece of the Puzzle?

    OpenAIRE

    Temple, Elizabeth C.; Driver, Matthew; Brown, Rhonda F.

    2014-01-01

    Objective: Comorbidity between anxiety and cannabis use is common yet the nature of the association between these conditions is not clear. Four theories were assessed, and a fifth hypothesis tested to determine if the misattribution of stress symptomology plays a role in the association between state-anxiety and cannabis. Methods: Three-hundred-sixteen participants ranging in age from 18 to 71?years completed a short online questionnaire asking about their history of cannabis use and sympt...

  3. Perceptions of cannabis as a stigmatized medicine: a qualitative descriptive study

    OpenAIRE

    Bottorff Joan L; Bissell Laura JL; Balneaves Lynda G; Oliffe John L; Capler N Rielle; Buxton Jane

    2013-01-01

    Abstract Background Despite its increasing prevalence and acceptance among the general public, cannabis use continues to be viewed as an aberrant activity in many contexts. However, little is known about how stigma associated with cannabis use affects individuals who use cannabis for therapeutic purposes (CTP) and what strategies these individuals employ to manage associated stigma. The aim of this Canadian study was to describe users’ perceptions of and responses to the stigma attached to us...

  4. Interaction Between Functional Genetic Variation of DRD2 and Cannabis Use on Risk of Psychosis.

    Science.gov (United States)

    Colizzi, Marco; Iyegbe, Conrad; Powell, John; Ursini, Gianluca; Porcelli, Annamaria; Bonvino, Aurora; Taurisano, Paolo; Romano, Raffaella; Masellis, Rita; Blasi, Giuseppe; Morgan, Craig; Aitchison, Katherine; Mondelli, Valeria; Luzi, Sonija; Kolliakou, Anna; David, Anthony; Murray, Robin M; Bertolino, Alessandro; Di Forti, Marta

    2015-09-01

    Both cannabis use and the dopamine receptor (DRD2) gene have been associated with schizophrenia, psychosis-like experiences, and cognition. However, there are no published data investigating whether genetically determined variation in DRD2 dopaminergic signaling might play a role in individual susceptibility to cannabis-associated psychosis. We genotyped (1) a case-control study of 272 patients with their first episode of psychosis and 234 controls, and also from (2) a sample of 252 healthy subjects, for functional variation in DRD2, rs1076560. Data on history of cannabis use were collected on all the studied subjects by administering the Cannabis Experience Questionnaire. In the healthy subjects' sample, we also collected data on schizotypy and cognitive performance using the Schizotypal Personality Questionnaire and the N-back working memory task. In the case-control study, we found a significant interaction between the rs1076560 DRD2 genotype and cannabis use in influencing the likelihood of a psychotic disorder. Among cannabis users, carriers of the DRD2, rs1076560, T allele showed a 3-fold increased probability to suffer a psychotic disorder compared with GG carriers (OR = 3.07; 95% confidence interval [CI]: 1.22-7.63). Among daily users, T carrying subjects showed a 5-fold increase in the odds of psychosis compared to GG carriers (OR = 4.82; 95% CI: 1.39-16.71). Among the healthy subjects, T carrying cannabis users had increased schizotypy compared with T carrying cannabis-naïve subjects, GG cannabis users, and GG cannabis-naïve subjects (all P ? .025). T carrying cannabis users had reduced working memory accuracy compared with the other groups (all P ? .008). Thus, variation of the DRD2, rs1076560, genotype may modulate the psychosis-inducing effect of cannabis use. PMID:25829376

  5. Adolescent Cannabis Problems and Young Adult Depression: Male-Female Stratified Propensity Score Analyses

    OpenAIRE

    Harder, Valerie S.; Elizabeth A. Stuart; Anthony, James C.

    2008-01-01

    Cannabis use and depression are two of the most prevalent conditions worldwide. Adolescent cannabis use is linked to depression in many studies, but the effects of adolescent cannabis involvement on young adult depression remain unclear and may differ for males versus females. In this cohort study of youth from a mid-Atlantic metropolitan area of the United States, repeated assessments from 1985 (at age 6 years) through 2002 (at age 21 years) were made for 1,494 individuals (55% female). Meas...

  6. Cannabis use and depression: a longitudinal study of a national cohort of Swedish conscripts

    OpenAIRE

    Manrique-Garcia Edison; Zammit Stanley; Dalman Christina; Hemmingsson Tomas; Allebeck Peter

    2012-01-01

    Abstract Background While there is increasing evidence on the association between cannabis use and psychotic outcomes, it is still unclear whether this also applies to depression. We aim to assess whether risk of depression and other affective outcomes is increased among cannabis users. Methods A cohort study of 45 087 Swedish men with data on cannabis use at ages 18–20. Diagnoses of unipolar disorder, bipolar disorder, affective psychosis and schizoaffective disorder were identified from inp...

  7. Stress-Related Factors in Cannabis Use and Misuse: Implications for Prevention and Treatment

    OpenAIRE

    Hyman, Scott M.; SINHA, RAJITA

    2008-01-01

    We examined the role of stress as a risk factor and motivation for cannabis use/misuse. A systematic review of studies gathered from PsychINFO and MEDLINE databases was conducted. Findings suggest that cannabis is commonly used as a stress-coping strategy. Negative life events, trauma, and maladaptive coping were all related to consumption. Cannabis use for stress-coping purposes was most evident when examining chronic as compared with experimental use. While many individuals may be able to u...

  8. INCANT: a transnational randomized trial of Multidimensional Family Therapy versus treatment as usual for adolescents with cannabis use disorder

    Directory of Open Access Journals (Sweden)

    Grichting Esther

    2010-04-01

    Full Text Available Abstract Background In 2003, the governments of Belgium, France, Germany, the Netherlands and Switzerland agreed that there was a need in Europe for a treatment programme for adolescents with cannabis use disorders and other behavioural problems. Based on an exhaustive literature review of evidence-based treatments and an international experts meeting, Multidimensional Family Therapy (MDFT was selected for a pilot study first, which was successful, and then for a joint, transnational randomized controlled trial named INCANT (INternational CAnnabis Need for Treatment. Methods/design INCANT is a randomized controlled trial (RCT with an open-label, parallel group design. This study compares MDFT with treatment as usual (TAU at and across sites in Brussels, Berlin, Paris, The Hague and Geneva. Assessments are at baseline and at 3, 6, 9 and 12 months after randomization. A minimum of 450 cases in total is required; sites will recruit 60 cases each in Belgium and Switzerland, and a maximum of 120 each in France, Germany and the Netherlands. Eligible for INCANT are adolescents from 13 through 18 years of age with a cannabis use disorder (dependence or abuse, with at least one parent willing to take part in the treatment. Randomization is concealed to, and therefore beyond control by, the researcher/site requesting it. Randomization is stratified as to gender, age and level of cannabis consumption. Assessments focus on substance use; mental function; behavioural problems; and functioning regarding family, school, peers and leisure time. For outcome analyses, the study will use state of the art latent growth curve modelling techniques, including all randomized participants according to the intention-to-treat principle. INCANT has been approved by the appropriate ethical boards in Belgium, France, Germany, the Netherlands, Switzerland, and the University of Miami Miller School of Medicine. INCANT is funded by the (federal Ministries of Health of Belgium, Germany, the Netherlands, Switzerland, and by MILDT: the Mission Interministerielle de Lutte Contra la Drogue et de Toximanie, France. Discussion Until recently, cannabis use disorders in adolescents were not viewed in Europe as requiring treatment, and the co-occurrence of such disorders with other mental and behavioural problems was underestimated. This has changed now. Initially, there was doubt that a RCT would be feasible in treatment sectors and countries with no experience in this type of study. INCANT has proven that such doubts are unjustified. Governments and treatment sites from the five participating countries agreed on a sound study protocol, and the INCANT trial is now underway as planned. Trial registration ISRCTN51014277

  9. Analysis of relationships between perimenopausal symptoms and professional functioning and life satisfaction – Subjective perception of the dependence in women aged 40+

    Directory of Open Access Journals (Sweden)

    Iwona Nowakowska

    2015-07-01

    Full Text Available Background: The aim of the study was to analyse and present the opinions of women in perimenopause on subjectively perceived symptoms characteristic of the climacteric period, and connected with their professional functioning, as well as to evaluate the effects of selected variables on the incidence and severity of these symptoms and the women’s life satisfaction. Material and Methods: The study included 250 professionally active women in perimenopausal age (40–57 years. The study used the Satisfaction with Life Scale (SWLS to evaluate life satisfaction of women and the Kupperman Index (KI as quantitative and qualitative self-assessment of climacteric symptoms. The authors also used a questionnaire of their own design that contains an index of defined symptoms of perimenopause, which warrants the use of Pareto-Lorenz analysis. Results: The obtained results prove the presence of statistically significant correlations between the occurrence and severity of menopausal symptoms and the place of enployment (p = 0.04912, gynecological care (p = 0.00325, hormone replacement therapy (HRT (p = 0.01523 and assessment of life satisfaction (p = 0.0325. Among the symptoms particularly influencing effective professional functioning, women pointed out hot flashes, irritability, reduced concentration and coordination, sleep disturbances, and increased sweating. Conclusions: There is a statistically significant correlation between the woman’s place of employment, gynecological care, HRT, the evaluation of life satisfaction and the severity of perimenopausal symptoms. A set of symptoms whose presence and severity influence the sense of life satisfaction and evaluation of professional functioning was observed. Among the most frequently reported symptoms that exert an adverse effect on professional functioning of women are: hot flushes, irritability, reduced concentration and coordination, sleep disturbances, and increased sweating. Med Pr 2015;66(3:351–358

  10. Application of medical cannabis in patients with central nerve system disorders

    Directory of Open Access Journals (Sweden)

    Lidia Kotu?a

    2015-05-01

    Full Text Available Cannabis sativa is an annual plant in the Cannabaceae family, species of the genus Cannabis. Cannabis contains active elements, including ?9-tetrahydrocanabinol (THC and cannabidiol (CBD. Neurological disorders are typically associated with neurodegeneration. It means that there is no causal treatment. Usually we can only modulate disease. It is very necessary to patients to reduce pain sensation or excessive muscle tension. The paper contains a description of therapeutic possibilities treatment of cannabis in neurological disorders such as Alzheimer’s disease, multiple sclerosis, Tourette syndrome and spasticity.

  11. The Check Your Cannabis Screener: A New Online Personalized Feedback Tool

    OpenAIRE

    Cunningham, John A; Van Mierlo, Trevor

    2009-01-01

    This brief report describes the development and first year of use of an Internet-based screener for Cannabis users. Two versions of the Check Your Cannabis screener were compared, one linked to an already established harm reduction website for young Cannabis users (as an exercise called “Check how I compare with others,” on www.WhatsWithWeed.ca) and the other a standalone version (www.CheckYourCannabis.net). The What’s With Weed version attracted ten times more users and had a significantly y...

  12. Coping-motivated marijuana use correlates with DSM-5 cannabis use disorder and psychological distress among emerging adults.

    Science.gov (United States)

    Moitra, Ethan; Christopher, Paul P; Anderson, Bradley J; Stein, Michael D

    2015-09-01

    Compared to other age cohorts, emerging adults, ages 18-25 years, have the highest rates of marijuana (MJ) use. We examined the relationship of using MJ to cope with negative emotions, relative to using MJ for enhancement or social purposes, to MJ-associated problems and psychological distress among emerging adults. Participants were 288 community-dwelling emerging adults who reported current MJ use as part of a "Health Behaviors" study. Linear and logistic regressions were used to evaluate the adjusted association of coping-motivated MJ use with the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) cannabis use disorder, MJ-related problem severity, depressive symptoms, and perceived stress. After adjusting for other variables in the regression model, using MJ to cope was positively associated with having DSM-5 cannabis use disorder (OR = 1.85, 95% CI [1.31, 2.62], p stress (b = .37, 95% CI [.22, .51], p motivation may be clinically important among emerging adults. (PsycINFO Database Record PMID:25915689

  13. Design paper: The CapOpus trial: a randomized, parallel-group, observer-blinded clinical trial of specialized addiction treatment versus treatment as usual for young patients with cannabis abuse and psychosis

    DEFF Research Database (Denmark)

    HjorthØj, Carsten; Fohlmann, Allan

    2008-01-01

    BACKGROUND: A number of studies indicate a link between cannabis-use and psychosis as well as more severe psychosis in those with existing psychotic disorders. There is currently insufficient evidence to decide the optimal way to treat cannabis abuse among patients with psychosis. OBJECTIVES: The major objective for the CapOpus trial is to evaluate the additional effect on cannabis abuse of a specialized addiction treatment program adding group treatment and motivational interviewing to treatment as usual. DESIGN: The trial is designed as a randomized, parallel-group, observer-blinded clinical trial. Patients are primarily recruited through early-psychosis detection teams, community mental health centers, and assertive community treatment teams. Patients are randomized to one of two treatment arms, both lasting six months: 1) specialized addiction treatment plus treatment as usual or 2) treatment as usual. The specialized addiction treatment is manualized and consists of both individual and group-based motivational interviewing and cognitive behavioral therapy, and incorporates both the family and the case manager of the patient.The primary outcome measure will be changes in amount of cannabis consumption over time. Other outcome measures will be psychosis symptoms, cognitive functioning, quality of life, social functioning, and cost-benefit analyses. TRIAL REGISTRATION: ClinicalTrials.gov NCT00484302.

  14. Design paper: The CapOpus trial: A randomized, parallel-group, observer-blinded clinical trial of specialized addiction treatment versus treatment as usual for young patients with cannabis abuse and psychosis

    Directory of Open Access Journals (Sweden)

    Gluud Christian

    2008-07-01

    Full Text Available Abstract Background A number of studies indicate a link between cannabis-use and psychosis as well as more severe psychosis in those with existing psychotic disorders. There is currently insufficient evidence to decide the optimal way to treat cannabis abuse among patients with psychosis. Objectives The major objective for the CapOpus trial is to evaluate the additional effect on cannabis abuse of a specialized addiction treatment program adding group treatment and motivational interviewing to treatment as usual. Design The trial is designed as a randomized, parallel-group, observer-blinded clinical trial. Patients are primarily recruited through early-psychosis detection teams, community mental health centers, and assertive community treatment teams. Patients are randomized to one of two treatment arms, both lasting six months: 1 specialized addiction treatment plus treatment as usual or 2 treatment as usual. The specialized addiction treatment is manualized and consists of both individual and group-based motivational interviewing and cognitive behavioral therapy, and incorporates both the family and the case manager of the patient. The primary outcome measure will be changes in amount of cannabis consumption over time. Other outcome measures will be psychosis symptoms, cognitive functioning, quality of life, social functioning, and cost-benefit analyses. Trial registration ClinicalTrials.gov NCT00484302.

  15. Antigiardial Activity and Toxicological Exploration of Cannabis Sativa Extracts

    Directory of Open Access Journals (Sweden)

    Mahmoud M.DAHAB

    2013-05-01

    Full Text Available The present study has been attempt to elucidate antigiardial activity and explore the cytoxicity, investigation on liver Diagnostic Enzymes and Changes in serum constituents of Cannabis Sativa aerial parts and seeds, which were extracted by Petroleum ether and methanol. Aerial parts methanolic extract gave 63.6% mortality after 72 hours at concentration 1000 ppm (IC50 0.13 ppm comparing with metrondizole (IC50 0.0125 ppm. While the other extracts found inactive as antigiardiasis after 72 hours. The slight increase in Aspartate amino transferase (AST, Alanine amino transferase (ALT and Alkaline phosphatase (ALP liver enzyme and total protein, urea, albumin and calcium which indicate some degree hepatic nefropathy effect of such plant petroleum ether extract. Moreover, phytochemical examination was carried out firstly and revealed that, the petroleum ether extract of Cannabis sativa seed do not contain tetrahydrocannbinol (THC, cannabinol (CBN and cannabidaiol (CBD. However, all extracts showed no significant cytotoxic activity against vero cell line.

  16. Aspectos terapêuticos de compostos da planta Cannabis sativa

    OpenAIRE

    Honório Káthia Maria; Arroio Agnaldo; Silva Albérico Borges Ferreira da

    2006-01-01

    Several cannabinoid compounds present therapeutic properties, but also have psychotropic effects, limiting their use as medicine. Nowadays, many important discoveries on the compounds extracted from the plant Cannabis sativa (cannabinoids) have contributed to understand the therapeutic properties of these compounds. The main discoveries in the last years on the cannabinoid compounds were: the cannabinoid receptors CB1 and CB2, the endogenous cannabinoids and the possible mechanisms of action ...

  17. Crop physiology of fibre hemp (Cannabis sativa L.).

    OpenAIRE

    Werf, H., van der

    1994-01-01

    Fibre hemp ( Cannabis sativa L.) may be an alternative to wood as a raw material for the production of paper pulp. The effects of enviromnental factors and cultural measures on the functioning, yield and quality of fibre hemp crops in the Netherlands were investigated.Until flowering (generally in August), the radiation use efficiency (RUE, above-ground dry matter accumulated per unit of photosynthetically active radiation intercepted) of hemp was 2.2 g MJ -1, after flowering it dropped to 1...

  18. Effect of hydrolysis on identifying prenatal cannabis exposure

    OpenAIRE

    Gray, Teresa R.; Barnes, Allan J.; Huestis, Marilyn A.

    2010-01-01

    Identification of prenatal cannabis exposure is important due to potential cognitive and behavioral consequences. A two-dimensional gas chromatography–mass spectrometry method for cannabinol, ?9-tetrahydrocannabinol (THC), 11-hydroxy-THC (11-OH-THC), 8?,11-dihydroxy-THC, and 11-nor-9-carboxy-THC (THCCOOH) quantification in human meconium was developed and validated. Alkaline, enzymatic, and enzyme–alkaline tandem hydrolysis conditions were optimized with THC- and THCCOOH-glucuronide reference...

  19. Pregnenolone can protect the brain from cannabis intoxication.

    OpenAIRE

    2014-01-01

    Pregnenolone is considered the inactive precursor of all steroid hormones and its potential functional effects have been largely neglected. The administration of the main active principle of Cannabis sativa (marijuana) ?9-tetrahydrocannabinol (THC) substantially increases the synthesis of pregnenolone in the brain via the activation of type-1 cannabinoid (CB1) receptor. Pregnenolone then, acting as a signaling specific inhibitor of the CB1 receptor, reduces several effects of THC. This negati...

  20. Cannabis and endocannabinoid modulators: Therapeutic promises and challenges

    OpenAIRE

    GRANT, Igor; Cahn, B. Rael

    2005-01-01

    The discovery that botanical cannabinoids such as delta-9 tetrahydrocannabinol exert some of their effect through binding specific cannabinoid receptor sites has led to the discovery of an endocannabinoid signaling system, which in turn has spurred research into the mechanisms of action and addiction potential of cannabis on the one hand, while opening the possibility of developing novel therapeutic agents on the other. This paper reviews current understanding of CB1, CB2, and other possible ...

  1. [Tetrahydrocannabinol pharmacokinetics; new synthetic cannabinoids; road safety and cannabis].

    Science.gov (United States)

    Goullé, Jean-Perre; Guerbet, Michel

    2015-03-01

    Delta-9-tetrahydrocannabinol (THC) is the main psychoactive ingredient of cannabis, a drug which is commonly smoked This paper focuses on the pharmacokinetics of THC. The average THC content in cannabis plant material has risen by a factor offour over the past 20 years, from 4% to 16%. This increase has important implications not only for the pharmacokinetics but also for the pharmacology of THC The mean bioavailability of THC in smoked cannabis is about 25%. In a cigarette containing 3.55% of THC, a peak plasma level of about 160 ng/mL occurs approximately 10 min after inhalation. THC is quickly cleared from plasma in a multiphasic manner and is widely distributed to tissues, leading to its pharmacologic effects. Body fat is a long-term storage site. This particular pharmacokinetic behavior explains the lack of correlation between the THC blood level and clinical effects, contrary to ethanol. The main THC metabolites are 11-OH-THC (the only active metabolite) and THC-COOH, which is eliminated in feces and urine over several weeks. Therefore, abstinence can be established by analyzing THC-COOH in urine, while blood THC analysis is used to confirm recent exposure. Cannabis is the main illicit drug found among vehicle drivers. Various traffic safety studies indicate that recent use of this drug at least doubles the risk of causing an accident, and that simultaneous alcohol consumption multiplies this risk by afactor of 14. Since 2009, synthetic cannabinoids have emerged on the illicit drug market. These substances act on the same CB1 receptors as THC, but with higher afinity. Their pharmacokinetics differs from that of THC, as they are metabolized into multiple derivatives, most of which are more active than THC itself. PMID:26427296

  2. Phytochemical and genetic analyses of ancient cannabis from Central Asia

    OpenAIRE

    Russo, Ethan B; Jiang, Hong-En; Li, Xiao; Sutton, Alan; Carboni, Andrea; del Bianco, Francesca; Mandolino, Giuseppe; Potter, David J.; Zhao, You-Xing; BERA, Subir; Zhang, Yong-Bing; Lü, En-Guo; Ferguson, David K.; Hueber, Francis; Zhao, Liang-Cheng

    2008-01-01

    The Yanghai Tombs near Turpan, Xinjiang-Uighur Autonomous Region, China have recently been excavated to reveal the 2700-year-old grave of a Caucasoid shaman whose accoutrements included a large cache of cannabis, superbly preserved by climatic and burial conditions. A multidisciplinary international team demonstrated through botanical examination, phytochemical investigation, and genetic deoxyribonucleic acid analysis by polymerase chain reaction that this material contained tetrahydrocannabi...

  3. Influence of mevinolin on chloroplast terpenoids in Cannabis sativa

    OpenAIRE

    Mansouri, Hakimeh; Salari, Fatemeh

    2014-01-01

    Plants synthesize a myriad of isoprenoid products that are required both for essential constitutive processes and for adaptive responses to the environment. Two independent pathways for the biosynthesis of isoprenoid precursors coexist within the plant cell: the cytosolic mevalonic acid (MVA) pathway and the plastidial methylerythritol phosphate (MEP) pathway. In this study, we investigated the inhibitory effect of the MVA pathway on isoprenoid biosynthesized by the MEP pathway in Cannabis sa...

  4. Effect of hydrolysis on identifying prenatal cannabis exposure.

    Science.gov (United States)

    Gray, Teresa R; Barnes, Allan J; Huestis, Marilyn A

    2010-07-01

    Identification of prenatal cannabis exposure is important due to potential cognitive and behavioral consequences. A two-dimensional gas chromatography-mass spectrometry method for cannabinol, Delta(9)-tetrahydrocannabinol (THC), 11-hydroxy-THC (11-OH-THC), 8beta,11-dihydroxy-THC, and 11-nor-9-carboxy-THC (THCCOOH) quantification in human meconium was developed and validated. Alkaline, enzymatic, and enzyme-alkaline tandem hydrolysis conditions were optimized with THC- and THCCOOH-glucuronide reference standards. Limits of quantification ranged from 10 to 15 ng/g, and calibration curves were linear to 500 ng/g. Bias and intra-day and inter-day imprecision were glucuronide was effectively cleaved by enzyme, but not base. Conversely, THCCOOH-glucuronide was most sensitive to alkaline hydrolysis. Enzyme-alkaline tandem hydrolysis maximized efficiency for both glucuronides. Identification of cannabinoid-positive meconium specimens nearly doubled following alkaline and enzyme-alkaline hydrolysis. Although no 11-OH-THC glucuronide standard is available, enzymatic hydrolysis improved 11-OH-THC detection in authentic specimens. Maximal identification of cannabis-exposed neonates and the widest range of cannabis biomarkers are achieved with enzyme-alkaline tandem hydrolysis. PMID:20517601

  5. Aspectos terapêuticos de compostos da planta Cannabis sativa / Therapeutical aspects of compounds of the plant Cannabis sativa

    Scientific Electronic Library Online (English)

    Káthia Maria, Honório; Agnaldo, Arroio; Albérico Borges Ferreira da, Silva.

    2006-04-01

    Full Text Available [...] Abstract in english Several cannabinoid compounds present therapeutic properties, but also have psychotropic effects, limiting their use as medicine. Nowadays, many important discoveries on the compounds extracted from the plant Cannabis sativa (cannabinoids) have contributed to understand the therapeutic properties of [...] these compounds. The main discoveries in the last years on the cannabinoid compounds were: the cannabinoid receptors CB1 and CB2, the endogenous cannabinoids and the possible mechanisms of action involved in the interaction between cannabinoid compounds and the biological receptors. So, from the therapeutical aspects presented in this work, we intended to show the evolution of the Cannabis sativa research and the possible medicinal use of cannabinoid compounds.

  6. Temperament and character traits associated with the use of alcohol, cannabis, cocaine, benzodiazepines, and hallucinogens: evidence from a large Brazilian web survey

    Scientific Electronic Library Online (English)

    Ricardo, Schneider Jr.; Gustavo L., Ottoni; Hudson W. de, Carvalho; Elaine, Elisabetsky; Diogo R., Lara.

    2015-03-01

    Full Text Available Objectives: To evaluate how personality traits are associated with occasional use, abuse, and dependence of alcohol, cannabis, cocaine, benzodiazepines, and hallucinogens in a large availability sample of adults via online questionnaires. Methods: The sample consisted of 8,646 individuals (24.7% me [...] n and 75.3% women) who completed an anonymous web survey. Involvement with drugs and temperament/character traits were assessed through the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) and the Temperament and Character Inventory - Revised (TCI-R), respectively. Interactions among variables were analyzed using MANOVA with Bonferroni adjustment. Results: Novelty seeking was the trait most associated with increased involvement with alcohol, cannabis, and cocaine. There was a significant association between harm avoidance and benzodiazepine use. Persistence was lower in cannabis-, benzodiazepine-, and cocaine-dependent subjects, as well as in hallucinogen abusers. Self-directedness was reduced in dependents of all drug classes. No strong relationships were found between other temperament or character dimensions and the severity of drug use. Conclusions: Novelty seeking was associated with increased involvement with all drugs studied in this sample, although to a lesser extent with benzodiazepines and hallucinogens. The temperament and character profile for benzodiazepine use was different from that of other drugs due to the relationship with higher harm avoidance and self-transcendence and lower self-directedness.

  7. Temperament and character traits associated with the use of alcohol, cannabis, cocaine, benzodiazepines, and hallucinogens: evidence from a large Brazilian web survey

    Scientific Electronic Library Online (English)

    Ricardo, Schneider Jr.; Gustavo L., Ottoni; Hudson W. de, Carvalho; Elaine, Elisabetsky; Diogo R., Lara.

    Full Text Available Objectives: To evaluate how personality traits are associated with occasional use, abuse, and dependence of alcohol, cannabis, cocaine, benzodiazepines, and hallucinogens in a large availability sample of adults [...] via online questionnaires. Methods: The sample consisted of 8,646 individuals (24.7% men and 75.3% women) who completed an anonymous web survey. Involvement with drugs and temperament/character traits were assessed through the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) and the Temperament and Character Inventory - Revised (TCI-R), respectively. Interactions among variables were analyzed using MANOVA with Bonferroni adjustment. Results: Novelty seeking was the trait most associated with increased involvement with alcohol, cannabis, and cocaine. There was a significant association between harm avoidance and benzodiazepine use. Persistence was lower in cannabis-, benzodiazepine-, and cocaine-dependent subjects, as well as in hallucinogen abusers. Self-directedness was reduced in dependents of all drug classes. No strong relationships were found between other temperament or character dimensions and the severity of drug use. Conclusions: Novelty seeking was associated with increased involvement with all drugs studied in this sample, although to a lesser extent with benzodiazepines and hallucinogens. The temperament and character profile for benzodiazepine use was different from that of other drugs due to the relationship with higher harm avoidance and self-transcendence and lower self-directedness.

  8. Cannabis Use and Related Harms in the Transition to Young Adulthood: A Longitudinal Study of Australian Secondary School Students

    Science.gov (United States)

    Scholes-Balog, Kirsty E.; Hemphill, Sheryl A.; Patton, George C.; Toumbourou, John W.

    2013-01-01

    The current study documents the changing rates of cannabis use, misuse and cannabis-related social harms among Australian adolescents as they grow into young adulthood. It utilised data from a longitudinal study of young people at ages 15, 16, 17, and 19. The rates of cannabis use were found to increase as participants aged; past year use…

  9. Aspectos terapêuticos de compostos da planta Cannabis sativa Therapeutical aspects of compounds of the plant Cannabis sativa

    OpenAIRE

    Káthia Maria Honório; Agnaldo Arroio; Albérico Borges Ferreira da Silva

    2006-01-01

    Several cannabinoid compounds present therapeutic properties, but also have psychotropic effects, limiting their use as medicine. Nowadays, many important discoveries on the compounds extracted from the plant Cannabis sativa (cannabinoids) have contributed to understand the therapeutic properties of these compounds. The main discoveries in the last years on the cannabinoid compounds were: the cannabinoid receptors CB1 and CB2, the endogenous cannabinoids and the possible mechanisms of action ...

  10. Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug Canabidiol, um componente da Cannabis sativa, como um ansiolítico

    OpenAIRE

    Alexandre Rafael de Mello Schier; Natalia Pinho de Oliveira Ribeiro; Adriana Cardoso de Oliveira e Silva; Jaime Eduardo Cecílio Hallak; Crippa, José Alexandre S.; Nardi, Antonio E; Antonio Waldo Zuardi

    2012-01-01

    OBJECTIVES: To review and describe studies of the non-psychotomimetic constituent of Cannabis sativa, cannabidiol (CBD), as an anxiolytic drug and discuss its possible mechanisms of action. METHOD: The articles selected for the review were identified through searches in English, Portuguese, and Spanish in the electronic databases ISI Web of Knowledge, SciELO, PubMed, and PsycINFO, combining the search terms "cannabidiol and anxiolytic", "cannabidiol and anxiolytic-like", and "cannabidiol and ...

  11. Correlations and agreement between delta-9-tetrahydrocannabinol (THC) in blood plasma and timeline follow-back (TLFB)-assisted self-reported use of cannabis of patients with cannabis use disorder and psychotic illness attending the CapOpus randomized clinical trial

    DEFF Research Database (Denmark)

    HjorthØj, Carsten Rygaard; Fohlmann, Allan

    2012-01-01

    Aims? To assess correlations and agreement between timeline follow-back (TLFB)-assisted self-report and blood samples for cannabis use. Design? Secondary analysis of a randomized trial. Setting? Copenhagen, Denmark. Participants? One hundred and three patients from the CapOpus trial with cannabis use disorder and psychosis, providing 239 self-reports of cannabis use and 88 valid blood samples. Measurements? Delta-9-tetrahydrocannabinol (THC), 11-hydroxy-delta-9-tetrahydrocannabinol (11-OH-THC) and 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid (THC-COOH) detected in plasma using high-performance liquid chromatography with tandem mass spectrometry detection. Self-report of cannabis-use last month by TLFB. Pearson's r, sensitivity and specificity calculated as measures of correlation or agreement. Findings? Correlations were strong; r?=?0.75 for number of days and r?=?0.83 for number of standard joints in the preceding month when excluding outliers. Including outliers, coefficients were moderate to strong (r?=?0.49). There were differences in subgroups, mainly inconsistent, depending on inclusion or exclusion of outliers. Sensitivity and specificity for TLFB detecting the presence or absence of cannabis use were 95.7% [95% confidence interval (CI) 88.0-99.1%) and 72.2% (95% CI 46.5-90.3%), respectively. Using 19 days as cut-off on TLFB, they were 94.3% (95% CI 86.0-98.4%) and 94.4% (95% CI 72.2-99.9%), respectively. Area under the receiver operating characteristic (ROC) curve was 0.96. Conclusions? Timeline follow-back (TLFB)-assisted self-report of cannabis use correlates highly with plasma-delta-9-tetrahydrocannabinol in patients with comorbid cannabis use disorder and psychosis. Sensitivity and specificity of timeline follow-back appear to be optimized with 19 days as the cut-off point. As such, timeline follow-back may be superior to analysis of blood when going beyond 19 days of recall.

  12. Cannabis-Induced Bipolar Disorder with Psychotic Features: A Case Report

    OpenAIRE

    Khan, Masood A; Akella, Sailaja

    2009-01-01

    There has been considerable debate regarding the causal relationship between chronic cannabis abuse and psychiatric disorders. Clinicians agree that cannabis use can cause acute adverse mental effects that mimic psychiatric disorders, such as schizophrenia and bipolar disorder. Although there is good evidence to support this, the connections are complex and not fully understood.

  13. Cannabis use in adolescents: the impact of risk and protective factors and social functioning.

    Science.gov (United States)

    Best, David; Gross, Samantha; Manning, Victoria; Gossop, Michael; Witton, John; Strang, John

    2005-11-01

    The study uses a school-based sample to test the social and familial risk and protective factors relating to cannabis use. Based on a self-completion survey of 2078 14-16-year-olds (mean age of 15 years) attending seven standard state-run secondary schools in south London, an assessment was made of rates and risk factors for cannabis use. Twenty-four per cent of the total sample had ever used cannabis, with 15% having done so in the month prior to assessment. In addition to greater likelihood of illicit drug use, lifetime cannabis users were less likely to spend time regularly with both their mothers and fathers, but more likely to spend free time with friends who smoked, drank alcohol and used illicit drugs, and with friends involved in criminal activities. Among those who had ever used cannabis, frequency of cannabis use was predicted (using linear regression) by two onset factors (earlier initiation of drinking and cannabis use were both linked to more frequent use) and two social factors (more time spent with drug-using friends and less time spent with the mother). Overall, the study showed that early onset, itself predicted by social networks, is linked to more frequent use of cannabis and that this appears to be sustained by less time spent with parents and more with drug-using peers. PMID:16361204

  14. Effect of Long-Term Cannabis Use on Axonal Fibre Connectivity

    Science.gov (United States)

    Zalesky, Andrew; Solowij, Nadia; Yucel, Murat; Lubman, Dan I.; Takagi, Michael; Harding, Ian H.; Lorenzetti, Valentina; Wang, Ruopeng; Searle, Karissa; Pantelis, Christos; Seal, Marc

    2012-01-01

    Cannabis use typically begins during adolescence and early adulthood, a period when cannabinoid receptors are still abundant in white matter pathways across the brain. However, few studies to date have explored the impact of regular cannabis use on white matter structure, with no previous studies examining its impact on axonal connectivity. The…

  15. Social Skills as Precursors of Cannabis Use in Young Adolescents: A Trails Study

    Science.gov (United States)

    Griffith-Lendering, Merel F. H.; Huijbregts, Stephan C. J.; Huizink, Anja C.; Ormel, Hans; Verhulst, Frank C.; Vollebergh, Wilma A. M.; Swaab, Hanna

    2011-01-01

    Social skills (cooperation, assertion, and self-control) were assessed by teachers for a longitudinal cohort of (pre)adolescents, with measurements at average ages 11.1 (baseline) and 16.3 years (follow-up). Prospective associations with participants' self-reported use of cannabis, (age of) onset of cannabis use, and frequency of use at follow-up…

  16. Evolution of substance use, neurological and psychiatric symptoms in schizophrenia and substance use disorder patients: a 12-week, pilot, case-control trial with quetiapine

    Directory of Open Access Journals (Sweden)

    StephanePotvin

    2011-05-01

    Full Text Available Neurological and psychiatric symptoms are consequences of substance abuse in schizophrenia and non-schizophrenia patients. The present case-control study examined changes in substance abuse/dependence and neurological and psychiatric symptoms in substance abusers with (DD group, n=26 and without schizophrenia (SUD group, n=24 and in non-abusing schizophrenia patients (SCZ group, n=23 undergoing 12-week treatment with the atypical antipsychotic, quetiapine. Neurological and psychiatric symptoms were evaluated with the Positive and Negative Syndrome Scale, the Calgary Depression Scale for Schizophrenia, the Extrapyramidal Symptoms Rating Scale and the Barnes Akathisia Rating Scale. At endpoint, DD and SCZ patients were receiving significantly higher doses of quetiapine (mean = 554mg/d and 478mg/d, respectively, relative to SUD patients (mean = 150mg/d. We found that SUD patients showed greater improvement in weekly dollars spent on alcohol and drugs and SUD severity, compared to DD patients. At endpoint, there was no significant difference in dollars spent, but DD patients still had a higher mean SUD severity. Interestingly, DD patients had significantly higher Parkinsonism and depression than SCZ patients at baseline and endpoint. On the other hand, we found that SUD patients had significantly more akathisia at baseline, improved more than SCZ patients and this was related to cannabis abuse/dependence. Finally, SUD patients improved more in PANSS positive scores than DD and SCZ patients. Taken together, our results provide evidence for increased vulnerability to the adverse effects of alcohol and drugs in schizophrenia patients. They also suggest that substance abuse/withdrawal may mimic some symptoms of schizophrenia. Future studies will need to determine the role quetiapine played in these improvements.

  17. Cannabis Use and Mental Health: A Review of Recent Epidemiological Research

    Directory of Open Access Journals (Sweden)

    T.H. Richardson

    2010-01-01

    Full Text Available Cannabis is the most commonly used drug in the world. This review examines recent epidemiological research on the relationships between cannabis use and mental health problems. Relationships with depression, anxiety disorders, mania and psychosis are examined, with relevant issues such as the effect of confounding variables, temporal directions and causality being discussed. Factors which influence the relationship such as dose-response effects, age of first cannabis use and risk of mental health problems are also examined. Causality is often difficult to establish, as cannabis is often used by those with mental illness for self-medication. However, there is substantial evidence to suggest that cannabis may induce or exacerbate a number of mental health problems.

  18. Re-branding cannabis: the next generation of chronic pain medicine?

    Science.gov (United States)

    Carter, Gregory T; Javaher, Simone P; Nguyen, Michael Hv; Garret, Sharon; Carlini, Beatriz H

    2015-01-01

    The field of pain medicine is at a crossroads given the epidemic of addiction and overdose deaths from prescription opioids. Cannabis and its active ingredients, cannabinoids, are a much safer therapeutic option. Despite being slowed by legal restrictions and stigma, research continues to show that when used appropriately, cannabis is safe and effective for many forms of chronic pain and other conditions, and has no overdose levels. Current literature indicates many chronic pain patients could be treated with cannabis alone or with lower doses of opioids. To make progress, cannabis needs to be re-branded as a legitimate medicine and rescheduled to a more pharmacologically justifiable class of compounds. This paper discusses the data supporting re-branding and rescheduling of cannabis. PMID:25537695

  19. Perfil de consumo de cocaína, cannabis y opiáceos en el laboratorio toxicológico CENATOXA Profile of consumption of cocaine, cannabis and opiates in the toxicology laboratory CENATOXA

    Directory of Open Access Journals (Sweden)

    Patricia Noemí Quiroga

    2008-12-01

    Full Text Available Con el propósito de conocer, en la población que concurre al laboratorio del CENATOXA, qué droga de abuso se consume más, cuál es la modalidad de consumo y el perfil de la consulta, se realizó un estudio retrospectivo de 2.635 casos a los que durante el período 1995-2006 se les solicitó investigación en orina de cannabis, cocaína y opiáceos. Los análisis se realizaron utilizando pruebas inmunológicas, cromatografía en capa delgada normalizada y cromatografía gaseosa-espectrometría de masas. El 20% de las muestras (n=529 resultaron positivas, correspondiendo el 50,66% a cannabis, el 37,43% a cocaína, el 2,08% a opiáceos y el 9,83% a la combinación cannabis-cocaína. Los varones constituyeron el 62% de los casos positivos. El mayor consumo de cannabis se observó entre los 11 y 30 años, el de cocaína entre los 21 y 40 años y la combinación de ambas drogas entre los 11 y 30 años. Los motivos de la solicitud de análisis correspondieron mayoritariamente y en proporciones similares al control de la adicción (31,1% y a la sospecha de consumo (29,67%. El cannabis fue la droga ilegal más usada, predominó el monoconsumo, los principales usuarios fueron varones y los más comprometidos fueron los menores de 30 años.A study was conducted in order to know what drugs of abuse are most commonly consumed by the population that comes to CENATOXA, as well as which the consumption patterns and consultation profiles are. A retrospective study was conducted in 2,635 cases for which, during 1995 to 2006, a toxicologycal urine analysis of cocaine, cannabis and opiates was requested. The analytical methodologies applied were immunoassay tests, standardized thin layer chromatography and gas chromatography-mass spectrometry. In the studied sample (n=529, 20% were positive: 50.66% was due to cannabis, 37.43% to cocaine, 2.08% to opiates and 9.83% to combination of cannabis-cocaine. Sixty-two per cent of positive cases were male subjects, and the highest consumption of cannabis was seen in the 11 to 30 year-old age group; that of cocaine was seen in the 21 to 40 year-old age group and the combination of cannabis-cocaine in the 11 to 30 year-old group. In assessing the reason for test request a similar predominance of addiction control (31.1% and drug abuse suspicion (29.67% was found. Cannabis is the drug of abuse most commonly consumed; mono consumption is usual in this population and drug consumption is higher in males and people under 30 years old.

  20. Perfil de consumo de cocaína, cannabis y opiáceos en el laboratorio toxicológico CENATOXA / Profile of consumption of cocaine, cannabis and opiates in the toxicology laboratory CENATOXA

    Scientific Electronic Library Online (English)

    Patricia Noemí, Quiroga; Isabel, Yohena; Cecilia Mariel, Contartese; Herme, González; Clara Magdalena, López.

    2008-12-01

    Full Text Available Con el propósito de conocer, en la población que concurre al laboratorio del CENATOXA, qué droga de abuso se consume más, cuál es la modalidad de consumo y el perfil de la consulta, se realizó un estudio retrospectivo de 2.635 casos a los que durante el período 1995-2006 se les solicitó investigació [...] n en orina de cannabis, cocaína y opiáceos. Los análisis se realizaron utilizando pruebas inmunológicas, cromatografía en capa delgada normalizada y cromatografía gaseosa-espectrometría de masas. El 20% de las muestras (n=529) resultaron positivas, correspondiendo el 50,66% a cannabis, el 37,43% a cocaína, el 2,08% a opiáceos y el 9,83% a la combinación cannabis-cocaína. Los varones constituyeron el 62% de los casos positivos. El mayor consumo de cannabis se observó entre los 11 y 30 años, el de cocaína entre los 21 y 40 años y la combinación de ambas drogas entre los 11 y 30 años. Los motivos de la solicitud de análisis correspondieron mayoritariamente y en proporciones similares al control de la adicción (31,1%) y a la sospecha de consumo (29,67%). El cannabis fue la droga ilegal más usada, predominó el monoconsumo, los principales usuarios fueron varones y los más comprometidos fueron los menores de 30 años. Abstract in english A study was conducted in order to know what drugs of abuse are most commonly consumed by the population that comes to CENATOXA, as well as which the consumption patterns and consultation profiles are. A retrospective study was conducted in 2,635 cases for which, during 1995 to 2006, a toxicologycal [...] urine analysis of cocaine, cannabis and opiates was requested. The analytical methodologies applied were immunoassay tests, standardized thin layer chromatography and gas chromatography-mass spectrometry. In the studied sample (n=529), 20% were positive: 50.66% was due to cannabis, 37.43% to cocaine, 2.08% to opiates and 9.83% to combination of cannabis-cocaine. Sixty-two per cent of positive cases were male subjects, and the highest consumption of cannabis was seen in the 11 to 30 year-old age group; that of cocaine was seen in the 21 to 40 year-old age group and the combination of cannabis-cocaine in the 11 to 30 year-old group. In assessing the reason for test request a similar predominance of addiction control (31.1%) and drug abuse suspicion (29.67%) was found. Cannabis is the drug of abuse most commonly consumed; mono consumption is usual in this population and drug consumption is higher in males and people under 30 years old.

  1. The association between delusional-like experiences, and tobacco, alcohol or cannabis use: a nationwide population-based survey

    Directory of Open Access Journals (Sweden)

    Saha Sukanta

    2011-12-01

    Full Text Available Abstract Background Previous population-based studies have found that delusional-like experiences (DLE are prevalent in the community, and are associated with a wide range of mental health disorders including substance use. The aim of the study was to explore the association between DLE and three commonly used substances - tobacco, alcohol and cannabis. Methods Subjects were drawn from the Australian National Survey of Mental Health and Wellbeing 2007. The Composite International Diagnostic Interview was used to identify DLE, common psychiatric disorders, and substance use. We examined the relationship between the variables of interest using logistic regression, adjusting for potential confounding factors. Results Of 8 773 participants, 8.4% (n = 776 subjects endorsed one or more DLE. With respect to tobacco use, compared to nonusers, DLE were more common in those who (a had daily use, (b commenced usage aged 15 years or less, and (c those who smoked heavily (23 or more cigarettes per day. Participants with cannabis use disorders were more likely to endorse DLE; this association was most prominent in those with an onset of 16 years or younger. In contrast, the pattern of association between DLE versus alcohol use or dependence was less consistent, however those with early onset alcohol use disorders were more likely to endorse DLE probe items. Conclusions While cannabis use disorders have been previously linked with DLE, our findings linking alcohol and tobacco use and DLE suggest that the influence of these substances on psychosis-related outcomes warrants closer scrutiny in longitudinal prospective studies.

  2. Multiple Myeloma Symptoms

    Science.gov (United States)

    ... ET. CALL NOW Home » About Multiple Myeloma » Symptoms Multiple Myeloma Symptoms Multiple myeloma symptoms may vary by patient, ... to be managed or prevented. The most common multiple myeloma symptoms may include: • Bone pain or bone fractures • ...

  3. Symptoms of Acoustic Neuroma

    Science.gov (United States)

    ... Search ANAUSA.org Connect with us! Symptoms of Acoustic Neuroma Early symptoms are easily overlooked, thus making ... are symptoms, however, indicating the possibility of an acoustic neuroma. The first symptom in 90% of those ...

  4. EVALUACIÓN NEUROPSICOLÓGICA EN UN CASO DE CONSUMO DE CANNABIS / NEUROPSYCHOLOGICAL ASSESSMENT IN A CASE OF CANNABIS / AVALIAÇÃO NEUROPSICOLÓGICA EM UM CASO DE CANNABIS

    Scientific Electronic Library Online (English)

    Jacobo José, Brofman Epelbaum; Abel Armando, Delgado Mota.

    2012-03-01

    Full Text Available Nos últimos anos tem havido um aumento na demanda por avaliações neuropsicológicas, o objetivo é dirigido para o tratamento às necessidades das pessoas afetadas por alterações nas funções cerebrais superiores. A detecção de déficits neuropsicológicos associados ao uso de drogas que causam dependênci [...] a é muito complicado devido ao grande número de variáveis que devem ser abordadas e as dificuldades metodológicas relacionadas ao seu controle. Este artigo é baseado na avaliação neuropsicológica de um paciente de 20 anos que tem um uso crônico de cannabis por cinco anos e um diagnóstico psiquiátrico de hiperatividade do déficit de atenção residual. Pesquisas recentes nesta área têm determinado que os efeitos cognitivos do consumo de cannabis se devem a três pressupostos fundamentais (Papa e Yurgelun-Todd, 1996): a remoção ou a suspensão do uso de drogas, aumentando receptores CB1 ou um efeito neurotoxicidade do medicamento ou pode ser devido a uma anormalidade preexistente no desenvolvimento do cérebro ou uma combinação de várias destas (Schlaepfer, Lancaster, Heidbreder, Kosel, Fisch e Pearlson, 2005). Os substratos cerebrais envolvidos são mais consistentes com a hipótese de uma disfunção específica frontocerebelar após abuso crônico (Quickfall e Crockford, 2006). O resultado do abuso crônico concentra-se em processos de atenção, memória e funções executivas (Verdejo-Garcia, Lopez-Torrecilla, Orozco Gimenez, e Perez-Garcia, 2004). Abstract in spanish En los últimos años ha existido un aumento en la demanda de evaluaciones neuropsicológicas cuyo objetivo se dirige hacia las necesidades de tratamiento que tienen las personas afectadas por alteraciones en las funciones cerebrales superiores. La detección de los déficits neuropsicológicos asociados [...] con el uso de las drogas adictivas es un tema muy complicado, debido a la gran cantidad de variables que deben tenerse en cuenta y las dificultades metodológicas relacionadas con su control. Éste artículo se basa en la evaluación neuropsicológica de un paciente de veintidós años de edad que presenta un consumo crónico de cannabis de cinco años y un diagnóstico psiquiátrico de déficit de atención e hiperactividad residual. Las investigaciones recientes en este campo han determinado que los efectos cognitivos del consumo por cannabis son debidos a tres hipótesis fundamentales (Pope and Yurgelun-Todd, 1996): a un retiro o suspensión del consumo de la droga por incremento de receptores CB1 o a un efecto de neurotoxicidad de la droga o que puede deberse a una anormalidad preexistente en el desarrollo cerebral o una combinación de varios de estos (Schlaepfer, Lancaster, Heidbreder, Kosel, Fisch and Pearlson, 2005). Los sustratos cerebrales con mayor implicación son congruentes con la hipótesis de una disfunción frontocerebelar específico después de abuso crónico (Quickfall and Crockford, 2006). El resultado del abuso crónico se centra en los procesos atencionales, memoria y funciones ejecutivas (Verdejo-García, López-Torrecillas, Orozco Giménez, and Pérez-García, 2004).

  5. Older women and men with urinary symptoms.

    OpenAIRE

    Stenzelius, Karin; Westergren, Albert; Mattiasson, Anders; Rahm Hallberg, Ingalill

    2006-01-01

    The aim was to compare urinary symptoms and their influence on daily life among elderly (75+) women and men in a sample that previously had reported difficulties controlling urine (urine incontinence (UI)) and/or other urinary symptoms (OU). A further aim was to find underlying structures of urinary symptoms and to identify symptoms that had an impact on seeking medical help and need of help in daily activities (dependency). In total, 771 persons (352 men and 419 women) over 75 years answered...

  6. Cannabis use and mental health-related quality of life among individuals with depressive disorders.

    Science.gov (United States)

    Aspis, Itay; Feingold, Daniel; Weiser, Mark; Rehm, Jurgen; Shoval, Gal; Lev-Ran, Shaul

    2015-12-15

    Cannabis is the most widely used illicit substance among individuals with depressive disorders. This study aimed to evaluate whether among individuals with depressive disorders, higher frequency of cannabis use would be associated with poorer Quality of Life (QoL), based on a large nationally representative US sample. Individuals with depressive disorders (N=3416) were divided into categories according to no use (N=3096), occasional use (less than weekly, N=176) and regular (at least weekly, N=144) use of cannabis in the past 12 months. QoL was assessed using the Short-Form 12 (SF-12) questionnaire. Women who used cannabis regularly had a significantly lower SF-12 Mental Component Summary score (MCS) compared to non-users, with a mean difference of 0.4 Standard Deviations (SDs). Comparison of subscale scores showed no significant differences. No significant difference was noted when comparing women who used cannabis occasionally to non-users. No differences were found among men when comparing MCS and mental subscale scores of both regular and occasional users to non-users. Our findings highlight the importance of taking gender and the frequency of cannabis use into account, when assessing functional and emotional aspects of cannabis use among individuals with depressive disorders. PMID:26388103

  7. Perceptions of cannabis as a stigmatized medicine: a qualitative descriptive study

    Directory of Open Access Journals (Sweden)

    Bottorff Joan L

    2013-02-01

    Full Text Available Abstract Background Despite its increasing prevalence and acceptance among the general public, cannabis use continues to be viewed as an aberrant activity in many contexts. However, little is known about how stigma associated with cannabis use affects individuals who use cannabis for therapeutic purposes (CTP and what strategies these individuals employ to manage associated stigma. The aim of this Canadian study was to describe users’ perceptions of and responses to the stigma attached to using CTP. Methods Twenty-three individuals who were using CTP for a range of health problems took part in semi-structured interviews. Transcribed data were analyzed using an inductive approach and comparative strategies to explore participants’ perceptions of CTP and identify themes. Results Participant experiences of stigma were related to negative views of cannabis as a recreational drug, the current criminal sanctions associated with cannabis use, and using cannabis in the context of stigmatizing vulnerability (related to existing illness and disability. Strategies for managing the resulting stigma of using CTP included: keeping CTP ‘undercover’; educating those who did not approve of or understand CTP use; and using cannabis responsibly. Conclusions Understanding how individuals perceive and respond to stigma can inform the development of strategies aimed at reducing stigma associated with the use of CTP and thereby address barriers faced by those using this medicine.

  8. Characteristics of cannabis users seeking treatment in São Paulo, Brazil Características de los fumadores de marihuana que buscan tratamiento en São Paulo, Brasil

    Directory of Open Access Journals (Sweden)

    Flávia Serebrenic Jungerman

    2008-06-01

    Full Text Available OBJECTIVES: This article describes a sample of 160 adults selected to participate in a randomized controlled trial conducted at a specialized outpatient clinic for cannabis users in Brazil. It correlates consumption with several measures of marijuana use, comparing it with other samples. METHODS: Instruments used were the Composite International Diagnostic Interview (CIDI and Wender Utah Rating Scale for screening and demographic data interviews, and the ASI, time-line follow back (TLFB, Marijuana Withdrawal and Marijuana Problem Scales, and Diagnostic and Statistical Manual of Mental Disorders (DSM-III-R Checklist for cannabis dependence. RESULTS: Participants in the study were mostly single, white men; their mean age was 32.3 years. They had a mean of 15.6 years of formal education and 61.6% worked. The cohort started using marijuana at a mean age of 16.5 years and developed daily use by a mean age of 21 years. Subjects in the sample had used marijuana for a mean of 15 years. They used it for 92.2% of the 90 days prior to the interview and smoked a mean of 1.99 marijuana cigarettes per day during this period. Individuals in the group had experimented with other drugs, especially cocaine. CONCLUSIONS: Marijuana users in this sample matched the profiles of those investigated elsewhere, although they reported fewer symptoms of dependence. Marijuana users should be considered independently in substance abuse programs, because they require specific attention and treatment. Broader epidemiological studies should be conducted to determine the extent of marijuana use within the Brazilian population.OBJETIVOS: Describir una muestra de 160 adultos seleccionados para participar en un ensayo aleatorizado controlado, realizado en una clínica ambulatoria especializada para consumidores de marihuana en Brasil. Se asoció el consumo de marihuana con varias medidas relacionadas con este hábito y se comparó con otras muestras. MÉTODOS: Se empleó la Entrevista Diagnóstica Internacional Compuesta (CIDI y la Escala de Valoración de Wender Utah para las entrevistas de tamizaje y la obtención de datos demográficos, y el Índice de Intensidad de la Adicción (ASI, la Línea Cronológica Retrospectiva (TLFB, la Escala de Abandono de la Marihuana, la Escala de Problemas por Marihuana y la lista de comprobación para la dependencia de la marihuana del Manual Diagnóstico y Estadístico de Trastornos Mentales (DSM-III-R. RESULTADOS: La mayoría de los participantes eran hombres blancos solteros; en promedio, la edad fue de 32,3 años y el nivel de escolarización de 15,6 años; 61,6% trabajaba. Como promedio, esta cohorte comenzó a fumar marihuana a una edad de 16,5 años y llegó a consumirla diariamente a los 21. Los participantes habían consumido marihuana durante 15 años y la consumieron 92,2% de los 90 días previos a la encuesta, con un consumo diario medio en ese lapso de 1,99 cigarrillos de marihuana. Miembros del grupo habían experimentado con otras drogas, principalmente cocaína. CONCLUSIONES: Los consumidores de marihuana estudiados se ajustan a los perfiles encontrados en otras investigaciones similares, aunque manifestaron menos síntomas de dependencia. En los programas para consumidores de estupefacientes se debe considerar a los consumidores de marihuana de manera independiente, ya que necesitan atención y tratamiento específicos. Se deben emprender estudios epidemiológicos más amplios para determinar la magnitud del consumo de marihuana en la población brasileña.

  9. Characteristics of cannabis users seeking treatment in São Paulo, Brazil / Características de los fumadores de marihuana que buscan tratamiento en São Paulo, Brasil

    Scientific Electronic Library Online (English)

    Flávia Serebrenic, Jungerman; Ronaldo, Laranjeira.

    2008-06-01

    Full Text Available OBJETIVOS: Describir una muestra de 160 adultos seleccionados para participar en un ensayo aleatorizado controlado, realizado en una clínica ambulatoria especializada para consumidores de marihuana en Brasil. Se asoció el consumo de marihuana con varias medidas relacionadas con este hábito y se comp [...] aró con otras muestras. MÉTODOS: Se empleó la Entrevista Diagnóstica Internacional Compuesta (CIDI) y la Escala de Valoración de Wender Utah para las entrevistas de tamizaje y la obtención de datos demográficos, y el Índice de Intensidad de la Adicción (ASI), la Línea Cronológica Retrospectiva (TLFB), la Escala de Abandono de la Marihuana, la Escala de Problemas por Marihuana y la lista de comprobación para la dependencia de la marihuana del Manual Diagnóstico y Estadístico de Trastornos Mentales (DSM-III-R). RESULTADOS: La mayoría de los participantes eran hombres blancos solteros; en promedio, la edad fue de 32,3 años y el nivel de escolarización de 15,6 años; 61,6% trabajaba. Como promedio, esta cohorte comenzó a fumar marihuana a una edad de 16,5 años y llegó a consumirla diariamente a los 21. Los participantes habían consumido marihuana durante 15 años y la consumieron 92,2% de los 90 días previos a la encuesta, con un consumo diario medio en ese lapso de 1,99 cigarrillos de marihuana. Miembros del grupo habían experimentado con otras drogas, principalmente cocaína. CONCLUSIONES: Los consumidores de marihuana estudiados se ajustan a los perfiles encontrados en otras investigaciones similares, aunque manifestaron menos síntomas de dependencia. En los programas para consumidores de estupefacientes se debe considerar a los consumidores de marihuana de manera independiente, ya que necesitan atención y tratamiento específicos. Se deben emprender estudios epidemiológicos más amplios para determinar la magnitud del consumo de marihuana en la población brasileña. Abstract in english OBJECTIVES: This article describes a sample of 160 adults selected to participate in a randomized controlled trial conducted at a specialized outpatient clinic for cannabis users in Brazil. It correlates consumption with several measures of marijuana use, comparing it with other samples. METHODS: In [...] struments used were the Composite International Diagnostic Interview (CIDI) and Wender Utah Rating Scale for screening and demographic data interviews, and the ASI, time-line follow back (TLFB), Marijuana Withdrawal and Marijuana Problem Scales, and Diagnostic and Statistical Manual of Mental Disorders (DSM-III-R) Checklist for cannabis dependence. RESULTS: Participants in the study were mostly single, white men; their mean age was 32.3 years. They had a mean of 15.6 years of formal education and 61.6% worked. The cohort started using marijuana at a mean age of 16.5 years and developed daily use by a mean age of 21 years. Subjects in the sample had used marijuana for a mean of 15 years. They used it for 92.2% of the 90 days prior to the interview and smoked a mean of 1.99 marijuana cigarettes per day during this period. Individuals in the group had experimented with other drugs, especially cocaine. CONCLUSIONS: Marijuana users in this sample matched the profiles of those investigated elsewhere, although they reported fewer symptoms of dependence. Marijuana users should be considered independently in substance abuse programs, because they require specific attention and treatment. Broader epidemiological studies should be conducted to determine the extent of marijuana use within the Brazilian population.

  10. The Cannabis Dilemma: A Review of Its Associated Risks and Clinical Efficacy.

    Science.gov (United States)

    Zhang, Melvyn Weibin; Ho, Roger C M

    2015-01-01

    Cannabis, also known as marijuana, has 9-tetrahydrocannabinol as the main constituent. There has been strict legislation governing the utilization of cannabis locally and worldwide. However, there has been an increasing push to make cannabis legalized, in view of its potential medical and therapeutic effects, for various medical disorders ranging from development disorders to cancer treatment, and being an adjunctive medication for various neurological conditions. It is the aim of this review paper to explore the evidence base for its proposed therapeutic efficacy and to compare the evidence base supporting its proposed therapeutic efficacy with its known and well-researched medical and psychiatric side effects. PMID:26539302

  11. Quality and Yield of Cannabis Products : Danish seizures from 2008-2011

    DEFF Research Database (Denmark)

    Kastorp, Grith; Lindholst, Christian

    Abstract. 180 seizures containing 667 different samples of cannabis products from 5 police districts in Jutland were examined from 2008 to the present. The samples were divided into the groups: hashish, marihuana (leaves and buds) and whole plants (indoors and outdoors). Cannabis seized from indoor cultivation was examined in order to determine THC content and yield. The results are used by the Danish Police Attorney to estimate expected yields in cases with unripe cannabis plants. The results indicate that the THC content found in locally grown marihuana is slightly higher than in hashish. However, the way the plants are snipped during growth has a major impact on the overall yield.

  12. The Cannabis Dilemma: A Review of Its Associated Risks and Clinical Efficacy

    Science.gov (United States)

    Zhang, Melvyn Weibin; Ho, Roger C. M.

    2015-01-01

    Cannabis, also known as marijuana, has 9-tetrahydrocannabinol as the main constituent. There has been strict legislation governing the utilization of cannabis locally and worldwide. However, there has been an increasing push to make cannabis legalized, in view of its potential medical and therapeutic effects, for various medical disorders ranging from development disorders to cancer treatment, and being an adjunctive medication for various neurological conditions. It is the aim of this review paper to explore the evidence base for its proposed therapeutic efficacy and to compare the evidence base supporting its proposed therapeutic efficacy with its known and well-researched medical and psychiatric side effects. PMID:26539302

  13. An fMRI study of neuronal activation in schizophrenia patients with and without previous cannabis use

    Directory of Open Access Journals (Sweden)

    Else-MarieLøberg

    2012-10-01

    Full Text Available Previous studies have mostly shown positive effects of cannabis use on cognition in patients with schizophrenia, which could reflect lower neurocognitive vulnerability. There are however no studies comparing whether such cognitive differences have neuronal correlates. Thus, the aim of the present study was to compare whether patients with previous cannabis use differ in brain activation from patients who has never used cannabis. The patients groups were compared on the ability to up-regulate an effort mode network during a cognitive task and down-regulate activation in the same network during a task-absent condition. Task-present and task-absent brain activation was measured by functional magnetic resonance neuroimaging (fMRI. Twenty-six patients with a DSM-IV and ICD-10 diagnosis of schizophrenia were grouped into a previous cannabis user group and a no-cannabis group. An auditory dichotic listening task with instructions of attention focus on either the right or left ear stimulus was used to tap verbal processing, attention and cognitive control, calculated as an aggregate score. When comparing the two groups, there were remaining activations in the task-present condition for the cannabis group, not seen in the no-cannabis group, while there was remaining activation in the task-absent condition for the no-cannabis group, not seen in the cannabis group. Thus, the patients with previous cannabis use showed increased activation in an effort mode network and decreased activation in the default mode network as compared to the no-cannabis group. It is concluded that the present study show some differences in brain activation to a cognitively challenging task between previous cannabis and no-cannabis schizophrenia patients.

  14. Socio-demographic features of cannabis and heroin abuse in Bombay.

    OpenAIRE

    Shastri S; Kolhatkar K

    1989-01-01

    A study of socio-demographic features of 680 cannabis and heroin addicts showed that the factors like, age, religion, family structure, peer groups and the easy availability of these drugs contribute to the problem of addiction.

  15. Stroke with neuropsychiatric sequelae after cannabis use in a man: a case report

    Directory of Open Access Journals (Sweden)

    Giroud Maurice

    2011-06-01

    Full Text Available Abstract Introduction The outcome of cerebral ischemic stroke associated with cannabis use is usually favorable. Here we report the first case of cannabis-related stroke followed by neuropsychiatric sequelae. Case presentation A 24-year-old Caucasian man was discovered in a deeply comatose non-reactive state after cannabis use. A magnetic resonance imaging scan of his brain showed bilateral multiple ischemic infarcts. The patient remained deeply comatose for four days, after which time he developed other behavioral impairments and recurrent seizures. Conclusion Stroke related to cannabis use can be followed by severe neuropsychiatric sequelae. Concomitant alcohol intoxication is essential neither to the occurrence of this neurologic event nor to its severity.

  16. In silicio expression analysis of PKS genes isolated from Cannabis sativa L.

    Scientific Electronic Library Online (English)

    Isvett J., Flores-Sanchez; Huub J.M., Linthorst; Robert, Verpoorte.

    Full Text Available Cannabinoids, flavonoids, and stilbenoids have been identified in the annual dioecious plant Cannabis sativa L. Of these, the cannabinoids are the best known group of this plant's natural products. Polyketide synthases (PKSs) are responsible for the biosynthesis of diverse secondary metabolites, inc [...] luding flavonoids and stilbenoids. Biosynthetically, the cannabinoids are polyketide substituted with terpenoid moiety. Using an RT-PCR homology search, PKS cDNAs were isolated from cannabis plants. The deduced amino acid sequences showed 51%-73% identity to other CHS/STS type sequences of the PKS family. Further, phylogenetic analysis revealed that these PKS cDNAs grouped with other non-chalcone-producing PKSs. Homology modeling analysis of these cannabis PKSs predicts a 3D overall fold, similar to alfalfa CHS2, with small steric differences on the residues that shape the active site of the cannabis PKSs.

  17. Early-Onset, Regular Cannabis Use Is Linked to IQ Decline

    Science.gov (United States)

    ... cannabis on the brain could result in poor academic performance and school dropout, which might produce further declines ... Risky Behavior Smoking Stimulant Drug Therapy for ADHD Stress Withdrawal See All NIDA Notes Articles Get this ...

  18. Efeitos cerebrais da maconha: resultados dos estudos de neuroimagem Brain effects of cannabis: neuroimaging findings

    OpenAIRE

    José Alexandre Crippa; ACIOLY L.T. LACERDA; Edson Amaro; Geraldo Busatto Filho; Antonio Waldo Zuardi; Bressan, Rodrigo A.

    2005-01-01

    A maconha é a droga ilícita mais utilizada. Apesar disto, apenas um pequeno número de estudos investigaram as conseqüências neurotóxicas de longo prazo do uso de cannabis. As técnicas de neuroimagem se constituem em poderosos instrumentos para investigar alterações neuroanatômicas e neurofuncionais e suas correlações clínicas e neuropsicológicas. Uma revisão computadorizada da literatura foi conduzida nos indexadores MEDLINE e PsycLIT entre 1966 e novembro de 2004 com os termos 'cannabis', 'm...

  19. Regulating compassion: an overview of Canada's federal medical cannabis policy and practice

    OpenAIRE

    Lucas Philippe G

    2008-01-01

    Abstract Background In response to a number of court challenges brought forth by Canadian patients who demonstrated that they benefited from the use of medicinal cannabis but remained vulnerable to arrest and persecution as a result of its status as a controlled substance, in 1999 Canada became the second nation in the world to initiate a centralized medicinal cannabis program. Over its six years of existence, this controversial program has been found unconstitutional by a number of courts, a...

  20. The Normalization of Cannabis Use among Young People - Symbolic Boundary Work in Focus Groups

    DEFF Research Database (Denmark)

    Järvinen, Margaretha; Demant, Jakob

    2011-01-01

    This paper analyzes "techniques of neutralization" among young people discussing cannabis in focus group interviews. The paper is based on data from focus group interviews with young Danes followed from when they were 14-15 years old in 2004 until they were 18-19 years old in 2008. In this period, the participants' attitudes towards cannabis undergo a radical change from being negative and sceptical into being predominantly positive and accepting - a change we describe as a "normalization" of ca...

  1. The normalisation of cannabis use among young people: Symbolic boundary work in focus groups

    DEFF Research Database (Denmark)

    Jarvinen, Margaretha; Demant, Jakob Johan

    2011-01-01

    This paper analyses ‘techniques of neutralisation’ among young people discussing cannabis in focus group interviews. The paper is based on data from focus group interviews with young Danes followed from when they were 14–15 years old in 2004 until they were 18–19 years old in 2008. In this period, the participants’ attitudes towards cannabis undergo a radical change from being negative and sceptical into being predominantly positive and accepting; a change we describe as a ‘normalisation’ of can...

  2. The Importance of Family Relations for Cannabis Users: The Case of Serbian Adolescents

    OpenAIRE

    Zorica Terzic Supic; Milena Santric Milicevic; Isidora Sbutega; Vladimir Vasic

    2013-01-01

    Background: Adolescence is transitional stage of physical and mental human development occuring between childhood and adult life. Social interactions and environmental factors together are important predictors of adolescent cannabis use. This study aimed to examine the relationship between the social determinants and adolescents behavior with cannabis consumption.Methods: A cross sectional study as part of the European School Survey Project on Alcohol and other Drugs was conducted among 6.150...

  3. Excessive cannabis use is associated with earlier age at onset in bipolar disorder

    OpenAIRE

    Lagerberg, Trine V; Sundet, Kjetil; Aminoff, Sofie R.; Berg, Akiah O; Ringen, Petter A; Andreassen, Ole A; Melle, Ingrid

    2011-01-01

    The aim of the study was to investigate which factors are associated with age at onset in bipolar disorder with a specific focus on excessive alcohol and cannabis use, and the sequence of the onsets of excessive substance use and bipolar disorder. We investigated a naturalistic sample of 151 patients with bipolar I and II disorder receiving psychiatric treatment. Whether the presence of excessive substance use prior to bipolar disorder onset or the type of substance used (alcohol or cannabis)...

  4. Coping with cannabis in a Caribbean country : from problem formulation to going public

    Directory of Open Access Journals (Sweden)

    Hymie Rubenstein

    1998-07-01

    Full Text Available Analyzes the dialectic between problem discovery and formulation, ethical considerations, and the public dissemination of research results. Author describes his personal experience of fieldwork, the moral-ethical dilemmas it involved, and the circulation of research findings on cannabis production and consumption in St. Vincent. He became frustrated that his academic publications were only accessible to a tiny portion of St. Vincent's population and therefore decided to publish about cannabis in the local media.

  5. Cannabis use, time perspective and risk perception: Evidence of a moderating effect.

    OpenAIRE

    Apostolidis, Thémis; Fieulaine, Nicolas; Simonin, Laurent; Rolland, Géraldine

    2006-01-01

    This study explores the relationship between time perspective (TP), cannabis use and risk perceptions associated to this substance. A sample of French students (n=198) were provided with a valid French version of the ZTPI scale. Risk perceptions linked to cannabis consumption were evaluated from a list of 22 items referring to different risks. Respondents were asked to declare how frequently they consumed this substance. Data analysis was based on firstly, ZTPI scores, secondly, declared cons...

  6. Latent Classes of Substance Use in Adolescent Cannabis Users: Predictors and Subsequent Substance-Related Harm

    OpenAIRE

    Fallu, Jean-Sébastien; Brière, Frédéric N.; Janosz, Michel

    2014-01-01

    Cannabis use is highly prevalent in late adolescence, but not all users experience significant negative consequences. Little information is available to identify the substance use patterns and risk factors of users who are at greater risk of experiencing negative consequences. In this prospective study, we aimed to empirically identify latent classes of substance use in adolescent cannabis users and to examine how these classes relate to antecedent psychosocial predictors and subsequent subst...

  7. Cannabis abuse and brain morphology in schizophrenia: a review of the available evidence

    OpenAIRE

    Malchow, Berend; Hasan, Alkomiet; Fusar-Poli, Paolo; Schmitt, Andrea; Falkai, Peter; Wobrock, Thomas

    2012-01-01

    Substance abuse is the most prevalent comorbid psychiatric condition associated with schizophrenia, and cannabis is the illicit drug most often abused. Apart from worsening the course of schizophrenia, frequent cannabis use especially at an early age seems to be an important risk factor for developing schizophrenia. Although a large body of neuroimaging studies gives evidence for structural alterations in many different brain regions in schizophrenia patients, there is still limited knowledge...

  8. Predictors of age at onset of tobacco and cannabis use in Danish adolescents

    DEFF Research Database (Denmark)

    Wium-Andersen, Ida Kim; Wium-Andersen, Marie Kim; Becker, Ulrik; Thomsen, Simon Francis

    2010-01-01

    INTRODUCTION: Early onset of tobacco and cannabis use predicts later substance abuse and risk behaviour and has large health consequences. OBJECTIVES: The aim of this study was to examine risk factors for the age at onset of smoking and cannabis use among a group of Danish children between 7 years and 18 years of age. METHODS: Four hundred and eighty randomly selected children and their parents participated in a study about the prevalence of asthma. The study included questions about alcohol, to...

  9. Gone to Pot – A Review of the Association between Cannabis and Psychosis

    OpenAIRE

    DeepakCD'Souza

    2014-01-01

    Cannabis is the most commonly used illicit drug worldwide, with approximately 5 million daily users worldwide. Emerging evidence supports a number of associations between cannabis and psychosis/psychotic disorders, including schizophrenia. These associations based on case-studies, surveys, epidemiological studies, and experimental studies indicate that cannabinoids can produce acute, transient effects; acute, persistent effects as well as delayed, persistent effects that recapitulate the psyc...

  10. Medical Marijuana programs: implications for cannabis control policy--observations from Canada.

    Science.gov (United States)

    Fischer, Benedikt; Kuganesan, Sharan; Room, Robin

    2015-01-01

    While prohibition has been the dominant regime of cannabis control in most countries for decades, an increasing number of countries have been implementing cannabis control reforms recently, including decriminalization or even legalization frameworks. Canada has held out from this trend, although it has among the highest cannabis use rates in the world. Cannabis use is universally criminalized, and the current (conservative) federal government has vowed not to implement any softening reforms to cannabis control. As a result of several higher court decisions, the then federal government was forced to implement a 'medical marijuana access regulations' program in 2001 to allow severely ill patients therapeutic use and access to therapeutic cannabis while shielding them from prosecution. The program's regulations and approval processes were complex and subject to extensive criticism; initial uptake was low and most medical marijuana users continued their use and supply outside the program's auspices. This year, the government introduced new 'marijuana for medical purposes regulations', which allow physicians to 'authorize' medical marijuana use for virtually any health condition for which this is considered beneficial; supply is facilitated by licensed commercial producers. It is expected that some 500,000 users, and dozens of commercial producers will soon be approved under the program, arguably constituting - as with medical marijuana schemes elsewhere, e.g. in California--de facto 'legalization'. We discuss the question whether the evolving scope and realities of 'medical cannabis' provisions in Canada offer a 'sneaky side door' or a 'better third way' to cannabis control reform, and what the potential wider implications are of these developments. PMID:25287942

  11. Familial predisposition for psychiatric disorder: comparison of subjects treated for cannabis-induced psychosis and schizophrenia

    DEFF Research Database (Denmark)

    Arendt, Mikkel; Mortensen, Preben B; Rosenberg, Raben; Pedersen, Carsten B; Waltoft, Berit L

    2008-01-01

    CONTEXT: Cannabis-induced psychosis is considered a distinct clinical entity in the existing psychiatric diagnostic systems. However, the validity of the diagnosis is uncertain. OBJECTIVES: To establish rate ratios of developing cannabis-induced psychosis associated with predisposition to psychosis and other psychiatric disorders in a first-degree relative and to compare them with the corresponding rate ratios for developing schizophrenia spectrum disorders. DESIGN: A population-based cohort was...

  12. Cannabis, a complex plant: different compounds and different effects on individuals

    OpenAIRE

    Atakan, Zerrin

    2012-01-01

    Cannabis is a complex plant, with major compounds such as delta-9-tetrahydrocannabinol and cannabidiol, which have opposing effects. The discovery of its compounds has led to the further discovery of an important neurotransmitter system called the endocannabinoid system. This system is widely distributed in the brain and in the body, and is considered to be responsible for numerous significant functions. There has been a recent and consistent worldwide increase in cannabis potency, with incre...

  13. Considerações sobre a toxicocinética da Cannabis sativa L. ou maconha, com enfase no homem / Some aspects of pharmacokinetics of Cannabis sativa L. (Marihuana) with emphasis on man

    Scientific Electronic Library Online (English)

    Luiz Marques de, Sá.

    Full Text Available O presente artigo consiste em uma análise sobre a origem da Cannabis no Brasil, suas principais substâncias químicas, realçando o ?9 tetrahidrocanabinol como responsável pelos efeitos farmacológicos. é citado também o fato de existirem duas formas de numeração dos carbonos do ?THC. Para melhor enten [...] der a toxicocinética foram feitas considerações sobre as doses de maconha, que vão variar de acordo com o usuário, e origem do vegetal. Finalmente é feito urn estudo detalhado sobre, absorção, distribuição, armazenamento, biotransformação e eliminação dos diversos componentes químicos da maconha. Abstract in english This paper contains an analysis of the origin of the introduction of Cannabis in Brazil, the identify of its chemical components, mainly tetrahydrocannabinol responsible for the pharmacological effects of Cannabis. Toxicokinetic studies were developed in relation the amounts of marihuana consumed, c [...] haracteristics of the user and origin of the drug. Absorption, distribution, storage, biotransformation and elimination of marihuana derived metabolites were studies.

  14. Considerações sobre a toxicocinética da Cannabis sativa L. ou maconha, com enfase no homem Some aspects of pharmacokinetics of Cannabis sativa L. (Marihuana with emphasis on man

    Directory of Open Access Journals (Sweden)

    Luiz Marques de Sá

    1989-01-01

    Full Text Available O presente artigo consiste em uma análise sobre a origem da Cannabis no Brasil, suas principais substâncias químicas, realçando o ?9 tetrahidrocanabinol como responsável pelos efeitos farmacológicos. é citado também o fato de existirem duas formas de numeração dos carbonos do ?THC. Para melhor entender a toxicocinética foram feitas considerações sobre as doses de maconha, que vão variar de acordo com o usuário, e origem do vegetal. Finalmente é feito urn estudo detalhado sobre, absorção, distribuição, armazenamento, biotransformação e eliminação dos diversos componentes químicos da maconha.This paper contains an analysis of the origin of the introduction of Cannabis in Brazil, the identify of its chemical components, mainly tetrahydrocannabinol responsible for the pharmacological effects of Cannabis. Toxicokinetic studies were developed in relation the amounts of marihuana consumed, characteristics of the user and origin of the drug. Absorption, distribution, storage, biotransformation and elimination of marihuana derived metabolites were studies.

  15. Telling true from false: cannabis users show increased susceptibility to false memories.

    Science.gov (United States)

    Riba, J; Valle, M; Sampedro, F; Rodríguez-Pujadas, A; Martínez-Horta, S; Kulisevsky, J; Rodríguez-Fornells, A

    2015-06-01

    Previous studies on the neurocognitive impact of cannabis use have found working and declarative memory deficits that tend to normalize with abstinence. An unexplored aspect of cognitive function in chronic cannabis users is the ability to distinguish between veridical and illusory memories, a crucial aspect of reality monitoring that relies on adequate memory function and cognitive control. Using functional magnetic resonance imaging, we show that abstinent cannabis users have an increased susceptibility to false memories, failing to identify lure stimuli as events that never occurred. In addition to impaired performance, cannabis users display reduced activation in areas associated with memory processing within the lateral and medial temporal lobe (MTL), and in parietal and frontal brain regions involved in attention and performance monitoring. Furthermore, cannabis consumption was inversely correlated with MTL activity, suggesting that the drug is especially detrimental to the episodic aspects of memory. These findings indicate that cannabis users have an increased susceptibility to memory distortions even when abstinent and drug-free, suggesting a long-lasting compromise of memory and cognitive control mechanisms involved in reality monitoring. PMID:25824306

  16. ?9-Tetrahydrocannabinol content in cannabis samples seized in Novi Sad during 2008

    Directory of Open Access Journals (Sweden)

    MAJA DJURENDI?-BRENESEL

    2010-07-01

    Full Text Available The three main cannabinoids ?9-tetrahydrocannabinol (?9-THC, cannabidiol (CBD and cannabinol (CBN were identified and determined quantitatively using a GCD (GC-EI instrument in 280 samples of illicit herbal cannabis, seized by the Police authorities in Novi Sad, during 2008. The samples were sent to the Institute of Forensic Medicine, Clinical Center Vojvodina, for forensic chemical analysis. The cannabinoid content of the samples enabled the classification of the cannabis into three chemical phenotypes and the differentiation into drug and textile-cannabis, using the Waller classification index. This differentiation has great forensic significance in the classification of certain cases as a criminal action. The experimental results showed that the ?9-THC content in illicitly circulated cannabis slightly decreased from January to December 2008, as did the quality of the drug-cannabis. The reasons for the quality variations could lie in the geographical origin of the cannabis plants, the conditions of plants storage, various parts of the plants in samples and the time elapsed between harvesting and chemical analysis.

  17. Ultrasound-assisted extraction of volatile compounds from industrial Cannabis sativa L. inflorescences

    Directory of Open Access Journals (Sweden)

    C. Da Porto

    2014-02-01

    Full Text Available Summary. This study investigated the use of ultrasound-assisted extraction (UAE to recovery  volatile compounds from the inflorescences of a fiber type Cannabis sativa L. cultivar. The results show that ultrasonic treatment not longer than 5 min allows to obtain an enhanced concentration of terpenes in comparison with maceration. Instead, an ultrasonic treatment longer than 5 min increased  the concentration of ?-9-tetraidrocannabinol (THC. A preliminary screening of cannabis inflorescences scent was performed by headspace solid-phase microextraction (HS-SPME with gas chromatography-mass spectrometry (GC-MS avoiding the chemical modification and artifact formation that can occur in conventional methods . Industrial relevance. Inflorescences of fiber type Cannabis sativa cultivars are generally considered waste parts for fiber industry, although the inflorescences’ volatiles are pleasant to the human sensory system. Cannabis scent originate from volatile monoterpenes and sesquiterpenes . Traditionally, the recovery of floral fragrances from plants is by water distillation (hydro-distillation or steam distillation to produce essential oils. However, these techniques take at least several hours and require the application of heating, which can produce the degradation of thermo labile compounds present in the starting plant material. Ultrasound-assisted extraction can be use as alternative method to extract aroma compounds from inflorescences of fiber type  Cannabis sativa. The extracts so obtained could be used as ingredients for perfumes (cosmetic industry or flavorings for beverages (food industry.Keywords. Ultrasound; Extraction; Cannabis sativa L.; terpenes; THC; HS-SPME

  18. Prediction of cannabis and cocaine use in adolescence using decision trees and logistic regression

    Directory of Open Access Journals (Sweden)

    Alfonso L. Palmer

    2010-01-01

    Full Text Available Spain is one of the European countries with the highest prevalence of cannabis and cocaine use among young people. The aim of this study was to investigate the factors related to the consumption of cocaine and cannabis among adolescents. A questionnaire was administered to 9,284 students between 14 and 18 years of age in Palma de Mallorca (47.1% boys and 52.9% girls whose mean age was 15.59 years. Logistic regression and decision trees were carried out in order to model the consumption of cannabis and cocaine. The results show the use of legal substances and committing fraudulence or theft are the main variables that raise the odds of consuming cannabis. In boys, cannabis consumption and a family history of drug use increase the odds of consuming cocaine, whereas in girls the use of alcohol, behaviours of fraudulence or theft and difficulty in some personal skills influence their odds of consuming cocaine. Finally, ease of access to the substance greatly raises the odds of consuming cocaine and cannabis in both genders. Decision trees highlight the role of consuming other substances and committing fraudulence or theft. The results of this study gain importance when it comes to putting into practice effective prevention programmes.

  19. Predictors of onset of cannabis and other drug use in male young adults: results from a longitudinal study

    OpenAIRE

    Haug, Severin; López Núñez, Carla; Becker, Julia; Gmel, Gerhard; Schaub, Michael P.

    2014-01-01

    Background: The use of cannabis and other illegal drugs is particularly prevalent in male young adults and is associated with severe health problems. This longitudinal study explored variables associated with the onset of cannabis use and the onset of illegal drug use other than cannabis separately in male young adults, including demographics, religion and religiosity, health, social context, substance use, and personality. Furthermore, we explored how far the gateway hypothesis and the commo...

  20. Prevalence of Cannabis Residues in Psychiatric Patients: A Case Study of Two Mental Health Referral Hospitals in Uganda

    OpenAIRE

    Epaenetus A. Awuzu; Emmanuel Kaye; Patrick Vudriko

    2014-01-01

    Various studies have reported that abuse of cannabis is a risk factor for psychosis. The aims of this study were to determine the prevalence of delta 9-tetrahydrocanabinol (?9-THC), a major metabolite of cannabis, in psychiatric patients in Uganda, and to assess the diagnostic capacity of two referral mental health hospitals to screen patients for exposure to cannabis in Uganda. Socio-demographic characteristics of the patients were collected through questionnaires and review of medical recor...

  1. The Choice of Screening Instrument Matters: The Case of Problematic Cannabis Use Screening in Spanish Population of Adolescents

    OpenAIRE

    Thanki, Danica; Domingo-Salvany, Antónia; Barrio Anta, Gregorio; Sánchez Mañez, Amparo; Llorens Aleixandre, Noelia; Suelves, Josep Maria; Brime Beteta, Begoña; Vicente, Julián

    2013-01-01

    The aim of this study was to examine the feasibility of problem cannabis use screening instruments administration within wide school surveys, their psychometric properties, overlaps, and relationships with other variables. Students from 7 Spanish regions, aged 14–18, who attended secondary schools were sampled by two-stage cluster sampling (net sample 14,589). Standardized, anonymous questionnaire including DSM-IV cannabis abuse criteria, Cannabis Abuse Screening Test (CAST), and Severity of ...

  2. Trichomes of Cannabis sativa as viewed with scanning electron microscope

    Energy Technology Data Exchange (ETDEWEB)

    Ledbetter, M.C.; Krikorian, A.D.

    1975-06-01

    Direct examination of fresh, unfixed and uncoated specimens from vegetative and floral parts of Cannabis sativa with the scanning electron microscope enables one to obtain a faithful representation of their surface morphology. The presence of two major types of trichomes has been confirmed: a glandular type comprising or terminating in a globoid structure, and a conically-shaped nonglandular type. Moreover, three or possibly four distinct glandular types can be distinguished: sessile globoid, small-stalked and large-stalked globoid, and a peltate type. The nonglandular trichomes can be distinguished by the nature of their surfaces: those with a warty surface, and those which are relatively smooth. The range of size and distribution, and the special features of all these types of trichomes are also provided.

  3. The feasibility of converting Cannabis sativa L. oil into biodiesel.

    Science.gov (United States)

    Li, Si-Yu; Stuart, James D; Li, Yi; Parnas, Richard S

    2010-11-01

    Cannabis sativa Linn, known as industrial hemp, was utilized for biodiesel production in this study. Oil from hemp seed was converted to biodiesel through base-catalyzed transesterification. The conversion is greater than 99.5% while the product yield is 97%. Several ASTM tests for biodiesel quality were implemented on the biodiesel product, including acid number, sulfur content, flash point, kinematic viscosity, and free and total glycerin content. In addition, the biodiesel has a low cloud point (-5 degrees C) and kinematic viscosity (3.48mm(2)/s). This may be attributed to the high content of poly-unsaturated fatty acid of hemp seed oil and its unique 3:1 ratio of linoleic to alpha-linolenic acid. PMID:20624607

  4. Minor oxygenated cannabinoids from high potency Cannabis sativa L.

    Science.gov (United States)

    Ahmed, Safwat A; Ross, Samir A; Slade, Desmond; Radwan, Mohamed M; Khan, Ikhlas A; ElSohly, Mahmoud A

    2015-09-01

    Nine oxygenated cannabinoids were isolated from a high potency Cannabis sativa L. variety. Structure elucidation was achieved using spectroscopic techniques, including 1D and 2D NMR, HRMS and GC-MS. These minor compounds include four hexahydrocannabinols, four tetrahydrocannabinols, and one hydroxylated cannabinol, namely 9?-hydroxyhexahydrocannabinol, 7-oxo-9?-hydroxyhexa-hydrocannabinol, 10?-hydroxyhexahydrocannabinol, 10aR-hydroxyhexahydrocannabinol, ?(9)-THC aldehyde A, 8-oxo-?(9)-THC, 10a?-hydroxy-10-oxo-?(8)-THC, 9?-hydroxy-10-oxo-?(6a,10a)-THC, and 1'S-hydroxycannabinol, respectively. The latter compound showed moderate anti-MRSa (IC50 10.0?g/mL), moderate antileishmanial (IC50 14.0?g/mL) and mild antimalarial activity against Plasmodium falciparum (D6 clone) and P. falciparum (W2 clone) with IC50 values of 3.4 and 2.3?g/mL, respectively. PMID:26093324

  5. CANABIC: CANnabis and Adolescents: effect of a Brief Intervention on their Consumption - study protocol for a randomized controlled trial.

    OpenAIRE

    Laporte, Catherine; Vaillant-Roussel, Hélène; Pereira, Bruno; Blanc, Olivier; Tanguy, Gilles; Frappé, Paul; Costa, David; Gaboreau, Yoann; Badin, Mélanie; Marty, Laurent; Clément, Gilles; Dubray, Claude; Falissard, Bruno; Llorca, Pierre-Michel; Vorilhon, Philippe

    2014-01-01

    BACKGROUND: Cannabis is the most consumed illegal substance in France. General practitioners (GPs) are the health professionals who are most consulted by adolescents. Brief intervention (BI) is a promising care initiative for the consumption of cannabis, and could be a tool for GPs in caring for adolescents who consume cannabis. The aim of the CANABIC study is to measure the impact of a BI carried out by a GP on the consumption of cannabis by adolescents of 15 to 25 years of age. METHODS: A r...

  6. [Inhalant abusers and psychiatric symptoms].

    Science.gov (United States)

    Okudaira, K; Yabana, T; Takahashi, H; Iizuka, H; Nakajima, K; Saito, A

    1996-01-01

    There are different opinions about the cause of chronic psychiatric symptoms observed in drug abusers between Japanese and foreign psychiatrists. The Japanese seem to recognize the chronic psychosis as the result of drug abuse. In the other hand, foreigners diagnose these cases as dual diagnosis of drug abuse and psychosis. Authors studied the problem in this research. One of the authors has examined 120 inhalant abusers of all, in- and out-patients in Kanagawa Prefectural Center of Psychiatry, Serigaya Hospital from 1991 to 1995. These patients were classified into three groups: psychosis group (23 patients), dependence group (51 patients) and abuse group (46 patients) according to their clinical courses and psychiatric symptoms. The psychosis group consists of patients who showed psychiatric symptoms such as hallucination, delusion and thought disturbance for long time after detoxification. The dependence group contains patients whose inhalant dependence was severe and met DSM-4 Diagnostic Criteria for Substance Dependence, but manifested no chronic psychiatric symptoms after detoxification. The patients belonging to abuse group were at the earlier stages of inhalant abuse and had no chronic psychiatric symptoms. The average age of the first inhalant abuse was 14.7 years old in the psychosis group, 14.8 years in the dependence group and 14.7 years in the abuse group. The average years of abuse was 9.0 years in the psychosis group, and 8.5 years in the dependence group. There was little difference between these two groups. The psychosis patients manifested chronic symptoms 5.7 years on average after the first abuse of inhalants. About one forth (26.1%) of the psychosis patients and only 5.9% of the dependence patients had family history of schizophrenia. The difference was statistically significant. These results suggest that chronic psychiatric symptoms are caused not only by inhalant abuse, but also by the genetic factors of psychosis of each patient. There have been several reports that many patients with dual diagnosis of substance dependence and other mental disorders are poly-drug abusers. In our study, 43.4% of the psychosis group patients and 19.6% of the dependence group patients had the past history of abuse of other drugs including methamphetamine and marijuana. The difference was, however, not statistically significant. PMID:8710994

  7. Behavioral and biochemical effects of Cannabis Sativa and their modulation by antidepressant drugs

    Scientific Electronic Library Online (English)

    Omar M.E., Abdel-Salam; Rehab Fawzy, Abdel-Rahman; Alaa El-Din M., Gaafar.

    Full Text Available Nos propusimos estudiar el efecto de Cannabis sativa sobre el estrés oxidativo en cerebro y determinar si las respuestas causadas por canabis sobre el comportamiento podrían revertirse por fármacos antidepresivos estándar. Cannabis sativa (5, 10 o 15 mg/kg) (expresada como ?9-tetrahidrocanabinol) se [...] administró subcutáneamente (s.c.) sola o con fluoxetina, sertralina o imipramina una vez al día por 24 días. En la prueba de nado forzado, el tiempo de in movilidad, se incrementó significativamente en los ratones tratados con canabis (5-15 mg/kg, s.c.) a partir del 9° día post-administración. Fluoxetina (20mg/kg, s.c.), coadministrada con canabis (5 mg/kg, s.c.), dio como resultado una disminución significativa en el tiempo de inmovilidad alrededor del día 21 del estudio comparado con el grupo tratado sólo con canabis. Los ratones co-administrados con sertralina o imipramina y canabis no fueron estadísticamente diferentes del grupo control de vehículo respecto al tiempo de inmovilidad. Canabis provocó una disminución significativa en la actividad de levantamientos que fue aumentada tanto por fluoxetina como por sertralina. Cannabis sativa incrementó la glutationa reducida en cerebro y disminuyó los niveles de óxido nítrico. Flouxetina, sertralina o imipramina administrados con canabis disminuyó la malondialdehido e incrementó la glutationa reducida. En conclusión: La administración de canabis disminuye el estrés oxidativo cerebral pero ejerce un efecto parecido a la depresión y disminuye la actividad de levantamientos que puede revertirse por fármacos antidepresivos. Abstract in english We aimed to study the effect of Cannabis sativa on brain oxidative stress and determine whether behavioral responses caused by cannabis could be reversed by standard antidepressant drugs. Cannabis sativa (5, 10 or 15 mg/kg) (expressed as ?9-tetrahydrocannabinol) was given alone or with fluoxetine, s [...] ertraline or imipramine, once daily subcutaneously (s.c.) for 24 days. In the forced-swimming test, the immobility time, was significantly increased in mice treated with cannabis (5-15 mg/kg, s.c.) starting from the 9th day post-injection. Fluoxetine (20 mg/kg, s.c.) coadministered with cannabis (5 mg/kg, s.c.) resulted in significant decrease in the immobility time by the day 21 of the study compared with the cannabis only group. Mice co-administered sertraline or imipramine with cannabis were not statistically different from the vehicle control group as regards their immobility time. Cannabis resulted in a significant decrease in the rearing activity which was ameliorated by either fluoxetine or sertraline. Cannabis sativa increased brain reduced glutathione, but decreased the level of nitric oxide. Fluoxetine, sertraline or imipramine given with cannabis decreased malondialdehyde and increased reduced glutathione. In conclusion: The administration of cannabis decreases brain oxidative stress but exerts depressive-like effect and decreases rearing activity which can be reversed by antidepressant drugs.

  8. Disposition of smoked cannabis with high ?9-tetrahydrocannabinol content: A kinetic model

    International Nuclear Information System (INIS)

    Introduction: No model exists to describe the disposition and kinetics of inhaled cannabis containing a high THC dose. We aimed to develop a kinetic model providing estimates of the THC serum concentrations after smoking cannabis cigarettes containing high THC doses (up to 69 mg THC). Methods: Twenty-four male non-daily cannabis users smoked cannabis cigarettes containing 29.3 mg, 49.1 mg, and 69.4 mg THC. Blood samples were collected over a period of 0-8 h and serum THC concentrations were measured. A two-compartment open model was fitted on the individual observed data. Results: Large inter-individual variability was observed in the pharmacokinetic parameters. The median pharmacokinetic parameters generated by the model were Cmax = 175 ng/mL, Tmax = 14 min, and AUC0-8h = 8150 ng x min/mL for the 69.4 mg THC dose. Median model results show an almost linear dose response relation for Cmax/Dose = 2.8 x 10-6/mL and AUC0-8h/Dose = 136 x 10-6 min/mL. However, for increasing dose level, there was a clear decreasing trend: Cmax/Dose = 3.4, 2.6 and 2.5 x 10-6/mL and AUC0-8h/Dose = 157, 133 and 117 x 10-6 min/mL for the 29.3, 49.1 and 69.4 mg dose, respectively. Within the restriction of 8 h of observation, the apparent terminal half life of THC was 150 min. Conclusion: The model offers insight into the pharmacokinetics of THC in recreational cannabis users smoking cannabis containing high doses of THC mixed with tobacco. The model is an objective method for providing serum THC concentrations up to 8 h after smoking cannabis with a high THC content (up to 23%).

  9. Cannabis Smoking And Risk Of Lung Cancer - A Systematic Review And Meta-Analysis

    Directory of Open Access Journals (Sweden)

    khalid BOUTI

    2014-12-01

    Full Text Available Background: Cannabis is the illicit psychoactive substance the most consumed in the world. Little is known about the association between the use of cannabis and the risk of lung cancer.Objective:The objective of this meta-analysis is to determine whether use of cannabis is a risk factor for lung cancer.Methods: We conducted a systematic review and meta-analyses of all languages articles using relevant computerised databases. MEDLINE (online PubMed, Web of knowledge, Embase, EBSCO CINAHL, ScienceDirect, Scopus, Cochrane Library, and Directory of Open Access Journals were searched to September 2014 for cohorts and case-control studies that assessed the risk of lung cancer associated with cannabis smoking.  The literature search was performed with a combination of medical subject headings terms, "cannabis" and "lung neoplasms". Data extraction: Two investigators independently analysed and extracted results from eligible studies.Our study's registration number on PROSPERO is  CRD42014008872.Results: The search strategy identified 2476 citations. 13 studies were eligible for inclusion: 2 pooled analysis of 9 case-control studies, one case-control study and 3 cohorts.The cumulative analysis for all the studies under a fixed-effects model showed that cannabis smoking determined an increased risk of developing lung cancer in the future (relative risk 1.22, 95% confidence interval 0.999–1.5; p=0.051, with no evidence of heterogeneity across the studies (I2: 34%; p¼0.01.Conclusions: The use of cannabis with or without tobacco smoking is associated with an increased risk for lung cancer.

  10. "Mr Police Officer, I Thought Cannabis Was Legal"--Introducing New Policy regarding Cannabis in Belgium: A Story of Good Intentions and Babel

    Science.gov (United States)

    Gelders, Dave; Laenen, Freya Vander

    2007-01-01

    Over the last five years, the announced new policy on drugs, cannabis in particular, has been the subject of much debate within the Belgian Federal Government and between the government and the opposition parties. Unclear policies and poor public communication from the Federal Government, the competent minister and the other parties caused immense…

  11. Review of biologic matrices (urine, blood, hair) as indicators of recent or ongoing cannabis use.

    Science.gov (United States)

    Musshoff, Frank; Madea, Burkhard

    2006-04-01

    Especially for cannabinoids, analytical procedures for the verification of recent use and generally for the assessment of the extent of drug abuse are of interest in clinical and forensic toxicology. For confirmation of abstinence, urine analysis seems to be a useful tool. Serial monitoring of THC-COOH to creatinine ratios can differentiate between recent drug use and residual THC-COOH excretion (THC-COOH/creatinine ratio > or = 0.5 compared with previous specimen ratio). For an assessment of the extent of cannabis use, the determination of free and bound THC-COOH and especially of THC and 11-OH-THC glucuronides are suggested as useful but need further confirmation. Blood analysis is preferred for the interpretation of acute effects after cannabis abuse. The cannabis influence factor (CIF) was demonstrated as a better tool to interpret the concentrations of THC and its metabolites in blood in forensic cases and therefore it was proposed to assume absolute driving inability because of cannabis intoxication from a CIF > or = 10. Additionally, a higher CIF is indicative of a recent cannabis abuse. Also discrimination between occasional use of cannabis and regular drug consumption is possible by analysis of THC-COOH in blood samples because of the long plasma half-life of THC-COOH and its accumulation in the blood of frequent cannabis consumers. In routine tests, blood samples have to be taken within a prescribed 8-day-period, and a THC-COOH concentration >75 ng/mL is assumed to be associated with regular consumption of cannabis products, whereas plasma THC-COOH concentrations cannabinoids. THC and especially the main metabolite THC-COOH have a very low incorporation rate into hair and THC is not highly bound to melanin, resulting in much lower concentrations in hair compared with other drugs. Additionally, THC is present in cannabis smoke and also can be incorporated into the hair only by contamination. For the determination of the main metabolite THC-COOH in the picogram or femtogram per milligram range, which indicates an active consumption, special analytical procedures, such as GC/MS/MS techniques, are required. PMID:16628124

  12. Long term marijuana users seeking medical cannabis in California (2001–2007: demographics, social characteristics, patterns of cannabis and other drug use of 4117 applicants

    Directory of Open Access Journals (Sweden)

    Bou-Matar Ché B

    2007-11-01

    Full Text Available Abstract Background Cannabis (marijuana had been used for medicinal purposes for millennia. Cannabinoid agonists are now attracting growing interest and there is also evidence that botanical cannabis is being used as self-medication for stress and anxiety as well as adjunctive therapy by the seriously ill and by patients with terminal illnesses. California became the first state to authorize medicinal use of cannabis in 1996, and it was recently estimated that between 250,000 and 350,000 Californians may now possess the physician's recommendation required to use it medically. More limited medical use has also been approved in 12 additional states and new initiatives are being considered in others. Despite that evidence of increasing public acceptance of "medical" use, a definitional problem remains and all use for any purpose is still prohibited by federal law. Results California's 1996 initiative allowed cannabis to be recommended, not only for serious illnesses, but also "for any other illness for which marijuana provides relief," thus maximally broadening the range of allowable indications. In effect, the range of conditions now being treated with federally illegal cannabis, the modes in which it is being used, and the demographics of the population using it became potentially discoverable through the required screening of applicants. This report examines the demographic profiles and other selected characteristics of 4117 California marijuana users (62% from the Greater Bay Area who applied for medical recommendations between late 2001 and mid 2007. Conclusion This study yielded a somewhat unexpected profile of a hitherto hidden population of users of America's most popular illegal drug. It also raises questions about some of the basic assumptions held by both proponents and opponents of current policy.

  13. Cannabis use and quality of life of adolescents and young adults: findings from an Australian birth cohort.

    Science.gov (United States)

    Fischer, Jane A; Clavarino, Alexandra M; Plotnikova, Maria; Najman, Jackob M

    2015-01-01

    Cannabis is generally used to enhance mood (quality of life), but it is not known whether it has this effect in the medium to longer term. Little is currently known about the temporal sequence between cannabis use and the quality of life (QOL). Data are taken from a prospective longitudinal study of pregnant women recruited at their first antenatal visit in Brisbane, Australia. Offspring data from the follow-ups with 14-year-olds and 21-year-olds are used here. Indicators of QOL, happiness, and satisfaction at 14 years are considered as predictors of subsequent cannabis use. The association between cannabis use and QOL at 21 years, adjusting for prior QOL (14 years), is also examined. Socio-demographic characteristics were included as potential confounders relevant to QOL assessments. In this cohort, lower QOL in the early teenage years predicted subsequent onset of cannabis use in young adulthood. After adjustment for socio-demographic characteristics and for QOL pre-cannabis use, participants who used cannabis more frequently had a lower QOL at the 21-years follow-up. Frequent use of cannabis does not appear to enhance the user's QOL and appears to be associated with a reduced QOL into young adulthood. PMID:25950590

  14. Inter simple sequence repeats separate efficiently hemp from marijuana (Cannabis sativa L.)

    Scientific Electronic Library Online (English)

    Erdogan E, Hakki; Seyit A, Kayis; Emine, Pinarkara; Ayla, Sag.

    2007-10-15

    Full Text Available Cannabis sativa L. is a multiple-use plant that provides raw material for the production of seed oil, natural fiber for textiles, automotive and pulp industries. It has also been used in insulating boards, ropes, varnishes, animal feed, and as medicinal agents. Cannabis has potential to be used for [...] phytoremediation: however, its cultivation is strictly controlled due to its psychoactive nature and usage in producing drugs such as marijuana, and hashish. In this study, psychoactive type Cannabis samples, which were seized from 23 different locations of Turkey, and nine hemp type Cannabis accessions, as well as an unknown accession were used. Our interest was to identify the genetic relatedness of the seized samples and to separate drug and hemp type plants. Inter Simple Sequence Repeats (ISSRs) were employed for analysis based on single plant material (SET1) and bulked samples of them (SET2). Data was analysed via cluster analysis and principal coordinate analysis (PCoA). PCoA analyses, by using SET1 and SET2, were able to efficiently discriminate the seized samples from the fiber type accessions. However, separation of the plants was not clear via unweighted pair-group method using arithmetic average (UPGMA) dendogram in SET1, while they were clearly separated in SET2. Hemp type accessions showed high levels of variation compared to drug type Cannabis both in SET1 and SET2.

  15. A prospective study of natural recovery from cannabis use in early psychosis

    Scientific Electronic Library Online (English)

    Shane, Rebgetz; Leanne, Hides; David J., Kavanagh; Sharon, Dawe; Ross M., Young.

    2014-12-01

    Full Text Available Background and Objectives: Cannabis use is common in early psychosis and has been linked to adverse outcomes. However, factors that influence and maintain change in cannabis use in this population are poorly understood. An existing prospective dataset was used to predict abstinence from cannabis use [...] over the 6 months following inpatient admission for early psychosis. Methods: Participants were 67 inpatients with early psychosis who had used cannabis in the 6 weeks prior to admission. Current diagnoses of psychotic and substance use disorders were confirmed using a clinical checklist and structured diagnostic interview. Measures of clinical, substance use and social and occupational functioning were administered at baseline and at least fortnightly over the 6-month follow up. Results: No substance use or clinical variables were associated with 6-months’ of cannabis abstinence. Only Caucasian ethnicity, living in private accommodation and receiving an income before the admission were predictive. Only private accommodation and receiving an income were significant predictors of abstinence when these variables were entered into a multivariate analysis. Conclusions: While the observed relationships do not necessarily imply causation, they suggest that more optimal substance use outcomes could be achieved by addressing the accommodation and employment needs of patients.

  16. Cannabis use in early adolescence: Evidence of amygdala hypersensitivity to signals of threat.

    Science.gov (United States)

    Spechler, Philip A; Orr, Catherine A; Chaarani, Bader; Kan, Kees-Jan; Mackey, Scott; Morton, Aaron; Snowe, Mitchell P; Hudson, Kelsey E; Althoff, Robert R; Higgins, Stephen T; Cattrell, Anna; Flor, Herta; Nees, Frauke; Banaschewski, Tobias; Bokde, Arun L W; Whelan, Robert; Büchel, Christian; Bromberg, Uli; Conrod, Patricia; Frouin, Vincent; Papadopoulos, Dimitri; Gallinat, Jurgen; Heinz, Andreas; Walter, Henrik; Ittermann, Bernd; Gowland, Penny; Paus, Tomáš; Poustka, Luise; Martinot, Jean-Luc; Artiges, Eric; Smolka, Michael N; Schumann, Gunter; Garavan, Hugh

    2015-12-01

    Cannabis use in adolescence may be characterized by differences in the neural basis of affective processing. In this study, we used an fMRI affective face processing task to compare a large group (n=70) of 14-year olds with a history of cannabis use to a group (n=70) of never-using controls matched on numerous characteristics including IQ, SES, alcohol and cigarette use. The task contained short movies displaying angry and neutral faces. Results indicated that cannabis users had greater reactivity in the bilateral amygdalae to angry faces than neutral faces, an effect that was not observed in their abstinent peers. In contrast, activity levels in the cannabis users in cortical areas including the right temporal-parietal junction and bilateral dorsolateral prefrontal cortex did not discriminate between the two face conditions, but did differ in controls. Results did not change after excluding subjects with any psychiatric symptomology. Given the high density of cannabinoid receptors in the amygdala, our findings suggest cannabis use in early adolescence is associated with hypersensitivity to signals of threat. Hypersensitivity to negative affect in adolescence may place the subject at-risk for mood disorders in adulthood. PMID:26347227

  17. The use of tobacco and cannabis at an international music festival

    DEFF Research Database (Denmark)

    Hesse, Morten; Tutenges, Sébastien

    2010-01-01

    Background: Music festivals are known to attract a high proportion of drug users.Methods: Using a survey of 1,772 visitors at the Roskilde Festival in Denmark, we assessed substance use at the festival, the incidence of use of substances among never-users and the incidence of use among lifetime users who had not used a substance in the past 12 months. Results: New onset of tobacco use was reported by 9.2% of never-smokers, and new onset of cannabis use was reported by 9.3% of never-smokers of cannabis. Resumption of tobacco use was reported by 24% of past year abstainers, and resumption of cannabis use was reported by 30% of past year abstainers. New onset of other types of substances was reported by less than 0.5% of subjects, but among past year abstainers, 5–10% reported resumption of amphetamine, ketamine, MDMA and cocaine use. New onset smokers of cannabis were significantly younger than never-smokers. Conclusion: Music festivals such as the Roskilde Festival may be important arenas for the prevention ofonset of tobacco and cannabis use and for a return to substance use.

  18. Intoxicación accidental por cannabis: presentación de cuatro casos pediátricos en un hospital terciario del sur de España / Accidental cannabis poisoning in children: report of four cases in a tertiary care center from southern Spain

    Scientific Electronic Library Online (English)

    Borja, Croche Santander; María Teresa, Alonso Salas; Mercedes, Loscertales Abril.

    2011-02-01

    Full Text Available Introducción. El cannabis es la droga ilegal más consumida en España. La intoxicación accidental por cannabis es una forma infrecuente de intoxicación en niños; pero potencialmente grave. Objetivo. Describir la presentación clínica, diagnóstico y tratamiento de niños con intoxicación accidental por [...] cannabis en un hospital pediátrico de tercer nivel. Presentamos 4 pacientes con intoxicación accidental por cannabis. La clínica de presentación fue deterioro brusco del nivel de conciencia, tendencia al sueño, ataxia, temblor, apnea, hipotonía y convulsión. La pesquisa de tóxicos en orina detectó tetrahidrocannabinol (THC) en todos los casos. En los cuatro pacientes se establecieron medidas de soporte. Todos los casos se recuperaron satisfactoriamente y fueron dados de alta a las 24 horas del ingreso. Conclusión. Se ha de mantener un alto índice de sospecha para la intoxicación por cannabis en niños previamente sanos con aparición brusca de síntomas neurológicos de etiología desconocida. Abstract in english Introduction. Cannabis is the most frequently consumed illicit substance in Spain. Pediatric accidental cannabis poisoning is an uncommon but life-threatening intoxication. Objective. To describe clinical findings, diagnosis and management of children with accidental cannabis poisoning in a tertiary [...] care pediatric hospital. We report four patients with accidental cannabis poisoning. Clinical presentation included reduced level of consciousness, drowsiness, ataxia, tremble, apnea, hypotonia, and seizures. Tetrahydrocannabinol (THC) was detected by urine screening for cannabinoids and other toxic substances in all cases. The four patients were treated with supportive care. All cases recovered uneventfully and were discharged within 24 hours of admission. Conclusion. The possibility of cannabis poisoning should be considered in cases of unexplained acute onset of neurological findings in previously healthy children.

  19. Intervenções farmacológica e psicossocial para os distúrbios por uso da cannabis Pharmacological and psychosocial interventions for cannabisuse disorders

    Directory of Open Access Journals (Sweden)

    Alan J. Budney

    2010-05-01

    Full Text Available OBJETIVO: A cannabis continua sendo a substância ilegal mais amplamente utilizada na maioria dos países desenvolvidos. Seu potencial aditivo foi estabelecido e a necessidade de intervenções em problemas relacionados à cannabis se tornou clara. Este artigo faz uma revisão sobre as pesquisas que avaliam os tratamentos potenciais para transtornos por uso de cannabis. MÉTODO: Uma busca nos bancos de dados de publicações identificou os estudos e revisões na literatura científica sobre as intervenções psicossociais e farmacológicas nos transtornos por uso de cannabis. RESULTADOS: Para adultos, as intervenções com base comportamental geram efeitos positivos significativos na abstinência e nas reduções no uso de cannabis. Em adolescentes, tratamentos similares e intervenções com base na família demonstraram eficácia. Entre os estudos, os índices de resposta parecem ser modestos mesmo com os mais potentes tratamentos psicossociais. As avaliações das abordagens farmacológicas para os transtornos por uso de cannabis têm ainda que fornecer dados sobre a eficácia clínica de qualquer medicação específica. Enfoques baseados em agonistas e antagonistas parecem ser os mais promissores. Os avanços na compreensão da neurobiologia do sistema canabinoide são fonte de otimismo no sentido de que a síntese de compostos que alteram o funcionamento do sítio receptor CB1 possa produzir medicações promissoras. CONCLUSÃO: As pesquisas clínicas identificaram tratamentos psicossociais eficazes, mas ainda não produziram farmacoterapias eficazes. Muitos estudos ainda têm que ser feitos para aumentar a potência e o acesso às intervenções para aqueles que buscam o tratamento para transtornos por uso de cannabis.OBJECTIVE: Cannabis remains the most widely used illicit substance in most developed countries. Its addictive potential has been established and the need for interventions for cannabis-related problems has become apparent. This article provides a review of the research evaluating potential treatments for cannabis use disorders. METHOD: A search of publication databases identified research studies and reviews of the scientific literature on psychosocial and pharmacological interventions for cannabis use disorders. RESULTS: For adults, behaviorally-based interventions engender significant positive effects on abstinence and reductions in cannabis use. With adolescents, similar treatments and family-based interventions have demonstrated efficacy. Across studies, response rates appear modest even with the most potent psychosocial treatments. Evaluations of pharmacological approaches to cannabis use disorders have yet to provide clinical efficacy data for any specific medication. Agonist and antagonist approaches appear to offer the most promise. Advances in understanding of the neurobiology of the cannabinoid system provide optimism that the synthesis of compounds that alter CB1 receptor site functioning may produce promising medications. CONCLUSION: Clinical research has identified effective psychosocial treatments, but has yet to yield effective pharmacotherapies. Much work remains to enhance the potency of and access to interventions for those seeking treatment for cannabis use disorders.

  20. Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug / Canabidiol, um componente da Cannabis sativa, como um ansiolítico

    Scientific Electronic Library Online (English)

    Alexandre Rafael de Mello, Schier; Natalia Pinho de Oliveira, Ribeiro; Adriana Cardoso de Oliveira e, Silva; Jaime Eduardo Cecílio, Hallak; José Alexandre S., Crippa; Antonio E., Nardi; Antonio Waldo, Zuardi.

    2012-06-01

    Full Text Available OBJETIVOS: Revisar e descrever os estudos do constituinte não psicotomimético da Cannabis sativa, o canabidiol (CBD), como ansiolítico e discutir seus possíveis mecanismos de ação. MÉTODO: Os artigos selecionados para a presente revisão foram identificados por meio de busca eletrônica em inglês, por [...] tuguês e espanhol nos bancos de dados ISI Web of Knowledge, SciELO, PubMed e PsycINFO e combinando os termos "canabidiol e ansiolíticos", "canabidiol e semelhante ao ansiolítico" e "canabidiol e ansiedade". Foram também revisadas as listas de referências dos artigos incluídos, de revisões da literatura e de capítulos de livro. Incluímos trabalhos experimentais em humanos e em animais, sem limite de tempo. RESULTADOS: Estudos com modelos animais de ansiedade e envolvendo voluntários saudáveis sugerem claramente que o CBD possui efeitos ansiolíticos. Além disso, o CBD mostrou-se capaz de reduzir a ansiedade em pacientes com transtorno de ansiedade social. CONCLUSÃO: Futuros ensaios clínicos com pacientes portadores de diferentes transtornos de ansiedade, em especial pacientes com transtorno do pânico, obsessivo-compulsivo, ansiedade social e estresse pós-traumático, são oportunos. Além disso, ainda é necessário determinar a adequada faixa terapêutica do CBD e os exatos mecanismos envolvidos nessa ação ansiolítica. Abstract in english OBJECTIVES: To review and describe studies of the non-psychotomimetic constituent of Cannabis sativa, cannabidiol (CBD), as an anxiolytic drug and discuss its possible mechanisms of action. METHOD: The articles selected for the review were identified through searches in English, Portuguese, and Span [...] ish in the electronic databases ISI Web of Knowledge, SciELO, PubMed, and PsycINFO, combining the search terms "cannabidiol and anxiolytic", "cannabidiol and anxiolytic-like", and "cannabidiol and anxiety". The reference lists of the publications included, review articles, and book chapters were handsearched for additional references. Experimental animal and human studies were included, with no time restraints. RESULTS: Studies using animal models of anxiety and involving healthy volunteers clearly suggest an anxiolytic-like effect of CBD. Moreover, CBD was shown to reduce anxiety in patients with social anxiety disorder. CONCLUSION: Future clinical trials involving patients with different anxiety disorders are warranted, especially of panic disorder, obsessive-compulsive disorder, social anxiety disorder, and post-traumatic stress disorders. The adequate therapeutic window of CBD and the precise mechanisms involved in its anxiolytic action remain to be determined.

  1. Induction of mutants in Cannabis Sativa L. by ? radiation

    International Nuclear Information System (INIS)

    A description is given of the mutations induced in a well known cultivar of fibre hemp belonging to the species Cannabis sativa in order to obtain new phenotypic characters that could unequivocally differentiate it from drug hemp. Two new dioecious hemp cultivars, characterized by clear morphological markers and low (?0.2%)?-9-tetrahydrocannabinol (THC) content, have been obtained by mutagenesis of seeds irradiated with 60Co ? rays(optimum dose 300-350 Gy) and selection of the segregant progenies. These new cultivars, named red petiole (exhibiting anthocyanin leaf petioles) and yellow apex (exhibiting yellow distal leaflets), have been compared with varieties C.S., carmagnola and fibranova by growing them in three different areas (centre-north and south) of Italy. These agronomical trials highlighted the good performance of both new cultivars as for yield in dry matter and in fibre, not significantly different from the results of carmagnola. Besides, the new cultivars showed THC contents (0.09 and 0.17%) lower than the threshold set by the E.U. (0.2%). (Author)

  2. Crystallization of ?1-tetrahydrocannabinolic acid (THCA) synthase from Cannabis sativa

    International Nuclear Information System (INIS)

    ?1-Tetrahydrocannabinolic acid (THCA) synthase from C. sativa was crystallized. The crystal diffracted to 2.7 Å resolution with sufficient quality for further structure determination. ?1-Tetrahydrocannabinolic acid (THCA) synthase is a novel oxidoreductase that catalyzes the biosynthesis of the psychoactive compound THCA in Cannabis sativa (Mexican strain). In order to investigate the structure–function relationship of THCA synthase, this enzyme was overproduced in insect cells, purified and finally crystallized in 0.1 M HEPES buffer pH 7.5 containing 1.4 M sodium citrate. A single crystal suitable for X-ray diffraction measurement was obtained in 0.09 M HEPES buffer pH 7.5 containing 1.26 M sodium citrate. The crystal diffracted to 2.7 Å resolution at beamline BL41XU, SPring-8. The crystal belonged to the primitive cubic space group P432, with unit-cell parameters a = b = c = 178.2 Å. The calculated Matthews coefficient was approximately 4.1 or 2.0 Å3 Da?1 assuming the presence of one or two molecules of THCA synthase in the asymmetric unit, respectively

  3. Gene duplication and divergence affecting drug content in Cannabis sativa.

    Science.gov (United States)

    Weiblen, George D; Wenger, Jonathan P; Craft, Kathleen J; ElSohly, Mahmoud A; Mehmedic, Zlatko; Treiber, Erin L; Marks, M David

    2015-12-01

    Cannabis sativa is an economically important source of durable fibers, nutritious seeds, and psychoactive drugs but few economic plants are so poorly understood genetically. Marijuana and hemp were crossed to evaluate competing models of cannabinoid inheritance and to explain the predominance of tetrahydrocannabinolic acid (THCA) in marijuana compared with cannabidiolic acid (CBDA) in hemp. Individuals in the resulting F2 population were assessed for differential expression of cannabinoid synthase genes and were used in linkage mapping. Genetic markers associated with divergent cannabinoid phenotypes were identified. Although phenotypic segregation and a major quantitative trait locus (QTL) for the THCA/CBDA ratio were consistent with a simple model of codominant alleles at a single locus, the diversity of THCA and CBDA synthase sequences observed in the mapping population, the position of enzyme coding loci on the map, and patterns of expression suggest multiple linked loci. Phylogenetic analysis further suggests a history of duplication and divergence affecting drug content. Marijuana is distinguished from hemp by a nonfunctional CBDA synthase that appears to have been positively selected to enhance psychoactivity. An unlinked QTL for cannabinoid quantity may also have played a role in the recent escalation of drug potency. PMID:26189495

  4. Estudio de la actividad antisecretora de ácido gástrico del Cannabis sativa en un modelo animal

    Directory of Open Access Journals (Sweden)

    Germán Gabriel Castillo

    2006-12-01

    Full Text Available Introducción: Hay pocos estudios que describan el efecto de los cannabinoides en el sistema gástrico, pues en sólo uno se encontró referencia a alteraciones del pH gástrico. Objetivo: Determinar el efecto antisecretor de la especie Cannabis sativa. Metodología: Se utilizaron 45 ratas Sprague Dawley que se sometieron a un ayuno de 24 horas, al cabo del cual se les ligó el píloro durante 2 ó 4 horas según el grupo experimental. Luego, se anestesiaron, se extirparon los estómagos y se analizó el contenido gástrico en términos de volumen y pH.Resultados: Se encontró que el extracto de Cannabis aumentó el pH gástrico con respecto al grupo control (p0.05. El volumen medido no mostró diferencias entre los grupos.Conclusiones: Estos resultados, sugieren que el extracto de Cannabis sativa disminuye la secreción de ácido en el estómago.

  5. Medically Unexplained Symptoms

    Science.gov (United States)

    ... require different treatment. Most people can control their symptoms with diet, stress management, and medications prescribed by their health care provider. TREATMENTS FOR MEDICALLY UNEXPLAINED ... medically unexplained symptoms often characterized by chronic pain or persistent fatigue ...

  6. Initial Symptoms of ALS

    Science.gov (United States)

    ... Chapters Certified Centers and Clinics Support Groups About ALS About Us Our Research In Your Community Advocate ... Diagnosis En español Symptoms The initial symptoms of ALS can be quite varied in different people. One ...

  7. Rosacea: Signs and Symptoms

    Science.gov (United States)

    ... Diseases and treatments Q - T Rosacea Signs, symptoms Rosacea: Signs and symptoms Rosacea causes more than a ... ophthalmologist (doctor who specializes in treating eye diseases). Rosacea can affect quality of life Rosacea can affect ...

  8. Acne: Signs and Symptoms

    Science.gov (United States)

    ... Diseases and treatments A - D Acne Signs, symptoms Acne: Signs and symptoms Blackheads and whiteheads Blackheads and ... sandpaper. View as one page View as slideshow Acne signs Many people think that acne is just ...

  9. Vitiligo: Signs and Symptoms

    Science.gov (United States)

    ... Diseases and treatments U - W Vitiligo Signs, symptoms Vitiligo: Signs and symptoms Vitiligo causes loss of color. ... amount of color loss or type of vitiligo. Vitiligo has types and subtypes If you are diagnosed ...

  10. Cannabis use and violence in three remote Aboriginal Australian communities: Analysis of clinic presentations.

    Science.gov (United States)

    Kylie Lee, K S; Sukavatvibul, Krisakorn; Conigrave, Katherine M

    2015-12-01

    Anecdotal reports have linked cannabis use to violence in some remote Australian Aboriginal communities. We examine the relationship between cannabis use and presentations to local clinics for violence-related trauma at a population level. As part of a larger study, estimates of cannabis and alcohol use status were obtained for 264 randomly selected individuals aged 14-42. These estimates were collected from Aboriginal health workers and respected community informants using a previously validated approach. Clinic records for the sample were audited for physical trauma presentations between January 2004 and June 2006. One in 3 individuals (n?=?88/264) presented to the clinic with physical trauma. Of these, the majority (65.9%, n?=?58/88) had at least one presentation that was violence-related. Nearly 2 in every 3 of the total presentations for trauma following violence (n?=?40/63) involved the use of a weapon. Hunting tools were most often used, followed by wooden or rock implements. Individuals who reported any current cannabis use were nearly 4 times more likely than nonusers to present at least once for violent trauma after adjusting for current alcohol use, age, and sex (OR?=?3.8, 95% CI [1.5, 9.8]). Aboriginal individuals in these remote communities experience high rates of physical trauma and violence, often involving weapons. A comprehensive study is needed to explore the association between cannabis and violence. At the same time, an investment in local programmes is needed to address cannabis use and underlying risk factors for substance use and for violence. PMID:26045571

  11. E-Cigarettes: A Review of New Trends in Cannabis Use

    Directory of Open Access Journals (Sweden)

    Christian Giroud

    2015-08-01

    Full Text Available The emergence of electronic cigarettes (e-cigs has given cannabis smokers a new method of inhaling cannabinoids. E-cigs differ from traditional marijuana cigarettes in several respects. First, it is assumed that vaporizing cannabinoids at lower temperatures is safer because it produces smaller amounts of toxic substances than the hot combustion of a marijuana cigarette. Recreational cannabis users can discretely “vape” deodorized cannabis extracts with minimal annoyance to the people around them and less chance of detection. There are nevertheless several drawbacks worth mentioning: although manufacturing commercial (or homemade cannabinoid-enriched electronic liquids (e-liquids requires lengthy, complex processing, some are readily on the Internet despite their lack of quality control, expiry date, and conditions of preservation and, above all, any toxicological and clinical assessment. Besides these safety problems, the regulatory situation surrounding e-liquids is often unclear. More simply ground cannabis flowering heads or concentrated, oily THC extracts (such as butane honey oil or BHO can be vaped in specially designed, pen-sized marijuana vaporizers. Analysis of a commercial e-liquid rich in cannabidiol showed that it contained a smaller dose of active ingredient than advertised; testing our laboratory-made, purified BHO, however, confirmed that it could be vaped in an e-cig to deliver a psychoactive dose of THC. The health consequences specific to vaping these cannabis preparations remain largely unknown and speculative due to the absence of comprehensive, robust scientific studies. The most significant health concerns involve the vaping of cannabinoids by children and teenagers. E-cigs could provide an alternative gateway to cannabis use for young people. Furthermore, vaping cannabinoids could lead to environmental and passive contamination.

  12. E-Cigarettes: A Review of New Trends in Cannabis Use.

    Science.gov (United States)

    Giroud, Christian; de Cesare, Mariangela; Berthet, Aurélie; Varlet, Vincent; Concha-Lozano, Nicolas; Favrat, Bernard

    2015-08-01

    The emergence of electronic cigarettes (e-cigs) has given cannabis smokers a new method of inhaling cannabinoids. E-cigs differ from traditional marijuana cigarettes in several respects. First, it is assumed that vaporizing cannabinoids at lower temperatures is safer because it produces smaller amounts of toxic substances than the hot combustion of a marijuana cigarette. Recreational cannabis users can discretely "vape" deodorized cannabis extracts with minimal annoyance to the people around them and less chance of detection. There are nevertheless several drawbacks worth mentioning: although manufacturing commercial (or homemade) cannabinoid-enriched electronic liquids (e-liquids) requires lengthy, complex processing, some are readily on the Internet despite their lack of quality control, expiry date, and conditions of preservation and, above all, any toxicological and clinical assessment. Besides these safety problems, the regulatory situation surrounding e-liquids is often unclear. More simply ground cannabis flowering heads or concentrated, oily THC extracts (such as butane honey oil or BHO) can be vaped in specially designed, pen-sized marijuana vaporizers. Analysis of a commercial e-liquid rich in cannabidiol showed that it contained a smaller dose of active ingredient than advertised; testing our laboratory-made, purified BHO, however, confirmed that it could be vaped in an e-cig to deliver a psychoactive dose of THC. The health consequences specific to vaping these cannabis preparations remain largely unknown and speculative due to the absence of comprehensive, robust scientific studies. The most significant health concerns involve the vaping of cannabinoids by children and teenagers. E-cigs could provide an alternative gateway to cannabis use for young people. Furthermore, vaping cannabinoids could lead to environmental and passive contamination. PMID:26308021

  13. E-Cigarettes: A Review of New Trends in Cannabis Use

    Science.gov (United States)

    Giroud, Christian; de Cesare, Mariangela; Berthet, Aurélie; Varlet, Vincent; Concha-Lozano, Nicolas; Favrat, Bernard

    2015-01-01

    The emergence of electronic cigarettes (e-cigs) has given cannabis smokers a new method of inhaling cannabinoids. E-cigs differ from traditional marijuana cigarettes in several respects. First, it is assumed that vaporizing cannabinoids at lower temperatures is safer because it produces smaller amounts of toxic substances than the hot combustion of a marijuana cigarette. Recreational cannabis users can discretely “vape” deodorized cannabis extracts with minimal annoyance to the people around them and less chance of detection. There are nevertheless several drawbacks worth mentioning: although manufacturing commercial (or homemade) cannabinoid-enriched electronic liquids (e-liquids) requires lengthy, complex processing, some are readily on the Internet despite their lack of quality control, expiry date, and conditions of preservation and, above all, any toxicological and clinical assessment. Besides these safety problems, the regulatory situation surrounding e-liquids is often unclear. More simply ground cannabis flowering heads or concentrated, oily THC extracts (such as butane honey oil or BHO) can be vaped in specially designed, pen-sized marijuana vaporizers. Analysis of a commercial e-liquid rich in cannabidiol showed that it contained a smaller dose of active ingredient than advertised; testing our laboratory-made, purified BHO, however, confirmed that it could be vaped in an e-cig to deliver a psychoactive dose of THC. The health consequences specific to vaping these cannabis preparations remain largely unknown and speculative due to the absence of comprehensive, robust scientific studies. The most significant health concerns involve the vaping of cannabinoids by children and teenagers. E-cigs could provide an alternative gateway to cannabis use for young people. Furthermore, vaping cannabinoids could lead to environmental and passive contamination. PMID:26308021

  14. Clustering of smoking, alcohol drinking and cannabis use in adolescents in a rapidly developing country

    Directory of Open Access Journals (Sweden)

    Chiolero Arnaud

    2006-06-01

    Full Text Available Abstract Background Smoking, alcohol drinking and cannabis use ("risk behaviors" are often initiated at a young age but few epidemiological studies have assessed their joined prevalence in children in developing countries. This study aims at examining the joint prevalence of these behaviors in adolescents in the Seychelles, a rapidly developing country in the Indian Ocean. Methods Cross-sectional survey in a representative sample of secondary school students using an anonymous self-administered questionnaire (Global Youth Tobacco Survey. The questionnaire was completed by 1,321 (92% of 1,442 eligible students aged 11 to 17 years. Main variables of interest included smoking cigarettes on ?1 day in the past 30 days; drinking any alcohol beverage on ?1 day in the past 30 days and using cannabis at least once in the past 12 months. Results In boys and girls, respectively, prevalence (95% CI was 30% (26–34/21% (18–25 for smoking, 49% (45–54/48% (43–52 for drinking, and 17% (15–20/8% (6–10 for cannabis use. The prevalence of all these behaviors increased with age. Smokers were two times more likely than non-smokers to drink and nine times more likely to use cannabis. Drinkers were three times more likely than non-drinkers to smoke or to use cannabis. Comparison of observed versus expected frequencies of combination categories demonstrated clustering of these risk behaviors in students (P Conclusion Smoking, drinking and cannabis use were common and clustered among adolescents of a rapidly developing country. These findings stress the need for early and integrated prevention programs.

  15. Universality properties of school-based preventive intervention targeted at cannabis use.

    Science.gov (United States)

    Miovský, Michal; Vo?ková, Hana; Gabrhelík, Roman; Š?astná, Lenka

    2015-02-01

    This study aims to examine the effect of school-based preventive intervention on cannabis use in Czech adolescents with different levels of risk factors and provide evidence of its universality. A randomized controlled prevention trial with six waves was conducted over a period of 33 months. We used a two-level logistic random-intercept model for panel data; we first looked at the statistical significance of the effect of the intervention on cannabis use, controlling for the characteristics of the children and time dummies. Then we analyzed the effects of the interactions between the intervention and the characteristics of the children on cannabis use and related it to the definition of universal preventive interventions. The setting for the study was in basic schools in the Czech Republic in the years 2007-2010. A total of 1,874 sixth-graders (mean age 11.82 years) who completed the baseline testing. According to our results, the prevention intervention was effective. We found all the selected characteristics of the children to be relevant in relation to cannabis use, except their relationships with their friends. We showed empirically that the intervention is universal in two dimensions for the selected characteristics of the children. First, all adolescents who undergo the intervention are expected to benefit. Second, with respect to the effect of the intervention on cannabis use, the total level of individual risk of cannabis use is superior to the composition of the risk factors in the individual risk profile. We present indicative evidence that the drug prevention intervention may be considered a true universal preventive intervention. PMID:24420651

  16. Management of somatic symptoms

    DEFF Research Database (Denmark)

    Schröder, Andreas; Dimsdale, Joel

    2014-01-01

    ABSTRACT: Somatic symptoms that cannot be attributed to organic disease account for 15 to 20% of primary care consultations and up to 50% in specialized settings. About 6% of the general population has chronic somatic symptoms that affect functioning and quality of life. This chapter focuses on the recognition and effective management of patients with excessive and disabling somatic symptoms. The clinical presentation of somatic symptoms is categorized into three groups of patients: those with m...

  17. Isolation of Cannabinoids from the plant Cannabis sativa and its potential anticancer activity

    Directory of Open Access Journals (Sweden)

    Tariq. A. L

    2012-03-01

    Full Text Available The plant leaves were identified as Cannabis sativa L. The cannabniods were extracted by aqueous extract found a total yield of 3.8g while as acetone extract 4.8g. The protein content in crude extract of Cannabis sativa L for aqeous extract found 112?g/ml and for acetone extract 160?g/ml. The molecular weight of protein by SDS PGAGE found to be 70KDa. The HPLC intension percentage for aqueous was 11 while for acetone extract it found 25. The actone extract exhibited more anticancer activity against HT29, MCF7 and SF-26 Cells

  18. Combined cannabis/methaqualone withdrawal treated with psychotropic analgesic nitrous oxide.

    Science.gov (United States)

    Gillman, Mark A; Harker, Nadine; Lichtigfeld, Frederick J

    2006-07-01

    This article reports the first single-blind study using psychotropic analgesic nitrous oxide (PAN) for treating acute withdrawal states following the abuse of methaqualone combined and smoked with cannabis. Smoked methaqualone combined with cannabis is called "white pipe" (WP). South Africa is the only country in the world where WP is a major form of substance abuse. This article demonstrates in 101 consecutively treated patients given placebo (100% oxygen) followed by PAN that this therapy produced a measurable therapeutic effect (more than 50% improvement) in 87 patients. This study confirms that WP is a form of substance abuse confined mainly to young adult male subjects. PMID:16861151

  19. Advice of the Italian CCTN on the toxicity of Cannabis sativa

    Energy Technology Data Exchange (ETDEWEB)

    Camoni, I. [ed.] [Istituto Superiore di Sanita`, Rome (Italy). Lab. di Tossicologia Applicata; Mucci, N. [ed.] [ISPESL, Monteporzio Catone, Roma (Italy). Dip. di Medicina del Lavoro; Paroli, E. [ed.] [Rome, Univ. `La Sapienza` (Italy). Fac. di Medicina, Ist. di Farmacologia

    1998-06-01

    This recommendation of the Italian National Toxicological Committee (CCTN) regards the possible toxic effects of some products derived from Cannabis sativa, indica variety. The CCTN has especially evaluated genotoxic, immunological and toxic to reproduction effects of these substances, on the basis of the results from both experimental studies and observations on humans. [Italiano] Il documento contiene il parere della CCTN sui potenziali effetti tossici di alcuni derivati della Cannabis sativa, varieta` indica. Il parere e` stato elaborato sulla base dei risultati sia di studi sperimentali sia dei limitati studi sull`uomo, prendendo in particolare considerazione gli effetti genotossici, tossico-riproduttivi ed immunologici.

  20. Consumo de cannabis en los estudiantes de secundaria de Barcelona: inicio en el consumo, efectos experimentados y expectativas / Cannabis consumption among secondary school pupils of Barcelona [Spain]: initial use, reported effects and expectancies

    Scientific Electronic Library Online (English)

    Eva, Morales; Carles, Ariza; Manel, Nebot; Anna, Pérez; Francesca, Sánchez.

    2008-08-01

    Full Text Available Objetivos: Describir las circunstancias del inicio del consumo, las razones para hacerlo, los efectos experimentados y las expectativas relacionadas con el consumo de cannabis en adolescentes de Barcelona. Métodos: Encuesta transversal realizada a una muestra de escolares de 3.º de ESO en 2005. El c [...] uestionario era confidencial y autocumplimentado. Se dispone de datos de 2.043 alumnos de 47 centros escolares de Barcelona. Resultados: El 37,5% de los escolares declaró haber probado el cannabis, de los cuales un 10% lo hizo en el último mes. El consumo fue superior en centros públicos que en concertados-privados (p Abstract in english Objectives: To describe the circumstances of initial use of Cannabis, as well as the reasons for consumption, reported effects and expectations related to cannabis use, among adolescents in Barcelona. Methods: A cross-sectional survey was conducted in a sample of pupils in the third year of compulso [...] ry secondary education in 2005. The questionnaire was confidential and self-completed. Data were gathered from 2,043 secondary school pupils from 47 schools in Barcelona. Results: A total of 37.5% of students reported cannabis consumption at some time, and 10.0% of these students had used cannabis in the previous month. Cannabis use was more common in public schools than in subsidized or private schools (p

  1. Nonsmoker Exposure to Secondhand Cannabis Smoke. III. Oral Fluid and Blood Drug Concentrations and Corresponding Subjective Effects.

    Science.gov (United States)

    Cone, Edward J; Bigelow, George E; Herrmann, Evan S; Mitchell, John M; LoDico, Charles; Flegel, Ronald; Vandrey, Ryan

    2015-09-01

    The increasing use of highly potent strains of cannabis prompted this new evaluation of human toxicology and subjective effects following passive exposure to cannabis smoke. The study was designed to produce extreme cannabis smoke exposure conditions tolerable to drug-free nonsmokers. Six experienced cannabis users smoked cannabis cigarettes [5.3% ?(9)-tetrahydrocannabinol (THC) in Session 1 and 11.3% THC in Sessions 2 and 3] in a closed chamber. Six nonsmokers were seated alternately with smokers during exposure sessions of 1 h duration. Sessions 1 and 2 were conducted with no ventilation and ventilation was employed in Session 3. Oral fluid, whole blood and subjective effect measures were obtained before and at multiple time points after each session. Oral fluid was analyzed by ELISA (4 ng/mL cutoff concentration) and by LC-MS-MS (limit of quantitation) for THC (1 ng/mL) and total THCCOOH (0.02 ng/mL). Blood was analyzed by LC-MS-MS (0.5 ng/mL) for THC, 11-OH-THC and free THCCOOH. Positive tests for THC in oral fluid and blood were obtained for nonsmokers up to 3 h following exposure. Ratings of subjective effects correlated with the degree of exposure. Subjective effect measures and amounts of THC absorbed by nonsmokers (relative to smokers) indicated that extreme secondhand cannabis smoke exposure mimicked, though to a lesser extent, active cannabis smoking. PMID:26139312

  2. Evaluating the relationship between cannabis use and IQ in youth and young adults at clinical high risk of psychosis.

    Science.gov (United States)

    Buchy, Lisa; Seidman, Larry J; Cadenhead, Kristin S; Cannon, Tyrone D; Cornblatt, Barbara A; McGlashan, Thomas H; Perkins, Diana O; Stone, William; Tsuang, Ming T; Walker, Elaine F; Woods, Scott W; Bearden, Carrie E; Mathalon, Daniel H; Addington, Jean

    2015-12-30

    Among people with psychosis, those with a history of cannabis use show better cognitive performance than those who are cannabis naïve. It is unknown whether this pattern is present in youth at clinical high risk (CHR) of psychosis. We evaluated relationships between IQ and cannabis use while controlling for use of other substances known to impact cognition in 678 CHR and 263 healthy control (HC) participants. IQ was estimated using the Vocabulary and Block Design subtests of the Wechsler Abbreviated Scale of Intelligence. Drug and alcohol use severity and frequency were assessed with the Alcohol and Drug Use Scale, and we inquired participants' age at first use. CHR were further separated into early and late age at onset of cannabis use sub-groups, and low-, moderate- and high-frequency sub-groups. No significant differences in IQ emerged between CHR or HC cannabis users vs. non-users, or between use frequency groups. CHR late-onset users showed significantly higher IQ than CHR early-onset users. Age at onset of cannabis use was significantly and positively correlated with IQ in CHR only. Results suggest that age at onset of cannabis may be a more important factor for IQ than use current use or use frequency in CHR. PMID:26626949

  3. Comparison of cannabinoid concentrations in oral fluid and whole blood between occasional and regular cannabis smokers prior to and after smoking a cannabis joint

    OpenAIRE

    Fabritius, Marie; Chtioui, Haithem; Battistella, Giovanni; Annoni, Jean Marie; Dao, Kim; Favrat, Bernard; Fornari, Eleonora; Lauer, Estelle; Maeder, Philippe; Giroud, Christian

    2014-01-01

    A cross-over controlled administration study of smoked cannabis was carried out on occasional and heavy smokers. The participants smoked a joint (11 % ?9-tetrahydrocannabinol (THC)) or a matching placebo on two different occasions. Whole blood (WB) and oral fluid (OF) samples were collected before and up to 3.5 h after smoking the joints. Pharmacokinetic analyses were obtained from these data. Questionnaires assessing the subjective effects were administered to the subjects during each sessio...

  4. Interaction between COMT haplotypes and cannabis in schizophrenia: a case-only study in two samples from Spain.

    Science.gov (United States)

    Costas, Javier; Sanjuán, Julio; Ramos-Ríos, Ramón; Paz, Eduardo; Agra, Santiago; Tolosa, Amparo; Páramo, Mario; Brenlla, Julio; Arrojo, Manuel

    2011-04-01

    Cannabis use is one of the environmental factors with more solid evidence contributing to schizophrenia risk, especially in genetically susceptible individuals. One of the genes that may interact with cannabis is COMT, although available data are scarce. Here, we present a case-only study of the putative COMT-cannabis interaction in schizophrenia. Two Spanish samples from Santiago de Compostela and Valencia were screened for cannabis use. One hundred and fifty five individuals from a total of 748 patients were identified as cannabis users. Five SNPs in COMT, defining three common functional haplotypes with different enzymatic activities, were genotyped and analyzed for association at the SNP, haplotype and genotype levels. An association was detected between cannabis use and low activity variants (P<0.01) in the joint analysis and results were consistent between the two samples. Schizophrenic subjects homozygous for the Met allele at rs4680 doubled the probability of lifetime prevalence of cannabis use in comparison to Val homozygous (Mantel-Haenszel OR=2.07, 95% CI: 1.27-3.26, P=0.0031, in the combined sample). These data are in contrast to those from Caspi et al. (Biol. Psychiatry 57 (2005)1117-1127) who found association between schizophrenia/schizophreniform disorder and homozygosity at the high activity Val variant of rs4680. The results of our study are discussed in the context of previous findings, suggesting the involvement of COMT polymorphisms in the association between cannabis use and schizophrenia as well as the existence of additional factors mediating this association. However, further research is needed to confirm the COMT-cannabis interaction. PMID:21310591

  5. Legalized or Not? Poor Public Communication Causes Confusion over the New Cannabis Policy in Belgium

    Science.gov (United States)

    Gelders, Dave; Van Mierlo, Jan

    2004-01-01

    During the last three years, the newly announced drug policy, specifically cannabis, has been the subject of debate between the Government and the opposition parties within the Belgian Federal Government. Public communication by the Federal Government and the competent ministers was incomplete, untimely, inconsistent, tendentious and polemical.…

  6. The Co-Use of Tobacco and Cannabis among Adolescents over a 30-Year Period

    Science.gov (United States)

    Webster, Lauren; Chaiton, Michael; Kirst, Maritt

    2014-01-01

    Background: This study explores the patterns of use and co-use of tobacco and cannabis among Ontario adolescents over 3 decades and if characteristics of co-users and single substance users have changed. Methods: Co-use trends for 1981-2011 were analyzed using the Centre for Addiction and Mental Health Ontario Student Drug Use and Health Survey,…

  7. Adolescent Tobacco and Cannabis Use: Young Adult Outcomes from the Ontario Child Health Study

    Science.gov (United States)

    Georgiades, Katholiki; Boyle, Michael H.

    2007-01-01

    Background: This study examines the longitudinal associations between adolescent tobacco and cannabis use and young adult functioning. Methods: Data for analysis come from the Ontario Child Health Study (OCHS), a prospective study of child health, psychiatric disorder and adolescent substance use in a general population sample that began in 1983,…

  8. Externalizing Behavior Problems and Cigarette Smoking as Predictors of Cannabis Use: The TRAILS Study

    Science.gov (United States)

    Korhonen, Tellervo; van Leeuwen, Andrea Prince; Reijneveld, Sijmen A.; Ormel, Johan; Verhulst, Frank C.; Huizink, Anja C.

    2010-01-01

    Objective: To examine externalizing behavior problems and cigarette smoking as predictors of subsequent cannabis use. Method: Dutch adolescents (N = 1,606; 854 girls and 752 boys) from the TRacking Adolescents' Individual Lives Survey (TRAILS) ongoing longitudinal study were examined at baseline (ages 10-12 [T1]) and at two follow-up assessments…

  9. Parietal Lobe Volume Deficits in Adolescents with Schizophrenia and Adolescents with Cannabis Use Disorders

    Science.gov (United States)

    Kumra, Sanjiv; Robinson, Paul; Tambyraja, Rabindra; Jensen, Daniel; Schimunek, Caroline; Houri, Alaa; Reis, Tiffany; Lim, Kelvin

    2012-01-01

    Objective: In early-onset schizophrenia (EOS), the earliest structural brain volumetric abnormalities appear in the parietal cortices. Early exposure to cannabis may represent an environmental risk factor for developing schizophrenia. This study characterized cerebral cortical gray matter structure in adolescents in regions of interest (ROIs) that…

  10. "High" Achievers? Cannabis Access and Student Performance. CEP Discussion Paper No. 1340

    Science.gov (United States)

    Marie, Olivier; Zölitz, Ulf

    2015-01-01

    This paper investigates how legal cannabis access affects student performance. Identification comes from an exceptional policy introduced in the city of Maastricht which discriminated legal access based on individuals' nationality. We apply a difference-in-difference approach using administrative panel data on over 54,000 course grades of local…

  11. Cannabis and Anxiety and Depression in Young Adults: A Large Prospective Study

    Science.gov (United States)

    Hayatbakhsh, Mohammad R.; Najman, Jake M.; Jamrozik, Konrad; Mamun, Abdullah A.; Alati, Rosa; Bor, William

    2007-01-01

    Objective: To examine whether age of first use or frequency of use of cannabis is associated with anxiety and depression (AD) in young adults, independent of known potential confounders, including the use of other illicit drugs. Method: A cohort of 3,239 Australian young adults was followed from birth to the age of 21 when data on AD were obtained…

  12. A Meta-Analytic Review of School-Based Prevention for Cannabis Use

    Science.gov (United States)

    Porath-Waller, Amy J.; Beasley, Erin; Beirness, Douglas J.

    2010-01-01

    This investigation used meta-analytic techniques to evaluate the effectiveness of school-based prevention programming in reducing cannabis use among youth aged 12 to 19. It summarized the results from 15 studies published in peer-reviewed journals since 1999 and identified features that influenced program effectiveness. The results from the set of…

  13. Effects of Parthenium hysterophorus L. on Soil Characteristics Initially Inhabited to Cannabis sativa L.

    Directory of Open Access Journals (Sweden)

    Rizwana Aleem Qureshi

    2006-01-01

    Full Text Available Parthenium hysterophorus is a new entry and successfully growing on all types of soils in fields and waste lands. Parthenium is drought resistant highly resistant weed which sustain its survival in highly unfavorable conditions where other delicate flora can not grow. Due to its allelopathic nature, no other plant can grow near it successfully and the chemical nature of the soil also changes which further accelerate the unfavourness for the other species. Because of the weedy characteristics and production of large number of seeds, it grew on an alarming rate and presently it has occupied the large areas in NWFP and Punjab with increasing tendency. It has been found that this weed can grow in association of many other plants of which Cannabis sativa is more important but further studies indicated that even Cannabis is replaced by this weed which means it is highly tolerant and hardy in its nature and due to absence of some natural enemy (Predate it tends to grow on unprecented rate. During the present study it has been observed that Parthenium can grow in variety of soil types with different pH values. Mostly sandy loam and sandy clay loam are found highly conductive for its growth. It is nature of its wide adaptability of various soil types due to which it is found replacing the Cannabis and other natural flora. However, well grown Cannabis plants compete for survival with this weed.

  14. Multimethod alexithymia assessment in adolescents and young adults with a cannabis use disorder.

    Science.gov (United States)

    Dorard, Géraldine; Berthoz, Sylvie; Haviland, Mark G; Phan, Olivier; Corcos, Maurice; Bungener, Catherine

    2008-01-01

    The value of alexithymia assessments in medical and psychiatric research is well documented, but such assessments in cannabis abusers are scarce. Moreover, despite repeated calls for multimethod alexithymia evaluations, researchers typically use 1 self-report only: the 20-item Toronto Alexithymia Scale. Herein, we evaluated (1) the psychometric properties of the Observer Alexithymia Scale (OAS), (2) the correspondence between 3 alexithymia measures, (3) OAS raters' affect and its relationship to OAS scores, and (4) cannabis abusers' alexithymic features. Eighty-seven cannabis abusers completed self-reports measuring alexithymia (Toronto Alexithymia Scale, Bermond-Vorst Alexithymia Questionnaire-B), depression (13-item Beck Depression Inventory), and anxiety (State and Trait Anxiety Inventory-Form Y) and asked relatives to rate them using the OAS. The raters also completed the self-report scales. The OAS met acceptable reliability and validity standards, with the exception of relatively low interrater reliability for one of its subscales. Rater affect appeared to influence OAS scores, albeit slightly. Patients' OAS scores were higher than scores reported for people-in-general samples and lower than those for outpatient clinical samples. Alexithymia rates were similar to those previously reported in cannabis abusers. Our results demonstrated the adequacy and appropriateness of the OAS in these (and related) clinical samples, which may encourage multimethod alexithymia assessments in both research and clinical practice. PMID:18970907

  15. Photosynthetic response of Cannabis sativa L., an important medicinal plant, to elevated levels of CO2

    OpenAIRE

    Chandra, Suman; Lata, Hemant; Ikhlas A. Khan; Elsohly, Mahmoud A

    2011-01-01

    The effect of elevated CO2 concentrations (545 and 700 ?mol mol?1) on gas exchange and stomatal response of four high ?9-THC yielding varieties of Cannabis sativa (HPM, K2, MX and W1) was studied to assess their response to the rising atmospheric CO2 concentration. In general, elevated CO2 concentration (700 ?mol mol?1) significantly (p?

  16. Cannabidiolic acid, a major cannabinoid in fiber-type cannabis, is an inhibitor of MDA-MB-231 breast cancer cell migration.

    Science.gov (United States)

    Takeda, Shuso; Okajima, Shunsuke; Miyoshi, Hiroko; Yoshida, Kazutaka; Okamoto, Yoshiko; Okada, Tomoko; Amamoto, Toshiaki; Watanabe, Kazuhito; Omiecinski, Curtis J; Aramaki, Hironori

    2012-11-15

    Cannabidiol (CBD), a major non-psychotropic constituent of fiber-type cannabis plant, has been reported to possess diverse biological activities, including anti-proliferative effect on cancer cells. Although CBD is obtained from non-enzymatic decarboxylation of its parent molecule, cannabidiolic acid (CBDA), few studies have investigated whether CBDA itself is biologically active. Results of the current investigation revealed that CBDA inhibits migration of the highly invasive MDA-MB-231 human breast cancer cells, apparently through a mechanism involving inhibition of cAMP-dependent protein kinase A, coupled with an activation of the small GTPase, RhoA. It is established that activation of the RhoA signaling pathway leads to inhibition of the mobility of various cancer cells, including MDA-MB-231 cells. The data presented in this report suggest for the first time that as an active component in the cannabis plant, CBDA offers potential therapeutic modality in the abrogation of cancer cell migration, including aggressive breast cancers. PMID:22963825

  17. Management of somatic symptoms

    DEFF Research Database (Denmark)

    Schröder, Andreas; Dimsdale, Joel

    2014-01-01

    ABSTRACT: Somatic symptoms that cannot be attributed to organic disease account for 15 to 20% of primary care consultations and up to 50% in specialized settings. About 6% of the general population has chronic somatic symptoms that affect functioning and quality of life. This chapter focuses on the recognition and effective management of patients with excessive and disabling somatic symptoms. The clinical presentation of somatic symptoms is categorized into three groups of patients: those with multiple somatic symptoms, those with health anxiety, and those with conversion disorder. The chapter provides information to assist with making a diagnosis and differential diagnosis. Management includes ways to improve the physician–patient interaction that will benefit the patient, a step-care model based on illness severity and complexity, and psychological and pharmacologic treatment. The chapter is enhanced by figures and tables that summarize health anxiety, symptoms, differential diagnoses, and management strategies, as well as by case studies and examples.

  18. Early psychosis symptoms

    International Nuclear Information System (INIS)

    Objective: To determine the prodromal symptoms of schizophrenia in the pathways to help-seeking. Study Design: A cross-sectional study. Place and Duration of Study: The Department of Psychiatry, the Aga Khan University, Karachi, from 2008 to 2009. Methodology: A total of 93 patients were interviewed in the pathways to care of schizophrenia. The diagnosis was based on ICD-10 criteria. The pathways to care were assessed through a semi-structured questionnaire. The onset, course and symptoms of psychosis were assessed through Interview for Retrospective Assessment at Age at Onset of Psychosis (IROAS). Results: Fifty five (59%) participants were male while 41% (n=38%) were female. Using IROAS, 108 symptoms were identified as concerning behaviour. Alternatively, 60 (55%) concerning behaviours were reported in the open-ended inquiry of the reasons for help seeking as assessed by the pathways to care questionnaire with a statistically significant difference between most symptoms category. The difference was most pronounced (p < 0.001) for depressed mood (66%), worries (65%), tension (63%), withdrawal/mistrust (54%) and loss of self-confidence (53%). Thought withdrawal (22%) and passivity (15%) were elicited only through structured interview (IROAS). When symptoms were categorized together, about 83% of the subjects presented with affective and non-specific prodromal symptoms. Roughly, 10% of the subjects presented with positive symptoms and 3% presented with the negative symptoms of psychosis. The non-specific, affective symptoms appear to predominate the prodromal phase of the illness. Conclusion: Prodromal symptoms of schizophrenia include non-specific, affective symptoms. Attention needs to be paid on identifying the prodromal symptoms and change in social functioning in order to identify those who are at risk of long term psychosis. (author)

  19. Differential effects of cannabis extracts and pure plant cannabinoids on hippocampal neurones and glia.

    Science.gov (United States)

    Ryan, Duncan; Drysdale, Alison J; Pertwee, Roger G; Platt, Bettina

    2006-11-20

    We have shown previously that the plant cannabinoid cannabidiol (CBD) elevates intracellular calcium levels in both cultured hippocampal neurones and glia. Here, we investigated whether the main psychotropic constituent of cannabis, Delta(9)-tetrahydrocannabinol (THC) alone or in combination with other cannabis constituents can cause similar responses, and whether THC affects the responses induced by CBD. Our experiments were performed with 1 microM pure THC (pTHC), with 1 microM pure CBD (pCBD), with a high-THC, low CBD cannabis extract (eTHC), with a high-CBD, low THC cannabis extract (eCBD), with a mixture of eTHC and eCBD (THC:CBD=1:1) or with corresponding 'mock extracts' that contained only pTHC and pCBD mixed in the same proportion as in eTHC, eCBD or the 1:1 mixture of eTHC and eCBD. We detected significant differences in neurones both between the effects of pTHC and eTHC and between the effects of pCBD and eCBD. There were also differences between the Ca(2+) responses evoked in both neurones and glia by eTHC and mock eTHC, but not between eCBD and mock eCBD. A particularly striking observation was the much increased response size and maximal responder rates induced by the mixture of eTHC and eCBD than by the corresponding 1:1 mixture of pTHC and pCBD. Our data suggest that THC shares the ability of CBD to elevate Ca(2+) levels in neurones and glia, that THC and CBD interact synergistically and that the cannabis extracts have other constituents yet to be identified that can significantly modulate the ability of THC and CBD to raise Ca(2+) levels. PMID:16997463

  20. O relaxamento respiratório no manejo do craving e dos sintomas de ansiedade em dependentes de crack Deep breathing in the management of craving and anxiety symptoms of crack-cocaine-dependent patients

    Directory of Open Access Journals (Sweden)

    Taís Cardoso de Zeni

    2009-01-01

    Full Text Available INTRODUÇÃO: O objetivo deste estudo foi verificar a efetividade do relaxamento respiratório no manejo do craving e dos sintomas de ansiedade em dependentes de crack internados para tratamento em uma unidade de desintoxicação. MÉTODO: Ensaio clínico do tipo quase-experimental de análise quantitativa. A amostra foi por conveniência, sendo composta por 32 homens dependentes de cocaína (crack. Eles tinham a cocaína como a droga de escolha e haviam utilizado esta substância por última vez entre 2 e 3 semanas antes do início do tratamento, conseguindo realizar a técnica do relaxamento respiratório adequadamente do ponto de vista biomecânico. Os instrumentos aplicados foram: Cocaine Craving Questionnaire-Brief (CCQB, escala analógica visual (EAV, Inventário Beck de ansiedade (BAI e ficha com dados sociodemográficos e referentes ao padrão de consumo de substâncias psicoativas (FDS. Foi realizada uma intervenção em grupo na qual, inicialmente, foram aplicados o CCQB, a EAV e o BAI. Depois, foram apresentadas imagens relacionadas ao uso do crack e foram reaplicados os mesmos instrumentos. A seguir, foi realizado o relaxamento respiratório durante 10 minutos e foram aplicados, pela terceira vez, os instrumentos. Após esta intervenção, foi realizada uma entrevista individual com aplicação da FDS. RESULTADOS: Os resultados desta pesquisa demonstraram uma redução dos escores do CCQB, da EAV e do BAI pelo relaxamento respiratório em uma amostra cujo perfil corresponde ao padrão geral dos usuários de crack. CONCLUSÃO: Este estudo, apesar de ter algumas limitações metodológicas, sugere que o relaxamento respiratório pode ser uma estratégia efetiva no manejo do craving e dos sintomas de ansiedade em dependentes de crack.INTRODUCTION: The objective of this study was to verify the effectiveness of deep breathing in the management of craving and anxiety symptoms in crack-cocaine-dependent patients hospitalized for treatment in a detoxification unit. METHODS: This is a quasi-experimental clinical trial using a quantitative analysis. The convenience sample comprised 32 crack-cocaine-dependent males. These subjects had cocaine as their drug of choice, having used this substance between 2 and 3 weeks prior to the beginning of the treatment, and were able to adequately perform the deep breathing technique. The instruments used were: the Cocaine Craving Questionnaire-Brief (CCQB, the visual analogue scale (VAS, the Beck Anxiety Inventory (BAI, and a form containing sociodemographic information and data related to the pattern of consumption of psychoactive substances (SDF. A group intervention was conducted with the administration of the CCQB, the VAS, and the BAI. After that, images related to the use of crack-cocaine were shown to the subjects and the same instruments were administered again. Next, the participants performed the deep breathing technique for 10 minutes, and the instruments were administered one more time. Finally, an individual interview was done and the SDF was completed. RESULTS: Our findings demonstrated a decrease in the scores on the CCQB, the VAS and the BAI after the deep breathing technique was performed in a sample whose profile represents the general pattern of crack-cocaine users. CONCLUSION: In spite of some methodological limitations, the present study suggests that the deep breathing technique is effective in the management of craving and anxiety symptoms in crack-cocaine-dependent patients.